<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> ESSA Pharma Inc. (Form: 20-F, Received: 12/14/2016 08:49:33) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_IDENTITY_OF_PERSONNEL **FIS_OFFER_STATISTICS **FIS_KEY_INFORMATION **FIS_COMPANY_INFORMATION **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_OPERATING_AND_FINANCIAL_REVIEW **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_BENEFICIAL_OWNERS **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS_2 **FIS_BENEFICIAL_OWNERS_3 **FIS_FINANCIAL_DATA **FIS_LEGAL_PROCEEDINGS **FIS_LISTING **FIS_ADDITIONAL_INFORMATION **FIS_MARKET_RISK **FIS_OTHER_SECURITIES **FIS_PART_II **FIS_DEFAULTS **FIS_MATERIAL_MODIFICATIONS **FIS_CONTROL_AND_PROCEDURES **FIS_AUDITORS_OPINION **FIS_AUDIT_COMMITTEE_EXPERT **FIS_CODE_OF_ETHICS **FIS_ACCOUNTANT_FEES **FIS_EXEMPTIONS_FROM_LISTING **FIS_PURCHASES_OF_EQUITY **FIS_CHANGE_IN_ACCOUNTANT **FIS_CORPORATE_GOVERNANCE **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_III **FIS_FINANCIAL_STATEMENTS **FIS_FINANCIAL_STATEMENTS_2 **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION_2 **FIS_CASH_FLOW **FIS_INCOME_STATEMENT **FIS_CASH_FLOW_2 **FIS_STOCKHOLDERS_EQUITY **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_4 FIS_EXHIBIT_4_2 FIS_EXHIBIT_12 FIS_EXHIBIT_12_2 FIS_EXHIBIT_13 ">
<META NAME="DETECTED PAGES" CONTENT="185">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="ESSAPHARMAFORM20F_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 14PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
<BR>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	WASHINGTON, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	FORM 20-F
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OR
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9746;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the fiscal year ended
<U>
	&nbsp;&nbsp;September
	30, 2016
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OR
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the transition period from
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	to
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OR
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Date of event requiring this shell company
	report
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Commission file number:
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 24PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ESSA Pharma Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Exact name of Registrant as specified in
	its charter)
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Not Applicable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Translation of Registrant&rsquo;s name into
	English)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	British Columbia, Canada
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Jurisdiction of incorporation or organization)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Suite 720, 999 West Broadway, Vancouver,
	British Columbia, Canada, V5Z 1K5
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Address of principal executive offices)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	David Wood, Chief Financial Officer; Tel-
	(778)-331-0962; Fax-(604)-738-4080
<BR>
	Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Name, Telephone, E-mail, and/or Facsimile
	number and Address of Company Contact Person)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered or to be registered
	pursuant to Section&nbsp;12(b) of the Act:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
<B>
	Title of Each Class
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name of each exchange on which registered
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Common Shares
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NASDAQ Capital Market
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered or to be registered
	pursuant to Section&nbsp;12(g) of the Act: None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Securities for which there is a reporting
	obligation pursuant to Section&nbsp;15(d) of the Act: None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate the number of outstanding shares of each of the issuer&rsquo;s
	classes of capital or common stock as of the close of the period covered by the annual report: Not applicable
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark whether Registrant is a well-known seasoned
	issuer, as defined in Rule 405 of the Securities Act &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If this report is an annual or transition report, indicate by check
	mark if Registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934.
	&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark whether the Registrant (1)&nbsp;has filed
	all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
	(or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing
	requirements for the past 90 days. Yes&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark whether the Registrant (1)&nbsp;has submitted
	electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
	to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such period that the registrant
	was required to submit and post such files). &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark whether Registrant is a large accelerated
	filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;accelerated filer and large accelerated filer&rdquo;
	in Rule 12b-2 of the Exchange Act
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Large accelerated Filer&nbsp;&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Accelerated Filer&nbsp;&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-accelerated Filer&nbsp;&#9746;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark which basis of accounting the Registrant
	has used to prepare the financial statements included in this filing:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 23%">
<FONT STYLE="FONT-SIZE: 10PT">
	U.S.&nbsp;GAAP&nbsp;&#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 52%">
<FONT STYLE="FONT-SIZE: 10PT">
	International Financial Reporting Standards as issued by the International Accounting Standards Board&nbsp;&#9746;
</FONT>
</TD>
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other&nbsp;&#9744;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If &ldquo;Other&rdquo; has been check in response to the previous
	question, by check mark which financial statement item Registrant has elected to follow:&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;17&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;18&nbsp;&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If this is an annual report, indicate by check mark whether Registrant
	is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9746;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	GENERAL MATTERS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	GLOSSARY OF TERMS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PART I
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 15%; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 75%; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%; PADDING-RIGHT: 0.5IN; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 1.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 2.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OFFER STATISTICS AND EXPECTED TIMETABLE
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 3.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	KEY INFORMATION
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 4.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	INFORMATION ON THE COMPANY
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	43
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;4A
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNRESOLVED STAFF COMMENTS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	65
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 5.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	65
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 6.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	76
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 7.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	96
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 8.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FINANCIAL INFORMATION
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	99
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 9.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	THE OFFER AND LISTING
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	99
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 10.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ADDITIONAL INFORMATION
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	101
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 11.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	107
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 12.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	107
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PART II
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	108
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5IN; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 13.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	108
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 14.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	108
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 15.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CONTROLS AND PROCEDURES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	108
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16A
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	AUDIT COMMITTEE FINANCIAL EXPERT
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16B
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CODE OF ETHICS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16C
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PRINCIPAL ACCOUNTANT FEES AND SERVICES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16D
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	EXEMPTIONS FROM LISTING STANDARDS FOR AUDIT COMMITTEES
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16E
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16F
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	109
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16G
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CORPORATE GOVERNANCE
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM&nbsp;16H
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	MINE SAFETY DISCLOSURE
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PART III
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5IN; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5IN; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 17.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FINANCIAL STATEMENTS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 18.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FINANCIAL STATEMENTS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.25IN; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 19.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	EXHIBITS
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	110
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 12PT 0 6PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	i&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	GENERAL
	MATTERS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In this Annual Report on Form 20-F (&ldquo;
<B>
	Annual Report
</B>
	&rdquo;),
	all references to the &ldquo;
<B>
	Company
</B>
	&rdquo;, &ldquo;
<B>
	ESSA
</B>
	&rdquo;, &ldquo;
<B>
	our
</B>
	&rdquo;, &ldquo;
<B>
	us
</B>
	&rdquo;
	or &ldquo;
<B>
	we
</B>
	&rdquo; refer to ESSA Pharma Inc. and its subsidiary, unless the context clearly requires otherwise. Certain
	terms used herein are defined in the text and others are included in the glossary of terms. See &ldquo;
<I>
	Glossary of Terms
</I>
	&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA uses the United States dollar as its reporting currency. All
	references to &ldquo;
<B>
	$
</B>
	&rdquo; or &ldquo;
<B>
	US$
</B>
	&rdquo; are to United States dollars and references to &ldquo;
<B>
	C$
</B>
	&rdquo;
	are to Canadian dollars. On December 14, 2016 the noon exchange rate for the conversion of Canadian dollars into U.S. dollars as
	reported by the Bank of Canada was C$1.00 = US$X. See also Item&nbsp;3 - &ldquo;
<I>
	Key Information
</I>
	&rdquo; for more detailed
	currency and conversion information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	CAUTIONARY
	NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This Annual Report includes certain statements that are &ldquo;forward-looking
	statements&rdquo; within the meaning of the U.S. Private Securities Litigation Reform Act and applicable Canadian securities laws.
	All statements in this Annual Report, other than statements of historical facts, are forward-looking statements. These statements
	appear in a number of different places in this Annual Report and can be identified by words such as &ldquo;anticipates&rdquo;,
	&ldquo;estimates&rdquo;, &ldquo;projects&rdquo;, &ldquo;expects&rdquo;, &ldquo;intends&rdquo;, &ldquo;believes&rdquo;, &ldquo;plans&rdquo;,
	&ldquo;will&rdquo;, &ldquo;could&rdquo;, &ldquo;may&rdquo;, &ldquo;projects&rdquo;, or their negatives or other comparable words.
	Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company&rsquo;s
	actual results, performance or achievements to be materially different from any future results, performance or achievements that
	may be expressed or implied by such forward-looking statements. Examples of such forward-looking statements include, but are not
	limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the initiation, timing, cost, progress and success of ESSA&rsquo;s research and development programs, pre-clinical studies and clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to advance its product candidate into, and successfully complete, clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to achieve profitability;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to obtain funding for operations, including research funding;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to recruit sufficient numbers of patients for future clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to establish and maintain relationships with collaborators with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the implementation of the Company&rsquo;s business model and strategic plans;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to develop and commercialize product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s commercialization, marketing and manufacturing capabilities and strategy;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s expectations regarding federal, state, provincial and foreign regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in the United States, Canada, the European Union and other jurisdictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the therapeutic benefits, effectiveness and safety of the Company&rsquo;s product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the accuracy of the Company&rsquo;s estimates of the size and characteristics of the markets that may be addressed by the Company&rsquo;s product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the rate and degree of market acceptance and clinical utility of the Company&rsquo;s product candidate, if any;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the timing of, and the Company&rsquo;s ability and the Company&rsquo;s collaborators&rsquo; ability, if any, to obtain and maintain regulatory approvals for the Company&rsquo;s product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s expectations regarding market risk, including interest rate changes and foreign currency fluctuations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to engage and retain the employees required to grow its business;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the compensation that is expected to be paid to the Company&rsquo;s employees;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s future financial performance and projected expenditures;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	developments relating to the Company&rsquo;s competitors and its industry, including the success of competing therapies that are or may become available; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	estimates of the Company&rsquo;s expenses, future revenue, capital requirements and its needs for additional financing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Such statements reflect ESSA&rsquo;s current views with respect
	to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that
	are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
	and contingencies. Many factors could cause ESSA&rsquo;s actual results, performance or achievements to be materially different
	from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making
	the forward looking statements included in this Annual Report, the Company has made various material assumptions, including but
	not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to obtain positive results of clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to obtain required regulatory approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to successfully out-license or sell its future products, if any, and in-license and develop new products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	favorable general business and economic conditions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the availability of financing on reasonable terms;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to attract and retain skilled staff;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	market competition;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the products and technology offered by the Company&rsquo;s competitors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s ability to protect patents and proprietary rights.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In evaluating forward-looking statements, current and prospective
	shareholders should specifically consider various factors, including the risks outlined herein under the heading &ldquo;
<I>
	Risk
	Factors
</I>
	&rdquo; in Item&nbsp;3 of this Annual Report. Some of these risks and assumptions include, among others:
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	uncertainty as to the Company&rsquo;s ability to raise additional funding;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company&rsquo;s ability to continue as a going concern;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company&rsquo;s incurrence of significant losses in every quarter since its inception and anticipation that it will continue
	to incur significant losses in the future;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to raising additional capital, which may include dilution to the Company&rsquo;s existing shareholders, restrictions
	on the Company&rsquo;s operations or requirements to relinquish rights to ESSA&rsquo;s technologies or any future product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company&rsquo;s limited operating history;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company's ability to comply with the CPRIT Agreement;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company&rsquo;s future success is dependent primarily on the regulatory approval and commercialization of a single product
	candidate;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to continue to license its product candidates or technology from third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	uncertainty related to the Company&rsquo;s ability to obtain required regulatory approvals for ESSA&rsquo;s proposed products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company's ability to successfully commercialize its product candidate or other future product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the possibility that the Company&rsquo;s product candidates may have undesirable side effects:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to clinical drug development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to conduct a clinical trial or submit a future NDA/NDS or IND/CTA (each, as defined
	herein);
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to enroll subjects in clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks that the FDA (as defined herein) may not accept data from trials conducted in such locations outside the United States;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ongoing obligations and continued regulatory review;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to potential administrative or judicial sanctions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the risk of increased costs associated with prolonged, delayed or terminated clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s failure to obtain regulatory approval in international jurisdictions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to new legislation, new regulatory requirements, and the continuing efforts of governmental and third party payors
	to contain or reduce the costs of healthcare;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the risk that third parties may not carry out their contractual duties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the possibility that the Company&rsquo;s relationships with CROs (as defined herein) may terminate;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s lack of experience manufacturing its product candidates on a large clinical or commercial
	sale and its lack of manufacturing facility;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company&rsquo;s reliance on proprietary technology;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the Company may not be able to protect its intellectual property rights throughout the world;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	claims by third parties asserting that the Company, or its employees have misappropriated their intellectual property, or claiming
	ownership of what the Company regards as its intellectual property;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company's ability to manage growth;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to attract and maintain highly qualified personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to potential conflicts of interest between the Company and its directors and officers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	competition from other biotechnology and pharmaceutical companies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to movements in foreign currency exchange rates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain
	the Company&rsquo;s future revenues;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to convince public payors and hospitals to include ESSA&rsquo;s potential future
	products on their approved formulary lists;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to establish an effective sales force and marketing infrastructure, or enter into
	acceptable third-party sales and marketing or licensing arrangements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to achieve or maintain expected levels of market acceptance for its products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to realize benefits from acquired businesses or products or form strategic alliances
	in the future;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to collaborations with third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks that employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards
	and requirements, which could cause significant liability for ESSA and harm its reputation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to product liability lawsuits;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to computer system failures;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	business disruptions that could seriously harm the Company&rsquo;s future revenues and financial condition and increase ESSA&rsquo;s
	costs and expenses;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	compulsory licensing and/or generic competition;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s dependence on the use of information technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the increased costs and effort as a result of ESSA becoming a public company;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks inherent in foreign operations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	laws and regulations governing international operations may preclude the Company from developing, manufacturing and selling
	certain product candidates outside of the United States and Canada and require ESSA to develop and implement costly compliance
	programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to laws that govern fraud and abuse and patients' rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to comply with environmental, health and safety laws and regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the different disclosure obligations for a U.S. domestic reporting company and a foreign private issuer such
	as ESSA;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks relating to the Company&rsquo;s ability to maintain its status as a foreign private issuer in the future;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the risk that the Company could become a &ldquo;passive foreign investment company;&rdquo;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s status as an emerging growth company;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to United States investors' ability to effect service of process or enforcement of actions against the Company;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company's dividend policy;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks associated with future sales of the Company&rsquo;s securities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company&rsquo;s ability to implement and maintain effective internal controls;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to the Company's ability to maintain an active trading market for its Common Shares;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	share price volatility associated with the Company&rsquo;s thinly traded common shares;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to market price and trading volume volatility; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	risks related to analyst coverage.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Should one or more of these risks or uncertainties, or a risk that
	is not currently known to ESSA, materialize, or should assumptions underlying those forward-looking statements prove incorrect,
	actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this
	Annual Report and the Company does not intend, and do not assume any obligation, to update these forward-looking statements, except
	as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future
	performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company advises you that these cautionary remarks expressly
	qualify in their entirety all forward-looking statements attributable to the Company or persons acting on its behalf.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	GLOSSARY
	OF TERMS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As used in this Annual Report, the following terms have the respective
	meaning as specified below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2014 Agency Agreement
</B>
	&rdquo; means the agency agreement
	between the Company and Haywood Securities Inc. dated as of October&nbsp;22, 2014;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2015 Agency Agreement
</B>
	&rdquo; means the agency agreement
	between the Company and Bloom Burton&nbsp;&amp; Co. Limited dated as of January&nbsp;16, 2015;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2014 Financing
</B>
	&rdquo; means a brokered private placement
	offering of 1,185,400 preferred shares at a price of $2.00 per preferred share for aggregate proceeds of $2,370,800;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2014 Special Warrant Financing
</B>
	&rdquo; means the issuance
	on October&nbsp;22, 2014 and October&nbsp;23, 2014 of an aggregate of 679,640 2014 Special Warrants by the Company at $2.00 per
	2014 Special Warrant, all of which were issued in accordance with the 2014 Special Warrant Indenture and 252,500 of which were
	issued in accordance with the 2014 Agency Agreement;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2014 Special Warrant Indenture
</B>
	&rdquo; means the special
	warrant indenture between the Company and the Special Warrant Agent dated as of October&nbsp;22, 2014;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2015 Special Warrant Financing
</B>
	&rdquo; has the meaning
	given to it under the heading &ldquo;
<I>
	History and development of the Company
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2015 Special Warrant Indenture
</B>
	&rdquo; means the special
	warrant indenture between the Company and the Special Warrant Agent dated as of January&nbsp;16, 2015;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2014 Special Warrants
</B>
	&rdquo; means the 679,640 special
	warrants of the Company issued on October&nbsp;22, 2014 and October&nbsp;23, 2014 at a price of $2.00 per 2014 Special Warrant
	for gross proceeds of approximately $1,359,280;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	2015 Special Warrants
</B>
	&rdquo; means the 4,363,634 special
	warrants of the Company issued on January&nbsp;16, 2015 at a price of US$2.75 per 2015 Special Warrant for gross proceeds of approximately
	US$12,000,000;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	AR
</B>
	&rdquo; means androgen receptor;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Articles
</B>
	&rdquo; means the Articles of the Company;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Astellas
</B>
	&rdquo; means Astellas Pharma Inc.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Audit Committee
</B>
	&rdquo; means the Company&rsquo;s audit
	committee;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Auditor
</B>
	&rdquo; means Davidson&nbsp;&amp; Company LLP;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	BC Cancer Agency
</B>
	&rdquo; means the British Columbia
	Cancer Agency;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Bloom Burton
</B>
	&rdquo; means Bloom Burton&nbsp;&amp;
	Co. Limited;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Bloom Burton Warrants
</B>
	&rdquo; means the 25,000 warrants
	issued to Bloom Burton Healthcare Structured Lending Fund to purchase 25,000 Common Shares at an exercise price of $2.00 per Common
	Share and expiring on April&nbsp;15, 2019;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Board
</B>
	&rdquo; means the board of directors of ESSA;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Broker Warrants
</B>
	&rdquo; means the aggregate 361,852
	warrants of the Company issued to the financing agents in connection with the 2014 Financing, the 2014 Special Warrant Financing
	and the 2015 Special Warrant Financing;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Cardiome
</B>
	&rdquo; means Cardiome Pharma Corp.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CBP
</B>
	&rdquo; means CREB-binding protein;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CEO
</B>
	&rdquo; means Chief Executive Officer;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CFO
</B>
	&rdquo; means Chief Financial Officer;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CFPOA
</B>
	&rdquo; means the Canadian Corruption of Foreign
	Public Officials Act;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	cGMP
</B>
	&rdquo; means current Good Manufacturing Practice;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CMO
</B>
	&rdquo; means contract manufacturing organizations;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CMS
</B>
	&rdquo; means Centers for Medicare&nbsp;&amp; Medicaid
	Services;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Common Shares
</B>
	&rdquo; means the common shares in the
	capital of the Company;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Convertible Debenture
</B>
	&rdquo; has the meaning given
	to it under the heading &ldquo;
<I>
	History and development of the Company
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CPRIT
</B>
	&rdquo; means the Cancer Prevention and Research
	Institute of Texas;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CPRIT Agreement
</B>
	&rdquo; refers to the CPRIT Grant Agreement
	executed by the Chief Executive Officer of CPRIT on July&nbsp;9, 2014;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CPRIT Grant
</B>
	&rdquo; has the meaning given to it under
	the heading &ldquo;
<I>
	History and development of the Company
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CRO
</B>
	&rdquo; means Contract Research Organizations;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CRPC
</B>
	&rdquo; means castration-resistant prostate cancer;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	CTA
</B>
	&rdquo; means Clinical Trial Application, the approval
	of which is the key step in obtaining Canadian regulatory approval to commence clinical trials in Canada. It is similar to the
	IND application submitted to the FDA in the United States;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	EMA
</B>
	&rdquo; means European Medicine Agency;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	ESSA Texas
</B>
	&rdquo; means ESSA Pharmaceuticals Corp.,
	a corporation existing under the laws of the State of Texas;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	FCPA
</B>
	&rdquo; means the U.S. Foreign Corrupt Practices
	Act;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	FDA
</B>
	&rdquo; means the U.S. Food and Drug Administration;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	GCP
</B>
	&rdquo; means Good Clinical Practices;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	GLP
</B>
	&rdquo; means Good Laboratory Practices;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	GMP
</B>
	&rdquo; means Good Manufacturing Practices;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Guidelines
</B>
	&rdquo; means National Policy 58-201 &ndash;
<I>
	Corporate Governance Guidelines;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	HIPAA
</B>
	&rdquo; means the U.S. Health Insurance Portability
	and Accountability Act of 1996;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	IFRS
</B>
	&rdquo; means International Financial Reporting
	Standards, as issued by the International Accounting Standards Board;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	in vitro
</B>
	&rdquo; means experimentation in a test tube,
	or, generally, in a controlled environment outside a living organism;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	in vivo
</B>
	&rdquo; means experimentation done in or on
	the living tissue of a whole, living organism as opposed to a partial or dead one;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	IND
</B>
	&rdquo; means Investigational New Drug;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	IRB
</B>
	&rdquo; means Institutional Review Boards;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	LBD
</B>
	&rdquo; means the ligand-binding domain of the
	androgen receptor;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	LHRH
</B>
	&rdquo; means Luteinizing hormone releasing hormone;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	License Agreement
</B>
	&rdquo; means the licensing agreement
	between the Company and the Licensors dated December&nbsp;22, 2010, and amended on February&nbsp;10, 2011 and May&nbsp;27, 2014,
	for certain patent rights and technology related to the Licensed IP, as further described under the heading &ldquo;
<I>
	Patents and
	Proprietary Rights
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Licensed IP
</B>
	&rdquo; has the meaning given to it under
	the heading &ldquo;
<I>
	History and development of the Company - Patents and Proprietary Rights
</I>
	&rdquo; in Item&nbsp;4 of this
	Annual Report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Licensors
</B>
	&rdquo; means UBC and the BC Cancer Agency;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Liquidity Event
</B>
	&rdquo; has the meaning given to it
	in the Articles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	MMA
</B>
	&rdquo; means the U.S. Medicare Modernization Act;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Nasdaq
</B>
	&rdquo; means one of the Nasdaq Global Select
	Market, the Nasdaq Global Market or the Nasdaq Capital Market market tiers of the NASDAQ Stock Market LLC (a U.S. national securities
	exchange);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NDA
</B>
	&rdquo; means New Drug Application;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NDS
</B>
	&rdquo; means New Drug Submission;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NEO
</B>
	&rdquo; means Named Executive Officer;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NI 52-109
</B>
	&rdquo; means National Instrument 52-109
	&ndash;
<I>
	Certification of Disclosure in Issuers&rsquo; Annual and Interim Filings of the Canadian Securities Administrators;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NI 52-110
</B>
	&rdquo; means National Instrument 52-110
	&ndash;
<I>
	Audit Committees;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NI 58-101
</B>
	&rdquo; means National Instrument 58-101
	&ndash;
<I>
	Disclosure of Corporate Governance Practices;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	NTD
</B>
	&rdquo; means amino-terminal domain;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Options
</B>
	&rdquo; means options to acquire Common Shares;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Penalty Conversion Ratio
</B>
	&rdquo; has the meaning given
	to it under the heading &ldquo;
<I>
	Outstanding Security Data
</I>
	&rdquo;;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	PFIC
</B>
	&rdquo; means a passive foreign investment company;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Preferred Shares
</B>
	&rdquo; means the Class&nbsp;A preferred
	shares in the capital of the Company;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Project
</B>
	&rdquo; means ESSA&rsquo;s development of EPI-506
	towards completion of Phase 1/2 clinical proof-of-concept;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	PSA
</B>
	&rdquo; means prostate-specific antigen;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	QEF
</B>
	&rdquo; means qualified electing fund;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	R&amp;D
</B>
	&rdquo; means research and development;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Recognized Exchange
</B>
	&rdquo; means, collectively, the
	Toronto Stock Exchange, the TSX-V, the Nasdaq Stock Market, the New York Stock Exchange, any other equity market based in North
	America having listing standards similar to those of the TSX-V as determined by the Board in its sole discretion, acting reasonably
	or any other equity market as may be approved by holders representing at least 66 and 2/3&nbsp;% of the issued and outstanding
	Preferred Shares;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Sarbanes-Oxley
</B>
	&rdquo; means the Sarbanes-Oxley Act
	of 2002;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	SCID
</B>
	&rdquo; means Severe Combined Immunodeficiency;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	SEDAR
</B>
	&rdquo; means the System for Electronic Document
	Analysis and Retrieval;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	SEC
</B>
	&rdquo; means the U.S. Securities and Exchange
	Commission;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Special Warrant Agent
</B>
	&rdquo; means Computershare Trust
	Company of Canada;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	Stock Option Plan
</B>
	&rdquo; means the stock option plan
	of the Company dated May&nbsp;21, 2015;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	TPD
</B>
	&rdquo; means the Therapeutic Products Division
	of Health Canada;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	TSX
</B>
	&rdquo; means the Toronto Stock Exchange;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	TSX-V
</B>
	&rdquo; means the TSX Venture Exchange;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	UBC
</B>
	&rdquo; means the University of British Columbia;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	U.S.
</B>
	&rdquo; means the United States of America; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&ldquo;
<B>
	U.S. Anti-Kickback Statute
</B>
	&rdquo; refers to the federal
	Anti-Kickback Statute, which is a criminal statute that prohibits the exchange of anything of value in an effort to induce or reward
	the referral of federal health care program business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	PART
	I
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_IDENTITY_OF_PERSONNEL>
<A NAME="FIS_IDENTITY_OF_PERSONNEL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 1.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>
	IDENTITY
	OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Directors and Senior Management
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Advisors
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Auditors
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_IDENTITY_OF_PERSONNEL>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_OFFER_STATISTICS>
<A NAME="FIS_OFFER_STATISTICS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OFFER
	STATISTICS AND EXPECTED TIMETABLE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_OFFER_STATISTICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_KEY_INFORMATION>
<A NAME="FIS_KEY_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEY INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Selected Financial Data
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth selected consolidated financial information
	for the periods indicated, prepared in accordance with IFRS. In 2013, the Company changed its fiscal year end from December&nbsp;31
	to September&nbsp;30, commencing with the 2013 fiscal year and to continue each year going forward. The selected consolidated financial
	information as at and for the nine months ended September&nbsp;30, 2013 and as at and for the years ended September 30, 2016, September
	30, 2015, September&nbsp;30, 2014,&nbsp;and December&nbsp;31, 2012 has been derived from ESSA&rsquo;s audited financial statements
	and accompanying notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The selected consolidated financial information should be read in
	conjunction with &ldquo;Management&rsquo;s Discussion and Analysis&rdquo; and the audited financial statements and accompanying
	notes contained elsewhere in this Annual Report. The selected consolidated financial information set out below may not be indicative
	of ESSA&rsquo;s future performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Figures in US$
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	unless stated otherwise
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year Ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year Ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year Ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Period from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	January&nbsp;1, 2013 to
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30, 2013
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year Ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	December&nbsp;31,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2012
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.15IN; WIDTH: 17%; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Operating Revenues
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Total Operating Expenses
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(19,642,164
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,328,849
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,824,537
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,059,740
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,888,546
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Net Loss for the Period
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(13,139,788
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,676,587
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,823,929
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,058,733
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,887,159
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Comprehensive Loss for the Period
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(13,477,551
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11,341,799
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,895,667
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,058,733
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,887,159
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Basic and diluted loss per Common Share
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.49
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.53
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.12
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.07
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Total Assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,402,562
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,539,773
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,201,833
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	658,541
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,442,036
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Net Assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(536,857
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,455,512
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,974,128
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	478,322
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,308,717
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Capital Stock
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25,974,742
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	19,419,004
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,193,735
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,193,735
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,193,735
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Number of Shares Adjusted to Reflect Changes in Capital
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	29,096,889
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	22,629,271
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,687,534
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,687,534
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,687,534
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-INDENT: -0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Dividends Declared per Share
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Excluding long-term debt and redeemable preferred stock.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Capitalization and Indebtedness
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Reasons for the Offer and Use of Proceeds
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Risk Factors
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	An investment in ESSA involves a high degree of risk and should
	be considered highly speculative due to the nature and present early stage of the Company&rsquo;s business. The following risks
	are the material risks that the Company faces; however, the risks below are not the only ones ESSA faces. Additional risks and
	uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the
	following risks occur, the Company&rsquo;s business, financial condition and results of operations could be seriously harmed and
	you could lose all or part of your investment. Before deciding to invest in any Common Shares, investors should carefully consider
	the risk factors described below.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to ESSA&rsquo;s Financial Position and Need for
	Additional Capital
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA will have significant additional future capital needs
	and there are uncertainties as to the Company&rsquo;s ability to raise additional funding.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Management has forecasted that ESSA&rsquo;s working capital will
	not be sufficient to execute its planned expenditures for the coming year. ESSA will require significant additional capital resources
	to continue and expand its business, including the further development of its only clinical product candidate, EPI-506. Advancing
	ESSA&rsquo;s product candidate or acquisition and development of any new products or product candidates will require considerable
	resources and additional access to capital. In addition, ESSA&rsquo;s future cash requirements may vary materially from those now
	expected. For example, ESSA&rsquo;s future capital requirements may increase if:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company experiences setbacks in its progress with non-clinical studies or if clinical trials are delayed;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company is required to perform additional non-clinical studies and clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company elects to develop, acquire or license new technologies, products or businesses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company experiences generic competition from other life sciences companies or in more markets than anticipated;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company experiences delays or unexpected increases in connection with obtaining regulatory approvals in the various markets where ESSA hopes to sell its products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company experiences unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either ESSA or ESSA&rsquo;s competition; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company experiences scientific progress sooner than expected in its discovery and R&amp;D projects, if ESSA expands the magnitude and scope of these activities, or if ESSA changes its focus as a result of ESSA&rsquo;s discoveries.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA could potentially seek additional funding through strategic
	collaborations, alliances and licensing arrangements, through public or private equity or debt financing, or through other transactions.
	However, if sales are slow to increase or if capital market conditions in general, or with respect to life sciences companies such
	as ESSA&rsquo;s, are unfavourable, ESSA&rsquo;s ability to obtain significant additional funding on acceptable terms, if at all,
	will be negatively affected. There is no certainty that any such financing will be provided or provided on favourable terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If sufficient capital is not available, ESSA may be required to
	delay or abandon its business expansion or R&amp;D projects, either of which could have a material adverse effect on ESSA&rsquo;s
	business, financial condition, prospects or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	ESSA&rsquo;s 2016 year-end financial
	statements state that its recurring losses and limited cash resources raise substantial doubt as to its ability to continue as
	a going concern.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s financial statements for the year ended September 30,
	2016 were prepared on a &ldquo;going concern basis&rdquo; and the audit report contains a &ldquo;going concern qualification&rdquo;
	(see the Audit Report on the Financial Statements for the year ended September 30, 2016 and Note 1 to those Financial Statements).
	ESSA&rsquo;s financial statements assume it will continue as a going concern, but to be able to do so it will need to raise additional
	capital to fund its operations until positive operating cash flow is achieved, if ever. There can be no assurance that ESSA will
	be able to raise sufficient additional capital at terms commercially acceptable, if at all, to continue its operations.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	1
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	&nbsp;
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	&nbsp;
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<SUP>
	1
</SUP>
</FONT>
	[
<FONT>
<B>
	NTD
</B>
	: ESSA to provide draft financial statements once able. Skadden to review for going concern.]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	&nbsp;
</SUP>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company has incurred significant losses in every quarter
	since its inception and anticipates that it will continue to incur significant losses in the future and may never generate profits
	from operations or maintain profitability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a development stage pharmaceutical company with a limited
	operating history. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront
	capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable
	safety profile, gain regulatory approval or become commercially viable. ESSA does not have any products approved by regulatory
	authorities for marketing or commercial sale and have not generated any revenue from product sales, or otherwise, to date. Furthermore,
	ESSA continues to incur significant research, development and other expenses related to its ongoing operations. As a result, ESSA
	is not profitable and has incurred losses in every reporting period since inception in 2009. For the year ended September 30, 2016,
	September 30, 2015 and September 30, 2014, ESSA reported a net loss of $13,139,788, $9,676,587, and $1,823,929, respectively. As
	of September&nbsp;30, 2016, ESSA had an accumulated deficit since inception of $28,240,634.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company expects to continue to incur significant expenses and
	operating losses for the foreseeable future. ESSA anticipates these losses to increase as it continues the R&amp;D of, and seek
	regulatory approvals for, any of its future product candidates and potentially begin to commercialize any products that may achieve
	regulatory approval. ESSA may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that
	may adversely affect its financial condition. The size of ESSA&rsquo;s future net losses will depend, in part, on the rate of future
	growth of ESSA&rsquo;s expenses and ability to generate revenues. The Company&rsquo;s prior losses and expected future losses have
	had and will continue to have an adverse effect on the Company&rsquo;s financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Even if the Company is able to commercialize any product candidate,
	there can be no assurance that the Company will generate significant revenues or ever achieve profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company expects to continue to incur substantial losses for
	the foreseeable future, and these losses may be increasing. The Company is uncertain about when or if it will be able to achieve
	or sustain profitability. If the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent
	periods. Failure to become and remain profitable would impair the Company&rsquo;s ability to sustain operations and adversely affect
	the price of the Common Shares and its ability to raise capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Raising additional capital may cause dilution to ESSA&rsquo;s
	existing shareholders, restrict ESSA&rsquo;s operations or require ESSA to relinquish rights to technologies or any future product
	candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Until the Company can generate substantial revenue from product
	sales, if ever, the Company expects to finance future cash needs through a combination of private and public equity offerings,
	debt financings, strategic collaborations and alliances and licensing arrangements. Additional financing that the Company may pursue
	may involve the sale of its Common Shares or financial instruments that are exchangeable for, or convertible into, its Common Shares,
	which could result in significant dilution to ESSA&rsquo;s shareholders and the terms may include liquidation or other preferences
	that adversely affect the rights of existing shareholders. Additional capital may not be available on reasonable terms, if at all.
	Furthermore, these securities may have rights senior to those of ESSA&rsquo;s Common Shares and could contain covenants that include
	restrictive covenants limiting ESSA&rsquo;s ability to take important actions and potentially impair ESSA&rsquo;s competitiveness,
	such as limitations on ESSA&rsquo;s ability to incur additional debt, make capital expenditures, acquire, sell or license intellectual
	property rights or declare dividends. If ESSA raises additional funds through strategic collaborations and alliances or licensing
	arrangements with third parties, ESSA may have to relinquish valuable rights to technologies or future product candidates, or grant
	licenses on terms that are not favorable to ESSA. If the Company is unable to raise additional funds when needed, the Company may
	be required to delay, limit, reduce or terminate its product development or commercialization efforts or grant rights to develop
	and market product candidates that ESSA would otherwise prefer to develop and market ourselves.
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA has a limited operating history, which may make it difficult
	for you to evaluate the success of ESSA&rsquo;s business to date and to assess ESSA&rsquo;s future viability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s operations to date have been primarily limited
	to organizing and staffing ESSA, acquiring the in-licensing of intellectual property, discovering and developing novel small molecule
	product candidates, conducting preliminary pre-clinical research, and commencing the Phase 1 clinical study. ESSA has not yet obtained
	regulatory approval for any of the Company&rsquo;s product candidates. Consequently, evaluating ESSA&rsquo;s performance, viability
	or future success will be more difficult than if ESSA had a longer operating history or approved products on the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company remains subject to the restrictions and conditions
	of the CPRIT Agreement.&nbsp;Failure to comply with the CPRIT Agreement may adversely affect ESSA&rsquo;s financial condition and
	results of operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has relied on the CPRIT Grant to fund a portion of its operations
	to date. In the third quarter of 2015, ESSA received US$3.7 million from the CPRIT Grant upon the clearance of the IND by the FDA.
	ESSA expects to receive additional proceeds from the CPRIT Grant of US$5.4 million, expected in Q1 of calendar 2017 upon completion
	of the Phase 1 safety portion of our Phase 1/2 clinical trial. The CPRIT Grant is subject to ESSA&rsquo;s compliance with the scope
	of work outlined in the CPRIT Agreement and demonstration of its progress towards achievement of the milestones set forth in the
	CPRIT Agreement.&nbsp;If ESSA fails to comply with the terms of the CPRIT Agreement, it may not receive the remaining tranches
	of the CPRIT Grant&nbsp;or it may be required to reimburse some or the entire CPRIT Grant. Further, the CPRIT Grant may only be
	applied to a limited number of allowable expenses. Failure to obtain the remaining tranches of the CPRIT Grant or being required
	to reimburse all or a portion of the CPRIT Grant may cause a halt or delay in ESSA&rsquo;s ongoing operations, which may adversely
	affect its financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the Company fails to comply with the terms of the CPRIT Agreement,
	CPRIT will have the option to pursue the transfer and assignment of the Company&rsquo;s rights, title and interest in the intellectual
	property rights and technologies developed as a result of the CPRIT Grant. Failure to maintain ownership over the Company&rsquo;s
	intellectual property and technologies would adversely affect the Company&rsquo;s financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ESSA&rsquo;s Product Candidate and Regulatory Matters
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s future success is dependent primarily on successful
	completion of its Phase 1 clinical trial.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company is conducting a Phase 1 study on its only clinical product
	candidate, EPI-506, to determine safety, tolerability, maximum tolerated dose and pharmacokinetics. If EPI-506 should prove to
	be unsafe or not tolerated by patients, the Company&rsquo;s ability to finance may be severely jeopardized and the Company may
	not be able to continue as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s future success is dependent primarily on the
	regulatory approval and commercialization of a single product, which is still in early clinical development.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
	The Company does not have
	any products that have obtained regulatory approval. Currently, ESSA&rsquo;s only clinical product candidate is EPI-506, and
	the Company is in the process of conducting a Phase 1/2 clinical study to determine the safety, tolerability, maximum
	tolerated dose, pharmacokinetics and potential therapeutic benefits of EPI-506 in patients with metastatic CRPC. As a result,
	the Company&rsquo;s near-term prospects, including its ability to finance its operations and generate revenue, are
	substantially dependent on its ability to obtain regulatory approval for, and, if approved, to successfully commercialize
	EPI-506 in a timely manner. ESSA cannot commercialize EPI-506 or other future product candidates in the United States without
	first obtaining regulatory approval for the product from the FDA; similarly, ESSA cannot commercialize EPI-506 or other
	future product candidates outside of the United States without obtaining regulatory approval from comparable foreign
	regulatory authorities. The FDA review process typically varies in time and may take years to complete and approval is not
	guaranteed. Obtaining regulatory approval of ESSA&rsquo;s product candidates will depend on many factors, including, but not
	limited to, the following:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	successfully completing formulation and process development activities;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	completing clinical trials that demonstrate the efficacy and safety of ESSA&rsquo;s product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	receiving marketing approval from applicable regulatory authorities;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	establishing commercial manufacturing capabilities;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	launching commercial sales, marketing and distribution operations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	acceptance of ESSA&rsquo;s product candidates by patients, the medical community and third-party payors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	a continued acceptable safety profile following approval; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	competing effectively with other therapies, including with respect to the sales and marketing of ESSA&rsquo;s product candidates,
	if approved.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Many of these factors are wholly or partially beyond ESSA&rsquo;s
	control, including clinical development, the regulatory submission process and changes in the competitive landscape. If ESSA does
	not achieve one or more of these factors in a timely manner, it could experience significant delays or an inability to develop
	ESSA&rsquo;s product candidates at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If the Company breaches any of the agreements under which
	the Company licenses rights to its product candidate or technology from third-parties, the Company could lose license rights that
	are important to ESSA&rsquo;s business. ESSA&rsquo;s current license agreement may not provide an adequate remedy for its breach
	by the licensor.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is developing its EPI-series product candidates pursuant to
	a License Agreement with UBC and the BC Cancer Agency. The Company is subject to a number of risks associated with the Company&rsquo;s
	collaboration with UBC and the BC Cancer Agency, including the risk that UBC or the BC Cancer Agency may terminate the license
	agreement upon the occurrence of certain specified events. ESSA&rsquo;s license agreement requires, among other things, that the
	Company make certain payments and use reasonable commercial efforts to meet certain clinical and regulatory milestones. See &ldquo;
<I>
	Patents
	and Proprietary Rights
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report. If ESSA fails to comply with any of these obligations or
	otherwise breaches this or similar agreements, UBC, the BC Cancer Agency or any future licensors may have the right to terminate
	the license. ESSA could also suffer the consequences of non-compliance or breaches by licensors in connection with ESSA&rsquo;s
	license agreements. Such non-compliance or breaches by such third parties could in turn result in ESSA&rsquo;s breaches or defaults
	under the Company&rsquo;s agreements with the Company&rsquo;s other collaboration partners, and the Company could be found liable
	for damages or lose certain rights, including rights to develop and/or commercialize a product or product candidate. Loss of ESSA&rsquo;s
	rights to the Licensed IP or any similar license granted to ESSA in the future, or the exclusivity rights provided therein, could
	harm ESSA&rsquo;s financial condition and operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company may not be able to obtain required regulatory
	approvals for the Company&rsquo;s proposed products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The research, testing, manufacturing, labeling, packaging, storage,
	approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products developed by ESSA
	or ESSA&rsquo;s future collaborative partners, if any, is subject to extensive regulation by federal, provincial, state and local
	governmental authorities and those regulations differ from country to country. ESSA&rsquo;s potential future product candidates
	will be principally regulated in the United States by the FDA, in Canada by the TPD, in the European Union by the EMA and the regulators
	in the individual European Union member countries and by other similar regulatory authorities in Japan and other jurisdictions.
	Government regulation substantially increases the cost and risk of researching, developing, manufacturing and selling products.
	Following several widely publicized issues in recent years, the FDA and similar regulatory authorities in other jurisdictions have
	become increasingly focused on product safety. This development has led to requests for more clinical trial data, for the inclusion
	of a significantly higher number of patients in clinical trials and for more detailed analysis of trial results. Consequently,
	the process of obtaining regulatory approvals, particularly from the FDA, has become more costly, time consuming and challenging
	than in the past. Any product developed by ESSA or ESSA&rsquo;s future collaborative partners, if any, must receive all relevant
	regulatory approvals or clearances from the applicable regulatory authorities before it may be marketed and sold in a particular
	country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA will not be permitted to market any potential products in the
	United States, Canada or in other countries where ESSA intends to market its potential future product candidates until such product
	candidate receives approval of a NDA from the FDA or similar approval in other countries as restrictions apply. In the United States,
	the FDA generally requires the completion of pre-clinical testing and clinical trials of each drug to establish its safety and
	efficacy and extensive pharmaceutical development to ensure its quality before an NDA is approved. This process can take many years
	and require the expenditure of substantial resources and may include post-marketing studies and surveillance. Regulatory authorities
	in other jurisdictions impose similar requirements. Of the large number of drugs in development, only a small percentage result
	in the submission of an NDA to the FDA and even fewer are approved for commercialization. To date, the Company has not submitted
	an NDA for any of the Company&rsquo;s potential products to the FDA or comparable applications to other regulatory authorities.
	If the Company&rsquo;s development efforts for potential products are not successful for the treatment of CRPC and regulatory approval
	is not obtained in a timely fashion or at all, the Company&rsquo;s business will be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The receipt of required regulatory approvals for the Company&rsquo;s
	potential future products is uncertain and subject to a number of risks, including the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the FDA, IRB
<B>
	s
</B>
	or comparable foreign regulatory authorities may disagree with the design or implementation of the Company&rsquo;s clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company may not be able to provide acceptable evidence of the safety, efficacy or quality of its potential products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the results of the Company&rsquo;s clinical trials may not meet the level of statistical or clinical significance required by the FDA or other regulatory agencies for marketing approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the dosing of the Company&rsquo;s potential products in a particular clinical trial may not be at an optimal level;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	patients in the Company&rsquo;s clinical trials may suffer adverse effects for reasons that may or may not be related to the Company&rsquo;s potential products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the data collected from the Company&rsquo;s clinical trials may not be sufficient to support the submission of an NDA for the Company&rsquo;s potential products or to obtain regulatory approval in the United States, Canada, or elsewhere;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the FDA or comparable foreign regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which the Company contracts for clinical and commercial supplies; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering the Company&rsquo;s clinical data insufficient for approval.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The FDA and other regulators have substantial discretion in the
	approval process and may refuse to accept any application or may decide that the Company&rsquo;s data is insufficient for approval
	and require additional clinical trials, or other studies. In addition, varying interpretations of the data obtained from pre-clinical
	studies and clinical trials could delay, limit or prevent regulatory approval of the Company&rsquo;s potential products. ESSA,
	or ESSA&rsquo;s future collaborative partner, if any, must obtain and maintain regulatory authorization to conduct clinical trials.
	ESSA&rsquo;s pre-clinical research is subject to GLP and other requirements and ESSA&rsquo;s clinical research is subject to good
	clinical practice and other requirements. Failure to adhere to these requirements could invalidate ESSA&rsquo;s data. In addition,
	the relevant regulatory authority or independent review board may modify, suspend or terminate a clinical trial at any time for
	various reasons, including a belief that the risks to study subjects outweigh the benefits. Further, the process of obtaining regulatory
	approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other
	things, the type, complexity and novelty of the prescription product candidates involved, the jurisdiction in which regulatory
	approval is sought and the substantial discretion of the regulatory authorities. If regulatory approval is obtained in one jurisdiction,
	that does not necessarily mean that ESSA&rsquo;s potential products will receive regulatory approval in all jurisdictions in which
	the Company may seek approval, or any regulatory approval obtained may not be as broad as what was obtained in other jurisdictions.
	However, the failure to obtain approval for ESSA&rsquo;s potential products in one or more jurisdictions may negatively impact
	the Company&rsquo;s ability to obtain approval in a different jurisdiction. Accordingly, despite ESSA&rsquo;s expenditures and
	investment of time and effort, it may be unable to receive required regulatory approvals for product candidates developed by it.
	If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained,
	or any approved products are not commercially successful, ESSA&rsquo;s business, financial condition and results of operations
	may be materially harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA may not be able to successfully commercialize EPI-506
	or other future product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Even if EPI-506 or other future product candidates were to successfully
	obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations
	related to use restrictions for specified age groups, warnings, precautions or contraindications, may be subject to burdensome
	post-approval study or risk management requirements, or may be limited to a subset of CRPC patients with limited commercial value.
	If ESSA is unable to obtain regulatory approval for EPI-506 in one or more jurisdictions, or any approval contains significant
	limitations, ESSA may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any
	other future product candidates that ESSA may discover, in-license, develop or acquire in the future. Also, any regulatory approval
	of EPI-506 or any future product candidates, once obtained, may be withdrawn. Furthermore, even if ESSA obtains regulatory approval
	for EPI-506, the commercial success of EPI-506 will depend on a number of factors, including the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	development of a commercial organization or establishment of a commercial collaboration with a commercial infrastructure;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	establishment of commercially viable pricing and approval for adequate reimbursement from third-party and government payors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the ability of ESSA&rsquo;s third-party manufacturers to manufacture quantities of EPI-506 using commercially efficient processes and at a scale sufficient to meet anticipated demand and enable ESSA to reduce its cost of manufacturing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA&rsquo;s success in educating physicians and patients about the benefits, administration and use of EPI-506;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the effectiveness of ESSA&rsquo;s own or its potential strategic collaborators&rsquo; marketing, sales and distribution strategy and operations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	acceptance of EPI-506 as safe and effective by patients and the medical community; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	a continued acceptable safety profile of EPI-506 following approval.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Many of these factors are beyond ESSA&rsquo;s control. If ESSA,
	or its potential commercialization collaborators, are unable to successfully commercialize EPI-506, ESSA may not be able to earn
	sufficient revenues to continue the Company&rsquo;s business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
<B>
<I>
	The Company&rsquo;s product candidates may have undesirable
	side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market,
	require them to include safety warnings or otherwise limit their sales.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	Although EPI-506 and any other future product candidates will
	undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of ESSA&rsquo;s
	product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved
	product has been marketed. EPI-506 is still in early clinical development., and is in the process of being tested in humans. &nbsp;The
	results of future clinical trials may show that EPI-506 or any other future product candidate cause undesirable or unacceptable
	side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval
	from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with
	restrictive label warnings, limited patient populations or potential product liability claims.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	If any of ESSA&rsquo;s product candidates receive marketing
	approval and it or others later identify undesirable or unacceptable side effects caused by such products:
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	regulatory authorities may require us to take ESSA&rsquo;s approved product off the market;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts
	to physicians and pharmacies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	it may be required to change the way the product is administered, conduct additional clinical trials or change the labeling
	of the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	it may be subject to limitations on how it may promote the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	sales of the product may decrease significantly;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	it may be subject to litigation or product liability claims; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	ESSA&rsquo;s reputation may suffer.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 12PT 0">
	Any of these events could prevent ESSA or its future collaborative
	partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization
	costs and expenses, which in turn could delay or prevent ESSA from generating significant revenue from the sale of ESSA&rsquo;s
	products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Clinical drug development involves a lengthy and expensive
	process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results and ESSA&rsquo;s
	current product candidate may not have favourable results in later trials or in the commercial setting.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Clinical testing is expensive and can take many years to complete,
	and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. ESSA&rsquo;s planned
	clinical trials may produce negative or inconclusive results, and ESSA or any of its current and future collaborators may decide,
	or regulators may require ESSA, to conduct additional clinical or pre-clinical testing. The results of pre-clinical studies and
	early clinical trials may not be predictive of the results of later-stage clinical trials. Pre-clinical tests and Phase 1 and Phase
	2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side
	effects of product candidates at various doses and schedules. Success in pre-clinical or animal studies and early clinical trials
	does not ensure that later large scale efficacy trials will be successful nor does it predict final results. Favourable results
	in early trials may not be repeated in later trials. The Company cannot assure you that the FDA/TPD or other similar government
	bodies will view the results as the Company does or that any future trials of ESSA&rsquo;s proposed products for other indications
	will achieve positive results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy
	traits despite having progressed through pre-clinical studies and initial clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	A number of companies in the pharmaceutical industry have suffered
	significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
	results in earlier trials. Any future clinical trial results for ESSA&rsquo;s proposed products may not be successful. Similarly,
	preclinical interim results of a clinical trial do not necessarily predict final results. A number of factors could contribute
	to a lack of favorable safety and efficacy results for ESSA&rsquo;s proposed products for other indications. For example, such
	trials could result in increased variability due to varying site characteristics, such as local standards of care, differences
	in evaluation period and due to varying patient characteristics including demographic factors and health status. There can be no
	assurance that the Company&rsquo;s clinical trials will demonstrate sufficient safety and efficacy for the FDA or TPD to approve
	ESSA&rsquo;s potential products for the treatment of CRPC, or any other indication that the Company may consider in any additional
	NDA or NDS submissions for ESSA&rsquo;s potential products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company will be required to demonstrate through larger-scale
	clinical trials that any potential future product is safe and effective for use in a diverse population before ESSA can seek regulatory
	approvals for its commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates
	proceeding through clinical and post-approval trials. If ESSA&rsquo;s potential products fail to demonstrate sufficient safety
	and efficacy in ongoing or future clinical trials, the Company could experience potentially significant delays in, or be required
	to abandon development of, ESSA&rsquo;s product candidate, EPI-506, currently under development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, clinical trials and nonclinical studies performed by
	research organizations and other independent third parties may yield negative results regarding the effect of ESSA&rsquo;s potential
	products on CRPC, either in absolute terms or relative to other products.
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	As an organization, ESSA has never conducted a clinical trial
	or previously submitted an NDA/NDS and may be unable to do so for EPI-506 or any other future products ESSA develops.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has initiated Phase 1 of its clinical development stage for
	EPI-506. However, ESSA still needs to conduct Phase 2 and Phase 3 of clinical trials. The conduct of Phase 3 clinical trials and
	the submission of a successful IND or CTA and NDA or NDS is a complicated process. As an organization, ESSA has not conducted a
	clinical trial before, has limited experience in preparing, submitting and prosecuting regulatory filings and has not submitted
	an NDA/NDS. ESSA&rsquo;s interactions with the FDA to date have been limited to the current clinical trial. Consequently, even
	if ESSA&rsquo;s initial clinical trials are successful, the Company may be unable to successfully and efficiently execute and complete
	necessary clinical trials in a way that leads to NDA or NDS submission and approval of ESSA&rsquo;s proposed products or any other
	future product candidate ESSA may develop. The Company may require more time and incur greater costs than competitors and may not
	succeed in obtaining regulatory approvals of products that the Company develops. Failure to commence or complete, or delays in,
	ESSA&rsquo;s planned clinical trials, would prevent ESSA from or delay ESSA in commercializing proposed products or any other future
	product candidate ESSA develops.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If ESSA is unable to enroll subjects in clinical trials, ESSA
	will be unable to complete these trials on a timely basis.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Patient enrollment, a significant factor in the timing of clinical
	trials, is affected by many factors including the size and nature of the patient population, the proximity of subjects to clinical
	sites, the eligibility criteria for the trial, the design of the clinical trial, ability to obtain and maintain patient consents,
	risk that enrolled subjects will drop out before completion, competing clinical trials and clinicians&rsquo; and patients&rsquo;
	perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new
	drugs that may be approved for the indications ESSA is investigating. Furthermore, ESSA relies on CRO
<B>
	s
</B>
	and clinical trial
	sites to ensure the proper and timely conduct of the Company&rsquo;s clinical trials, and while the Company has agreements governing
	their committed activities, the Company has limited influence over their actual performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If ESSA experiences delays in the completion or termination of any
	clinical trial of EPI-506 or any future product candidates, the commercial prospects of product candidates will be harmed, and
	ESSA&rsquo;s ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays
	in completing ESSA&rsquo;s clinical trials will increase costs, slow down product candidate development and approval process and
	could shorten any periods during which ESSA may have the exclusive right to commercialize product candidates or allow competitors
	to bring products to market before ESSA does, and jeopardize ESSA&rsquo;s ability to commence product sales, which would impair
	ESSA&rsquo;s ability to generate revenues and may harm ESSA&rsquo;s business, results of operations, financial condition and cash
	flows and future prospects. In addition, a delay in the commencement or completion of clinical trials may also ultimately lead
	to the denial of regulatory approval of ESSA&rsquo;s proposed products or future product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA intends to conduct trials for existing or future product
	candidates at sites outside the United States and the FDA may not accept data from trials conducted in such locations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Following receipt of a &ldquo;no objection letter&rdquo; related
	to its CTA in Canada, ESSA is conducting one or more clinical trials in Canada. ESSA may in the future choose to conduct more clinical
	trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance
	of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted
	and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent
	the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems
	clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the
	data will be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There
	can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA chooses to not accept
	data collected outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming
	and delay or permanently halt the development of the Company&rsquo;s proposed products or any future product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Even if the Company obtains marketing approval for any potential
	products, the Company will be subject to ongoing obligations and continued regulatory review, which may result in significant additional
	expense.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Even if the Company obtains U.S. or Canadian regulatory approval
	for its product candidate, EPI-506, which would not occur until the Company successfully completes multiple clinical trials, including
	Phase 3 clinical trials, the FDA or TPD may still impose significant restrictions on its indicated uses or marketing or the conditions
	of approval, or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase 4
	clinical trials or clinical outcome studies and post-market surveillance to monitor the safety and efficacy of ESSA&rsquo;s potential
	products. Even if the Company secures U.S. or Canadian regulatory approval, the Company would continue to be subject to ongoing
	regulatory requirements governing manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising,
	promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements include registration
	with the FDA, as well as continued compliance with GCP obligations, for any clinical trials that the Company conducts post approval.
	In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the
	FDA and other regulatory authorities for compliance with current cGMP requirements relating to quality control, quality assurance
	and corresponding maintenance of records and documents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	With respect to any product candidates for which ESSA obtains regulatory
	approval, ESSA will be subject to post-marketing regulatory obligations, including the requirements by the FDA, EMA and similar
	agencies in other jurisdictions to maintain records regarding product safety and to report to regulatory authorities serious or
	unexpected adverse events. Compliance with extensive post-marketing record keeping and reporting requirements requires a significant
	commitment of time and funds, which may limit ESSA&rsquo;s ability to successfully commercialize approved products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, manufacturing of approved drug products must comply
	with extensive regulations governing cGMP. Manufacturers and their facilities are subject to continual review and periodic inspections.
	As ESSA will be dependent on third parties for manufacturing, ESSA will have limited ability to ensure that any entity manufacturing
	products on its behalf is doing so in compliance with applicable cGMP requirements. Failure or delay by any manufacturer of ESSA&rsquo;s
	products to comply with cGMP regulations or to satisfy regulatory inspections could have a material adverse effect on ESSA, including
	potentially preventing ESSA from being able to supply products for clinical trials or commercial sales. In addition, manufacturers
	may need to obtain approval from regulatory authorities for product, manufacturing, or labeling changes, which requires time and
	money to obtain and can cause delays in product availability. ESSA is also required to comply with good distribution practices
	such as maintenance of storage and shipping conditions, as well as security of products, in order to ensure product quality determined
	by cGMP is maintained throughout the distribution network. In addition, ESSA is subject to regulations governing the import and
	export of its products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Sales and marketing of pharmaceutical products are subject to extensive
	federal and state or provincial laws governing on-label and off-label advertising, scientific/educational grants, gifts, consulting
	and pricing and are also subject to consumer protection and unfair competition laws. Compliance with extensive regulatory requirements
	requires training and monitoring of the sales force, which imposes a substantial cost on ESSA and ESSA&rsquo;s collaborators. To
	the extent any future ESSA products are marketed by collaborators, ESSA&rsquo;s ability to ensure their compliance with applicable
	regulations will be limited. In addition, ESSA is subject to regulations governing the design, testing, control, manufacturing,
	distribution, labeling, quality assurance, packaging, storage, shipping, import and export of ESSA&rsquo;s products and product
	candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Failure to comply with applicable legal and regulatory requirements
	may result in administrative or judicial sanctions.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the Company or a regulatory agency discovers previously unknown
	problems with a product, such as adverse events of unanticipated severity or frequency, lack of efficacy, problems with the facility
	where the product is manufactured, or the Company or its manufacturers fail to comply with applicable regulatory requirements,
	the Company may be subject to the following administrative or judicial sanctions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	issuance of warning letters or untitled letters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	clinical holds;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	injunctions or the imposition of civil or criminal penalties or monetary fines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	suspension or withdrawal of regulatory approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	suspension of any ongoing clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	refusal to approve pending applications or supplements to approved applications filed by the Company, or suspension or revocation of product license approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	suspension or imposition of restrictions on operations, including costly new manufacturing requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	withdrawal of the product from the market and product recalls; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	product seizure or detention or refusal to permit the import or export of product.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The occurrence of any event or penalty described above may inhibit
	the Company&rsquo;s ability to commercialize potential products and generate revenue. Adverse regulatory action, whether pre- or
	post-approval, can also potentially lead to product liability claims and increase the Company&rsquo;s product liability exposure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the future, the regulatory climate might change due to changes
	in the FDA and other regulatory authorities&rsquo; staffing, policies or regulations and such changes could impose additional post-marketing
	obligations or restrictions and related costs. While it is impossible to predict future legislative or administrative action, if
	the Company is not able to maintain regulatory compliance, the Company will not be able to market its drugs and its business could
	suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If clinical trials for ESSA&rsquo;s product candidates are
	prolonged, delayed or stopped, ESSA may be unable to obtain regulatory approval and commercialize ESSA&rsquo;s product candidates
	on a timely basis, or at all, which would require ESSA to incur additional costs and delay receipt of any product revenue.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	ESSA is currently enrolling a Phase 1/2 clinical trial of
	EPI-506 in patients metastatic Castration-resistant Prostate cancer (&ldquo;CRPC&rdquo;). ESSA may experience delays in its ongoing
	or future preclinical studies or clinical trials, and ESSA does not know whether future preclinical studies or clinical trials
	will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all.
	The commencement of these planned clinical trials could be substantially delayed or prevented by several factors, including:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	further discussions with the FDA or other regulatory agencies regarding the scope or design of ESSA&rsquo;s clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the limited number of, and competition for, suitable sites to conduct ESSA&rsquo;s clinical trials, many of which may already
	be engaged in other clinical trial programs, including some that may be for the same indication as ESSA&rsquo;s product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where
	enrollment is planned;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	inability to obtain sufficient funds required for a clinical trial;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	delay or failure to manufacture sufficient supplies of the product candidate for ESSA&rsquo;s clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective
	sites or clinical research organizations (&ldquo;CROs&rdquo;), the terms of which can be subject to extensive negotiation and may
	vary significantly among different sites or CROs; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	The completion of ESSA&rsquo;s clinical trials, once started,
	could also be substantially delayed or prevented by several factors, including:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	slower than expected rates of patient recruitment and enrollment;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	failure of patients to complete the clinical trial;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically
	significant treatment effects;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible
	deaths;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	lack of efficacy during clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	termination of ESSA&rsquo;s clinical trials by one or more clinical trial sites;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	inability or unwillingness of patients or clinical investigators to follow ESSA&rsquo;s clinical trial protocols;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	inability to monitor patients adequately during or after treatment by ESSA and/or ESSA&rsquo;s CROs;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	ESSA&rsquo;s CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations
	to ESSA in a timely manner, or at all, deviating from the protocol or dropping out of a study;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	in ability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical
	trial; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications
	in testing.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 6PT">
	Changes in regulatory requirements, policies and guidelines
	may also occur and ESSA may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory
	authorities. Such changes may require ESSA to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination,
	which may impact the costs, timing or successful completion of a clinical trial. ESSA&rsquo;s clinical trials may be suspended
	or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of ESSA&rsquo;s
	clinical trial sites with respect to that site, or ESSA, due to a number of factors, including:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	failure to conduct the clinical trial in accordance with regulatory requirements or ESSA&rsquo;s clinical protocols;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that
	have responsibility for the clinical development of any of ESSA&rsquo;s product candidates.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Product development costs for any of ESSA&rsquo;s potential products
	will increase if it has delays in testing or approval or if the Company needs to perform more or larger clinical studies than planned.
	Additionally, changes in regulatory requirements and policies may occur and the Company may need to amend clinical study protocols
	to reflect these changes. Amendments may require the Company to resubmit its clinical study protocols to the FDA, TPD or similar
	regulatory authorities or IRBs for re-examination, which may impact the costs, timing or successful completion of that study. Any
	delays in completing the Company&rsquo;s future clinical trials will increase its costs, slow down its development and approval
	process and jeopardize its ability to generate revenues. Any of these occurrences may have a material adverse effect on the Company&rsquo;s
	business, financial condition and prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Failure to obtain regulatory approval in international jurisdictions
	would prevent any future product candidates from being marketed outside the United States or Canada.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In order to market and sell ESSA&rsquo;s potential future products
	in the European Union and many other jurisdictions, it must obtain separate marketing approvals and comply with numerous and varying
	regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to
	obtain approval may differ substantially from that required to obtain FDA or TPD approval. The regulatory approval process outside
	of the United States or Canada generally includes all of the risks associated with obtaining FDA or TPD approval. In addition,
	in many countries outside the United States or Canada, it is required that the product be approved for reimbursement before the
	product can be approved for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory
	requirements could result in significant delays, difficulties and costs for ESSA and could delay or prevent the introduction of
	its potential products in certain countries. ESSA may not obtain approvals from regulatory authorities outside the United States
	or Canada on a timely basis, if at all. A failure or delay in obtaining regulatory approval in one country may have a negative
	effect on the regulatory approval process in others. ESSA may not be able to file for marketing approvals and may not receive necessary
	approvals to commercialize its potential products in any market. If ESSA is unable to obtain approval of any of its future product
	candidates by regulatory authorities in the European Union or another jurisdiction, the commercial prospects of that product candidate
	may be significantly diminished and its business prospects could decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 12PT">
<B>
<I>
	Recently enacted and future legislation in the United
	States may increase the difficulty and cost for the Company to obtain marketing approval of, and commercialize, its potential future
	products and affect the prices the Company may obtain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the United States, there have been a number of legislative and
	regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for ESSA&rsquo;s
	potential future products, restrict or regulate post-approval activities and affect the Company&rsquo;s ability to profitably sell
	potential future products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict
	sales and promotional activities for pharmaceutical products. The Company does not know whether additional legislative changes
	will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes
	on the marketing approvals of ESSA&rsquo;s potential future products, if any, may be. In addition, increased scrutiny by the U.S.
	Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject the Company
	to more stringent product labeling and post-marketing testing and other requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the United States, the Medicare Prescription Drug, Improvement
	and Modernization Act of 2003, also called the Medicare Modernization Act or the MMA, changed the way Medicare covers and pays
	for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
	reimbursement methodology based on average sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription
	drug plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. As a result
	of this legislation and the expansion of federal coverage of drug products, the Company expects that there will be additional pressure
	to contain and reduce costs. These cost reduction initiatives and other provisions of this legislation could decrease the coverage
	and price that the Company receives for ESSA&rsquo;s potential products and could seriously harm its business. While the MMA applies
	only to drug benefits for Medicare beneficiaries, private health insurance companies often follow Medicare coverage policy and
	payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may
	result in a similar reduction in payments from private health insurance companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In March 2010, President Obama signed into law the
<I>
	Patient Protection
	and Affordable Care Act
</I>
	, as amended by the
<I>
	Health Care and Education Affordability Reconciliation Act
</I>
	of 2010 (collectively,
	the &ldquo;
<B>
	Health Care Reform Law
</B>
	&rdquo;), a sweeping law intended to broaden access to health insurance, reduce or constrain
	the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and
	health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The
	Health Care Reform Law, among other things, increased the amount of Medicaid drug rebates to states. Further, the new law imposed
	a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions
	affecting compliance have also been enacted, which may possibly require the Company to modify its business practices with healthcare
	practitioners. Some of the provisions of the Health Care Reform Law have yet to be fully implemented, while certain provisions
	have been subject to judicial and Congressional challenges, which ESSA expects to continue in light of the pending change in administrations
	following the presidential election
<B>
	.
</B>
	Thus, the full impact of the Health Care Reform Law on ESSA&rsquo;s business remains
	unclear.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s business may be materially adversely affected
	by new legislation, new regulatory requirements and the continuing efforts of governmental and third-party payors to contain or
	reduce the costs of healthcare through various means.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Governments and regulatory authorities in Europe and other markets
	in which ESSA intends to sell its products may propose and adopt new legislation and regulatory requirements relating to pharmaceutical
	approval criteria and manufacturing requirements. Such legislation or regulatory requirements, or the failure to comply with such,
	could adversely impact ESSA&rsquo;s operations and could have a material adverse effect on ESSA&rsquo;s business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In recent years, national, federal, provincial, state, and local
	officials and legislators have proposed, or are reportedly considering proposing, a variety of price based reforms to the healthcare
	systems in the European Union, the United States and other countries. Some proposals include measures that would limit or eliminate
	payments for certain medical procedures and treatments or subject the pricing of pharmaceuticals to government control. Furthermore,
	in certain foreign markets, the pricing or profitability of healthcare products is subject to government controls and other measures
	that have been prepared by legislators and government officials. While ESSA cannot predict whether any such legislative or regulatory
	proposals or reforms will be adopted, the adoption of any such proposals or reforms could adversely affect the commercial viability
	of the Company&rsquo;s existing and potential products. Significant changes in the healthcare system in the European Union and
	other countries may have a substantial impact on the manner in which ESSA conducts its business. Such changes could also have a
	material adverse effect on ESSA&rsquo;s business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA relies on third parties to conduct its preclinical studies
	and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines,
	this could substantially harm ESSA&rsquo;s business because it may not be able to obtain regulatory approval for or commercialize
	EPI-506 or its future product candidates in a timely manner or at all.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has extensively relied upon and plans to continue to extensively
	rely upon third-party CROs to monitor and manage data for its ongoing preclinical and clinical programs. ESSA relies on these parties
	for execution of its preclinical studies and clinical trials, and it controls only some aspects of their activities. Nevertheless,
	ESSA is responsible for ensuring that each of its studies and clinical trials is conducted in accordance with the applicable protocol
	and legal, regulatory and scientific standards, and ESSA&rsquo;s reliance on the CROs does not relieve it of these responsibilities.
	ESSA also relies on third parties to assist in conducting its preclinical studies in accordance with GLP and the Animal Welfare
	Act requirements. ESSA and its CROs are required to comply with federal regulations and current GCP, which are international standards
	meant to protect the rights and health of patients that are enforced by the FDA and comparable foreign regulatory authorities for
	all of ESSA&rsquo;s products in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial
	sponsors, principal investigators and trial sites. If ESSA or any of its CROs fail to comply with applicable GCP, the clinical
	data generated in ESSA&rsquo;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
	may require it to perform additional clinical trials before approving ESSA&rsquo;s marketing applications. ESSA cannot assure you
	that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials
	comply with GCP requirements. In addition, ESSA&rsquo;s clinical trials must be conducted with product produced under cGMP requirements.
	Failure to comply with these regulations may require ESSA to repeat preclinical studies and clinical trials, which would delay
	the regulatory approval process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s CROs are not its employees, and except for remedies
	available to it under ESSA&rsquo;s agreements with such CROs, it cannot control whether or not they devote sufficient time and
	resources to our ongoing clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual
	duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised
	due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, ESSA&rsquo;s clinical trials
	may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize EPI-506
	or future product candidates. As a result, ESSA&rsquo;s results of operations and the commercial prospects for EPI-506 and its
	future product candidates would be harmed, its costs could increase and its ability to generate revenues could be delayed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Because ESSA has relied on third parties, its internal capacity
	to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to ESSA&rsquo;s
	standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service
	providers requires ESSA to disclose our proprietary information to these parties, which could increase the risk that this information
	will be misappropriated. ESSA currently has a small number of employees, which limits the internal resources we have available
	to identify and monitor third-party providers. To the extent ESSA is unable to identify and successfully manage the performance
	of third-party service providers in the future, its business may be adversely affected. Though ESSA carefully manages its relationships
	with its CROs, there can be no assurance that it will not encounter challenges or delays in the future or that these delays or
	challenges will not have a material adverse impact on ESSA&rsquo;s business, results of operations, financial condition and cash
	flows and future prospects.
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If ESSA&rsquo;s relationships with CROs terminate, its drug
	development efforts could be delayed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA relies on third-party vendors and CROs for preclinical studies
	and clinical trials related to its drug development efforts. Switching or adding additional CROs would involve additional cost
	and requires management time and focus. ESSA&rsquo;s CROs have the right to terminate their agreements with it in the event of
	an uncured material breach. If any of ESSA&rsquo;s relationships with its third-party CROs terminate, it could experience a significant
	delay in identifying, qualifying and managing performance of a comparable third-party service provider, which could adversely affect
	its development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not
	provide the same type or level of services as the original provider. ESSA may not be able to enter into arrangements with alternative
	CROs or to do so on commercially reasonable terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA has no experience manufacturing its product candidate
	on a large clinical or commercial scale and has no manufacturing facility. As a result, ESSA may in the future be dependent on
	third party manufacturers for the manufacture of EPI 506 or any other future product candidate as well as on third parties for
	ESSA&rsquo;s supply chain, and if ESSA experiences problems with any future third parties, the manufacturing of ESSA&rsquo;s potential
	product candidates or products could be delayed.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA does not own or operate facilities for the manufacture of future
	potential product candidates. ESSA currently has no plans to build internal clinical or commercial scale manufacturing capabilities.
	As a result, ESSA potentially may rely on third-party CMOs, in the future, for the chemical manufacture of active pharmaceutical
	ingredients for ESSA&rsquo;s potential products. Also, ESSA may potentially rely on another CMO for the production of the final
	product formulation. To meet ESSA&rsquo;s projected potential needs for clinical supplies to support its activities through regulatory
	approval and commercial manufacturing, the CMOs with whom ESSA may potentially work will need to increase the scale of production.
	ESSA may need to identify additional CMOs for continued production of supply for product candidates in the event the current potential
	CMOs ESSA chooses to utilize are unable to scale production, or if ESSA otherwise experiences any problems with them. Although
	alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive
	and take a significant amount of time to arrange for alternative suppliers. ESSA may encounter technical difficulties or delays
	in the transfer of any future potential product manufacturing on a commercial scale to additional third-party manufacturers. ESSA
	may be unable to enter into agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable
	terms. If ESSA is unable to arrange for alternative third-party manufacturing sources or to do so on commercially reasonable terms
	or in a timely manner, ESSA may not be able to complete development of its potential product candidates, market or distribute them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Reliance on third-party manufacturers entails risks to which ESSA
	would not be subject if ESSA manufactured product candidates or products ourselves, including reliance on the third party for regulatory
	compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors
	beyond ESSA&rsquo;s control, including a failure to synthesize and manufacture product candidates or any products ESSA may eventually
	commercialize in accordance with ESSA&rsquo;s specifications and the possibility of termination or nonrenewal of the agreement
	by the third party, based on its own business priorities, at a time that is costly or damaging to ESSA. In addition, the FDA and
	other regulatory authorities require that ESSA&rsquo;s product candidates and any products that ESSA may eventually commercialize
	be manufactured according to GMP and similar foreign standards. Any failure by ESSA&rsquo;s third-party manufacturers to comply
	with GMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates
	in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of ESSA&rsquo;s potential product
	candidates and could cause ESSA to incur higher costs and prevent ESSA from commercializing product candidates successfully. In
	addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously
	granted to ESSA, or take other regulatory or legal action, including recall or seizure of outside supplies of the product candidate,
	total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental
	applications, detention or product, refusal to permit the import or export of products, injunction, or imposing civil and criminal
	penalties.
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Any significant disruption in ESSA&rsquo;s supplier relationships
	could harm the Company&rsquo;s business. Any significant delay in the supply of a product candidate or its key materials for a
	potential ongoing clinical study could considerably delay completion of ESSA&rsquo;s potential clinical trials, product testing
	and regulatory approval of ESSA&rsquo;s potential product candidates. If ESSA&rsquo;s manufacturers or ESSA is unable to purchase
	these key materials after regulatory approval has been obtained for ESSA&rsquo;s product candidates, the commercial launch of ESSA&rsquo;s
	product candidates would be delayed or there would be a shortage in supply, which would impair ESSA&rsquo;s ability to generate
	revenues from the sale of its product candidates. It may take several years to establish an alternative source of supply for ESSA&rsquo;s
	product candidates and to have any such new source approved by the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to ESSA&rsquo;s Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA relies on proprietary technology, the protection of which
	can be unpredictable and costly.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s activities depend, in part, on its ability to
	(i)&nbsp;obtain and maintain patents, trade secret protection and operate without infringing the intellectual proprietary rights
	of third parties, (ii)&nbsp;successfully defend these patents (including patents owned by or licensed to the Company) against third-party
	challenges and (iii)&nbsp;successfully enforce these patents against third-party competitors. There is no assurance that the Company
	will be granted such patents or proprietary technology or that such granted patents or proprietary technology will not be circumvented
	through the adoption of a competitive, though non-infringing, process or product. The patent positions of pharmaceutical companies
	can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain
	unresolved. Changes in either the patent laws or in interpretations of patent laws may diminish the value of the Company&rsquo;s
	intellectual property. Accordingly, the Company cannot predict the breadth of claims that may be allowable or enforceable in its
	patents (including patents owned by or licensed to the Company). Failure to protect the Company&rsquo;s existing and future intellectual
	property rights could seriously harm its business and prospects and may result in the loss of its ability to exclude others from
	using the Company&rsquo;s technology or its own right to use the technologies. If the Company does not adequately ensure the right
	to use certain technologies, it may have to pay others for the right to use their intellectual property, pay damages for infringement
	or misappropriation or be enjoined from using such intellectual property. The Company&rsquo;s patents do not guarantee the right
	to use the technologies if other parties own intellectual property rights that are necessary in order to use such technologies.
	The Company&rsquo;s patent position is subject to complex factual and legal issues that may give rise to uncertainty as to the
	validity, scope and enforceability of a particular patent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, there is a risk that improved versions of ESSA&rsquo;s
	own product developed by third parties will be granted patent protection and compete with ESSA&rsquo;s products. For example, any
	patents ESSA obtains may not be sufficiently broad to prevent others from utilizing its technologies or from developing competing
	products and technologies. Third parties may attempt to circumvent ESSA&rsquo;s patents by means of alternative designs and processes
	or may independently develop similar products, duplicate any of ESSA&rsquo;s products not under patent protection, or design around
	the inventions ESSA claims in any of its existing patents, existing patent applications or future patents or patent applications.
	The actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many
	factors, including the type of patent, the scope of ESSA&rsquo;s coverage, the availability of regulatory related extensions, the
	availability of legal remedies in a particular country and the validity and enforceability of the patents. It is impossible to
	anticipate the breadth or degree of protection that patents will afford products developed by ESSA or their underlying technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In any case, there can be no assurance that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any rights under Canadian, U.S. or foreign patents owned by the Company or other patents that third parties license to the Company will not be curtailed;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company was the first inventor of inventions covered by its issued patents or pending applications or that the Company was the first to file patent applications for such inventions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s pending or future patent applications will be issued with the breadth of claim coverage sought by the Company, or be issued at all;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Company&rsquo;s competitors will not independently develop or patent technologies that are substantially equivalent or superior to the Company&rsquo;s technologies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	third parties will not attempt to circumvent ESSA&rsquo;s patents by means of alternative designs and processes or that third parties will not also independently develop similar products, duplicate any of ESSA&rsquo;s products not under patent protection, or design around the inventions ESSA claims in any of the Company&rsquo;s existing patents, existing patent applications or future patents or patent applications;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	any of the Company&rsquo;s trade secrets will not be learned independently by its competitors; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the steps the Company takes to protect its intellectual property will be adequate.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, effective patent, trademark, copyright and trade secret
	protection may be unavailable, limited or not sought in certain foreign countries. Further, countries ESSA may sell to may not
	protect its intellectual property to the same extent as the laws of the United States, Canada or Europe, and may lack rules and
	procedures required for defending ESSA&rsquo;s patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There is a risk that any patents issued relating to ESSA&rsquo;s
	products or any patents licensed to ESSA may be successfully challenged or that the practice of its products might infringe the
	patents of third parties. If the practice of ESSA&rsquo;s products infringes the patents of third parties, the Company may be required
	to design around such patents, potentially causing increased costs and delays in product development and introduction or precluding
	ESSA from developing, manufacturing or selling its planned products. In addition, disputes may arise as to the rights to know-how
	and inventions among ESSA&rsquo;s employees and consultants who use intellectual property owned by others for the work performed
	for the Company. The scope and validity of patents which may be obtained by third parties, the extent to which ESSA may wish or
	need to obtain patent licenses and the cost and availability of such licenses are currently unknown. If such licenses are obtained,
	it is likely they would be royalty bearing, which could reduce ESSA&rsquo;s income. If licenses cannot be obtained on an economical
	basis, delays in market introduction of its planned products could occur or introduction could be prevented, in some cases causing
	the expenditure of substantial funds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In certain instances, ESSA may elect not to seek patent protection
	but instead rely on the protection of the Company&rsquo;s technology through confidentiality agreements or trade secrets. There
	can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach or
	that such persons or institutions will not assert rights to intellectual property arising out of these relationships. The value
	of ESSA&rsquo;s assets could also be reduced to the extent that third parties are able to obtain patent protection with respect
	to aspects of ESSA&rsquo;s technology or products or that confidential measures ESSA has in place to protect the Company&rsquo;s
	proprietary technology are breached or become unenforceable. However, third parties may independently develop or obtain similar
	technology and such third parties may be able to market competing products and obtain regulatory approval through a showing of
	equivalency to one of ESSA&rsquo;s products which has obtained regulatory approval, without being required to undertake the same
	lengthy and expensive clinical studies that ESSA would have already completed. The cost of enforcing the Company&rsquo;s patent
	rights or defending rights against infringement charges by other patent holders may be significant and could limit operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Litigation may also be necessary to enforce patents issued or licensed
	to ESSA or to determine the scope and validity of a third party&rsquo;s proprietary rights. ESSA could incur substantial costs
	if the Company is required to defend itself in patent suits brought by third parties, if ESSA participates in patent suits brought
	against or initiated by ESSA&rsquo;s corporate collaborators or if ESSA initiates such suits. The Company may not have the necessary
	resources to participate in or defend any such activities or litigation. Even if ESSA did have the resources to vigorously pursue
	its interests in litigation, because of the complexity of the subject matter, it is impossible to predict whether ESSA would prevail
	in any such action. Any claims of patent infringement asserted by third parties may:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	divert the time and attention of the Company&rsquo;s technical personnel and management;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	cause product development or commercialization delays;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	require the Company to cease or modify its use of the technology and/or develop non-infringing technology; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	require the Company to enter into royalty or licensing agreements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	An adverse outcome in litigation or an interference to determine
	priority or other proceeding in a court or patent or selling office could subject ESSA to significant liabilities, require disputed
	rights to be licensed from third parties or require ESSA to cease using certain technology or products, any of which may have a
	material adverse effect on the Company&rsquo;s business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA may not be able to protect its intellectual property
	rights throughout the world.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 0">
	Filing, prosecuting and defending patents on EPI-506 and ESSA&rsquo;s
	future product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries
	do not protect intellectual property rights to the same extent as federal and state laws in the United States or federal and provincial
	laws in Canada. Consequently, ESSA may not be able to prevent third-parties from practicing its inventions in all countries outside
	the United States or Canada, or from selling or importing products made using its inventions in and into the United States, Canada
	or other jurisdictions. Competitors may use ESSA&rsquo;s technologies in jurisdictions where it has not obtained patent protection
	to develop their own products, and may export otherwise infringing products to territories where ESSA has patent protection, but
	where enforcement is not as strong as that in the United States or Canada. These products may compete with ESSA&rsquo;s products
	in jurisdictions where it does not have any issued patents and its patent claims or other intellectual property rights may not
	be effective or sufficient to prevent them from so competing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 12PT 0 0">
	Many companies have encountered significant problems in protecting
	and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain
	developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating
	to biopharmaceuticals, which could make it difficult for ESSA to stop the infringement of its patents or marketing of competing
	products in violation of its proprietary rights generally. Proceedings to enforce ESSA&rsquo;s patent rights in foreign jurisdictions
	could result in substantial cost and divert its efforts and attention from other aspects of its business. ESSA may not prevail
	in any lawsuits that it initiates and the damages or other remedies awarded, if any, may not be commercially meaningful.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The requirements for patentability may differ in certain countries,
	particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and
	specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no
	link between regulatory approval of a drug and its patent status. Furthermore, generic or biosimilar drug manufacturers or other
	competitors may challenge the scope, validity or enforceability of ESSA&rsquo;s patents, requiring it to engage in complex, lengthy
	and costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch
	biosimilar versions of ESSA&rsquo;s products. In addition to India, certain countries in Europe and developing countries, including
	China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those
	countries, ESSA may have limited remedies if patents are infringed or if it is compelled to grant a license to a third-party, which
	could materially diminish the value of those patents. This could limit ESSA&rsquo;s potential revenue opportunities. Accordingly,
	ESSA&rsquo;s efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial
	advantage from the intellectual property that it owns or licenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA may be subject to claims by third-parties asserting that
	ESSA, or ESSA&rsquo;s employees have misappropriated their intellectual property, or claiming ownership of what ESSA regards as
	its own intellectual property.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Certain of ESSA&rsquo;s employees, including senior management,
	were previously employed, or continue to be employed, at universities or other public institutions, or at other biotechnology or
	pharmaceutical companies, including ESSA&rsquo;s competitors or potential competitors. Some of these employees, executed proprietary
	rights, nondisclosure and noncompetition agreements, in connection with such previous employment. ESSA may be subject to claims
	that ESSA, or these employees, have used or disclosed confidential information or intellectual property, including trade secrets
	or other proprietary information, of any such employee&rsquo;s former employer. If ESSA fails in prosecuting or defending any such
	claims, in addition to paying monetary damages, ESSA may lose valuable intellectual property rights or personnel or sustain damages.
	Such intellectual property rights could be awarded to a third-party, and ESSA could be required to obtain a license from such third-party
	to commercialize ESSA&rsquo;s technology or products. Such a license may not be available on commercially reasonable terms or at
	all. Even if ESSA is successful in defending against such claims, litigation could result in substantial costs and be a distraction
	to management.
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Obtaining and maintaining ESSA&rsquo;s patent protection depends
	on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent
	agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Periodic maintenance and annuity fees on any issued patent are due
	to be paid to the United States Patent and Trademark Office (&ldquo;
<B>
	USPTO
</B>
	&rdquo;), the Canadian Intellectual Property Office
	(&ldquo;
<B>
	CIPO
</B>
	&rdquo;) and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO, CIPO
	and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
	similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a
	late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
	or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
	Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited
	to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize
	and submit formal documents. If ESSA or its future potential licensors fail to maintain the patents and patent applications covering
	EPI-506 or future product candidates, ESSA&rsquo;s competitive position would be adversely affected.
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Other Risks Related to ESSA&rsquo;s Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	In order to establish the Company&rsquo;s sales and marketing
	infrastructure, the Company will need to expand the size of its organization and the Company may experience difficulties in managing
	this growth.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As the Company&rsquo;s development and commercialization plans and
	strategies develop, the Company expects that it will need to expand the size of its employee base for managerial, operational,
	sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management,
	including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, the Company&rsquo;s
	management may have to divert a disproportionate amount of its attention away from the Company&rsquo;s day-to-day activities and
	devote a substantial amount of time to managing these growth activities. The Company&rsquo;s future financial performance and its
	ability to commercialize its potential products and any other future product candidates and its ability to compete effectively
	will depend, in part, on the Company&rsquo;s ability to effectively manage any future growth.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If the Company is not successful in attracting and retaining
	highly qualified personnel, the Company may not be able to successfully implement its business strategy.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s ability to compete in the highly competitive
	pharmaceuticals industry depends in large part upon its ability to attract and retain highly qualified managerial, scientific and
	medical personnel. Competition affects the Company&rsquo;s ability to hire and retain highly qualified personnel on acceptable
	terms. The Company is highly dependent on its management, scientific and medical personnel. The Company&rsquo;s management team
	has substantial knowledge in many different aspects of drug development and commercialization. Despite the Company&rsquo;s efforts
	to retain valuable employees, members of its management, scientific and medical teams may terminate their employment with the Company
	on short notice or, potentially, without any notice at all. The loss of the services of any of the Company&rsquo;s executive officers
	or other key employees could potentially harm its business, operating results or financial condition. The Company&rsquo;s success
	may also depend on its ability to attract, retain and motivate highly skilled junior, mid-level, and senior managers and scientific
	personnel. Other pharmaceutical companies with which the Company competes for qualified personnel have greater financial and other
	resources, different risk profiles, and a longer history in the industry than the Company does. They also may provide more diverse
	opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates
	than what the Company has to offer. If the Company is unable to continue to attract and retain high-quality personnel, the rate
	and success at which the Company can develop and commercialize product candidates would be limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The directors and officers of ESSA may be subject to conflicts
	of interest.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Some of the directors and officers are engaged and will continue
	to be engaged in the search for additional business opportunities on behalf of other corporations and situations may arise where
	these directors and officers will be in direct competition with the Company. Not all of the Company&rsquo;s directors or officers
	are subject to non-competition agreements. Some of the directors and officers of the Company are or may become directors or officers
	of the other companies engaged in other business ventures whose operations may, from time to time, be in direct competition with
	ESSA&rsquo;s operations. Conflicts, if any, will be dealt with in accordance with the relevant provisions of the
<I>
	Business Corporations
	Act
</I>
	(British Columbia) and under the Company&rsquo;s articles of incorporation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company faces intense competition from other biotechnology
	and pharmaceutical companies and its operating results will suffer if the Company fails to compete effectively.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The biotechnology and pharmaceutical industries are intensely competitive
	and subject to rapid and significant technological change. The Company&rsquo;s potential competitors in the United States, Canada,
	and globally include large, well-established pharmaceutical companies, specialty pharmaceutical sales and marketing companies and
	specialized cancer treatment companies. Many companies, as well as research organizations, currently engage in, or have in the
	past engaged in, efforts related to the development of products in the same therapeutic areas as ESSA does. Due to the size of
	the prostate cancer treatment market and the large unmet medical need for products that treat CRPC, a number of the world&rsquo;s
	largest pharmaceutical companies are developing, or could potentially develop, products that could compete with EPI-506 or the
	Company&rsquo;s future product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Many of the companies developing competing technologies and products
	in ESSA&rsquo;s field have significantly greater financial resources and expertise in discovery, R&amp;D, manufacturing, pre-clinical
	studies and clinical testing, obtaining regulatory approvals and marketing than ESSA does. Other smaller companies may also prove
	to be significant competitors, particularly through collaborative arrangements with large and established companies. Academic institutions,
	government agencies and other public and private research organizations may also conduct research, seek patent protection and establish
	collaborative arrangements for discovery, research, clinical development and marketing of products similar to ESSA&rsquo;s. There
	is a risk that one or more of ESSA&rsquo;s competitors may develop more effective or more affordable products and that such competitors
	will commercialize products that will render its product candidates obsolete. ESSA faces competition with respect to product efficacy
	and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of
	regulatory approvals, availability of resources, reimbursement coverage, price and patent positions of others. In addition, these
	companies and institutions also compete with ESSA in recruiting and retaining qualified personnel. If the Company is not able to
	compete effectively against its current and future competitors, its business will not grow and its financial condition and operations
	will suffer materially adverse effects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company may face exposure to adverse movements in foreign
	currency exchange rates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s business may expand internationally and as a result,
	a significant portion of its revenues, expenses, current assets and current liabilities may be preliminary denominated in foreign
	currencies, while its financial statements are expressed in U.S. dollars. A decrease in the value of such foreign currencies relative
	to the U.S. dollar could result in losses in revenues from currency exchange rate fluctuations. To date, ESSA has not hedged against
	risks associated with foreign exchange rate exposure. ESSA cannot be sure that any hedging techniques it may implement in the future
	will be successful or that its business, financial condition, and results of operations will not be materially adversely affected
	by exchange rate fluctuations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Third-party coverage and reimbursement and health care cost
	containment initiatives and treatment guidelines may constrain the Company&rsquo;s future revenues.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In many of the markets ESSA hopes to sell future products in, successful
	commercialization of any product candidate will depend, in part, on the extent to which coverage and reimbursement for these product
	candidates and related treatments will be available from government healthcare programs, private health insurers, managed care
	plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance
	organizations, decide which medications they will pay for and establish reimbursement levels. Third-party payors often rely upon
	Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy for coverage
	and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for
	products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming
	and costly process that will require ESSA to provide scientific and clinical support for the use of ESSA&rsquo;s products to each
	payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first
	instance.
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 12PT 0">
	A primary trend in the U.S. healthcare industry is cost containment.
	Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement
	for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined
	discounts from list prices and are challenging the prices charged for medical products. ESSA cannot be sure that coverage and reimbursement
	will be available for any product candidates that it or any future collaborator commercialize and, if reimbursement is available,
	the level of reimbursement. In addition, coverage and reimbursement may impact the demand for, or the price of, any product candidate
	for which ESSA or a collaborator obtains marketing approval. If coverage and reimbursement are not available or reimbursement is
	available only to limited levels, ESSA or its collaborators may not be able to successfully commercialize any product candidate
	for which marketing approval is obtained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There may be significant delays in obtaining coverage and reimbursement
	for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the TPD, FDA or
	other regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for
	in all cases or at a rate that covers ESSA&rsquo;s costs, including research, development, manufacture, sale and distribution expenses.
	Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover ESSA&rsquo;s and any collaborator&rsquo;s
	costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in
	which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments
	for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs
	or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be
	sold at lower prices than in the United States. ESSA&rsquo;s or any collaborator&rsquo;s inability to promptly obtain coverage
	and profitable payment rates from both government-funded and private payers for any approved products that ESSA or its collaborators
	develop could have a material adverse effect on ESSA&rsquo;s operating results, ability to raise capital needed to commercialize
	product candidates and overall financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If ESSA is not able to convince public payors and hospitals
	to include ESSA&rsquo;s potential future products on their approved formulary lists, revenues may not meet expectations and ESSA&rsquo;s
	business, results of operations and financial condition may be adversely affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Hospitals establish formularies, which are lists of drugs approved
	for use in the hospital. If a drug is not included on the hospital&rsquo;s formulary, the ability to promote and sell ESSA&rsquo;s
	potential future products may be limited or denied. If ESSA fails to secure and maintain formulary inclusion for potential future
	products on favorable terms or are significantly delayed in doing so, ESSA may have difficulty achieving market acceptance of potential
	future products and ESSA&rsquo;s business, results of operations and financial condition could be materially adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company has never marketed a drug before, and if the Company
	is unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing
	or licensing arrangements, the Company may be unable to generate any revenue.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA does not currently have an infrastructure for the sales, marketing
	and distribution of pharmaceutical drug products and the cost of establishing and maintaining such an infrastructure may exceed
	the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory
	authorities, ESSA must build its sales, marketing, managerial and other nontechnical capabilities or make arrangements with third
	parties to perform these services. If ESSA is unable to establish adequate sales, marketing and distribution capabilities, whether
	independently or with third parties, ESSA may not be able to generate product revenue and may not become profitable. ESSA will
	be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal
	commercial organization or the support of a third party to perform sales and marketing functions, ESSA may be unable to compete
	successfully against these more established companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s products may, if approved for sale, not achieve
	or maintain expected levels of market acceptance, which could have a material adverse effect on its business, financial condition
	and results of operations and could cause the market value of its securities to decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Even if ESSA is able to obtain regulatory approvals for its product
	candidates, the success of those products is dependent upon achieving and maintaining market acceptance. New product candidates
	that appear promising in development may fail to reach the market or may have only limited or no commercial success. Levels of
	market acceptance for ESSA&rsquo;s products could be impacted by several factors, many of which are not within ESSA&rsquo;s control,
	including but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	demonstration of clinical safety and efficacy of ESSA&rsquo;s potential products and other possible AR NTD inhibitors generally;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	safety, efficacy, convenience and cost-effectiveness of ESSA&rsquo;s products compared to products of its competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the prevalence and severity of any adverse side effects;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	scope of approved uses and marketing approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	limitations or warnings contained in FDA-approved labeling;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	timing of market approvals and market entry;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the willingness of physicians to prescribe ESSA&rsquo;s potential products and of the target patient population to try new therapies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the inclusion of AR NTD inhibitor products in applicable treatment guidelines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	new procedures or methods of treatment that may reduce the incidences of any of the indications for which ESSA&rsquo;s potential products shows utility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	difficulty in, or excessive costs to, manufacture;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	infringement or alleged infringement of the patents or intellectual property rights of others;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the introduction of any new products, including generic AR NTD inhibitor products, that may in the future become available to treat indications for which ESSA&rsquo;s potential product may be approved;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	availability of alternative products from ESSA&rsquo;s competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	acceptance of the price of ESSA&rsquo;s products; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ability to market ESSA&rsquo;s products effectively at the retail level.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, the success of any new product will depend on ESSA&rsquo;s
	ability to either successfully build its in-house sales capabilities or to secure new, or to realize the benefits of existing arrangements
	with third-party marketing or distribution partners. Seeking out, evaluating and negotiating marketing or distribution agreements
	may involve the commitment of substantial time and effort and may not ultimately result in an agreement. In addition, the third-party
	marketing or distribution partners may not be as successful in promoting ESSA&rsquo;s products as it had anticipated. If ESSA is
	unable to commercialize new products successfully, whether through a failure to achieve market acceptance, a failure to build its
	own in-house sales capabilities, a failure to secure new marketing partners or to realize the benefits of ESSA&rsquo;s arrangements
	with existing marketing partners, there may be a material adverse effect on ESSA&rsquo;s business, financial condition and results
	of operations and it could cause the market value of ESSA&rsquo;s securities to decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, by the time any products are ready to be commercialized,
	what ESSA believes to be the market for these products may have changed. The Company&rsquo;s estimates of the number of patients
	who have received or might have been candidates to use a specific product may not accurately reflect the true market or market
	prices for such products or the extent to which such products, if successfully developed, will actually be used by patients. ESSA&rsquo;s
	failure to successfully introduce and market its products that are under development would have a material adverse effect on its
	business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company may acquire businesses or products or form strategic
	alliances in the future and the Company may not realize the benefits of such acquisitions.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company may acquire additional businesses or products, form
	strategic alliances or create joint ventures with third parties that the Company believes will complement or augment its existing
	business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the Company acquires businesses in the future, it may not be
	able to realize the benefit of acquiring such businesses if the Company is unable to successfully integrate them with its existing
	operations and company culture. The Company may encounter numerous difficulties in developing, manufacturing and marketing any
	new products resulting from a strategic alliance or acquisition that delay or prevent the Company from realizing their expected
	benefits. The potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings
	or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, taxes,
	corporate governance and internal controls, regulatory compliance, employee, customer or partner disputes or issues and other legal
	and financial contingencies could decrease or eliminate the anticipated benefits and synergies of any acquisition and could negatively
	affect ESSA&rsquo;s future business and financial results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As part of ESSA&rsquo;s business strategy, it may also continue
	to acquire additional companies, products or technologies principally related to, or complementary to, ESSA&rsquo;s current operations.
	Any such acquisitions will be accompanied by certain risks including but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	exposure to unknown liabilities of acquired companies and the unknown issues with any associated technologies or research;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	higher than anticipated acquisition costs and expenses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the difficulty and expense of integrating operations, systems and personnel of acquired companies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	disruption of ESSA&rsquo;s ongoing business;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	inability to retain key customers, distributors, vendors and other business partners of the acquired company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	diversion of management&rsquo;s time and attention; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	possible dilution to shareholders.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Also, the anticipated benefit of any joint venture or acquisition
	may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In November 2016, ESSA entered
	into a loan and security agreement with Silicon Valley Bank (the &ldquo;
<B>
	2016 Loan and Security Agreement
</B>
	&rdquo;). The 2016
	Loan and Security Agreement restricts ESSA&rsquo;s ability to pursue certain mergers, acquisitions, amalgamations or consolidations
	that it may believe to be in its best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive
	issuances of ESSA&rsquo;s equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs
	of goodwill, any of which could harm ESSA&rsquo;s financial condition. ESSA cannot predict the number, timing or size of future
	joint ventures or acquisitions, or the effect that any such transactions might have on its operating results.
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA may not be able to successfully overcome these risks and other
	problems associated with acquisitions and this may adversely affect ESSA&rsquo;s business, financial condition or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA may seek to enter into collaborations with third parties
	for the development and commercialization of its product candidates. If ESSA fails to enter into such collaborations, or such collaborations
	are not successful, it may not be able to capitalize on the market potential of its product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company may seek third-party collaborators for development and
	commercialization of its product candidates. ESSA is not currently party to any such arrangement. However, if ESSA does enter into
	any such arrangements with any third parties in the future, it will likely have limited control over the amount and timing of resources
	that its collaborators dedicate to the development or commercialization of ESSA&rsquo;s product candidates. The Company&rsquo;s
	ability to generate revenues from these arrangements will depend on its collaborators&rsquo; abilities to successfully perform
	the functions assigned to them in these arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Collaborations involving ESSA&rsquo;s product candidates would pose
	the following risks:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators may not pursue development and commercialization of ESSA&rsquo;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&rsquo; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ESSA&rsquo;s products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ESSA&rsquo;s;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators with marketing and distribution rights to one or more of ESSA&rsquo;s products may not commit sufficient resources to the marketing and distribution of such product or products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators may not properly maintain or defend ESSA&rsquo;s intellectual property rights or may use ESSA&rsquo;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate ESSA&rsquo;s intellectual property or proprietary information or expose ESSA to potential litigation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborators may infringe the intellectual property rights of third parties, which may expose ESSA to litigation and potential liability;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	disputes may arise between the collaborators and ESSA that result in the delay or termination of the research, development or commercialization of ESSA&rsquo;s products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Collaboration agreements may not lead to development or commercialization
	of product candidates in the most efficient manner or at all. If a collaborator of ESSA&rsquo;s were to be involved in a business
	combination, the continued pursuit and emphasis on ESSA&rsquo;s product development or commercialization program could be delayed,
	diminished or terminated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s employees may engage in misconduct or other improper
	activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for ESSA
	and harm ESSA&rsquo;s reputation.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is exposed to the risk of employee fraud or other misconduct,
	including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities,
	provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards ESSA
	has established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations
	established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose
	unauthorized activities to ESSA. Employee misconduct could also involve the improper use of information obtained in the course
	of clinical trials, which could result in regulatory sanctions and serious harm to ESSA&rsquo;s reputation. If any such actions
	are instituted against ESSA and ESSA is not successful in defending itself or asserting ESSA&rsquo;s rights, those actions could
	have a significant impact on ESSA&rsquo;s business, results of operations, financial condition and cash flows from future prospects,
	including the imposition of significant fines or other sanctions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If product liability lawsuits are brought against the Company,
	it may incur substantial liabilities and may be required to cease the sale, marketing and distribution of its products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company could face a potential risk of product liability as
	a result of its potential sales, marketing and distribution activities relating to any future commercialization of any future product.
	For example, the Company may be sued if any product it develops allegedly causes injury or is found to be otherwise unsuitable
	during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
	in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach
	of warranties. Claims could also be asserted under U.S. state or Canadian provincial or other foreign consumer protection legislation.
	If the Company cannot successfully defend itself against product liability claims, it may incur substantial liabilities or be required
	to cease the sale, marketing and distribution of its products. Even successful defense against product liability claims would require
	significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	decreased demand for any future products that the Company may develop;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	injury to the Company&rsquo;s reputation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	withdrawal of clinical trial participants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	costs to defend the related litigation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	a diversion of management&rsquo;s time and the Company&rsquo;s resources;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	substantial monetary awards to consumers, trial participants or patients;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	product recalls, withdrawals or labeling, marketing or promotional restrictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	loss of revenue;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the inability to commercialize;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the inability to continue the sale, marketing and distribution of ESSA&rsquo;s potential future products; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	a decline in the price of the Preferred Shares or Common Shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company currently maintains insurance that it believes has sufficient
	coverage to protect against the liability risks discussed above and the Company believes this coverage is consistent with industry
	norms for companies at a similar stage of development. However, if the Company is unable to obtain and retain sufficient product
	liability insurance in the future at an acceptable cost to protect against potential product liability claims, the commercialization
	of products it develops could be hindered or prevented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company&rsquo;s business and operations would suffer in
	the event of computer system failures.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Despite the implementation of security measures, ESSA&rsquo;s internal
	computer systems and those of other third parties on which it relies are vulnerable to damage from computer viruses, unauthorized
	access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and
	cause interruptions in ESSA&rsquo;s operations, it could result in a material disruption of ESSA&rsquo;s drug development programs.
	To the extent that any disruption or security breach results in a loss of or damage to ESSA&rsquo;s data or applications, or inappropriate
	disclosure of confidential or proprietary information, ESSA could incur liability and the further development of ESSA&rsquo;s future
	product candidates could be delayed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Business disruptions could seriously harm ESSA&rsquo;s future
	revenues and financial condition and increase costs and expenses.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s operations could be subject to earthquakes, power shortages,
	telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics
	and other natural or manmade disasters or business interruptions, for which ESSA is predominantly self-insured. ESSA does not carry
	insurance for all categories of risk that ESSA&rsquo;s business may encounter. The occurrence of any of these business disruptions
	could seriously harm ESSA&rsquo;s operations and financial condition and increase costs and expenses. Further, any significant
	uninsured liability may require ESSA to pay substantial amounts, which would adversely affect ESSA&rsquo;s business, results of
	operations, financial condition and cash flows from future prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Compulsory licensing or generic competition may affect the
	Company&rsquo;s business in certain countries.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In a number of countries, governmental authorities and other groups
	have suggested that companies which manufacture medical products (e.g., pharmaceuticals) should make products available at a low
	cost. In some cases, governmental authorities have held that where a pharmaceutical company does not do so, its patents might not
	be enforceable to prevent generic competition. Alternatively, some governmental authorities could require that ESSA grant compulsory
	licenses to allow competitors to manufacture and sell their own versions of ESSA&rsquo;s products, thereby reducing ESSA&rsquo;s
	sales or the sales of ESSA&rsquo;s licensee(s). In all of these situations, the results of future operations in these countries
	if any, could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA&rsquo;s business depends heavily on the use of information
	technologies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Several key areas of ESSA&rsquo;s business depend on the use of
	information technologies. Despite ESSA&rsquo;s best efforts to prevent such behavior, third-parties may nonetheless attempt to
	hack into ESSA&rsquo;s systems and obtain data relating to ESSA&rsquo;s pre-clinical studies or proprietary information on potential
	products. If ESSA fails to maintain or protect ESSA&rsquo;s information systems and data integrity effectively, ESSA could lose,
	have difficulty attracting customers, have difficulty preventing, detecting, and controlling fraud, have regulatory sanctions or
	penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach,
	or suffer other adverse consequences. While ESSA has invested in the protection of data and information technology, there can be
	no assurance that ESSA&rsquo;s efforts, or those of ESSA&rsquo;s third-party collaborators, if any, to implement adequate security
	and quality measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system
	malfunction, or to prevent data from being stolen or corrupted in the event of a security breach. Any such loss or breach could
	have a material adverse effect on ESSA&rsquo;s business, operating results and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA incurs significantly increased costs and devotes substantial
	management time as a result of operating as a public company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As a public company, ESSA incurs significant legal, accounting and
	other expenses that it did not incur as a private company or as a Canadian public company. For example, ESSA is subject to the
	reporting requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;
<B>
	Exchange Act
</B>
	&rdquo;), and is required
	to comply with the applicable requirements of Sarbanes-Oxley and the Dodd-Frank Wall Street Reform and Consumer Protection Act,
	as well as rules and regulations subsequently implemented by the SEC and including the establishment and maintenance of effective
	disclosure and financial controls and changes in corporate governance practices. ESSA&rsquo;s continued compliance with these requirements
	increase its legal and financial compliance costs and make some activities more time consuming and costly. In addition, ESSA&rsquo;s
	management and other personnel need to divert attention from operational and other business matters to devote substantial time
	to these public company requirements. In particular, ESSA may or in the future incur significant expenses and devote substantial
	management effort toward ensuring compliance with the requirements of Section&nbsp;404 of Sarbanes-Oxley, which involves annual
	assessments of a company&rsquo;s internal controls over financial reporting. ESSA may in the future need to hire additional accounting
	and financial staff with appropriate public company experience and technical accounting knowledge and may need to establish an
	internal audit function. ESSA cannot always predict or estimate the amount of additional costs incurred as a result of becoming
	a public company or the timing of such costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to Additional Legal Compliance and Regulatory Matters
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA is subject to risks inherent in foreign operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA intends to pursue international market growth opportunities,
	such that international sales may account for a significant portion of its revenue. ESSA is subject to a number of risks associated
	with its potential international business operations, sales and marketing activities that may increase liability, costs, lengthen
	sales cycles and require significant management attention. These risks include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	compliance with the laws of the United States, Canada, the European Union and other jurisdictions where ESSA may conduct business, including import and export legislation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	increased reliance on third parties to establish and maintain foreign operations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the complexities and expenses of administering a business abroad;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	complications in compliance with, and unexpected changes in, foreign regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	foreign currency fluctuations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	foreign exchange controls and cash repatriation restrictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	tariffs and other trade barriers;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	difficulties in collecting accounts receivable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	differing tax structures and related potential adverse tax consequences;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	uncertainties of laws and enforcement relating to the protection of intellectual property or secured technology;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	litigation in foreign court systems;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	unauthorized copying or use of ESSA&rsquo;s intellectual property;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	cultural and language differences;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	difficulty in managing a geographically dispersed workforce in compliance with local laws and customs that vary from country to country; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	other factors, depending upon the country involved.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There can be no assurance that the policies and procedures ESSA
	implements to address or mitigate these risks will be successful, that ESSA&rsquo;s personnel will comply with them or that ESSA
	will not experience these factors in the future or that they will not have a material adverse effect on ESSA&rsquo;s business,
	results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Laws and regulations governing international operations may
	preclude ESSA from developing, manufacturing and selling certain product candidates outside of the United States and Canada and
	require ESSA to develop and implement costly compliance programs.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA must comply with numerous laws and regulations in each jurisdiction
	in which ESSA plans to operate. ESSA must also comply with U.S. laws applicable to the foreign operations of U.S. individuals,
	such as the FCPA, and Canadian laws applicable to the foreign operations of Canadian businesses and individuals, such as the CFPOA.
	The creation and implementation of international business practices compliance programs is costly and such programs are difficult
	to enforce, particularly where reliance on third parties is required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The CFPOA prohibits Canadian businesses and individuals from giving
	or offering to give a benefit of any kind to a foreign public official, or any other person for the benefit of the foreign public
	official, where the ultimate purpose is to obtain or retain a business advantage. Furthermore, a company may be found liable for
	violations by not only its employees, but also by its third-party agents. Any failure to comply with the CFPOA, as well as applicable
	laws and regulations in foreign jurisdictions, could result in substantial penalties or restrictions on ESSA&rsquo;s ability to
	conduct business in certain foreign jurisdictions, which may have a material adverse impact on ESSA and its share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The FCPA prohibits any U.S. individual or business from paying,
	offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party
	or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business
	in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply
	with certain accounting provisions requiring ESSA to maintain books and records that accurately and fairly reflect all transactions
	of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting
	controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice.
	The SEC is involved with enforcement of the books and records provisions of the FCPA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Compliance with the FCPA is expensive and difficult, particularly
	in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical
	industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered
	foreign officials. Certain payments to hospitals in connection with clinical studies and other work have been deemed to be improper
	payments to government officials and have led to FCPA enforcement actions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Violation of the FCPA can result in significant civil and criminal
	penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the
	pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor.
	The termination of a government contract or relationship as a result of ESSA&rsquo;s failure to satisfy any of its obligations
	under laws governing international business practices would have a negative impact on its operations and harm its reputation and
	ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for
	violations of the FCPA&rsquo;s accounting provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s employees or other agents may, without the Company&rsquo;s
	knowledge and despite the Company&rsquo;s efforts, engage in prohibited conduct under its policies and procedures and the CFPOA,
	FCPA or other anti-bribery laws that ESSA may be subject to for which it may be held responsible. If ESSA&rsquo;s employees or
	other agents are found to have engaged in such practices, it could suffer severe penalties and other consequences that may have
	a material adverse effect on its business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Various laws, regulations and executive orders also restrict the
	use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for
	national security purposes, as well as certain products and technical data relating to those products. If ESSA expands its presence
	outside of the United States in the future, it will be required to dedicate additional resources to comply with these laws, and
	these laws may preclude ESSA from developing, manufacturing, or selling certain products and product candidates outside of the
	United States, which could limit ESSA&rsquo;s growth potential and increase development costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA is subject to U.S. laws relating to fraud and abuse and
	patients&rsquo; rights.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As a pharmaceutical company, even though ESSA does not and will
	not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state
	healthcare laws and regulations pertaining to fraud and abuse and patients&rsquo; rights are and will be applicable to ESSA&rsquo;s
	future arrangements with third-party payors and customers who are in a position to purchase, recommend and/or prescribe ESSA&rsquo;s
	product candidates for which the Company obtains marketing approval. These broadly applicable fraud and abuse and other healthcare
	laws and regulations may constrain ESSA&rsquo;s future business or financial arrangements and relationships with healthcare professionals,
	principal investigators, consultants, customers, and third-party payors and other entities, including ESSA&rsquo;s marketing practices,
	educational programs and pricing policies. Restrictions under applicable federal and state healthcare laws and regulations that
	may affect ESSA&rsquo;s ability to operate include, but are not limited to, the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the U.S. Anti-Kickback Statute, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, among other things, prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Efforts to ensure that ESSA&rsquo;s business arrangements with third
	parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental
	authorities will conclude that ESSA&rsquo;s business practices may not comply with current or future statutes, regulations, agency
	guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If ESSA&rsquo;s operations
	are found to be in violation of any of these laws or any other governmental regulations that may apply to ESSA, the Company may
	be subject to penalties, including without limitation, significant civil, criminal and administrative penalties, damages, fines,
	disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational
	harm, administrative burdens and diminished profits and future earnings, and the curtailment or restructuring of ESSA&rsquo;s operations.
	If any physicians or other healthcare providers or entities with whom ESSA expects to do business are found to not be in compliance
	with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government
	funded healthcare programs. Moreover, ESSA expects there will continue to be federal and state laws and regulations, proposed and
	implemented, that could impact ESSA&rsquo;s operations and business. The extent to which future legislation or regulations, if
	any, relating to healthcare fraud abuse laws or enforcement, may be enacted or what effect such legislation or regulation would
	have on ESSA&rsquo;s business remains uncertain.
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If ESSA fails to comply with environmental, health and safety
	laws and regulations, ESSA could become subject to fines or penalties or incur costs that could have a material adverse effect
	on the success of ESSA&rsquo;s business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is subject to numerous environmental, health and safety laws
	and regulations in the United States and in Canada, including those governing laboratory procedures and the handling, use, storage,
	treatment and disposal of hazardous materials and wastes. ESSA&rsquo;s operations involve the use of hazardous and flammable materials,
	including chemicals and biological materials. ESSA&rsquo;s operations also produce hazardous waste products. The Company generally
	contracts with third parties for the disposal of these materials and wastes. ESSA cannot eliminate the risk of contamination or
	injury from these materials. In the event of contamination or injury resulting from ESSA&rsquo;s use of hazardous materials, it
	could be held liable for any resulting damages, and any liability could exceed its resources. ESSA also could incur significant
	costs associated with civil or criminal fines and penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Although ESSA maintains workers&rsquo; compensation insurance to
	cover for costs and expenses ESSA may incur due to injuries to employees resulting from the use of hazardous materials, this insurance
	may not provide adequate coverage against potential liabilities. ESSA does not maintain insurance for environmental liability or
	toxic tort claims that may be asserted against it in connection with its storage or disposal of biological or hazardous materials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, ESSA may incur substantial costs in order to comply
	with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may
	impair ESSA&rsquo;s research, development or production efforts. Failure to comply with these laws and regulations also may result
	in substantial fines, penalties or other sanctions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA is a &ldquo;foreign private issuer&rdquo; and has disclosure
	obligations that are different from those of U.S. domestic reporting companies. As a foreign private issuer, ESSA is subject to
	different U.S. securities laws and rules than a domestic U.S. issuer, which may limit the information publicly available to its
	shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a &ldquo;foreign private issuer,&rdquo; as such term is
	defined in Rule 405 under the Securities Act of 1933, as amended (the &ldquo;
<B>
	Securities Act
</B>
	&rdquo;), and is not subject
	to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, ESSA will be subject to
	reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies.
	ESSA will be required to file or furnish to the SEC the continuous disclosure documents that ESSA is required to file in Canada
	under Canadian securities laws. For example, ESSA will not be required to issue quarterly reports, proxy statements that comply
	with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is
	as detailed as that required of U.S. domestic reporting companies. ESSA will also have four months after the end of each fiscal
	year to file ESSA&rsquo;s annual reports with the SEC and will not be required to file current reports as frequently or promptly
	as U.S. domestic reporting companies. Furthermore, ESSA&rsquo;s officers, directors and principal shareholders are exempt from
	the insider reporting and short-swing profit recovery requirements in Section&nbsp;16 of the Exchange Act. Accordingly, ESSA&rsquo;s
	shareholders may not know on as timely a basis when ESSA&rsquo;s officers, directors and principal shareholders purchase or sell
	their common shares, as the reporting deadlines under the corresponding Canadian insider reporting requirements are longer. As
	a foreign private issuer, ESSA is also exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant
	to ensure that select groups of investors are not privy to specific information about an issuer before other investors. As a result
	of such varied reporting obligations, shareholders should not expect to receive the same information at the same time as information
	provided by U.S. domestic companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, as a foreign private issuer, ESSA has the option to
	follow certain Canadian corporate governance practices rather than those of, except to the extent that such laws would be contrary
	to U.S. securities laws, and provided that ESSA disclose the requirements ESSA is not following and describe the Canadian practices
	ESSA follows instead. As a result, ESSA&rsquo;s shareholders may not have the same protections afforded to shareholders of companies
	that are subject to all domestic U.S. corporate governance requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA may lose foreign private issuer status in the future,
	which could result in significant additional costs and expenses to the Company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA may in the future lose foreign private issuer status if a majority
	of ESSA&rsquo;s Common Shares are held in the United States and ESSA fails to meet the additional requirements necessary to avoid
	loss of foreign private issuer status, such as if: (i)&nbsp;a majority of ESSA&rsquo;s directors or executive officers are U.S.
	citizens or residents; (ii)&nbsp;a majority of ESSA&rsquo;s assets are located in the United States; or (iii)&nbsp;ESSA&rsquo;s
	business is administered principally in the United States. The regulatory and compliance costs to ESSA under U.S. securities laws
	as a U.S. domestic issuer will be significantly more than the costs incurred as a Canadian foreign private issuer. If ESSA is not
	a foreign private issuer, ESSA would be required to file periodic and current reports and Annual Reports on U.S. domestic issuer
	forms with the SEC, which are generally more detailed and extensive than the forms available to a foreign private issuer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, ESSA may lose the ability to rely upon exemptions from
	corporate governance requirements that are available to foreign private issuers. Further, if ESSA engages in capital raising activities
	after losing foreign private issuer status, there is a higher likelihood that investors may require ESSA to file resale Annual
	Reports with the SEC as a condition to any such financing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	There is a risk that ESSA is or could become a &ldquo;passive
	foreign investment company&rdquo; which would likely result in materially adverse U.S. federal income tax consequences for U.S.
	investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA believes it may have been classified as a PFIC for the taxable
	year ending September 30, 2016. Furthermore, ESSA believes it may be classified as a PFIC for the current taxable year and in future
	taxable years. However, the determination as to whether ESSA is a PFIC for any taxable year is based on the application of complex
	U.S. federal income tax rules that are subject to differing interpretations. If ESSA is a PFIC for any taxable year during which
	a U.S. Holder (as defined under &ldquo;Certain United States Federal Income Tax Considerations&rdquo;) holds the Common Shares,
	it would likely result in adverse U.S. federal income tax consequences for such U.S. Holder. U.S. Holders should carefully read
	&ldquo;Certain United States Federal Income Tax Considerations - Passive Foreign Investment Company Rules&rdquo; for more information
	and consult their own tax advisors regarding the likelihood and consequences of ESSA being treated as a PFIC for U.S. federal income
	tax purposes, including the advisability of making a qualified electing fund (&ldquo;
<B>
	QEF
</B>
	&rdquo;) election (including a protective
	election), which may mitigate certain possible adverse U.S. federal income tax consequences but may result in an inclusion in gross
	income without receipt of such income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company&rsquo;s status as an Emerging Growth Company and
	the reduced disclosure requirements applicable to Emerging Growth Companies, may make the Common Shares less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is an &ldquo;emerging growth company,&rdquo; as defined in
	Section&nbsp;2(a)(19) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &ldquo;
<B>
	JOBS
	Act
</B>
	&rdquo;). As such, the Company is eligible to take advantage of certain exemptions from various reporting requirements that
	are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not
	being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, Section&nbsp;107 of the JOBS Act also provides that
	an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B)
	of the Securities Act for complying with new or revised accounting standards, and delay compliance with new or revised accounting
	standards until those standards are applicable to private companies. ESSA will not take advantage of the extended transition period
	for complying with new or revised accounting standards. This election is irrevocable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA may take advantage of some or all of the reduced regulatory
	and reporting requirements that will be available to it so long as it qualifies as an &ldquo;emerging growth company&rdquo; and
	thus the level of information provided may be different than that of other U.S. public companies. If ESSA does take advantage of
	any of these exemptions, some investors may find its securities less attractive, which could result in a less active trading market
	for ESSA&rsquo;s Common Shares, and its share price may be more volatile as a result.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA could be an emerging growth company until the last day of the
	first fiscal year following the fifth anniversary of its first common equity offering, although circumstances could cause ESSA
	to lose that status earlier if annual revenues exceed US$1.0&nbsp;billion, if ESSA issues more than US$1.0&nbsp;billion in non-convertible
	debt in any three-year period or if ESSA becomes a &ldquo;large accelerated filer&rdquo; as defined in Rule&nbsp;12b-2 under the
	Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	It may be difficult for United States investors to effect
	services of process or enforcement of actions against the Company or certain of its directors and officers under U.S. federal securities
	laws.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company is incorporated under the laws of the Province of British
	Columbia, Canada. Its directors and officers reside in Canada or the United States. Because a number of these persons and a substantial
	portion of the assets of the Company are located outside the United States, it will be difficult for United States investors to
	effect service of process in the United States upon the Company or the directors or officers of the Company, or to realize in the
	United States upon judgments of United States courts predicated upon civil liabilities under the U.S. Exchange Act or other United
	States laws. There is substantial doubt as to whether an original action could be brought successfully in Canada against any of
	such persons or the Company predicated solely upon such civil liabilities and whether a judgment of a United States court predicated
	solely upon such civil liabilities would be enforceable in Canada by a Canadian court.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Relating to ESSA&rsquo;s Common Shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company has never declared dividends and may not do so
	in the future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has not declared or paid any cash dividends on Common Shares
	to date. The payment of dividends in the future will be dependent on ESSA&rsquo;s earnings and financial condition and on such
	other factors as ESSA&rsquo;s Board considers appropriate. Unless and until ESSA pays dividends, shareholders may not receive a
	return on their shares. There is no present intention by the Board to pay dividends on the Common Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The Company may experience future sales or issue additional
	securities.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The market price of the Company&rsquo;s equity securities could
	decline as a result of issuances of securities by the Company or sales by the Company&rsquo;s existing shareholders of Common Shares
	in the market, or the perception that such sales could occur. Sales of Common Shares by shareholders might also make it more difficulty
	for the Company to sell equity securities at a time and price that the Company deems appropriate. Sales or issuances of substantial
	numbers of Common Shares, or the perception that such sales could occur, may adversely affect the prevailing market prices of the
	Common Shares. With any additional sale or issuance of Common Shares, investors will suffer dilution to their voting power and
	the Company may experience dilution in its earnings per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If ESSA is unable to implement and maintain effective internal
	controls over financial reporting in the future, ESSA may not be able to report financial results accurately or prevent fraud.
	In that case, investors may lose confidence in the accuracy and completeness of ESSA&rsquo;s financial reports and the market price
	of ESSA&rsquo;s common shares may be negatively affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Maintaining effective internal control over financial reporting
	is necessary for ESSA to produce reliable financial reports and is important in helping to prevent financial fraud. If ESSA is
	unable to maintain adequate internal controls, ESSA&rsquo;s business and operating results could be harmed. As a non-accelerated
	public company, ESSA is not currently required to comply with Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (&ldquo;
<B>
	Sarbanes-Oxley
</B>
	&rdquo;).
	ESSA is no longer considered a &ldquo;venture issuer&rdquo; by virtue of having its securities listed on the TSX in July 2015.
	Non-venture issuers must establish and maintain disclosure controls and procedures and internal control over financial reporting.
	ESSA will be required to certify that it has established disclosure controls and procedures and internal controls over financial
	reporting for the period ended September 3, 2016. Pursuant to National Instrument 52-109 - Certification of Disclosure in Issuers&rsquo;
	Annual and Interim Filings of the Canadian Securities Administrators (&ldquo;
<B>
	NI 52-109
</B>
	&rdquo;), ESSA evaluates how to document
	and test internal control procedures to satisfy the requirements of Section&nbsp;404(a) of Sarbanes-Oxley and the related rules
	of the SEC and NI 52-109, which require, among other things, ESSA&rsquo;s management to assess annually the effectiveness of ESSA&rsquo;s
	internal control over financial reporting. During the course of this documentation and testing, ESSA may identify weaknesses or
	deficiencies that ESSA may be unable to remedy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Preparing ESSA&rsquo;s consolidated financial statements involves
	a number of complex manual and automated processes which are dependent on individual data input or review and require significant
	management judgment. One or more of these elements may result in errors that may not be detected and could result in a material
	misstatement of ESSA&rsquo;s consolidated financial statements. Management&rsquo;s significant estimates and judgements with respect
	to financial reporting are discussed and disclosed in the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The process of designing and implementing effective internal controls
	and procedures, and expanding ESSA&rsquo;s internal accounting capabilities, is a continuous effort that requires ESSA to anticipate
	and react to changes in ESSA&rsquo;s business and the economic and regulatory environments and expend significant resources to
	establish and maintain a system of internal controls that is adequate to satisfy ESSA&rsquo;s reporting obligations as a public
	company. The standards that must be met for management to assess the internal control over financial reporting as effective are
	complex, and require significant documentation, testing and possible remediation to meet the detailed standards. ESSA cannot be
	certain at this time whether the Company will be able to successfully complete the continuing implementation of controls and procedures
	or the certification and attestation requirements of Section&nbsp;404 and NI 52-109 on a continuous basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If a material misstatement occurs in the future, ESSA may fail to
	meet its future reporting obligations, it may need to restate its financial results and the price of its Common Shares may decline.
	Any failure of ESSA&rsquo;s internal controls could also adversely affect the results of the periodic management evaluations and
	any future annual independent registered public accounting firm attestation reports regarding the effectiveness of ESSA&rsquo;s
	internal control over financial reporting that may be required when Section&nbsp;404 of Sarbanes-Oxley becomes fully applicable
	to ESSA. Effective internal controls are necessary for ESSA to produce reliable financial reports and are important to helping
	prevent financial fraud. If ESSA cannot provide reliable financial reports or prevent fraud, ESSA&rsquo;s business and results
	of operations could be harmed, investors could lose confidence in ESSA&rsquo;s reported financial information, and the trading
	price of ESSA&rsquo;s Common Shares could drop significantly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	An active trading market for the Common Shares may not be
	sustained.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Although ESSA has listed the Common Shares on the Nasdaq and the
	TSX, an active trading market for the Common Shares may not be sustained. For example, certain trading days in the year ended September
	30, 2016 resulted in no volume of trading of ESSA&rsquo;s common shares on either of the NASDAQ or the TSX. If an active trading
	market for the Common Shares is not maintained, the liquidity of the Common Shares and the prices that may be obtained for the
	Common Shares will be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	ESSA's Common Shares are thinly traded, the prices at which
	Common Shares trade are volatile and the buying or selling actions of a few shareholders may adversely affect ESSA's share price.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 10PT; TEXT-ALIGN: JUSTIFY">
	As of September 30, 2016, ESSA's public
	float, which is defined as Common Shares outstanding minus Common Shares held by officers, directors, or beneficial holders of
	greater than 10% of ESSA's outstanding Common Shares, represented approximately 70% of ESSA's outstanding Common Shares.&nbsp;
	In addition, the Company is aware of a number of significant shareholders, defined as a holding greater than 5%, who have participated
	in recent financings. The average number of shares traded in any given day over the past year has been relatively small compared
	to the public float. Thus, the actions of a few shareholders either buying or selling ESSA's Common Shares may adversely affect
	the price of the Common Shares. Historically, securities similar to ESSA's Common Shares have experienced extreme price and volume
	fluctuations that do not necessarily relate to operating performance and could result in rapid and substantial losses for shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The market price and trading volume of ESSA's Common Shares
	may be volatile, which could result in rapid and substantial losses for its shareholders or securities litigation.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The market price of ESSA's Common Shares may be highly volatile
	and could be subject to wide fluctuations. In addition, the trading volume in the Common Shares may fluctuate and cause significant
	price variations to occur as demonstrated by ESSA&rsquo;s share price&rsquo;s low on the TSX (C$3.04) and corresponding high (C$9.10)
	for the year ended September 30, 2016. Adding further uncertainty to the market price of ESSA's Common Shares is its relatively
	limited trading history on the NASDAQ, where it began trading on July&nbsp;9, 2015. For the year ended September 30, 2016, ESSA&rsquo;s
	share price&rsquo;s low on the NASDAQ was $2.25 and corresponding high was $7.00. The market price of the Common Shares may fluctuate
	or decline significantly in the future. Some of the factors that could negatively affect ESSA's share price or result in fluctuations
	in the price or trading volume of the Common Shares include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	quarterly variations in operating results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	operating results that vary from the expectations of securities analysts and investors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	change in valuations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	changes in ESSA's operations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	expenses ESSA incurs related to future research;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	regulatory approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	fluctuations in the demand for ESSA's product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	changes in the industry in which ESSA operates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	announcements by ESSA or other companies of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures, capital commitments, plans, prospects, service offerings or operating results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	additions or departures of key personnel;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	future sales of ESSA&rsquo;s securities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	other risk factors discussed herein; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	other unforeseen events.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Stock markets in the United States and Canada have experienced extreme
	price and volume fluctuations. Market fluctuations, as well as general political and economic conditions such as acts of terrorism,
	prolonged economic uncertainty, a recession or interest rate or currency rate fluctuations, could adversely affect the market price
	of ESSA's Common Shares resulting in substantial losses for shareholders. Also, in the past, companies that have experienced volatility
	in the market price of their common shares have been subject to securities litigation. ESSA may be the target of this type of litigation
	in the future. Securities litigation against ESSA could result in substantial costs and divert management&rsquo;s attention from
	other business concerns, which could materially harm ESSA&rsquo;s business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If securities or industry analysts do not publish research
	or publish inaccurate or unfavorable research about ESSA&rsquo;s business, its stock price and trading volume could decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The trading market for ESSA&rsquo;s Common Shares depends in part
	on the research and reports that securities or industry analysts publish about it, or its business. If one or more of the securities
	or industry analysts who cover ESSA downgrade its Common Shares or publish inaccurate or unfavorable research about its business,
	its stock price would likely decline. If one or more of these analysts cease coverage of ESSA or fail to publish reports on it
	regularly, demand for ESSA&rsquo;s stock could decrease, which might cause its stock price and trading volume to decline.
</P>
</EFX_KEY_INFORMATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_COMPANY_INFORMATION>
<A NAME="FIS_COMPANY_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INFORMATION
	ON THE COMPANY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	A.
</I>
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	History and development of the Company
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	1.
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Name, Address and Incorporation; Trading Market
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.3IN; TEXT-INDENT: -0.3IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company was incorporated under the name &ldquo;ESSA Pharma Inc.&rdquo;
	pursuant to the
<I>
	Business Corporations Act
</I>
	(British Columbia) on January&nbsp;6, 2009. The Company&rsquo;s articles (the
	&ldquo;
<B>
	Articles
</B>
	&rdquo;) were amended on December&nbsp;16, 2010 to attach certain special rights and restrictions to the
	Common Shares, on April&nbsp;22, 2014 to authorize the creation of a new class of preferred shares in the capital of the Company,
	issuable in one or more series, and again on July&nbsp;28, 2014 to create the class A preferred shares in the capital of the Company
	(the &ldquo;
<B>
	Preferred Shares
</B>
	&rdquo;) and to attach certain special rights and restrictions to the Preferred Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s registered and records office is located at
	Suite 2600, 595 Burrard Street, Vancouver, British Columbia, Canada V7X 1L3. The head office is located at Suite 720 - 999 West
	Broadway, Vancouver, British Columbia, Canada V5Z 1K5.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Since July 28, 2015, the Company has been trading its Common Shares
	under the symbol &ldquo;EPI&rdquo; on the TSX after graduating from the TSX-V. Since July 9, 2015, the Company has been trading
	its Common Shares on the Nasdaq under the symbol &ldquo;EPIX.&rdquo;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	2.
</I>
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Summary Corporate History and Intercorporate Relationships
</I>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.3IN; TEXT-INDENT: -0.3IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Intercorporate Relationships
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company has one wholly-owned subsidiary, ESSA Pharmaceuticals
	Corp. (&ldquo;
<B>
	ESSA Texas
</B>
	&rdquo;), existing under the laws of the State of Texas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Overview
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a pharmaceutical company, currently in the clinical development
	stage, that is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (&ldquo;
<B>
	CRPC
</B>
	&rdquo;).
	The Company is developing drugs which selectively block the amino-terminal domain (&ldquo;
<B>
	NTD
</B>
	&rdquo;) of the androgen receptor
	(&ldquo;
<B>
	AR
</B>
	&rdquo;), potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients
	with the potential for increased progression-free and overall survival.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In 1999, Dr.&nbsp;Marianne Sadar, a Distinguished Scientist at the
	British Columbia Cancer Agency (the &ldquo;
<B>
	BC Cancer Agency
</B>
	&rdquo;), elucidated a unique drug target on the AR: the NTD.
	In 2003, Dr.&nbsp;Sadar and Dr.&nbsp;Raymond Andersen, a Professor at the University of British Columbia (&ldquo;
<B>
	UBC
</B>
	&rdquo;)
	known for his natural product libraries and medicinal chemistry experience and expertise, began a collaboration focused on discovery
	of small-molecule inhibitors of the AR NTD. By mid-2008, they together discovered a family of compounds that selectively inhibit
	the NTD target on the AR and demonstrated the efficacy of those molecules in recognized laboratory models of prostate cancer. These
	compounds are potential drugs for treatment of CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Drs. Sadar and Andersen incorporated ESSA in January 2009. In 2010,
	Robert Rieder and Dr.&nbsp;Richard Glickman, both former CEOs of Nasdaq-traded biopharmaceutical companies, completed the founding
	team at ESSA. Mr.&nbsp;Rieder was appointed CEO of the Company and Dr.&nbsp;Glickman was appointed Chairman of the board of directors
	of the Company (the &ldquo;
<B>
	Board
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA began substantive operations in 2010 with the licensing of
	intellectual property related to the research of Drs. Sadar and Andersen from the BC Cancer Agency and UBC (see &ldquo;
<I>
	Patents
	and Proprietary Rights
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report), and completion of a seed round financing. The 2010 seed
	financing raised a total of C$1,350,000 at a price of C$0.50 per Common Share from qualified investors on a private placement basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;&nbsp;&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2011
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In 2011, the Company invested C$674,000 in research activities which
	were necessary for the selection of a variant of ESSA&rsquo;s lead compound, EPI-001, that would be suitable to take forward into
	clinical development. Since many such EPI-001 variants had been identified that were effective in blocking the growth of human
	prostate cancer xenografts, this process took significant time. A &ldquo;xenograft&rdquo; is an experiment in which tissue from
	one species of animal is grafted into another species. In the context of ESSA&rsquo;s prostate cancer program, this involves grafting
	human prostate cancer tumor cell lines sub-cutaneously into mice, and measuring the growth rate of the resulting engrafted human
	tumor. A team of consultants was assembled who possessed the expertise and experience required to assist the Company in this endeavour.
	The key objective in this search was to identify a compound with higher potency than EPI-002, the best stereoisomer of the lead
	compound. The term &ldquo;stereoisomer&rdquo; means a molecule that is a mirror-image of another molecule that has identical chemical
	composition. By late 2011, ESSA had identified a compound named EPI-0011, which was highly potent and appeared suitable for further
	development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2012
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Between April and July 2012, ESSA undertook a second financing (the
	&ldquo;
<B>
	2012 Financing
</B>
	&rdquo;) from qualified investors on a private placement basis in order to finance the development
	of EPI-0011 to the IND phase. The 2012 Financing raised an aggregate of C$2,390,000 at a price of C$0.80 per Common Share. Subject
	to certain exempt issuances, the subscription agreements entered into between the Company and investors in connection with the
	2012 Financing included anti-dilution rights in the event the Company issues additional equity securities of the Company or securities
	convertible into equity securities of the Company at an issue price (or conversion, exchange or exercise price, as applicable)
	that is less than C$0.80. These anti-dilution rights expire on the earlier of (i)&nbsp;the three year anniversary of the date the
	Common Shares were issued to each such investor; (ii)&nbsp;the date the Company completes an initial public offering; (iii)&nbsp;the
	date the Company completes the sale of all or substantially all of its assets; and (iv)&nbsp;the date on which any person, acquires,
	directly or indirectly, any voting security of the Company and, immediately after such acquisition, directly or indirectly owns,
	or exercises control and direction over, voting securities representing more than 50% of the total voting power of all of the then
	outstanding voting securities of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During 2012, ESSA continued the pre-clinical development of EPI-0011.
	That effort was initially focused on identifying the best stereoisomer of EPI-0011 and then developing the selected stereoisomer,
	called EPI-00113. This development effort was initially directed toward establishing the dose of EPI-00113 required for efficacy
	and exploring the pharmacokinetics and toxicology of the compound. Unanticipated toxicity was observed in canines at doses that
	were very close to the expected therapeutic dose. On the basis of that finding, development work on EPI-00113 was halted. Subsequent
	investigation suggested that this toxicity was not characteristic of all members of this class of compounds, but was caused by
	a fluorine-containing metabolite of EPI-00113. Therefore, ESSA immediately began testing compounds which lacked any fluorine atom.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Also in 2012, ESSA applied to the Cancer Prevention and Research
	Institute of Texas (&ldquo;
<B>
	CPRIT
</B>
	&rdquo;) for a $12,000,000 grant (the &ldquo;
<B>
	CPRIT Grant
</B>
	&rdquo;) to help fund the
	clinical development of ESSA&rsquo;s program. In late 2012, ESSA was informed that CPRIT staff had recommended approval of the
	CPRIT Grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2013
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Early in 2013, ESSA learned that the CPRIT program had been temporarily
	suspended by the Texas State Legislature due to an irregularity in carrying out CPRIT&rsquo;s mandate. The irregularity was entirely
	unconnected to ESSA&rsquo;s application. ESSA continued its efforts during this time to identify and test a more-potent variant
	of its lead compound. This led to testing of a compound named EPI-506, a pro-drug of EPI-002. In vitro testing of EPI-506 showed
	that it was approximately two-fold more potent than EPI-002. In vivo experiments in established models of CRPC suggested an even
	higher increase in potency of EPI-506 over EPI-002 by oral dosing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2014
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In early 2014, in vivo experiments showed that EPI-506 had efficacy
	on human prostate cancer xenografts at oral doses in the 33 mg/kg range in mice. Toxicology studies showed that it was well tolerated
	in both mice and canines at doses at least two-fold higher than the therapeutic dose. On the basis of that data as well as other
	relevant data, the Company decided to commence a work program focused on receiving regulatory approval to commence human clinical
	testing of EPI-506 in CRPC patients. During the first quarter of 2014, ESSA was informed that the CPRIT Advisory Committee had
	approved the CPRIT Grant and on July&nbsp;9, 2014, the Chief Executive Officer of CPRIT executed the CPRIT Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;Pursuant to the terms of the CPRIT Agreement, CPRIT agreed
	to disburse to the Company up to $12,000,000 to be used in connection with ESSA&rsquo;s development of EPI-506 towards completion
	of Phase 1/2 clinical proof-of-concept (in this section, the &ldquo;
<B>
	Project
</B>
	&rdquo;), to be advanced upon request by the
	Company. If the Company does not request, or CPRIT&rsquo;s oversight committee does not authorize, advancement of funds for some
	or the entire CPRIT Grant proceeds, disbursement of CPRIT Grant proceeds for services performed and allowable expenses and costs
	incurred in connection with the Project will be on a reimbursement basis. Each year, the Company must confirm to CPRIT that it
	has funds dedicated to the Project equal to one half of the amount of the CPRIT Grant funds disbursed each fiscal year during the
	term of the CPRIT Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, the Company must conduct the Project within the State
	of Texas with Texas-based employees, contractors and/or collaborators unless otherwise allowed under the CPRIT Agreement and must
	use good faith efforts to purchase goods and services from suppliers in Texas to the extent reasonably possible, with a goal of
	achieving more than 50% of such purchases from suppliers in Texas, as well as reasonable efforts to purchase from certain under-utilized
	businesses enumerated by CPRIT. As of the date of this Annual Report, the Company has complied with these obligations by incorporating
	a subsidiary under the laws of the State of Texas, opening an office in Houston, Texas and basing senior staff in the Company&rsquo;s
	Houston office.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The CPRIT Grant is subject to the Company&rsquo;s compliance with
	the scope of work outlined in the CPRIT Agreement and demonstration of its progress towards achievement of the milestones set forth
	in the CPRIT Agreement. On July&nbsp;31, 2014, the Company received $2,791,333 from CPRIT, representing the first tranche of the
	aggregate $12,000,000 CPRIT Grant, and recorded this amount as deferred revenue. This amount will be recognized as revenue as eligible
	expenses are approved by CPRIT based on quarterly filings. The Company must dedicate $1,395,667 of Company funds unrelated to the
	CPRIT Grant to be used in connection with the Company&rsquo;s development program (being one half of the amount of the first tranche
	of the CPRIT Grant). To obtain an advance of the next tranche of the CPRIT Grant in the amount of $3,786,667, the Company had to
	successfully file an IND application with the FDA in 2015 (for more information on the IND application process, see &ldquo;
<I>
	Regulatory
	Environment
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report) and dedicate $1,893,333 of Company funds unrelated to the CPRIT Grant
	to be used in connection with the Company&rsquo;s development program (being one half of the amount of the second tranche of the
	CPRIT Grant). The IND summarizes pre-clinical work completed in connection with EPI-506. The Company filed an IND application with
	the FDA on March 31, 2015. On April 30, 2015, subsequent to filing the application, the Company received notification from the
	FDA in the US that the Company&rsquo;s IND application has been placed on clinical hold pending receipt by the FDA of additional
	chemistry and pharmaceutical data related to the stability of the drug substance and drug product and a Certificate of Analysis
	on drug product. On September 23, 2015, the Company received notice from the FDA that the Company&rsquo;s IND application has been
	approved. On November 5, 2015, the Company received a &ldquo;no objection letter&rdquo; for the CTA from the Health Protection
	Branch of Health Canada allowing the Company to conduct the clinical trial in Canada. The Company received the second tranche of
	the CPRIT Grant of $3,786,667 in October 2015. CPRIT&rsquo;s advance of the third and final tranche of the CPRIT Grant, amounting
	to $5,422,000, is conditional on the Company completing the Phase 1 safety portion of the Phase 1/2 clinical trial and dedicating
	$2,711,000 of Company funds unrelated to the CPRIT Grant to be used in connection with the Company&rsquo;s development program.
	The final milestone expected to be achieved by the Company using the advance of the third tranche of the CPRIT Grant is the completion
	of the Phase 2 efficacy portion of the Company&rsquo;s proposed Phase 1/2 clinical study by Q1 of calendar 2018 depending on the
	enrollment rate and number of dose escalation steps (see &ldquo;
<I>
	ESSA&rsquo;s Products and Programs &ndash; Development Program
</I>
	&rdquo;
	in Item&nbsp;4 of this Annual Report).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company must use commercially reasonable efforts to complete
	the goals of the Project in accordance with the timeline agreed to with CPRIT and must provide quarterly financial reporting to
	CPRIT to document all costs and allowable expenses paid with CPRIT Grant proceeds. As of the date of this Annual Report, ESSA is
	current with its CPRIT filings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company and its collaborators, as defined in the CPRIT Agreement
	included as Exhibit 4.1 to this Annual Report, retain ownership of all intellectual property created in connection with work undertaken
	using CPRIT Grant funds. However, CPRIT has a non-exclusive royalty-free worldwide license to exploit results of the Project for
	or on behalf of CPRIT and other agencies of the State of Texas for noncommercial purposes only.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA must also pay to CPRIT 4% royalties on gross revenues of sales
	of commercial products developed from the results of the Project up to a maximum of 200% of the CPRIT Grant funds awarded to ESSA
	and 2% royalties on such revenues thereafter. After termination of the CPRIT Agreement, ESSA may pay a one-time buyout fee in lieu
	of the aforementioned royalty payments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The CPRIT Agreement terminates on December&nbsp;31, 2017, subject
	to extension, unless terminated earlier (i)&nbsp;by mutual agreement of the parties, (ii)&nbsp;by ESSA for convenience on 30 days&rsquo;
	notice or (iii)&nbsp;by CPRIT if a key milestone is not met by ESSA, for certain material defaults of the CPRIT Agreement by ESSA
	or if allocated funds should become legally unavailable to CPRIT for use in the CPRIT Agreement and CPRIT is unable to obtain additional
	funding. If ESSA terminates the CPRIT Agreement for convenience or CPRIT terminates the CPRIT Agreement as a result of certain
	material defaults under the CPRIT Agreement by ESSA, or if ESSA relocates its development activities outside of Texas during the
	term of the CPRIT Agreement or within three years after the final payment of CPRIT Grant funds, ESSA must repay some or all CPRIT
	Grant funds, to the extent such default resulted in the CPRIT Grant being expended not in accordance with the CPRIT Agreement.
	In addition, if ESSA opts out of the CPRIT Agreement or if the CPRIT Agreement is terminated by CPRIT because of ESSA&rsquo;s default,
	CPRIT may require that ESSA transfer and assign to CPRIT all of its rights, title and interest in all intellectual property rights
	and technologies developed as a result of the CPRIT Grant. If, at the time the CPRIT Agreement terminates, a portion of the funds
	awarded have not been used by the Company for permissible services, expenses or costs relating to the Project and the Company has
	not received approval for an extension of the term of the CPRIT Agreement (which may not exceed six months), the Company must return
	such unused funds to CPRIT.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The CPRIT Agreement cannot be assigned by the Company without CPRIT&rsquo;s
	consent. The Company has agreed to indemnify CPRIT and the State of Texas from and against any and all claims, demands, costs,
	expenses, liabilities, causes of action and damages in any way related or in connection with ESSA&rsquo;s receipt or use of the
	CPRIT Grant funds. The funds available to the Company pursuant to the CPRIT Agreement are contingent upon funding being available
	from CPRIT for the term of the CPRIT Agreement. The Company does not have any right of action against CPRIT in the event that CPRIT
	is unable to perform its obligations under the CPRIT Agreement as a result of the suspension, termination, withdrawal, or failure
	of funding to CPRIT or lack of sufficient funding of CPRIT for the CPRIT Agreement. If the CPRIT Agreement is not funded, both
	ESSA and CPRIT will be relieved of their obligations under the CPRIT Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the fiscal year ended September&nbsp;30, 2014, ESSA received
	an initial advance of $2,793,533 from the CPRIT Grant. The CPRIT Grant is detailed in the accompanying financial statements for
	the fiscal year ended September&nbsp;30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Also during the first quarter of 2014, the Company retained Bloom
	Burton, a Toronto-based financial advisory firm, to help develop a financing strategy for ESSA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In April 2014, ESSA issued a convertible secured debenture to Bloom
	Burton Healthcare Structured Lending Fund in the amount of C$1,000,000 bearing interest at a rate of 12%&nbsp;per annum (the &ldquo;
<B>
	Convertible
	Debenture
</B>
	&rdquo;). Pursuant to its conversion terms, the Convertible Debenture, including all accrued interest thereon, was
	automatically converted into 517,500 Preferred Shares upon the closing of the first tranche of the 2014 Financing (as defined below).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Also during the second quarter of 2014, in connection with certain
	obligations under the CPRIT Grant, the Company established a wholly-owned subsidiary, ESSA Pharmaceuticals Corp., under the laws
	of the State of Texas, to manage the NTD development project related to the CPRIT Grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On July&nbsp;29, 2014, ESSA completed a brokered private placement
	offering of 1,185,400 Preferred Shares at a price of C$2.00 per Preferred Share for aggregate gross proceeds of C$2,370,800 (the
	&ldquo;
<B>
	2014 Financing
</B>
	&rdquo;). The 2014 Financing was completed with a syndicate of agents led by Bloom Burton, as lead
	agent, and which included Mackie Research Capital Corporation and Richardson GMP Limited. Pursuant to its conversion terms, the
	Convertible Debenture, including all accrued interest thereon, was automatically converted into 517,500 Preferred Shares upon the
	closing of the 2014 Financing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On October&nbsp;22, 2014 and October&nbsp;23, 2014, the Company
	carried out the 2014 Special Warrant Financing for gross proceeds of C$1,359,280. The Special Warrants issued in connection with
	the 2014 Special Warrant Financing were exercised into Preferred Shares on December 15, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In September 2014, the Company submitted its initial application
	to list the Common Shares on the TSX-V. On December&nbsp;9, 2014, the Company became a reporting issuer in Alberta, British Columbia
	and Ontario. On December&nbsp;22, 2014, the Company received conditional approval for its common shares to be listed on the TSX-V.
	As of January&nbsp;27, 2015, the Company began trading stock under the symbol &ldquo;EPI&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2015
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In January 2015, the Company issued the 2015 Special Warrants at
	a price of $2.75 per 2015 Special Warrant for gross proceeds of approximately $12,000,000 (the &ldquo;
<B>
	2015 Special Warrant Financing
</B>
	&rdquo;).
	Each 2015 Special Warrant was converted, without payment of any additional consideration, to one Common Share and deemed exercised
	upon completion of the Nasdaq listing in July 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In connection with the 2015 Special Warrant Financing, Bloom Burton
	and Roth Capital Partners, LLC, as agents, and selling group members, received total cash commissions equal to approximately $706,800
	and 257,018 Broker Warrants. Each such broker warrant is exercisable to purchase one Common Share until January&nbsp;16, 2017 at
	a price of $2.75 per broker warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company graduated to the Toronto Stock Exchange (&ldquo;
<B>
	TSX
</B>
	&rdquo;)
	in July 2015 from the TSX-V.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The IND application was filed with the FDA on March 31, 2015. On
	April&nbsp;30, 2015, the Company received notification from the FDA that the Company&rsquo;s IND application had been placed on
	clinical hold pending receipt by the FDA of additional chemistry and pharmaceutical data related to the stability of the drug substance
	and drug product and a certificate of analysis on drug product.&nbsp;The Company responded to the FDA and received FDA approval
	of its IND on September 23, 2015. This FDA approval permits the Company to initiate its planned Phase 1/2 clinical trial of its
	novel agent, EPI-506. Furthermore, the Health Protection Branch of Health Canada issued a &ldquo;no objection letter&rdquo; on
	November 5, 2015, which will allow ESSA to include Canadian sites in its Phase 1/2 clinical study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In October 2015, ESSA received a second advance of $3,786,667 from
	the CPRIT Grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In November 2015, the Company opened its first clinical trial
	sites and enrolled the first patient in the Phase 1/2 clinical study of EPI-506. In its Phase 1/2 clinical trial, ESSA
	intends to demonstrate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and efficacy of EPI-506 in
	metastatic CRPC patients who have failed abiraterone or enzalutamide therapy or both.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In December 2015, the Company filed a short form base shelf prospectus
	with securities regulatory authorities in British Columbia, Alberta and Ontario, and a corresponding shelf registration statement
	with the United States Securities and Exchange Commission (the &ldquo;
<B>
	SEC
</B>
	&rdquo;) on Form F-10. The shelf prospectus and
	the Form F-10, subject to Canadian and U.S. securities regulatory requirements, respectively, provides for the potential public
	offering from time to time over a 25-month period in Canada and the United States, of up to an aggregate of $100 million of ESSA&rsquo;s
	common shares, warrants, debt securities and other securities. The shelf prospectus and the Form F-10 are intended to give ESSA
	the flexibility to take advantage of financing opportunities when market conditions are favorable. The terms of such future offerings,
	if any, will be established at the time of such offerings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	2016
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 7, 2016, Dr. David R. Parkinson
	was appointed as the Company&rsquo;s President and Chief Executive Officer. Dr. Parkinson replaced Mr. Robert Rieder who announced
	his departure from the Company and resignation from the board of directors of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In January 2016, the Company completed a private placement of 4,545,452
	units of the Company at $3.30 per unit for gross proceeds of approximately $15,000,000&nbsp;(the &ldquo;
<B>
	January 2016 Financing
</B>
	&rdquo;).
	Each unit consists of one Common Share, one seven-year cash and cashless exercise warrant and one-half of one two-year cash exercise
	warrant (collectively, the &ldquo;
<B>
	2016 Warrants
</B>
	&rdquo;). Each of the 2016 Warrants has an exercise price of $3.30.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On January 14, 2016, effective on the closing
	of the January 2016 Financing, Scott Requadt, Managing Director of Clarus Ventures, LLC, was appointed to the Board of the Company.
	Pursuant to the terms of a subscription agreement between the Company and Clarus Lifesciences III, L.P. (&ldquo;
<B>
	Clarus
</B>
	&rdquo;)
	in connection with the January 2016 Financing, Clarus is entitled to nominate two directors to the Board of the Company, one of
	which must be an independent director and pre-approved by the Company. The nomination rights will continue for so long as Clarus
	holds greater than or equal to 1,060,606 common shares, subject to adjustment in certain circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On March 21, 2016, the Company completed a
	private placement of 1,666,666 common shares of the Company at $3.00 per share for aggregate gross proceeds of approximately $5,000,000
	(the &ldquo;
<B>
	March 2016 Financing
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On August 1, 2016, the Company appointed Peter
	Virsik as Executive Vice-President and Chief Operating Officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On November 18, 2016, the Company entered into
	a $10,000,000 capital term loan facility agreement with Silicon Valley Bank (&ldquo;
<B>
	SVB
</B>
	&rdquo;), pursuant to which the Company
	has initially drawn down $8,000,000, with a conditional option to receive an additional $2,000,000 by April 28, 2017 upon positive
	data for its ongoing Phase 1 clinical trial of EPI-506 and receipt of the third and final tranche of the CPRIT grant of $5,422,000.
	The term loans bear an interest rate of Wall Street Journal Prime Rate plus 3% per annum and will mature on September 1, 2020.
	The loan agreement requires a final payment of 8.6% of the amount advanced under the term loans, due upon the earlier of the maturity
	or termination of the term loan facility. The term loans are secured by perfected first priority lien on all the company&rsquo;s
	assets, with a negative pledge on intellectual property. The term loans are subject to standard events of default, including default
	in the event of a material adverse change. There are no financial covenants. Upon funding of the respective tranches, the Company
	granted to SVB warrants to purchase shares of the Company&rsquo;s common stock equal to 4% of the amount advanced, divided by the
	exercise price of the warrants, based on the five-day volume-weighted average trading price of the Company&rsquo;s common shares
	on the TSX, to be determined at the time of the issuance of the warrants. In connection with the initial $8,000,000 advance, the
	Company granted SVB and Life Sciences Loans II LLC an aggregate of 149,532 warrants, exercisable at a price of $2.14 per share
	for a period of seven years.
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Business Overview
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Introduction
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a clinical stage development pharmaceutical company focused
	on developing novel and proprietary therapies for the treatment of prostate cancer in patients whose disease is progressing despite
	treatment with current therapies, including abiraterone and enzalutamide. ESSA believes its product candidate, EPI-506, can significantly
	expand the interval of time in which patients suffering from metastatic castration resistant prostate cancer can benefit from hormone-based
	therapies. Specifically, EPI-506 acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that
	drives most prostate cancer growth. EPI-002, the primary metabolite of EPI-506, prevents AR activation by binding selectively to
	the N-terminal domain of the AR. A functional NTD is essential for activation of the AR. Blocking the NTD prevents activation of
	the AR by all currently known mechanisms of activation. In pre-clinical studies, blocking the NTD has demonstrated the capability
	to prevent AR activation and overcome the known AR-dependent mechanisms of CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Through ESSA&rsquo;s ongoing Phase 1/2 clinical study, the Company
	will explore the safety,&nbsp;tolerability,&nbsp;maximum tolerated dose and pharmacokinetics of EPI-506, in addition to tumor response
	parameters in&nbsp;asymptomatic&nbsp;or minimally symptomatic patients with metastatic CRPC who are no longer responding to either
	abiraterone or enzalutamide treatments, or both. Efficacy endpoints&nbsp;include prostate specific antigen (&ldquo;
<B>
	PSA
</B>
	&rdquo;)
	reduction, as well as other progression criteria.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	According to the American Cancer Society, in the United States,
	prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. Approximately one-third of all prostate
	cancer patients who have been treated for local disease will subsequently have rising serum levels of PSA, which is an indication
	of recurrent or advanced disease. Patients with advanced disease often undergo androgen ablation therapy using analogues of luteinizing
	hormone releasing hormone (&ldquo;
<B>
	LHRH
</B>
	&rdquo;) or surgical castration. Most advanced prostate cancer patients initially
	respond to androgen ablation therapy, however many experience a recurrence in tumor growth despite the reduction of testosterone
	to castrate levels, and at that point are considered to be suffering from CRPC. Following diagnosis of CRPC, patients are often
	treated with anti-androgens, which block the binding of androgens to the AR.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The growth of prostate tumors is mediated by an activated AR. Generally,
	there are three means of activating the AR. First, androgens such as dihydrotestosterone can activate AR by binding to its ligand-binding
	domain (&ldquo;
<B>
	LBD
</B>
	&rdquo;). Second, CRPC can be driven by constitutively-active variants of AR (&ldquo;
<B>
	vAR
</B>
	&rdquo;)
	that lack a LBD and do not require androgen for activation. The third mechanism involves certain signaling pathways that activate
	AR independent of androgen activity. Current drugs for the treatment of prostate cancer work by focusing on the first mechanism
	and preventing androgen from binding to LBD, but this approach eventually fails and may not block the other two mechanisms of AR
	activation. By directly and selectively blocking all known means of activating the AR, ESSA believes EPI-506 holds the potential
	to be effective in cases where current therapies have failed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	According to the Decision Resources Group, in 2014, there were approximately
	213,000 prevalent cases of CRPC, and that prevalence is expected to increase to approximately 235,000 in 2023. ESSA expects that
	EPI-506 could be effective for many of those patients. For the following reasons, ESSA intends to first focus on patients who have
	failed abiraterone or enzalutamide:
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	CRPC treatment remains the prostate cancer market segment with the greatest unmet need and is therefore a potentially large market;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA believes that the unique mechanism of action of its product candidate is well suited to treat patients who have failed LBD focused therapies; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA expects the large number of patients with unmet therapeutic needs in this area will facilitate timely enrollment in its clinical trials.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	EPI-506 is a potent pro-drug of EPI-002, a stereoisomer of ESSA&rsquo;s
	discovery compound, EPI-001. A pro-drug is a drug which after administration is converted into an active form through a normal
	metabolic process. Pro-drugs are typically utilized to administer and more efficiently deliver another drug, in this case EPI-002.
	ESSA believes that EPI-506 can deliver higher concentrations of EPI-002 to the target tissue than EPI-002 itself. In pre-clinical
	studies, EPI-001 has been shown to shrink benign prostate tissue in mice. The pro-drug EPI-506 has demonstrated similar biological
	effects at doses that are lower than those required for EPI-002.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The NTD of AR is flexible with a high degree of intrinsic disorder
	making it extremely difficult to be used for crystal structure-based drug design. To the Company&rsquo;s knowledge, no crystal
	structure has been identified in the AR NTD that could facilitate development of drugs which interact with this domain. ESSA is
	not currently aware of any success by other drug development companies in finding drugs that bind to this drug target.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has initiated a Phase 1/2 clinical trial with the Phase 1 dose-escalation
	group being conducted at 5 sites in the United States and Canada. The Phase 2&nbsp;dose expansion group study is anticipated to
	be conducted in the United States, Canada, the UK, and France. Key enrollment criteria are progressive, metastatic CRPC for patients
	who are no longer responding to abiraterone or enzalutamide. Efficacy endpoints&nbsp;include PSA response and radiographic progression
	criteria. ESSA will also assess biomarkers of resistance including splice variant status of patients. A biomarker is a measurable
	biological or chemical change that is believed to be associated with the severity or presence of a disease or condition. If the
	Phase 1/2 trial is successful, ESSA expects to seek approval from the FDA to commence a Phase 3 trial in a similar patient population.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The BCCA and UBC are joint owners of the intellectual property that
	constitutes ESSA&rsquo;s primary asset. The Company has entered into a joint agreement with the two institutions which provides
	exclusive access to the patent and patent applications to its EPI-series compounds, including EPI-506.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	One of ESSA's key resources is the experience embodied in its management
	team and scientific founders:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Management Team
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr. David R. Parkinson, President and Chief Executive
	Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	served as Vice President, Global Clinical Oncology for Novartis International AG, and Vice President, Oncology Development at Amgen, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	at both Novartis and Amgen, he was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr. Frank Perabo, Executive Vice-President of Clinical
	Development and Chief Medical Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	at Astellas Pharma Global Development, Inc. led worldwide clinical development of enzalutamide;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	also led two other successful urology development programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	David Wood, Chief Financial Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10 years as Head of Finance and Corporate Development at Celator Pharmaceuticals Inc., where he helped take the company public;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	20 years of experience in increasingly senior finance roles at various biotech companies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Peter Virsik, Executive Vice-President and Chief Operating Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	20 years of experience in corporate development, new product planning, licensing and alliance management with global pharmaceutical organizations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	at XenoPort, Inc., played a role in the licensing and commercialization of Horizant (gabapentin enacarbil).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Scientific Founders
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr. Marianne Sadar, Chief Scientific Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	internationally known for her research on identifying human mechanisms of activating the AR and developing therapeutics for advanced prostate cancer;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	served on approximately 50 scientific panels and as President of the Society of Basic Urological Research.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr. Raymond Andersen, Chief Technical Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	internationally known for his research on marine natural products and their potential as drug leads;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	discoveries have represented core technologies of several pharmaceutical companies and progressed to the clinical trial stage.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ESSA's Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA's therapeutic goal is initially to provide a safe and effective
	therapy for prostate cancer patients who have failed current therapies, and ultimately to treat all AR-dependent forms of recurrent
	or advanced prostate cancer. ESSA intends to accomplish those objectives while maximizing shareholder value. Specific components
	of ESSA's strategy include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Advancing EPI-506 through clinical development and
	regulatory approval in CRPC patients
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On September 23, 2015, ESSA announced that the FDA had approved
	its IND application. ESSA is currently initiating a Phase 1/2 trial to determine the safety, tolerability, maximum tolerated dose,
	pharmacokinetics and potential therapeutic benefits of EPI-506 in CRPC patients. If the Phase 1/2 trial proceeds as planned, ESSA
	expects completion of the trial by Q1 of 2018 calendar year depending on the enrollment rate and number of dose escalation steps.
	If the Phase 1/2 trial is successful, ESSA expects to commence a Phase 3 trial in a similar patient population. In order to accelerate
	the development timeline, ESSA intends to prepare for Phase 3 development concurrently with the execution of the Phase 1/2 trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Developing, EPI-506 as an essential component of a new standard
	of care for the treatment of pre-CRPC and expand usage earlier in the disease stage
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The activated AR is required for the growth and survival of most
	prostate cancer; therefore, ESSA believes the AR NTD is an ideal target for next-generation hormone therapy. If EPI-506 is successful
	in treating CRPC patients, it is reasonable to expect that EPI-506 may be effective in treating earlier stage patients. Therefore,
	ESSA may conduct additional clinical studies potentially leading to approval of EPI-506 for use in prostate cancer patients at
	an earlier disease stage.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Identifying new indication areas with high unmet medical need
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Several other diseases and conditions are impacted by activated
	AR, including certain sub-populations of breast cancer, Kennedy&rsquo;s disease (an orphan neurological condition) and male pattern
	baldness. While our primary focus will remain the treatment of prostate cancer, we may explore such applications in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Evaluating strategic collaborations to maximize value
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA currently retains all commercial rights for its EPI-series
	drug portfolio. ESSA intends to evaluate potential collaborations that could enhance the value of its prostate cancer program and
	allow it to leverage the expertise of strategic collaborators. ESSA also intends to explore collaborations in order to develop
	applications of its product candidate outside prostate cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview of Castration-Resistant Prostate Cancer
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	According to the American Cancer Society, in the United States,
	prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. The American Cancer Society estimates
	that, in the United States during 2015, approximately 221,000 new cases of prostate cancer will be diagnosed, and approximately
	28,000 men will die from the disease. Overall, in the United States, about one in seven men will be diagnosed with prostate cancer
	during his lifetime, and about one in 38 men will die from the disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Prostate cancer is most frequently diagnosed at an early stage,
	when it is confined to the prostate gland and its immediate surroundings. Advances in screening and diagnosis, including the widespread
	use of PSA screening, have allowed detection of the disease in its early stages. Patients with early-stage disease are typically
	treated with surgery or radiation therapy, or in limited circumstances, with both. For the majority of men, these procedures are
	successful in curing the disease. However, for others, these procedures are not curative and their prostate cancer ultimately recurs.
	Men with recurrent or metastatic prostate cancer are considered to have advanced prostate cancer. Pharmacological castration using
	analogues of LHRH, such as leuprolide. The Decision Resources Group estimates that approximately 151,000 men in the United States
	currently have advanced prostate cancer and are eligible for treatment with drug therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Drugs which competitively bind in the ligand-binding pocket of the
	LBD of the AR prevent both the binding of androgen and interaction of the AR with co-regulatory proteins, and therefore also prevent
	AR transcription activity. These drugs (called &ldquo;antiandrogens&rdquo;) are effective in inhibiting the growth of prostate
	cancer tumors. Current antiandrogens used for prostate cancer include bicalutamide, cyproterone acetate, enzalutamide, flutamide,
	nilutamide, and the investigational drugs ARN-509 and ODM-201.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	When the disease becomes resistant to initial androgen ablation
	therapy, second line hormonal treatments can be used depending on several factors that include the biology of the tumor, evidence
	of metastases, whether or not the patient is experiencing symptoms and if the disease comprises small cell carcinoma. However,
	castrate levels of androgen are typically maintained (i.e. patient remains on LHRH analogues) while other therapies are added to
	the patient&rsquo;s regime. Asymptomatic patients with rising PSA and evidence of metastasis will typically go on to receive second-line
	hormonal therapies that include abiraterone acetate, corticosteroids or enzalutamide. For symptomatic CRPC patients, docetaxel
	or radium-233 for bone metastases are generally the treatments of choice. Prostate small cell carcinoma can be treated with chemotherapies
	such as docetaxel as those carcinomas usually do not respond to AR targeted therapies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Abiraterone acetate plus prednisone was approved by the FDA and
	in many countries globally for patients with chemotherapy resistant metastatic CRPC in 2011. In the key clinical trials supporting
	initial approval for post-chemotherapy CRPC, abiraterone acetate plus prednisone demonstrated a statistically significant improvement
	in overall survival of 4.6 months in patients with metastatic CRPC who have failed one or two prior chemotherapy regimens. Abiraterone
	acetate plus prednisone has also been approved in the pre-chemotherapy setting. In the key supporting clinical trial, the co-primary
	endpoint showed a statistically significant increase in median radiographic progression-free survival with abiraterone plus prednisone
	versus prednisone alone of 16.5 months versus 8.3&nbsp;months, whereas improvement in median overall survival only showed a trend
	towards statistical significance. Treatment with abiraterone requires the concomitant usage of prednisone to ameliorate symptoms
	of mineralocorticoid excess, including fluid overload, hypertension and hypokalemia; abiraterone plus prednisone must be used with
	caution in those with a significant cardiovascular history, including congestive heart failure. These effects, as well as treatment-associated
	elevations in liver enzymes, necessitate monitoring for blood pressure, serum potassium, fluid retention, aspartate aminotransferase
	(&ldquo;
<B>
	AST
</B>
	&rdquo;), alanine transaminase (&ldquo;
<B>
	ALT
</B>
	&rdquo;) and bilirubin levels. Furthermore, the pharmacokinetics
	of abiraterone acetate demonstrate a large food effect, with exposure increasing up to ten-fold in the presence of food. For safe
	administration, food must not be eaten two hours before the drug is taken and for one hour afterwards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Enzalutamide was approved by the FDA as a treatment for patients
	with patients with chemotherapy resistant metastatic CRPC in 2012. In the initial pivotal clinical trial supporting FDA approval
	in the post-chemotherapy CRPC population, the median overall survival was 18.4 months in the enzalutamide group versus 13.6 months
	in the placebo group. The label extension to metastatic CRPC is supported by data from the trial in chemo-naive CRPC, which demonstrated
	a statistically significant 29% reduction in the risk of death over placebo, despite enrolling patients with visceral disease,
	a population with a poorer prognosis that has historically been excluded from this trial setting. This survival benefit was achieved
	without the requirement for concomitant prednisone. The safety profile of enzalutamide is considered favorable despite a high incidence
	of hypertension and the risk for seizure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The immunotherapy sipuleucel-T has been shown to increase the median
	survival time of CRPC patients by four months. Sipuleucel-T is generally considered a treatment option in advanced patients who
	are either asymptomatic or minimally symptomatic and with a good performance status (&ldquo;
<B>
	ECOG 0-1
</B>
	&rdquo;). Sipuleucel-T
	is not indicated for patients with hepatic metastases or less than six month life expectancy. In clinical trials, sipuleucel-T
	has shown no effect on serum PSA and does not affect the time to disease progression.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Radium-223 has been shown to extend survival in CRPC patients with
	symptomatic bone metastases and no known visceral metastatic disease. Limitations include the incidence of bone marrow suppression,
	primarily thrombocytopenia, and the need for this injectable radiopharmaceutical to be administered by trained personnel at select
	centers able to handle this product. In addition, the administration of radium-233 is associated with potential risks for other
	persons (e.g. medical staff, care givers and members of the patient&rsquo;s family) from radiation or contamination from body fluids
	such as spills of urine, feces, and vomit. Therefore, radiation protection precautions must be taken in accordance with national
	and local regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Androgen and the Androgen Receptor
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Androgens such as testosterone and dihydrotestosterone mediate their
	biological effects through the AR. In adult males, the testes produce the majority of androgen with some contribution from the
	adrenal glands and other tissues. Androgens play a role in a wide range of developmental and physiological responses and are involved
	in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation. The growth and survival of the
	prostate is dependent on androgen. When androgens increase in males during puberty there is an increase in growth of the prostate
	gland, and in adult males when androgens are reduced by castration there is involution of the prostate and apoptosis, or cell death,
	of prostate epithelial cells. Thus the prostate gland is an androgen-dependent organ where androgens are the predominant mitogenic
	stimulus. This dependency of the prostate epithelium on androgens provides the underlying rationale for treating advanced prostate
	cancer with androgen ablation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The AR is a ligand-activated transcription factor that mediates
	the biological effects of androgen. Without a functional full-length AR, the addition of androgen has no biological effects. The
	AR has distinct functional domains that include a C-terminal LBD, DNA-binding domain, the N-terminal domain and a hinge region.
	All current FDA-approved therapies that target the AR are directly or indirectly focused on its C-terminal LBD. Androgens such
	as testosterone and dihydrotestosterone bind to the LBD of the AR which result in changes in conformation and post-translational
	modifications, nuclear translocation and ultimately binding to the regulatory regions of DNA of target genes called androgen response
	elements. Thus, AR regulates the transcription of genes involved in prostate tissue growth and survival.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	AR is unique from other steroid hormone receptors in that it is
	the AF-1 region in the NTD that contributes to transcriptional activity, with little to no activity contributed from AF-2 in the
	LBD. AR LBD functions independent of the NTD and can still bind ligand even if the AF-1 region is deleted or mutated; however,
	no transcriptional activity can be achieved without the AF-1 region in the NTD. Previous research used deletion mutants of the
	AR to explore which regions of the AR were critical to its activity, with the following key findings:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	truncated AR (AR1-653) that lacked the LBD was found to be constitutively active, and mimicked the AR splice variants that were reported more than one decade later in 2008;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	deletion of AF-1 (residues 245-527) in the AR NTD yielded a receptor that could still bind androgen but was transcriptionally dead; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	deletion of AF1 also blocked all transcriptional activity of the truncated variant AR.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	It is generally believed that, in the majority of patients, CRPC
	continues to be driven by a transcriptionally-active AR in spite of maintaining castrate levels of androgen. Evidence to support
	the concept that CRPC remains dependent upon AR signaling includes:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1)
</TD>
<TD>
	many of the same genes that are increased by androgens become elevated in CRPC, such as PSA;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2)
</TD>
<TD>
	detection of nuclear localization of the AR in CRPC tissues supports that the AR may continue to be transcriptionally active
	in the absence of testicular androgens;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3)
</TD>
<TD>
	increased expression of the AR (full-length and AR splice variant) in tissues from CRPC;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4)
</TD>
<TD>
	survival advantages with enzalutamide and abiraterone (block synthesis of androgens) in CRPC patients; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5)
</TD>
<TD>
	correlation of levels of expression of AR splice variant with poor outcome and resistance to abiraterone and enzalutamide.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	AR-related mechanisms of CRPC
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The mechanisms for the development of CRPC have been intensely studied,
	in part because the emergence of CRPC is almost universal in recurrent prostate cancer treatment. The mechanisms described below
	represent the current state of knowledge in this regard.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Mutations Causing AR Activation by Antiandrogens
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Some patients receiving antiandrogens will develop antiandrogen
	withdrawal syndrome. This syndrome is characterized by a rising PSA and worsening symptoms while the patient is taking antiandrogens,
	followed by a decline in PSA or improvement when the patient is taken off antiandrogens. Prostate cancer cells obtained from patients
	with antiandrogen withdrawal syndrome may have gain-of-function mutations in the LBD of the AR. Thus, current antiandrogens used
	to block the LBD of the AR may become activators of the mutated AR and as a result, have the opposite effect from what they were
	intended to do.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Amplification or Over-Expression of AR
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Several studies have shown that androgen deprivation results in
	over-expression of the AR, thus giving any residual androgen more opportunities to bind and thereby activate the full-length AR.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Residual Androgens Activate AR
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	While in mature men, the majority of androgen is produced by the
	testes, androgen is produced by a number of other tissues including the adrenal glands and in some prostate cancer tumors. A variety
	of different pathways can produce androgen, as well. As blood levels of androgen are reduced through use of current androgen-suppressing
	drugs or surgical castration, androgen production by alternate pathways may become an important way in which ARs become activated.
	Recently, it has been shown that prostate cancer tumor tissue can synthesize androgen, leading potentially to concentrations of
	intra-tumoral androgen that are sufficient to activate the full-length AR.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Over-expression of AR Coactivators
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The AR requires interaction with an abundance of other proteins
	such as bridging factors and coactivators. An example of a bridging factor that is associated with CRPC is CREB-binding protein
	(&ldquo;
<B>
	CBP
</B>
	&rdquo;). CBP is a bridging factor that interacts with the NTD of the AR and is thought to be essential for AR
	transcriptional activity. CBP levels are increased in CRPC, which may lead to cancer growth driven by AR activity. Coactivators
	of AR have also been reported to be increased in CRPC which may subsequently results in abberant transactivation of AR.
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Ligand-independent Activation by Cytokines or Kinases
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There is evidence that cytokines and kinases can activate the NTD
	of the AR. It is possible that under castrate levels of androgen, cross-talk between the AR and signal transduction pathways circumvent
	the need for androgen for the activation of the AR for the growth and survival of CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Constitutively Active AR Splice Variants that Lack the Ligand-Binding
	Domain
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	CRPC may involve the expression of constitutively active splice-variants
	of the AR that lack the full ligand-binding domain. These AR splice variants are always activated and have a truncated LBD, thus
	do not require androgen to be transcriptionally active. Antiandrogens such as enzalutamide would have no effect on these AR splice
	variants because antiandrogens bind to the ligand-binding domain which is not present in these variants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s drugs have been shown in peer-reviewed and published
	journal articles to be active on all of the above pathways. Specifically:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EPI-002 does not cause activation of mutated AR that is activated by antiandrogens;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EPI-002 is active against VCaP xenografts cell lines that overexpress AR;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EPI-002 is not competitive with androgen for the LBD, hence their effects cannot be competed away by high localized concentrations of androgen;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EPI-001 blocks the interaction of CBP and RAP74 which are required for transcriptional activity and may contribute to tumor growth;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	EPI-001 blocks AR activation by IL-6, bone-derived factors and stimulation of the PKA pathway;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In vitro and in vivo, EPI-002 significantly inhibits LNCaP95 human
	prostate cancer cells that harbour constitutively-active AR splicer variant V7 and are resistant to enzalutamide; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	EPI-002 blocks gene expression regulated by full-length AR and V7.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Programs and Potential Products
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	The Company&rsquo;s EPI-Series Drugs
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s product candidate, EPI-506, is a selective, oral small
	molecule pro-drug that blocks the N-terminal domain of the AR. The AR is required for the growth and survival of most prostate
	cancer; therefore, the NTD of the AR is an ideal target for next-generation hormone therapy. Consistent with the inhibition of
	AR activity by other EPI compounds, experimentation conducted in a test-tube or in a controlled environment outside a living organism
	(&ldquo;
<I>
	in vitro
</I>
	&rdquo; studies) and experimentation done in or on the living tissue of a whole, living organism (&ldquo;
<I>
	in
	vivo
</I>
	&rdquo; studies) show that EPI-506 selectively blocks AR-dependent proliferation of human prostate cancer cells that express
	AR and do not inhibit the proliferation of cells that do not express functional AR or do not rely on the AR for growth and survival.
	By directly inhibiting the NTD of the AR, ESSA believes EPI-506 may be able to overcome resistance mechanisms in CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has initiated a Phase 1/2 clinical trial to determine the safety,
	tolerability, maximum tolerated dose, pharmacokinetics, and efficacy of EPI-506 in CRPC patients. EPI-506 is currently in Phase
	1, where the trial will evaluate the benefit of once-daily dosing with EPI-506, in single- and multiple-dose escalations. If a
	suitable dose is determined in the Phase 1 (dose escalation) portion of the trial, the Phase 2 (dose expansion) portion of the
	trial will then evaluate activity in three patient cohorts: post-enzalutamide CRPC, post-abiraterone CRPC, and post-enzalutamide
	and -abiraterone CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has licensed the EPI-family of drugs from the UBC and BCCA
	whose initial lead compound was EPI-001. It is a mixture of four stereoisomers, each of which has the same chemical constitution,
	but different spatial orientation of its constituent atoms. While all the stereoisomers are active against the AR NTD, the most
	effective stereoisomer of EPI-001 is EPI-002 and substantial experimentation with EPI-002 has been completed and published. EPI-506
	is a pro-drug of EPI-002, meaning that EPI-506 metabolizes to EPI-002 in vivo once it is dosed orally.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	EPI-506 and its metabolite, EPI-002, have been shown to block AR-dependent
	proliferation of human prostate cancer cells that express full-length and splice-variant ARs, including the AR splice-variant V7,
	and have no effect on the viability of cells that do not rely on AR signaling for growth and survival at concentrations that block
	AR activity. EPI-506 and EPI-002 blocked tumor growth of full-length AR expressing LNCaP xenografts and AR V7 splice-variant positive
	LNCaP95 and VCaP xenografts in castrated male mice. Importantly, EPI-001, a mixture of EPI-002 and three stereoisomers, blocked
	AR-dependent tumor growth of LNCaP xenografts in intact (non-castrated) male mice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Pre-clinical Studies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is focused on developing EPI-506 as its clinical-development
	product candidate. EPI-506 has been shown to be more potent than EPI-002 by oral dosing. ESSA believes that the improved potency
	of EPI-506 relates to its high lipophilicity and other drug product characteristics as compared to EPI-002. The
<I>
	in vivo
</I>
	efficacy of EPI compounds has been demonstrated using a variety of human prostate cancer xenograft models.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s initial work to support the CRPC indication
	consisted of pre-clinical pharmacodynamic and pharmacokinetic trials and bioanalytical development, as well as non-GLP and GLP
	toxicology trials in three species. To date, non-clinical data of EPI-506 suggest that the drug should be well-tolerated after
	daily oral administration. Formulation development work and bioanalytical development for pre-clinical studies and clinical research
	have been conducted at BRI Biopharmaceutical Research Inc. in Vancouver, Canada.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	To formally assess any potential safety issues related to EPI-506,
	ESSA has conducted various dose-ranging non-GLP and IND enabling 28-day GLP toxicity trials in rodents and non-rodents, dose-ranging
	trials that lead to 28-day GLP toxicology trials. Consistent with the development of other oncology therapies at this early stage,
	no reproductive toxicology trials are required, given the patient population to be treated. The toxicology trials incorporate toxicokinetic
	data in order to correlate potential toxic effects with EPI-506 exposure. A radiolabeled form of EPI-506 is available and will
	be used for further metabolism and distribution work in vivo.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company has used Southwest Research Institute in San Antonio,
	Texas for Current Good Manufacturing Practices (&ldquo;
<B>
	cGMP
</B>
	&rdquo;) manufacturing of EPI-506 for early clinical trials.
	Manufacturing for the ongoing Phase 1 clinical trial is being conducted by Sigma Aldrich Fine Chemicals, based in Sheboygan Falls,
	Wisconsin. Formulation and cGMP production of the final product candidate for clinical trials is performed by Catalent Pharma Solutions,
	St. Petersburg, Florida.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Planned Clinical Development Program
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Phase 1/2 Clinical Trial Design for Treating CRPC Patients:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA received FDA approval for its IND on September 23, 2015. Additionally,
	Health Canada approved ESSA's clinical trial authorization application on November 5, 2015. ESSA has initiated a Phase 1/2 trial
	at sites in the U.S. and Canada to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and potential therapeutic
	benefits of EPI-506 in CRPC patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Phase 1 portion of the trial is expected to enroll approximately
	30 patients with CRPC. Following single-dose evaluation, patients are expected to then receive once-daily oral dosing for 28 days
	to assess safety for dose escalation. Further, patients will continue to receive trial drug for 12 weeks or longer to assess efficacy.
	The endpoints of this part of the trial will be to assess safety, tolerability, maximum tolerated dose and pharmacokinetics of
	EPI-506. Efficacy endpoints include PSA response and radiographic progression criteria. ESSA plans to conduct this Phase 1 portion
	of the trial at five sites and anticipates Phase 1 completion by approximately Q1 of calendar 2017 depending on the enrollment
	rate and number of dose escalation steps.
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Phase 2 portion is currently expected to focus on CRPC patients with progressive metastatic disease and rising PSA who are
	no longer responding to abiraterone or enzalutamide, or both. The main outcomes to be measured are expected to be:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	PSA response (reduction in blood PSA level of 50% or more);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	PSA progression;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	radiographic progression; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	objective responses.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA expects to collect circulating tumor cells so that the status
	of AR splice variant and other relevant biological markers related to AR signaling can be determined. If Phase 1 proceeds to completion
	in Q1 of calendar 2017 as planned, ESSA expects to conduct the Phase 2 portion in the United States, Canada, the UK, and France,
	and expects study completion by approximately Q1 of calendar 2018.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Phase 3 Clinical Trial
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In order to obtain regulatory approval, ESSA will be required to
	carry out at least one Phase 3 trial. At this time, ESSA expects that these patients will be a similar population of CRPC patients
	that were enrolled in the Phase 1/2 trial. However, the results of the Phase 1/2 trial may require modification of the initial
	patient population based on response and biomarker assessment. In the Phase 3 clinical trials, the key end-point is expected to
	be overall survival relative to patients receiving the standard-of-care. It is expected that the clinical trial would be conducted
	at many sites around the world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The competition in the prostate cancer market is very high, with
	several pharmaceutical therapies already approved and many new molecules being tested for their effect in this patient population.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Currently approved or developmental therapies include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 33%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	GENERIC/PROGRAM
	NAME
</B>
</P>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 19%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	BRAND NAME
</B>
</P>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 26%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	COMPANY
	NAME(S)
</B>
</P>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 19%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	STAGE
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Enzalutamide
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Xtandi
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Astellas and Pfizer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Abiraterone acetate
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Zytiga
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Johnson &amp; Johnson
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Sipuleucel-T
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Provenge
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Valeant
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Docetaxel
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	n/a
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Sanofi and various
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Cabazitaxel
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Jevtana
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Sanofi
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Radium-233
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Xofigo
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Bayer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Marketed
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Apalutamide (ARN-509)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	n/a
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Johnson &amp; Johnson
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Phase III
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ODM-201
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	n/a
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Orion Corp. and Bayer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	Phase III
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In this market, ESSA believes that its competitive position is strong
	because its product candidate, if successful, will focus mechanistically on the approach to prostate cancer that has been shown
	to make the biggest difference to the survival of recurrent prostate cancer patients: blocking AR activation. Since EPI compounds
	have been shown to directly block the AR NTD, they have the potential to overcome the AR-dependent resistance pathways (discussed
	above) that may develop as a result of treatment with current hormone-related CRPC therapies that target the AR LBD. If successful,
	ESSA believes this could represent a significant step forward in the treatment of prostate cancer. To ESSA&rsquo;s knowledge, no
	other antagonist to the AR NTD is currently undergoing clinical trials for prostate cancer or any other indication.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Patents and Proprietary Rights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	License Agreement with UBC and the BCCA
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has in-licensed intellectual property embodied in issued patents,
	pending patents applications and know-how relating to compounds that modulate AR activity created through research work done at
	the BCCA and UBC (the &ldquo;
<B>
	Licensors
</B>
	&rdquo;) under the direction of Drs. Marianne Sadar and Raymond Andersen, respectively.
	ESSA refers to these intellectual property rights as the &ldquo;Licensed IP.&rdquo; ESSA&rsquo;s EPI-series drugs are covered in
	the Licensed IP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Pursuant to an agreement among ESSA and the Licensors dated as of
	December&nbsp;22, 2010, and amended on February&nbsp;10, 2011 and on May&nbsp;27, 2014 (the &ldquo;
<B>
	License Agreement
</B>
	&rdquo;),
	ESSA has been granted a worldwide, exclusive license to develop and commercialize products based on the Licensed IP. ESSA must
	pay a minimum annual royalty of C$40,000 in the 2014 calendar year, increasing to C$65,000 in each of 2015 and 2016 and C$85,000
	in 2017 and for each year thereafter. An additional C$50,000 and C$900,000 must be paid upon enrollment of a patient in a Phase
	2 and Phase 3 clinical trial, respectively,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Licensors may terminate upon ESSA&rsquo;s insolvency, or the
	License Agreement may be terminated by either party for certain material breaches by the other party, including the failure of
	ESSA and ESSA&rsquo;s sublicensees to spend a total of at least C$5,000,000, in cash or in kind, in connection with the commercialization
	of products relating directly to the Licensed IP by December&nbsp;22, 2015. ESSA has already spent more than C$5,000,000 in connection
	with the commercialization of products relating directly to the Licensed IP. ESSA is required to allocate reasonable time to the
	development and commercialization of the Licensed IP and to use reasonable efforts to promote, market and sell products covered
	by the Licensed IP. The terms of the License Agreement required ESSA to issue to the Licensors, in lieu of payment of an initial
	license fee, 1,000,034 Common Shares. If ESSA develops products covered by the Licensed IP in the future, it will be required to
	pay certain development and regulatory milestone payments up to an aggregate of C$2.4 million for the first drug product developed
	under the license and up to an aggregate of C$510,000 for each subsequent product. ESSA must also pay the Licensors low single-digit
	royalties based on aggregate worldwide net sales of products covered by the Licensed IP and a percentage of sublicensing revenue
	in the low teens. ESSA is also required to reimburse costs incurred by the Licensors related to the prosecution and maintenance
	of patents embodying the Licensed IP. The License Agreement will expire on the later of 20 years after the date of the License
	Agreement or the expiry of the last issued patent included in the Licensed IP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	ESSA&rsquo;s Intellectual Property Strategy
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Both ESSA and the broader pharmaceutical industry attach significant
	importance to patents for the protection of new technologies, products and processes. Accordingly, ESSA&rsquo;s success depends,
	in part, on its ability to obtain patents or rights thereto, to protect commercial secrets and carry on activities without infringing
	the rights of third parties. See &ldquo;
<I>
	Risk Factors
</I>
	&rdquo; in Item 3.D elsewhere in this Annual Report . Where appropriate,
	and consistent with management&rsquo;s objectives, patents are pursued once concepts have been validated through appropriate laboratory
	work. To that end, ESSA will continue to seek patents in relation to those components or concepts that it perceives to be important.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Patent Applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has licensed patents and patent applications with respect to
	its technology from the Licensors, jointly. ESSA has the right to acquire ownership of these patents and patent applications upon
	specified payment to the Licensors, and providing that payments required under the License Agreement continue to be made. The specific
	active patent applications to which ESSA has licensed rights are listed below, along with notes relating to the countries in which
	the patent applications have been filed and the expected expiration dates of such patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has one issued United States patent that covers EPI-506 and
	includes claims that protect EPI-506 as a composition of matter and the use of EPI-506 in the treatment of conditions including
	castration-resistant prostate cancer. This United States patent has an expiration date of May&nbsp;9, 2034. Counterpart non-U.S.
	patents will also have a standard expiration of May&nbsp;9, 2034, subject to possible patent term extensions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The remaining patents and pending applications licensed by ESSA
	are directed to alternative androgen receptor modulators, derivatives thereof, and methods for their use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Pending Licensed Applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<I>
	&nbsp;
</I>
<B>
	TITLE
</B>
	&nbsp;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	COUNTRY
</B>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	STANDARD
<BR>
	EXPIRATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	DATES
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Brazil, Canada, Chile, China, Colombia, Europe, Hong Kong, Indonesia, India, Japan, the Republic of Korea, the Russian Federation, United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BORDER-TOP: BLACK 0.5PT SOLID">
	July 2, 2029
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States and Europe
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	April 6, 2032
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ARIPO, Australia, Brazil, Canada, Chile, China, Colombia, Egypt, Europe, Hong Kong India, Indonesia, Israel, Japan, the Republic of Korea, Mexico, New Zealand, OAPI, Peru, Philippines, the Russian Federation, Saudi Arabia, Singapore, South Africa, Thailand, Trinidad &amp; Tobago, Ukraine, United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	May 9, 2034
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada and Europe
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	January 6, 2031
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	January 6, 2031
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States and Europe
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 17, 2032
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	FLUORO-CHLORO BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent Convention Treaty Application
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 14, 2035
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	18F COMPOUNDS FOR CANCER IMAGING AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent Convention Treaty Application
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 14, 2035
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Australia, Canada, Europe, Japan, the Republic of Korea, New Zealand, Singapore, United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;9,&nbsp;2034
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	BISPHENOL ETHER DERIVATIVES AND METHODS FOR USING THE SAME
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent Convention Treaty Application
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 12, 2036
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Patent Convention Treaty Application
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	January 13, 2036
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada and United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 2, 2036
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE AR
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States, Canada, Chile, Hong Kong and India
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 24, 2029
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States and as a Patent Convention Treaty application
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	May 29, 2035
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Granted Licensed Patents
</I>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 33%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 10PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TITLE
</B>
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-TOP: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 46%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	COUNTRY
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-TOP: 10PT; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 19%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 10PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	STANDARD
<BR>
	EXPIRATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 6.6PT; TEXT-ALIGN: CENTER">
<B>
	DATES
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States, Australia, Israel, Japan, the Russian Federation, Mexico, New Zealand, and South&nbsp;Africa
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	July 2, 2029
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	ESTER DERIVATIVES OF AR MODULATORS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Australia, United States
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	May 9, 2034
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -0.2IN">
	BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN
	RECEPTOR ACTIVITY MODULATORS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -0.2IN">
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Japan and United States
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	January 6, 2031
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	April 16, 2033
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 9, 2034
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.2IN; TEXT-INDENT: -0.2IN">
<FONT STYLE="FONT-SIZE: 10PT">
	SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE AR
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Australia, China, France, Germany, Italy, Spain, United Kingdom, Mexico, New Zealand and the Russian Federation
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 6.6PT">
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August&nbsp;24,&nbsp;2029
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Regulatory Environment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The production and manufacture of ESSA&rsquo;s product candidate
	and its R&amp;D activities are subject to regulation for safety, efficacy, quality and ethics by various governmental authorities
	around the world. In Canada, these activities are regulated by the Food and Drugs Act and the rules and regulations thereunder,
	which are enforced by the TPD. In the United States, drugs and biological products are subject to regulation by the FDA. Drug approval
	laws require licensing of manufacturing facilities, carefully controlled research and testing of products, government review and
	approval of experimental results prior to giving approval to sell drug products. Regulators also require that rigorous and specific
	standards such as cGMP, GLP and GCP are followed in the manufacture, testing and clinical development respectively of any drug
	product. See &ldquo;
<I>
	Risk Factors
</I>
	&rdquo; in Item 3.D elsewhere in this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The process of obtaining regulatory approvals and the corresponding
	compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial
	time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
	process, approval process or after approval may subject an applicant or sponsor to a variety of administrative or judicial sanctions,
	including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance
	of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production
	or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal
	investigations and penalties brought by the FDA and the Department of Justice (&ldquo;
<B>
	DOJ
</B>
	&rdquo;) or other governmental
	entities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	An applicant seeking approval to market and distribute a new drug
	product in the United States must typically undertake the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	completion of extensive nonclinical, sometimes referred to as preclinical laboratory tests, and preclinical animal trials and applicable requirements for the humane use of laboratory animals and formulation studies in compliance with applicable regulations, including GLPs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	submission to the FDA of an IND, which must take effect before human clinical trials may begin;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	approval by an IRB, representing each clinical site before each clinical trial may be initiated;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	performance of adequate and well-controlled human clinical trials according to the FDA&rsquo;s regulations commonly referred to as GCP regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	preparation and submission to the FDA of a NDA;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	review of the product by an FDA advisory committee, where appropriate or if applicable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s identity, strength, quality and purity;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	payment of user fees and securing FDA approval of the NDA; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies (&ldquo;
<B>
	REMS
</B>
	&rdquo;) and post-approval studies required by the FDA.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Pre-Clinical Studies
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Pre-clinical studies are conducted in vitro and in animals to evaluate
	pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the product candidate prior to its
	administration to humans in clinical studies and throughout development. The conduct of pre-clinical studies is subject to federal
	regulations and requirements, including GLP regulations. The results of the pre-clinical tests, together with manufacturing information,
	analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to
	the FDA as part of an IND. Some long-term pre-clinical testing, such as animal tests of reproductive adverse events and carcinogenicity,
	may continue after the IND is submitted. ESSA has completed GLP pre-clinical toxicology studies as required for the IND.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Initiation of Human Testing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Clinical trials involve the administration of the investigational
	product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include,
	among other things, the requirement that all research subjects provide their informed consent in writing before their participation
	in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives
	of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each
	clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes
	effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed
	clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding
	concerns before the clinical trial can begin. In Canada, this application is called a CTA. An IND/CTA application must be filed
	and accepted by the FDA or TPD, as applicable, before human clinical trials may begin. In addition, an IRB representing each institution
	participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution,
	and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other
	things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance
	with FDA regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Two key factors influencing the rate of progression of clinical
	trials are the rate at which patients can be enrolled to participate in the research program and whether effective treatments are
	currently available for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence
	and severity of the disease, the treatments available and the potential side effects of the drug to be tested and any restrictions
	for enrollment that may be imposed by regulatory agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Phase 1 Clinical Trials
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Phase 1 clinical trials for cancer therapeutics are typically conducted
	on a small number of patients to evaluate safety, dose limiting toxicities, tolerability, pharmacokinetics and to determine the
	dose for Phase 2 clinical trials in humans. ESSA expects to test the Company&rsquo;s drug in approximately 30 CRPC patients in
	this phase of the Company&rsquo;s development activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Phase 2 Clinical Trials
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Phase 2 clinical trials typically involve a larger patient population
	than Phase 1 clinical trials and are conducted to identify possible adverse effects and safety risks, to preliminarily evaluate
	the efficacy of a product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing
	schedule. As discussed above, ESSA expects to dose up to 120 patients in its Phase 2 trial, potentially adding patient cohorts
	depending on the advice of its clinical advisors. ESSA intends to focus on PSA response, radiographic progression and progression-free
	survival as the key outcomes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Phase 3 Clinical Trials
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Phase 3 clinical trials typically involve testing an experimental
	drug on a much larger population of patients suffering from the targeted condition or disease &ndash; in ESSA&rsquo;s case, CRPC.
	These studies involve testing the experimental drug in an expanded patient population at geographically dispersed test sites (multi-center
	trials) to establish clinical safety and effectiveness. These trials also generate information from which the overall risk-benefit
	relationship relating to the drug can be determined. As discussed above, ESSA expects to focus on survival measurements as the
	key outcome from this stage of its clinical development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In most cases FDA requires two adequate and well controlled Phase
	3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient
	in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive
	finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious
	outcome and confirmation of the result in a second trial would be practically or ethically impossible.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	New Drug Application
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Assuming successful completion of required clinical testing and
	other requirements, the results of the pre-clinical and clinical studies, together with detailed information relating to the product&rsquo;s
	chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA, or the
	TPD as part of an NDS, requesting approval to market the drug product for one or more indications. The NDS or NDA is then reviewed
	by the applicable regulatory body for approval to market the drug.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The FDA conducts a preliminary review of an NDA within 60 days of
	its receipt and informs the sponsor by the 74
<SUP>
	th
</SUP>
	day after the FDA&rsquo;s receipt of the submission to determine whether
	the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept
	an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application
	is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth
	substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are
	meant to be reviewed within ten months from the date of filing, and most applications for &ldquo;priority review&rdquo; products
	are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months
	to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA
	following the original submission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Before approving an NDA, the FDA typically will inspect the facility
	or facilities where the product is or will be manufactured. These pre-approval inspections cover all facilities associated with
	an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product manufacturing,
	and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes
	and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
	specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance
	with GCP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The cost of preparing and submitting an NDA is substantial. The
	submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2,169,000 and the manufacturer
	or sponsor under an approved new drug application are also subject to annual product and establishment user fees, currently exceeding
	$104,000 per product and $554,000 per establishment. These fees are typically increased annually.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	An NDS costs roughly $322,056 per submission and will also be subject
	to Drug Establishment Licensing fees, which currently exceed $16,000 per established facility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On the basis of the FDA&rsquo;s evaluation of the NDA and accompanying
	information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a
	complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
	for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial
	additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been
	addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed
	to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this
	additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the FDA approves a product, it may limit the approved indications
	for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that
	post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&rsquo;s safety after approval,
	require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
	distribution restrictions or other risk management mechanisms which can materially affect the potential market and profitability
	of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance
	programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes
	and additional labeling claims, are subject to further testing requirements and FDA review and approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Post-Approval Requirements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Drugs manufactured or distributed pursuant to FDA approvals are
	subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping,
	periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the
	product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject
	to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments
	at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, drug manufacturers and other entities involved in the
	manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and
	are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes
	to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations
	also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon
	the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend
	time, money, and effort in the area of production and quality control to maintain cGMP compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Once an approval is granted, the FDA may withdraw the approval if
	compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
	Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
	or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling
	to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of
	distribution or other restrictions under a REMS program. Other potential consequences include, among other things:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	fines, warning letters or holds on post-approval clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	product seizure or detention, or refusal to permit the import or export of products; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	injunctions or the imposition of civil or criminal penalties.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The FDA strictly regulates marketing, labeling, advertising and
	promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance
	with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the
	promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
	liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, the distribution of prescription pharmaceutical products
	is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal
	level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state
	laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in
	distribution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Orphan Designation and Exclusivity
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA may, in the future, seek orphan drug designation for its product
	candidates. Under the Orphan Drug Act, the FDA may designate a drug product as an &ldquo;orphan drug&rdquo; if it is intended to
	treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more
	in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United
	States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product
	designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and
	its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review
	and approval process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If a product with orphan status receives the first FDA approval
	for the disease or condition for which it has such designation, the product generally will be receive orphan product exclusivity.
	Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication
	for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication
	for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a
	drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what
	was designated in its orphan product application, it may not be entitled to exclusivity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Organizational Structure
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company has one wholly-owned subsidiary, ESSA Texas, existing
	under the laws of the State of Texas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Property, Plants and Equipment
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s operating plan does not include building infrastructure
	in the form of an in-house laboratory, capital equipment, headcount, or administrative burden.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA operates from its head office located in Vancouver, Canada.
	Operations related to the EPI-506 development program are based in Houston, Texas. ESSA does not own any real property. The following
	table outlines significant properties that ESSA currently leases:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 22%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	LOCATION
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 22%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	AREA
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(IN&nbsp;SQUARE&nbsp;FEET)
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	LEASE&nbsp;EXPIRATION&nbsp;DATE
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 15%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	USE
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Vancouver, Canada
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	200
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Monthly
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Office Space
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Houston, United States
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	9,363
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Dec. 31, 2019
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Office Space
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Canadian office space costs C$3,413 per month and is rented
	on a month to month basis. The United States office space costs $13,264 per month. ESSA believes that its current facilities are
	adequate to meet its ongoing needs and that, if ESSA requires additional space, it will be able to obtain additional facilities
	on commercially reasonable terms.
</P>
</EFX_COMPANY_INFORMATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;4A
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 88%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	UNRESOLVED STAFF COMMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="FIS_OPERATING_AND_FINANCIAL_REVIEW"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 5.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 88%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	A. Operating Results
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	The following discussion and analysis of the financial condition
	and results of operations of ESSA should be read in conjunction with the audited financial statements as at and for the fiscal
	years ended September 30, 2016, 2015 and 2014, together with the notes thereto. The financial information contained in this Annual
	Report is derived from the financial statements, which were prepared in accordance with IFRS.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a clinical stage pharmaceutical company focused on developing
	novel and proprietary therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment
	with current therapies, including abiraterone and enzalutamide. ESSA believes its product candidate, EPI-506, can significantly
	expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. Specifically, EPI-506
	acts by disrupting the AR signaling pathway, which is the primary pathway that drives prostate cancer growth. ESSA has shown that
	EPI-002, the primary metabolite of EPI-506, prevents AR activation by binding selectively to the NTD of the AR. A functional NTD
	is essential for activation of the AR. In pre-clinical studies, blocking the NTD has demonstrated the capability to prevent AR
	activation and overcome the known AR-dependent mechanisms of CRPC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On September 23, 2015, ESSA received FDA approval of its IND application
	to initiate a Phase 1/2 clinical study. On November 5, 2015, ESSA received a &ldquo;no objection letter&rdquo; from Health Canada,
	which will allow it to include Canadian sites in the Phase 1/2 clinical study. ESSA expects to execute a Phase 1/2 clinical study
	to explore the safety, tolerability, maximum tolerated dose and pharmacokinetics of EPI-506, in addition to tumor response rates
	in&nbsp;asymptomatic&nbsp;or minimally symptomatic patients who are no longer responding to either abiraterone or enzalutamide
	treatments, or both. Efficacy endpoints&nbsp;include PSA reduction, as well as other progression criteria.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	According to the American Cancer Society, in the United States,
	prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. Approximately one-third of all prostate
	cancer patients who have been treated for local disease will subsequently have rising serum levels of PSA, which is an indication
	of recurrent or advanced disease. Patients with advanced disease often undergo androgen ablation therapy using analogues of LHRH
	or surgical castration. Most advanced prostate cancer patients initially respond to androgen ablation therapy, however many experience
	a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to be suffering
	from CRPC. Following diagnosis of CRPC, patients are often treated with anti-androgens, which block the binding of androgens to
	the AR.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has never been profitable and has incurred net losses since
	inception.&nbsp;ESSA's net losses were $13,139,788, $9,676,587, and $1,823,929 for the years ended September&nbsp;30, 2016, 2015,
	and 2014, respectively. ESSA expects to incur losses for the foreseeable future, and it expects these losses to increase as it
	continues the development of, and seek regulatory approvals for, its product candidate. Because of the numerous risks and uncertainties
	associated with product development, ESSA is unable to predict the timing or amount of increased expenses or when, or if, it will
	be able to achieve or maintain profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth ESSA's consolidated statements of
	financial position and consolidated statements of loss and comprehensive loss as at and for the fiscal years ended September 30,
	2016, 2015, and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	(US$)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Income Statement Data
</I>
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30, 2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30, 2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30, 2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 34%; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Revenue
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other Income
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	647
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	217
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total operating expenses
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(19,642,164
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,328,849
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,824,537
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Research and development, net of recoveries
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13,060,201
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,975,928
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	671,600
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Financing costs
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	937,845
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	93,755
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	87,587
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	General and administration, net of recoveries
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,644,118
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,259,166
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,065,350
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Loss before income taxes
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12,988,516
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,676,587
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,823,929
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Net loss, net of income tax
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(13,139,788
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(9,676,587
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(1,823,929
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Balance Sheet Data
</I>
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Cash
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,985,095
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,579,288
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,699,980
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other current assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,034,114
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,510,940
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	126,911
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Intangible assets
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	255,623
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	284,081
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	360,840
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Equipment
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	127,730
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	165,464
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	14,102
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Total assets
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	10,402,562
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	7,539,773
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	4,201,833
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Accounts payable and accrued liabilities
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,538,761
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,091,162
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	587,353
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Income tax payable
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	91,191
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Derivative liability
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,309,467
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	993,099
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Product development and relocation grant
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,640,352
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Shareholders&rsquo; equity (deficiency)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(536,857
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,455,512
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,974,128
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Total liabilities and shareholders&rsquo; equity (deficiency)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	10,402,562
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	7,539,773
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	4,201,833
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations for the Fiscal Years Ended September 30,
	2016 and 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There was no revenue in any of the fiscal years as reported. The
	Company incurred a comprehensive loss of $13,477,551 for the year ended September 30, 2016 compared to a comprehensive loss of
	$11,341,799 for the year ended September 30, 2015. Variations in ESSA&rsquo;s expenses and net loss for the periods resulted primarily
	from the following factors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Research and Development Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Expenses increased in all categories of R&amp;D. R&amp;D expense
	included the following major expenses by nature:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,&nbsp;2016
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30,&nbsp;2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Clinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,920,104
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	304,142
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consulting
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,333,323
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,072,039
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Legal patents and license fees
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	905,392
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	554,712
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Manufacturing
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,601,407
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,417,551
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Other
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	306,657
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	299,470
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Pharmacology
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	866,527
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,420,276
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Program administration
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	381,429
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	428,096
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Royalties
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	46,228
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	30,550
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Salaries and benefits
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,194,047
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,671,567
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	322,160
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	779,263
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Travel
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	182,927
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	437,266
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	SRED tax credits
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(59,666
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	CPRIT grant claimed on eligible expenses
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(5,379,298
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13,060,201
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,975,928
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The overall R&amp;D expense for the year ended September 30, 2016
	was $13,060,201 compared to $4,975,928 for the year ended September 30, 2015, net of R&amp;D recoveries of $nil for the year ended
	September 30, 2016 and $5,438,964 for the year ended September 30, 2015. The gross expense for 2016 of $13,060,201 was higher as
	compared to $10,414,892 in 2015 due to increased overall activity following several significant financings in early 2016 that corresponded
	with the Company commencing Phase 1 of its clinical trial. Pharmacology costs of $866,527 (2015 - $1,420,276) have decreased compared
	to the comparative period in 2015 due to the completion of testing and experimentation on the Company&rsquo;s EPI-series drugs.
	The investment for the comparative period was significant as the Company worked with its research facility partners to complete
	the documentation and information to supplement its IND application as filed at the end of March 2015. Manufacturing costs of $3,601,407
	(2015 - $3,417,551) and clinical costs of $2,920,104 (2015 - $304,142) related to the commencement of the Phase 1/2 clinical trial
	in November 2015, including manufacture of batches of EPI-506 for use in the clinical trial, and work performed by the clinical
	research organization in preparation for and conducting of the clinical trial. Legal patent and license fees increased to $905,392
	for the year ended September 30, 2016 (2015 - $554,712) as the Company has submitted a number of patent applications for which
	the Company owns the rights. Consulting costs increased to $1,333,323 for the year ended September 30, 2016 (2015 - $1,072,039)
	as the Company has engaged professionals in Texas to conduct specific R&amp;D services for the Company in addition to regular payments
	made to the Company&rsquo;s Chief Scientific Officer and Chief Technical Officer. Salaries and benefits of $2,194,047 for the year
	ended September 30, 2016 (2015 - $1,671,567) related to additional research support staff added to formal payroll during the period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Share-based payments expense of $322,160 (2015 - $779,263) relates
	to the value assigned to stock options granted to key management and consultants of the Company. The expense is recognized in relation
	to the grant and vest of these equity instruments as measured by the Black-Scholes pricing model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	General and Administration Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administrative expenses include the following major
	expenses by nature:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,&nbsp;2016
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30,&nbsp;2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 62%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amortization
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;66,181
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;42,223
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Consulting and subcontractor fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;87,014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;293,522
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;204,049
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;128,362
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Insurance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;422,066
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;121,986
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Investor relations
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;317,822
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;219,312
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Office, insurance, IT and communications
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;288,968
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;275,200
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Professional fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;776,339
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,807,112
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Regulatory fees and transfer agent
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;131,302
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;535,088
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Rent
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;620,023
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;278,570
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Salaries and benefits
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,634,380
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;815,544
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;897,043
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;637,524
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Travel and entertainment
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;198,931
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;225,182
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	CPRIT grant claimed on eligible expenses
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;&nbsp;-
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;(120,459
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	5,644,118
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,259,166
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administration expenses increased to $5,644,118 from
	$5,259,166 in the year ended September 30, 2015. Significant components of the expense in 2016 included $776,339 (2015 - $1,807,112)
	in professional fees for legal and accounting services in conjunction with corporate activities including the Company&rsquo;s financing
	activities, initial listings on the TSX-V and the Nasdaq in fiscal 2015, and salaries and benefits expense of $1,634,380 (2015
	- $815,544) related to the addition of administrative staff as well as the resignation of the former CEO and appointment of a new
	CEO and COO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Share-Based Payments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Share-based payments expense of $897,043 (2015 - $637,524) relates
	to the value assigned to stock options granted to key management and consultants of the Company. The expense is recognized in relation
	to the grant and vest of these equity instruments and allocated to research and development, general and administration and financing
	expenditures relative to the activity of the underlying optionee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations for the Fiscal Year Ended September 30,
	2015 and the Fiscal Year ended September 30, 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There was no revenue in any of the fiscal years as reported. The
	Company incurred a comprehensive loss of $11,341,799 for the year ended September 30, 2015 compared to a comprehensive loss of
	$1,895,667 for the year ended September 30, 2014. Variations in ESSA&rsquo;s expenses and net loss for the periods resulted primarily
	from the following factors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Research and Development Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Expenses increased in all categories of R&amp;D. R&amp;D expense
	included the following major expenses by nature:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,&nbsp;2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30,&nbsp;2014
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Clinical
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	304,142
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Consulting
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,072,039
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;309,610
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Legal patents and license fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;554,712
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;309,855
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Manufacturing
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;3,417,551
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;411,078
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Other
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;299,470
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;26,899
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Pharmacology
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,420,276
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;385,260
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Program administration
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;428,096
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;-&nbsp; &nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Royalties
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;30,550
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;36,722
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Salaries and benefits
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,671,567
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;92,799
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;779,263
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;321,524
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Travel
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;437,226
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;63,774
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	SRED tax credits
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;(59,666
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;(215,984
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	CPRIT grant claimed on eligible expenses
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(5,379,298
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,069,937
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,975,928
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	671,600
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The overall R&amp;D expense for the year ended September 30, 2015
	was $4,975,928 compared to $671,600 for the year ended September 30, 2014. The expense for 2015 was higher as compared to 2014
	due to increased overall activity following several significant financings in the latter part of fiscal 2014 that permitted a more
	robust research program compared to the prior period when the Company was focusing on achieving the CPRIT grant and financing objectives.
	Manufacturing and pharmacology costs were $3,417,551 and $1,420,276 in the year ending September 30, 2015, respectively, compared
	to $411,078 and $385,260, respectively in the year ending September 30, 2014. This increase is related to the increase in spending
	on contracted lab facilities to conduct testing and experimentation on the Company&rsquo;s product candidates. Clinical costs were
	$304,142 in relation to work performed by the clinical trial organization in preparation for the clinical trial which commenced
	in November 2015. Legal patent and license fees increased to $554,712 for the year ended September 30, 2015 (2014 - $309,855) as
	the Company has submitted a number of patent applications for which the Company owns the rights. Consulting costs increased to
	$1,072,039 for the year ended September 30, 2015 (2014 - $309,610) as the Company has engaged professionals in Texas to conduct
	specific R&amp;D services for the Company in addition to regular payments made to the Company&rsquo;s Chief Scientific Officer
	and Chief Technical Officer. The fees to both the Chief Scientific Officer and Chief Technical Officer increased from C$60,000
	per year to C$120,000 per year following the successful completion of C$5,000,000 in equity financings during fiscal 2015. Salaries
	and benefits of $1,671,567 for the year ended September 30, 2015 (2014 - $92,799) related to the Company&rsquo;s Chief Medical
	Officer, Executive VP of Research and additional research support staff added to formal payroll in September 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Share-based payments expense of $779,263 (2014 - $321,524) relates
	to the value assigned to stock options granted to key management and consultants of the Company. The expense is recognized in relation
	to the grant and vest of these equity instruments as measured by the Black-Scholes pricing model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	General and Administration Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administrative expenses include the following major
	expenses by nature:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,&nbsp;2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	Year ended
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30,&nbsp;2014
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	Amortization
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 16%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;42,223
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	23,385
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Consulting and subcontractor fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;293,522
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;371,519
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;128,362
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;-&nbsp; &nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Insurance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;121,986
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;14,910
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Investor relations
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;219,312
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;-&nbsp; &nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Office, insurance, IT and communications
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;275,200
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;34,072
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Professional fees
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;1,807,112
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;442,133
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Regulatory fees and transfer agent
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;535,088
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;9,456
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Rent
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;278,570
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;36,194
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Salaries and benefits
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;815,544
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;87,365
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;637,524
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;117,215
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Travel and entertainment
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;225,182
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;12,797
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	CPRIT grant claimed on eligible expenses
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(120,459
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	(83,696
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,259,166
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 10PT">
	1,065,350
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administration expenses increased to $5,259,166 from
	$1,065,350 in the year ended September 30, 2014. Significant components of the expense in 2015 included $1,807,112 (2014 - $442,133)
	in professional fees for legal and accounting services in conjunction with corporate activities including the Company&rsquo;s financing
	activities, listing on the TSX-V and the Nasdaq, and a salaries and benefits expense of $815,544 (2014 - $87,365) related to the
	establishment of the CEO and CFO as full time employees of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Share-Based Payments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Share-based payments expense of $637,524 (2014 - $117,215) relates
	to the value assigned to stock options granted to key management and consultants of the Company. The expense is recognized in relation
	to the grant and vest of these equity instruments and allocated to research and development, general and administration and financing
	expenditures relative to the activity of the underlying optionee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Quarterly Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table summarizes selected unaudited consolidated financial
	data for each of the last eight quarters, prepared in accordance with IFRS. This data should be read in conjunction with the Company&rsquo;s
	audited financial statements and related notes included elsewhere in this Annual Report. These quarterly operating results are
	not necessarily indicative of ESSA&rsquo;s operating results for a full year or any future period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	For the Quarters Ended
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the Quarters Ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March&nbsp;31,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	December&nbsp;31,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 47%">
<FONT STYLE="FONT-SIZE: 10PT">
	Research and development expense
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,951,799
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,362,948
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,544,517
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,200,937
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	General and administration
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,236,873
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,305,780
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,874,597
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,226,868
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Comprehensive loss
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4,236,768
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3,865,757
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,335,215
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4,039,811
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Basic and diluted loss per share
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.15)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.04
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.18
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,402,562
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13,666,625
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17,470,959
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,622,698
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Long-term liabilities
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,309,467
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,350,043
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,217,777
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	588,408
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the Quarters Ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June&nbsp;30,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March&nbsp;31,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	December&nbsp;31,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 47%">
<FONT STYLE="FONT-SIZE: 10PT">
	Research and development expense (recoveries)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(791,822
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,590,652
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,532,553
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	644,545
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	General and administration
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,177,188
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,065,563
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,320,088
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	696,327
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Comprehensive loss
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(469,155
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4,858,400
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4,569,637
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,444,608
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Basic and diluted earnings (loss) per share
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.02
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.29
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.20
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.08
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total assets
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,539,773
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,744,588
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,979,382
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,983,434
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Long-term liabilities
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	993,099
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,239,274
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	880,516
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	296,975
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Research and Development Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In the quarter ended December 31, 2014, the
	Company the 2014 Special Warrant Financing. In addition, on January 16, 2015, the Company completed the 2015 Special Warrant Financing.
	Accordingly, with these additional resources, the Company accelerated its work relating to the IND filing resulting in a significant
	increase in R&amp;D expenses and comprehensive loss over prior periods. The IND application was filed on March 31, 2015 with additional
	chemistry and pharmaceutical data work provided to the FDA in the following quarters. The IND was ultimately approved in September
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the quarter ended September&nbsp;30, 2015, the Company recorded
	a receivable of $3,786,667 for its second tranche of the CPRIT Grant, which was recognized as recoveries of R&amp;D expenditures,
	resulting in a net recovery of $791,822 for the period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	General and Administration Expenditures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administrative expenses for the three month periods
	ended March 31, 2015, June 30, 2015 and September 30, 2015 have increased over the prior periods as the Company completed its Nasdaq
	listing and graduated to the TSX from the TSX-V, resulting in a higher overall corporate burden and engagement of professional
	services. Increased costs in the period were also related to the binding of directors&rsquo; and officers&rsquo; liability insurance
	as well as travel related to the private placement financing initiative.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and administrative expenses for the three months ended March
	31, 2016 have increased over the prior periods in relation to the January 2016 Financing and March 2016 Financing, pursuant to
	which the Company raised gross proceeds of $20,000,000. &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Critical Accounting Policies and Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company makes estimates and assumptions about the future that
	affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience
	and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future,
	actual experience may differ from these estimates and assumptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The effect of a change in an accounting estimate is recognized prospectively
	by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of
	the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation
	uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to
	the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made that
	relate to the following key estimates:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Intangible Assets &ndash; impairment
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The application of the Company&rsquo;s accounting policy for intangible
	assets expenditures requires judgment in determining whether it is likely that future economic benefits will flow to the Company,
	which may be based on assumptions about future events or circumstances. Estimates and assumptions may change if new information
	becomes available. If, after expenditures are capitalized, information becomes available suggesting that the recovery of expenditures
	is unlikely, the amount capitalized is written off in profit or loss in the period the new information becomes available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Intangible Assets &ndash; useful lives
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Following initial recognition, the Company carries the value of
	intangible assets at cost less accumulated amortization and any accumulated impairment losses. Amortization is recorded on a straight-line
	basis based upon management&rsquo;s estimate of the useful life and residual value. The estimates are reviewed at least annually
	and are updated if expectations change as a result of technical obsolescence or legal and other limits to use. A change in the
	useful life or residual value will impact the reported carrying value of the intangible assets resulting in a change in related
	amortization expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Product development and relocation grant
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Pursuant to the terms of the Company&rsquo;s CPRIT Grant, the Company
	must meet certain terms and conditions to qualify for the grant funding. The Company has assessed its performance relative to these
	terms as detail in &ldquo;
<I>
	Summary Corporate History and Intercorporate Relationships
</I>
	&rdquo; in Item&nbsp;4 of this Annual
	Report and has judged that there is reasonable assurance the Company will meet the terms of the grant and qualify for the funding.
	The Company has therefore taken into income a portion of the grant that represents expenses the Company has incurred to date under
	the grant parameters. The expenses are subject to assessment by CPRIT for compliance with the grant regulations which may result
	in certain expenses being denied and incurred in a future period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Share-based payments and compensation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company has applied estimates with respect to the valuation
	of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date
	the Company receives the goods or services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company measures the cost of equity-settled transactions with
	employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value
	for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms
	and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including
	the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making
	assumptions about them. The fair value of the underlying common shares is assessed as the most recent issuance price per common
	share for cash proceeds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	JOBS Act
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As a company with less than US$1.0 billion in revenue during the
	last fiscal year, ESSA qualifies as an &ldquo;emerging growth company&rdquo; pursuant to the JOBS Act. An emerging growth company
	may take advantage of specified exemptions from various requirements that are otherwise applicable generally to public companies
	in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The JOBS Act also permits an emerging growth company such as ESSA
	to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies.
	ESSA will not take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying
	with new or revised accounting standards. This election is irrevocable. ESSA will remain an emerging growth company until the earliest
	of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the last day of the Company&rsquo;s fiscal year during which it has total annual gross revenues of at least US$1.0 billion;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the last day of the Company&rsquo;s fiscal year following the fifth anniversary of the completion of an initial public offering;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the date on which Company has, during the previous three-year period, issued more than US$1.0 billion in non-convertible debt securities; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the date on which the Company is deemed to be a &ldquo;large accelerated filer&rdquo; under the Exchange Act, which would occur if the market value of ESSA&rsquo;s Common Shares that are held by non-affiliates exceeds US$700 million as of the last business day of its most recently completed second fiscal quarter.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As a result of ESSA&rsquo;s status as an emerging growth company,
	the information that the Company provides shareholders may be less comprehensive than what you might receive from other public
	companies that are not emerging growth companies. When ESSA is no longer deemed to be an emerging growth company, ESSA will not
	be entitled to the exemptions provided in the JOBS Act.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Liquidity and Capital Resources
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a clinical development stage company and does not currently
	generate revenue. In 2014, ESSA had sufficient funds from the money raised from a previous financing and from tax credit refunds
	to meet the operating plan for the majority of the year. These funds were supplemented by a convertible secured debenture issued
	by ESSA to Bloom Burton Healthcare Structured Lending Fund in the amount of C$1,000,000 bearing interest at a rate of 12%&nbsp;per
	annum (the &ldquo;
<B>
	Convertible Debenture
</B>
	&rdquo;), a brokered private placement offering of 1,185,400 preferred shares in
	ESSA&rsquo;s capital at a price of C$2.00 per preferred share for aggregate gross proceeds of C$2,370,800 (the &ldquo;
<B>
	2014 Financing
</B>
	&rdquo;)
	and the first advance of the CPRIT Grant in the amount of US$2,791,333. The Convertible Debenture to Bloom Burton in April 2014,
	was converted, pursuant to its conversion terms, into 517,500 class A Preferred Shares concurrently with the completion of the
	2014 Financing. In addition, on October&nbsp;22, 2014 and October&nbsp;23, 2014, ESSA issued an aggregate of 679,640 special warrants
	(&ldquo;
<B>
	2014 Special Warrants
</B>
	&rdquo;) by it at C$2.00 per 2014 Special Warrant (the &ldquo;
<B>
	2014 Special Warrant Financing
</B>
	&rdquo;)
	and, on January&nbsp;16, 2015 ESSA issued 4,363,634 special warrants at a price of $2.75 per 2015 Special Warrant for gross proceeds
	of approximately $12,000,000 (the &ldquo;
<B>
	2015 Special Warrant Financing
</B>
	&rdquo;). All of these 2014 Special Warrants and
	2015 Special Warrants have been converted to Common Shares. Immediately prior to the listing of Common Shares on the TSX-V, all
	of ESSA's outstanding Preferred Shares were converted to 2,382,540 Common Shares. In January 2016, the Company completed a private
	placement (the &ldquo;
<B>
	January 2016 Financing
</B>
	&rdquo;) of 4,545,452 Units of the Company at a price of $3.30 per Unit for
	gross proceeds of approximately $15,000,000. Each Unit consisted of one Common Share, one Seven-Year Warrant, and one-half of one
	Two-Year Warrant. In March 2016, the Company completed a private placement (the &ldquo;
<B>
	March 2016 Financing
</B>
	&rdquo;) of 1,666,666
	common shares at a price of $3.00 per share for gross proceeds of approximately $5,000,000. On November 18, 2016, the Company completed
	a debt financing of up to $10,000,000, of which $8,000,000 has been advanced (discussed under &ldquo;Item 4.A.2. Summary Corporate
	History&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Operational activities during the year ended September 30, 2016,
	were financed mainly by proceeds from the equity financings completed in January 2015, January 2016, March 2016 and the CPRIT Grant.
	At September 30, 2016, ESSA had available cash reserves of $8,985,095 and $15,882 in accounts receivable related to refundable
	GST input tax credits, to settle current liabilities of $3,629,952. This compares to cash of $1,579,288 and $3,849,605 in accounts
	receivable comprised of the second tranche advance of the CPRIT Grant and refundable GST input tax credits at September&nbsp;30,
	2015 to settle current liabilities of $2,091,162.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The 2014 Financing was completed on July&nbsp;29, 2014 for aggregate
	gross proceeds of C$2,370,800, the 2014 Special Warrant Financing was completed in October 2014 for aggregate gross proceeds of
	C$1,359,280, the&nbsp;2015 Special Warrant Financing was completed in January 2015 for gross proceeds of approximately $12,000,000,
	the January 2016 Financing was completed for gross proceeds of $15,000,000 and the March 2016 Financing was completed for gross
	proceeds of $5,000,000, each as previously described above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of September 30, 2016, ESSA had cash on hand of $8,985,095, up
	from $1,579,288 at September 30, 2015. The increase of $7,405,807 was due primarily to financing cash flows of $22,744,129 including
	the second CPRIT tranche of $3,786,667, offset by operating cash flows of $15,300,969. During the year ended September 30, 2016,
	the Company also purchased furniture and equipment of $9,983 (2015 - $174,054) and received $37,659 (2015 - $252,185) in proceeds
	on exercise of stock options and warrants. In November 2016, the Company completed a debt financing of up to $10,000,000, of which
	$8,000,000 has been advanced. Management continues to seek sources of additional financing which would assure continuation of the
	Company&rsquo;s operations and research programs. However, there is no certainty that such financing will be provided or provided
	on favourable terms. The Company believes that it will complete one or more of these arrangements in sufficient time to continue
	to execute its planned expenditures without interruption. Consistent with the operating model, ESSA has no plans to build infrastructure;
	however, ESSA preclinical and clinical expenditures related to the Phase 1/2 trial during 2016-2017 are expected to be in excess
	of $1,900,000 per month.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash Flows from Operating Activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2016, cash used in operating activities
	of $15,300,969 was attributable to a net loss of $13,139,788, net non-cash credits of $4,491,016, and net change of $2,329,835
	in ESSA's net operating assets and liabilities. The non-cash credits consisted primarily of a $1,246,946 charge in share-based
	payments, finance expense of $910,101 attributable to the warrant portion of the Units issued in the January 2016 Financing, offset
	by a $6,574,105 gain for the fair value of the derivative liability arising on Seven-Year Warrants, Two-Year Warrants, and broker
	warrants denominated in Canadian dollars. The change in operating assets and liabilities was primarily attributable to a $644,089
	net decrease in prepaid expenses due to recognition of deposits paid in prior periods to contract service organizations in relation
	to the ongoing Phase 1/2 trial, a $91,191 net increase in income tax payable, and a $1,545,577 net increase in accounts payable
	and accrued liabilities due to an increase in overall activity, including research and development costs associated with ESSA's
	clinical trial which commenced in November 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2015, cash used in operating activities
	of $13,339,982 was attributable to a net loss of $9,676,587, net non-cash credits of $3,756,346, and net change of $92,951 in ESSA's
	net operating assets and liabilities. The non-cash credits consisted primarily of a $907,598 charge for the change in fair value
	of the derivative liability arising on broker warrants denominated in US dollars, $1,510,542 in share-based payments, offset by
	$5,427,020 in product and relocation grant funds applied against R&amp;D expenditures. The change in operating assets and liabilities
	was primarily attributable to a $1,634,382 net increase in prepaid expenses due to deposits paid to contract service organizations
	in preparation for the Phase 1/2 trial, and a $1,736,929 net increase in accounts payable and accrued liabilities due to an increase
	in research and development costs associated with ESSA's pre-clinical studies, formulation work, preparation of the IND in order
	to initiate the clinical trial, corporate costs relating to preparation of documents for securities filings, and an increase in
	headcount.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash Flows from Investing Activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2016, cash used in investing activities
	was $9,983 due to acquisition of equipment and furniture associated with the office space in Houston, Texas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2015, cash used in investing activities
	was $174,054 due to acquisition of equipment and furniture associated with the establishment of office space in Houston, Texas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Cash Flows from Financing Activities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2016, cash provided by financing
	activities was $22,744,129, consisting primarily of $3,786,667 in proceeds received from the second tranche of the CPRIT Grant,
	$19,999,992 in proceeds received from the January 2016 Financing and March 2016 Financing, $37,659 in proceeds received from the
	exercise of stock options and warrants, offset by $1,080,189 in share issuance costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the year ended September 30, 2015, cash provided by financing
	activities was $12,591,482, consisting primarily of $13,208,938 in proceeds received from the issuance of ESSA&rsquo;s 2014 and
	2015 Special Warrants, $252,185 in proceeds received from the exercise of stock options and warrants, offset by $869,641 in share
	issuance costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA's future cash requirements may vary materially from those now
	expected due to a number of factors, including the costs associated with Phase 1/2 clinical trials in 2015-2018
	and to take advantage of strategic opportunities. In the future it may be necessary to raise additional funds. These funds may
	come from sources such as entering into strategic collaboration arrangements, the issuance of shares from treasury, or alternative
	sources of financing. However, there can be no assurance that ESSA will successfully raise funds to continue the development and
	commercialization of EPI-506 and its operational activities. See &ldquo;
<I>
	Risk Factors
</I>
	&rdquo; in Item 3.D elsewhere in this
	Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Research and Development, Patents and Licenses, etc.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Research and Development
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	It is currently anticipated that ESSA will carry out the development
	of EPI-506 to completion of Phase 1/2 clinical proof-of-concept by approximately Q1 of the 2018 calendar year. See &ldquo;
<I>
	Programs
	and Potential Products
</I>
	&rdquo; in Item&nbsp;4 of this Annual Report for further details of each stage of development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Key Patent Applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	See &quot;
<I>
	Patents and Proprietary Rights
</I>
	&quot; elsewhere
	in Item 4 of this Annual Report for details regarding ESSA's key patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Licensed Pending Applications
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	See &quot;
<I>
	Pending Licensed Applications
</I>
	&quot; elsewhere in
	Item 4 of this Annual Report for details regarding ESSA's licensed intellectual property pending applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Research and Development Policies
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Expenditures during the research phase of a project are recognized
	as expenses when incurred. Development costs are capitalized only when technical feasibility studies identify that the project
	will deliver future economic benefits and these benefits can be measured reliably.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company spent $13,060,201, $4,975,928, and $671,600, on R&amp;D,
	net of recoveries, during the fiscal years ended September&nbsp;30, 2016, 2015, and 2014, respectively. All of these costs have
	been recognized as an expense in the Company&rsquo;s statement of profit and loss in the respective periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	It is not possible to always estimate the timing of project completion
	due to the uncertainty of preclinical research and development projects and the results of associated scientific experiments. Analysis
	of costs between projects are influenced by the length and nature of the study and costs of material used.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In 2014, the CPRIT Grant award and funds raised through private
	placements allowed the Company to begin work on a pre-clinical program with a focus on receiving regulatory approval to commence
	human clinical testing of EPI-506 in CRPC patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In 2015, a total of $13,208,938 was raised through private placements
	and pre-clinical work continued.&nbsp; The IND application was prepared and submitted to the FDA in order to receive approval to
	commence the Phase 1/2 clinical study of EPI-506.&nbsp;Clinical sites were identified and agreements were negotiated with sites
	in order that the trial could commence once FDA approval of the IND was received.&nbsp; Upon approval of the IND, the Company received
	the second tranche of funds from CPRIT in the amount of $3,786,667.&nbsp; Manufacturing of clinical supplies for early clinical
	trials was performed by Southwest Research Institute in San Antonio, Texas. Current formulation and cGMP production of the final
	product candidate for clinical trials is being performed by Catalent Pharma Solutions, St. Petersburg, Florida and SAFC, Inc. in
	Madison, Wisconsin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In 2016, the Company raised, through private placements, an additional
	$20,000,000, which supported continuing manufacturing and formulation work as well as the ongoing Phase 1 clinical trial underway
	at five sites.&nbsp;&nbsp; The Company has also commenced preparation for the Phase 2 clinical study with regard to site identification
	and manufacture of clinical supplies of drug product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Trend Information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA is a clinical development stage company and does not currently
	generate revenue.&nbsp;The Company is focused on the development of small molecule drugs for the treatment of prostate cancer.
	The Company has acquired a license to certain Licensed IP.&nbsp;As at the date of this Annual Report, no products are in commercial
	production or use.&nbsp;The Company&rsquo;s financial success will be dependent upon its ability to obtain regulatory approval
	for, and if approved, successfully commercialize EPI-506.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Off-Balance Sheet Arrangements
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has no material undisclosed off-balance sheet arrangements
	that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues
	or expenses, liquidity, capital expenditures or capital resources that is material to investors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Tabular Disclosure of Contractual Obligations
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of September&nbsp;30, 2016, and in the normal course of business,
	ESSA has the following obligations to make future payments, representing contracts and other commitments that are known and committed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Payments Due by Period
</I>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Contractual
</I>
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Obligations
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Total
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	Less than 1
</I>
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	year
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	1-3 years
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	3-5 years
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	More than 5
</I>
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<I>
	years
</I>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 35%">
<FONT STYLE="FONT-SIZE: 10PT">
	Minimum Annual Royalty per License Agreement with UBC/BC Cancer Agency (
<I>
	in C$
</I>
	)
<SUP>
	(1)(2)(3)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,240,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	135,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	170,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	170,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	765,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Lease on office space (
<I>
	in C$
</I>
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	163,812
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	40,953
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	81,906
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	40,953
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Lease on U.S. office space
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	578,095
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	186,220
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	347,401
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	44,474
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total
<I>
	(in US$)
</I>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,421,722
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	417,299
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	678,229
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	321,519
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,004,675
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA has the worldwide, exclusive right to develop products based on the Licensed IP pursuant to the License Agreement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	As consideration for the License Agreement with UBC and the BC Cancer Agency, there are certain cumulative milestone payments totaling C$2,400,000 for the first compound, to be paid in stages at the start of Phase II and Phase III clinical trials, at application for marketing approval, and with further milestone payments on the second and additional compounds. These milestone payments are not represented in the tabular disclosure above due to the uncertain timing of the triggering events and associated payments.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA's agreements pertaining to the License Agreement with UBC and the BC Cancer Agency,
	and the lease on Canadian office space are valued in Canadian dollars. For the purposes of the calculations above, ESSA has
	converted the values to Canadian dollars based on the closing exchange rate on December 13, 2016, as reported by the Bank of
	Canada, being C$1.00=US$0.7614.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	G.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Safe Harbor
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	See &ldquo;
<I>
	Cautionary Note Regarding Forward-Looking Statements
</I>
	&rdquo;
	in the introduction to this Annual Report.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_OPERATING_AND_FINANCIAL_REVIEW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 6.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Directors and Senior Management
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table sets forth the names and municipalities of residence
	of the Company&rsquo;s directors and executive officers as well as their positions with the Company and principal occupations for
	the previous five years. All directors, officers and employees are required to sign standard confidentiality and non-disclosure
	agreements with the Company. Each director&rsquo;s terms of office expires at the next annual general meeting of the shareholders
	of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Name and Place of Residence
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Age
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 65%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Principal Occupations
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Dr. Raymond Andersen
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	69
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Technical Officer and Director (October 11, 2010-Present) and Secretary (January 6, 2009-Present),
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA Pharma Inc.; Professor of Chemistry and Earth, Ocean &amp; Atmospheric Sciences, University of British Columbia (2007-present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Franklin Berger
</I>
<SUP>
	(1)(3)
</SUP>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	New York, USA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	67
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, ESSA Pharma Inc. (March 2015&ndash;Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, Five Prime Therapeutics, Inc. (October 2010 &ndash; Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, Immune Design Corp. (March 2014 &ndash; Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, Bellus Health, Inc. (May 2010 &ndash; Present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Dr. Paul Cossum
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Texas, USA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	64
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Vice President, Research and Development (April 2014&ndash;Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, Pivotal BioSciences (January 2014&ndash;Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Science Officer, Global BioDevelopment (January 2006&ndash;Present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Richard M. Glickman
</I>
<SUP>
	(1)(2)
</SUP>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	58
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board, ESSA Pharma Inc. (October 2010-Present)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Co-founder and Executive Chairman, Aurinia Pharmaceuticals Inc. (September 2013 to February 2014)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board, Aurinia Pharmaceuticals Inc. (February 2014 to Present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	David Parkinson
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	California, USA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	66
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Executive Officer, ESSA Pharma Inc. (January 2016 &ndash; Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director,
	ESSA Pharma Inc. (June 2015 &ndash; January 2016);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Venture Partner, New Enterprise
	Associates (2012 &ndash; Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Acting CEO, Zyngenia Inc. (2013 &ndash; 2014);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	President
	and CEO, Nodality (2007 &ndash; 2012)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Name and Place of Residence
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Age
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 64%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Principal Occupations
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 63%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Dr. Frank Perabo
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Texas, USA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Vice-President and Chief Medical Officer, ESSA Pharma Inc. (September
	2014&ndash;Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Director of Medical Science Oncology (July 2011
	&ndash; September 2014),
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Senior Director (August 2010 &ndash; June 2011) and
	Director (January 2008 &ndash; June 2011), Astellas Pharma Global Development, Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Scott Requadt
</I>
<SUP>
	(2)(3)
</SUP>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Massachusetts, USA
</FONT>
<BR>
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	48
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director, ESSA Pharma Inc. (January 14, 2016-Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Managing Director, Clarus Ventures, LLC (2005-Present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Dr. Marianne Sadar
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director (January 6, 2009-Present)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Scientific Officer (October 11, 2010-Present) and President (January 6, 2009-October 11, 2010),
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA Pharma Inc. Distinguished Scientist (2012 - Present)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Senior Scientist (1998-2012)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia Cancer Agency Professor (2012 - Present)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Honorary Associate Professor (2009-2012)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Pathology and Laboratory Medicine, University of British Columbia; Provincial Program Leader for Prostate Cancer Research (2000-2012)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia Cancer Agency; Officer (2007-2015)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Past President (2014-2015) President (2013-2014)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Vice President (2012-2013)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Treasurer (2007-2011)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Society of Basic Urologic Research
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 30%">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Gary Sollis
</I>
<SUP>
	(1)(2)(3)
</SUP>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
<FONT STYLE="FONT-SIZE: 10PT">
	63
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 63%">
<FONT STYLE="FONT-SIZE: 10PT">
	Director, ESSA Pharma Inc. (April 26, 2012-Present);
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Partner, Dentons Canada LLP (May 1, 1995-Present)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Peter Virsik
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	California, USA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	45
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Executive Vice-President and Chief Operating Officer, ESSA Pharma
	Inc. (August 2016&ndash;Present);
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Senior Vice President (2013-2015) and Vice President (2011-2013),
	Corporate Development, XenoPort, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Vice President (2009-2011), Executive Director (2007-2009) and Senior
	Director (2005-2007), Business Development, XenoPort, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Associate Director (2004-2005) and Manager (2000-2004), Corporate
	Development, Gilead Sciences, Inc.
<BR>
<BR>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	David Wood
</I>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	British Columbia,
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	59
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Chief Financial Officer, ESSA Pharma Inc., (July 2013-Present);
<BR>
	Head of Finance, Secretary &amp; Treasurer, Celator Pharmaceuticals Inc. (April 2003-April 2013)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Cubist Pharmaceuticals Inc. (2000-2003)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Terragen Discovery Inc. (1996-2000)
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Member of the Audit Committee (as defined herein).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Member of the Compensation Committee.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Member of the Corporate Governance Committee.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Biographies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dr. Raymond Andersen, Chief Technical Officer, Secretary and
	Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr.&nbsp;Raymond Andersen is one of ESSA's co-founders. He has served
	as ESSA's Secretary since January 2009, and as a director and Chief Technical Officer since October 2010. He is responsible for
	participating in the research and development of ESSA's product candidates, and with the assessment and review of business and
	scientific matters. As an independent consultant, he devotes approximately 20% of his time to ESSA's affairs. He is also a Professor
	at UBC in the departments of Chemistry and Earth&nbsp;&amp; Ocean Sciences. He is internationally known for his research into the
	identity and structure of novel chemical compounds derived from marine organisms, the molecular routes to their biosynthesis, their
	role in ocean ecology, and their potential as new drugs. Among them are compounds that have anti-inflammatory and anti-cancer properties
	and these compounds are being developed as anti-asthma, and anti-tumour drugs. His industrial programs have led to deals with Aventis
	and Wyeth and the venture capital arms of Johnson&nbsp;&amp; Johnson and Pfizer. Dr.&nbsp;Andersen received his B.Sc. degree from
	the University of Alberta, a M.Sc. from UC Berkeley, and Ph.D. from U.C. San Diego. He carried out postdoctoral research at the
	Massachusetts Institute of Technology. In recognition of his pioneering achievements, Dr.&nbsp;Andersen was inducted into the Royal
	Society of Canada and recently received the R. U. Lemieux Award from the Canadian Society for Chemistry and the Jacob Biely Research
	Prize from UBC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Franklin Berger, Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Franklin Berger spent 12 years in sell-side equity research, most
	recently as Managing Director, U.S. Equity Research at J.P. Morgan Securities, Inc. (&ldquo;
<B>
	JPM
</B>
	&rdquo;) from May 1998 to
	March 2003. During his five years at as a Managing Director at JPM, he was involved with the issuance of over $12 billion in biotechnology
	company equity or equity-linked securities. The majority of these transactions were book-run and lead-managed by the JPM biotech
	team. He was associated with several notable financings in the biotechnology sector including the Genentech Inc. initial public
	offering, the first large Celgene Corporation financings as well as financings of several large-cap biotechnology companies in
	their rapid growth phase. His team covered 26 publicly-traded biotechnology companies. Mr.&nbsp;Berger began his career as a sell-side
	analyst at Josephthal&nbsp;&amp; Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research
	and Senior Biotechnology Analyst. Mr.&nbsp;Berger currently serves on the board of directors of three public biotechnology companies:
	Five Prime Therapeutics, Inc., Immune Design Corp. and Bellus Health, Inc. Mr.&nbsp;Berger received an AB in International Relations
	from Johns Hopkins University, a MA in International Economics from Johns Hopkins University for Advanced International Studies
	and a MBA from Harvard University.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dr. Paul Cossum, Executive Vice President of Research and Development
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr.&nbsp;Paul Cossum has more than 25 years of experience in product
	development roles in the biotechnology sector. Dr.&nbsp;Cossum has served as ESSA's Executive Vice President of Research and Development
	since August 2014. In this role, Dr.&nbsp;Cossum is responsible for the oversight of research and development of ESSA's product
	candidates. He began his career as a scientist in the Department of Pharmacological Sciences, and then Safety Evaluation, at Genentech.
	Thereafter followed roles of increasing responsibility at various biotech companies. He was Director of Pre-clinical Development
	at ISIS Pharmaceuticals, Vice-President of Pre-clinical R&amp;D at Aronex Pharmaceuticals, Executive Vice-President of Development
	at NewBiotics, and CEO and head of Development at Proacta. The latter two companies were involved in the development of prodrugs
	for various cancer indications. Most recently he served as President of the Texas BioAlliance, a non-profit organization that supported
	applicants and awardees of CPRIT with product development expertise. Dr.&nbsp;Cossum received BSc, M. Pharmacy and PhD degrees
	from the University of Tasmania, Australia, and then completed a post-doctoral fellowship at the Chemical Industry Institute of
	Toxicology in Research Triangle Park, NC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Richard M. Glickman, Chairman of the Board
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Richard M. Glickman has served as ESSA's Chairman of the Board since
	October 2010. As the Chairman of the Board, Mr.&nbsp;Glickman is responsible for the management of the Board to ensure ESSA has
	appropriate objectives and an effective strategy, and that ESSA is operating in accordance with a high standard of corporate governance.
	Mr.&nbsp;Glickman was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. (&ldquo;
<B>
	Aspreva
</B>
	&rdquo;)
	which was acquired by the Galenica group for $915 million. Prior to establishing Aspreva, Mr.&nbsp;Glickman was the co-founder
	and Chief Executive Officer of StressGen Biotechnologies Corporation. Mr.&nbsp;Glickman currently serves on Cardiome Pharma Corp.&rsquo;s
	board of directors as a member of the Compensation and Audit Committees and as its lead independent director. In addition, Mr.&nbsp;Glickman
	serves as Chairman of the Board of Aurinia Pharmaceuticals Inc., as Chairman of the Board of Engene Corporation and as a Director
	of Vida Pharmaceuticals.&nbsp;In addition, he has served on numerous biotechnology boards including roles as Chairman of Life Sciences
	B.C. (formerly the British Columbia Biotechnology Alliance), as a Director of the Canadian Genetic Diseases Network (a Canadian
	Centre of Excellence), a member of the federal government&rsquo;s National Biotechnology Advisory Committee, a member of the British
	Columbia Innovation Council and a director for the Vancouver Aquarium and Chair of its Research Committee. Mr.&nbsp;Glickman received
	the Ernst&nbsp;&amp; Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group, both Canada&rsquo;s
	and British Columbia&rsquo;s Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation
	of America Leadership Award.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dr. David Parkinson, President, Chief Executive Officer and Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr. David Parkinson has served as a director of the Company since
	June 2015 and has been serving full-time as the Company&rsquo;s President and Chief Executive Officer since January 2016. Since
	his appointment in January 2016, he has become a venture advisor at New Enterprise Associates, Inc., where previously he was a
	venture partner. From 2007 until 2012, Dr.&nbsp;Parkinson served as President and CEO of Nodality, a South San Francisco-based
	biotechnology company. Until 2007 Dr.&nbsp;Parkinson was Senior Vice President, Oncology Research and Development, at Biogen Idec.
	Prior to joining industry, Dr.&nbsp;Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the
	Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. Dr.&nbsp;Parkinson is
	a past Chairman of the FDA&rsquo;s Biologics Advisory Committee. He currently serves as director on the boards of Threshold Pharmaceuticals
	and Cerulean Pharma Inc., public biopharma companies focused on the discovery and development of anti-cancer drugs. Dr.&nbsp;Parkinson
	received his medical degree from the University of Toronto. He has held academic positions both at Tufts and at the University
	of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dr. Frank Perabo, Executive Vice President and Chief
	Medical Officer
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr.&nbsp;Frank Perabo has been employed full time as ESSA's Chief
	Medical Officer since September 2014. He is responsible for developing a clinical advisory board and assisting with the pre-clinical
	development of ESSA's product candidate. Dr.&nbsp;Perabo has more than 18 years of experience in pre-clinical and clinical drug
	development in Urologic Oncology. Before joining the Company, he served as Executive Director of Medical Science Oncology for 5
	years at Astellas Pharma Global Development, Inc. In this position he was instrumental in the development and global approvals
	of XTANDI (Enzalutamide). From January 2008 to June 2011, he served as a Director and then Senior Director at Astellas Europe,
	as Global Medical Lead in Urology, Gynecology and Pain working on pre-clinical to Phase 3 development, successfully directing Phase-3
	programs for OAB and BPH, as well as various other pre-clinical and clinical compounds in development. From 2001 to 2006, Dr.&nbsp;Perabo
	worked as independent consultant in business development, and pre-clinical and clinical research and development. From 2000 to
	2001, Dr.&nbsp;Perabo served as Scientific Director at Oncology World, Munich (a specialized CRO in Oncology) establishing clinical
	development and business strategies. He obtained his training in surgery and urology at the Universities of Munich, Freiburg and
	Bonn from 1993 to 1999 after graduating from the Medical School at the University of Munich with magna cum laude. He is a board
	certified urologist, and Associate Professor of Urology at Bonn University (Germany), and a Fellow of the European Board of Urology,
	next to being a member of several Urologic and Oncologic associations. In his career, he has received many awards and grants including
	an European Commission FP7 (Marie Curie Fellowship) grant, a grant from the Center for Translational Molecular Medicine, numerous
	awards for best scientific presentations, and the prestigious Maximilian-Nitze-Award of the German Urological Society for his work
	on tumor immune escape.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Scott Requadt, Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Scott Requadt, JD, MBA, is currently a Managing Director at Clarus
	Ventures, a life sciences venture capital fund. Scott has over 15 years of operating and investment experience in the pharmaceutical
	industry. Prior to joining Clarus in 2005, Mr. Requadt was Director, Business Development of TransForm Pharmaceuticals, and previously
	practiced for several years as an M&amp;A attorney at the NYC-based law firm of Davis Polk &amp; Wardwell. Before that, Mr. Requadt
	was a law clerk for a senior judge at the Supreme Court of Canada. Mr. Requadt holds a B.Com (Economics &amp; Finance) from McGill
	University, an LL.B from University of Toronto and an MBA from Harvard Business School (Baker Scholar). Mr. Requadt has been involved
	in multiple investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals and several R&amp;D risk-sharing
	collaborations with large pharma partners. He has previously been active on the Boards of TyRx, Catabasis, Oxford Immunotec, VBI
	Vaccines, Link Medicine and Biolex Therapeutics.
</P>
<!-- FIELD: PAGE; SEQUENCE: 82 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dr. Marianne Sadar, Chief Scientific Officer and Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dr.&nbsp;Marianne Sadar is one of ESSA's co-founders. Dr.&nbsp;Sadar
	has been a director since January 2009, and has acted as ESSA's Chief Scientific Officer since October 2010. She is responsible
	for participating in the research and development of ESSA's product candidates, and with the assessment and review of business
	and scientific matters. As an independent consultant, she devotes approximately 20% of her time to ESSA's affairs. She is a Distinguished
	Scientist at the BCCA and a Professor of Pathology and Laboratory Medicine at UBC. Dr.&nbsp;Sadar is internationally known for
	her research on identifying mechanisms of activating the AR and developing therapeutics for advanced prostate cancer that target
	the N-terminal domain of the AR. Her research was the first to show that the N-terminal domain of the AR could be activated by
	alternative pathways and she proposed this domain as a therapeutic target in 1999. Later, Dr.&nbsp;Sadar provided the first proof-of-concept
	that targeting the N-terminus of the AR results in a therapeutic response in an in vivo model of CRPC. Dr.&nbsp;Sadar received
	her B.Sc. from Simon Fraser University, and Ph.D. from the University of Bradford, U.K. She carried out post-doctoral training
	at AstraZeneca (Astra H&auml;ssle), Department of Drug Metabolism and Pharmacokinetics in M&ouml;lndal, Sweden and at the BCCA.
	She has served on approximately 50 scientific panels, and has been a recipient of awards including the Terry Fox Young Investigator
	Award, Simon Fraser University Alumni Award for Academic Excellence, and the first non- American to receive the Society of Women
	in Urology/Society of Basic Urologic Research &ldquo;Award for Excellence in Urologic Research&rdquo;. She has served as President
	of the Society of Basic Urologic Research (USA), member of the Scientific Advisor Boards for the Prostate Cancer Foundation (USA)
	and Coalition to Cure Prostate Cancer (Canada). Dr. Sadar is FY2017 Chair of the Programmatic/Integration Panel of the U.S. Army&rsquo;s
	Department of Defence Congressionally Directed Medical Research Programs Prostate Cancer Research Program (&ldquo;
<B>
	PCRP
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Gary Sollis, Director
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Mr.&nbsp;Gary Sollis has served as a director since April 2012.
	Mr.&nbsp;Sollis is a partner at the law firm of Dentons Canada LLP. He represents clients in the areas of corporate and securities
	law, with a focus on acquisitions, financings and reorganizations. He has acted for a variety of public and private companies in
	financing transactions, including public offerings, private placements of debt and equity, special warrant financings and public
	and private limited partnership offerings. Mr.&nbsp;Sollis has also assisted clients in connection with takeover bids, mergers,
	proxy contests, spin-offs, joint ventures and acquisitions of private businesses. He received a Bachelor of Laws degree from Dalhousie
	University.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Peter Virsik, Executive Vice President and Chief Operating Officer
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Peter Virsik joined the Company in August 2016 as Executive Vice
	President and Chief Operating Officer, bringing over 20 years of experience in corporate development, strategy, new product planning,
	alliance management, and finance. During his career, Mr. Virsik has completed over 30 licensing, M&amp;A and financial transactions,
	totaling over $3 billion in value. Most recently, he served as Senior Vice President, Corporate Development for XenoPort (acquired
	by Arbor Pharmaceuticals), leading licensing, strategy, new product planning and alliance management for the company. During his
	tenure at XenoPort, Mr. Virsik played an integral role in the licensing and commercialization of Horizant&reg; (gabapentin enacarbil).
	Prior to XenoPort, Mr. Virsik worked for Gilead Sciences from 2000 through 2005 in Corporate Development, where he was involved
	in building Gilead&rsquo;s HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta&reg;
	(elvitegravir). Before joining Gilead, Mr. Virsik worked at J.P. Morgan in the biotechnology equity research group and as a consultant
	for Ernst and Young. Mr. Virsik began his career in R&amp;D at Genentech. Mr. Virsik received an MBA from the Kellogg Graduate
	School of Management at Northwestern University, an MS in Microbiology from the University of Michigan, Ann Arbor, and a BA in
	Molecular and Cellular Biology from the University of California, Berkeley.
</P>
<!-- FIELD: PAGE; SEQUENCE: 83 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	David Wood, Chief Financial Officer
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	David Wood has been employed full time as ESSA's Chief Financial
	Officer since July 2013. He is responsible for managing all of ESSA's financial aspects, including financial reporting, treasury,
	and matters related to compliance and corporate governance, insurance, human resources, and facilities. Mr.&nbsp;Wood has over
	30 years of experience in management positions in both large corporations and early stage companies in North America and the U.K.
	Prior to joining us in 2013, he was Head of Finance and Corporate Development, Secretary and Treasurer at Celator Pharmaceuticals
	Inc. from 2003 to 2013. Prior to 2003, he was Managing Director of Cubist Pharmaceuticals (UK) Ltd., Senior Director, International
	Operations of Cubist Pharmaceuticals Inc. and Finance Director at TerraGen Discovery, Inc., Vancouver, B.C. During over 18 years
	working in the biopharmaceutical industry, he has overseen several merger and acquisition transactions and numerous financings
	which raised over $150 million. Mr.&nbsp;Wood began his career in the finance and exploration departments at Chevron Corp. He received
	an M.B.A. from the University of Western Ontario, a B.Sc. Honors in Biology, Queen&rsquo;s University, and a CPA, CMA accounting
	designation. Mr.&nbsp;Wood served on the governing body of the National Research Council of Canada from 2008 to 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Compensation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Executive Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Compensation Discussion and Analysis
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For the purposes of this Annual Report, a named executive officer
	(&ldquo;
<B>
	NEO
</B>
	&rdquo;) of the Company, using the definition contained in applicable Canadian securities laws, means each of
	the following individuals:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Chief Executive Officer (&ldquo;
<B>
	CEO
</B>
	&rdquo;) of the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the Chief Financial Officer (&ldquo;
<B>
	CFO
</B>
	&rdquo;) of the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	each of the three most highly compensated Executive Officers, or the three most highly compensated individuals acting in a similar capacity, other than the CEO and CFO, at the end of the most recently completed financial year whose total compensation was, individually, more than $150,000. &ldquo;
<B>
	Executive Officer
</B>
	&rdquo; means the chairman, and any vice-chairman, president, secretary or any vice-president and any officer of the Company or a subsidiary who performs a policymaking function in respect of the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	each individual who would be an NEO under paragraph (c)&nbsp;but for the fact that the individual was neither an executive officer of the Company, nor acting in a similar capacity, at the end of that financial year.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Each of Dr. David Parkinson, President and CEO, David Wood,
	CFO, Peter Virsik, Executive VP and Chief Operating Officer (&ldquo;
<B>
	EVP &amp; COO
</B>
	&rdquo;), Dr. Frank Perabo,
	Executive Vice-President of Clinical Development and Chief Medical Officer (&ldquo;
<B>
	EVP &amp; CMO
</B>
	&rdquo;), Dr. Paul
	Cossum, Executive Vice President of Research and Development (&ldquo;
<B>
	EVP of &nbsp;R&amp;D
</B>
	&rdquo;), and Dr. Marianne
	Sadar, Chief Scientific Officer (&ldquo;
<B>
	CSO
</B>
	&rdquo;), is an NEO of the Company for purposes of this disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Compensation Philosophy and Objectives
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s compensation philosophy for NEOs will be focused on
	its belief that capable and qualified employees are critical to the Company&rsquo;s success. Therefore, its compensation plan is
	designed to attract the very best individuals in each expertise arena and to use salaries and long term incentive compensation
	in the form of stock options or other suitable long-term incentives to attract and retain such employees. In making its determinations
	regarding the various elements of executive stock option grants, ESSA will seek to meet the following objectives:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to attract, retain and motivate talented executives who create and sustain ESSA&rsquo;s continued success within the context of compensation paid by other companies of comparable size engaged in similar business in appropriate regions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to align the interests of the ESSA&rsquo;s NEO&rsquo;s with the interests of shareholders of ESSA; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to incent extraordinary performance from the Company&rsquo;s key employees.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Elements of Compensation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Base Salary
</U>
	&ndash; The base salary review of any NEO will
	take into consideration the current competitive market conditions, experience, proven or expected performance, and the particular
	skills of the NEO. Base salary is not expected to be evaluated against a formal &ldquo;peer group&rdquo;. The base salaries for
	NEOs of ESSA as of the date of this Annual Report are:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 71%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NEO
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 28%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	BASE SALARY
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. David Parkinson (President &amp; CEO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	US$430,000/year
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood (CFO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	C$265,200/year
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Peter Virsik (EVP &amp; COO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	US$365,000/year
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Frank Perabo (EVP &amp; CMO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	US$438,600/year
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Paul Cossum (Executive VP of R&amp;D)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	US$285,600/year
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Marianne Sadar (CSO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	C$180,000/year
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Performance-Based Cash Bonuses
</U>
	&ndash; Cash bonuses are not
	a normal part of ESSA&rsquo;s executive compensation. However, the Company may elect to utilize such incentives where the role-related
	context and competitive environment suggest that such a compensation modality is appropriate. When and if utilized, the amount
	of cash bonus compensation will normally be paid on the basis of timely achievement of specific pre-agreed milestones. Each milestone
	will be selected based upon consideration of its impact on shareholder value creation and the ability of the Company to achieve
	the milestone during a specific interval. The amount of bonus compensation will be determined based upon achievement of the milestone,
	its importance to the Company&rsquo;s near and long term goals at the time such bonus is being considered, the bonus compensation
	awarded to similarly situated executives in similarly situated development-stage life-sciences companies or any other factors the
	Company may consider appropriate at the time such performance-based bonuses are decided upon. The quantity of bonus will normally
	be a percentage of base salary not to exceed 100%. However, in exceptional circumstances, the quantity of bonus paid may be connected
	to the shareholder value creation embodied in the pre-agreed milestones.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The bonuses available to the NEOs as of the date of this Annual
	Report are:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 48%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NEO
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 51%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	BONUS PAYABLE
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. David Parkinson (CEO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Up&nbsp;to&nbsp;50%&nbsp;of&nbsp;Base&nbsp;Salary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood (CFO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Up&nbsp;to&nbsp;40%&nbsp;of&nbsp;Base&nbsp;Salary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Peter Virsik (COO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Up&nbsp;to&nbsp;40%&nbsp;of&nbsp;Base&nbsp;Salary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Frank Perabo (EVP &amp; CMO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Up&nbsp;to&nbsp;40%&nbsp;of&nbsp;Base&nbsp;Salary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Marianne Sadar (CSO)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	C$10,000 per provisional patent application
	filed,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	C$10,000 per publication completed
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Up to the date of this Annual Report, the Company has generally
	relied on a flexible and informal approach to executive compensation for certain NEOs. Accordingly, the bonuses noted above of
	up to 40% of base salary available to Mr. Wood, Mr. Virsik, and Dr. Perabo were selected based on the Board&rsquo;s collective
	agreement regarding an appropriate bonus range and on discussions with Mr. Wood and Dr. Perabo about their expectations as CFO
	and EVP &amp; CMO of the Company, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Stock Options
</U>
	&ndash; Stock options are a key compensation
	element for companies such as ESSA. Because many of the most capable employees in ESSA&rsquo;s industry work for pharmaceutical
	companies who can offer attractive cash and bonus compensation and a high level of employment security, stock options represent
	a compensation element that balances the loss of employment security that such employees must accept when moving to a small development-stage
	company like ESSA. Stock options are also an important component of aligning the objectives of ESSA employees with those of shareholders.
	ESSA has issued significant stock options positions to senior employees and lesser amounts to lower-level employees. The precise
	amount of stock options to be offered was governed by the importance of the role within ESSA, by the competitive environment within
	which ESSA operates, and by the regulatory limits on stock option grants that cover organizations such as ESSA. This reflects ESSA&rsquo;s
	commitment to attracting and retaining world-level expertise to the Company. The stock options granted to the Company&rsquo;s NEOs
	as of the date of this Annual Report are:
</P>
<!-- FIELD: PAGE; SEQUENCE: 85 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NEO
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 64%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OPTIONS
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. David Parkinson (President &amp; CEO)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000 Options (C$14.90 exercise price per Common Share, expiring June 23, 2025, 600,000 Options (C$6.25 exercise price per Common Share, expiring January 12, 2021)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood (CFO)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	75,000 Options (C$0.80 exercise price per Common Share, expiring May&nbsp;20, 2019) and 200,000 Options (C$2.00 exercise price per Common Share, expiring July&nbsp;30, 2019)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Peter Virsik (EVP &amp; COO)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	290,000 Options (C$3.49 exercise price per Common Share, expiring August 9, 2021)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Frank Perabo (EVP &amp; CMO)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	500,000 Options (C$2.00 exercise price per Common Share, expiring September&nbsp;8, 2019)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Paul Cossum (EVP of R&amp;D)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	400,000 Options (C$2.00 exercise price per Common Share, expiring April&nbsp;14, 2019)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Marianne Sadar (CSO)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 9PT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	300,000 Options (C$0.80 exercise price per Common Share, expiring January 31, 2018)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Compensation Risks
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In making its compensation-related decisions, the Board carefully
	considers the risks implicitly or explicitly connected to such decisions. These risks include the risks associated with employing
	executives who are not world-class in their capabilities and experience, the risk of losing capable but under-compensated executives,
	and the financial risks connected to the Company&rsquo;s operations, of which executive compensation is an important part.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In adopting the compensation philosophy described above, the principal
	risks identified by ESSA are:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	that the Company will be forced to raise additional funding (causing dilution to shareholders) in order to attract and retain the calibre of executive employees that it seeks; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	that the Company will have insufficient funding to achieve its objectives.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	After careful consideration of these risks, the Board has adopted
	the compensation policy described above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	General Equity-Compensation Arrangements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On September&nbsp;4, 2014, ESSA adopted the Stock Option Plan, which
	was later amended and restated on May&nbsp;21, 2015 and on March 10, 2016. The Stock Option Plan is administered by the Chief Financial
	Officer of ESSA on the instructions of the Board or such director or other senior officer or employee of ESSA as may be designated
	by the Board from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Pursuant to the Stock Option Plan, ESSA may grant Options to any
	of its or its affiliates&rsquo;
<I>
	bona fide
</I>
	directors, officers, consultants and employees (including employees of persons
	providing certain management services to ESSA), and to any company, the 100% of share capital of which is beneficially owned by
	one or more of the foregoing persons. Option grants are contingent upon the determination of the Board that such grants and the
	exercise of such Options will not violate the securities laws of the jurisdiction in which the optionee resides. In addition, eligible
	persons cannot be granted an option that would exceed the &ldquo;Insider Participation Limit&rdquo; (as defined in the TSX Company
	Manual), and the aggregate number options granted to all &ldquo;Insiders&rdquo; (as defined in the TSX Company Manual) cannot exceed
	such &ldquo;Insider Participation Limit&rdquo;, unless, in either case, ESSA has obtained approval for disinterested shareholders
	to do so, in accordance with the TSX Company Manual. A person can receive grants of no more than 5% of ESSA&rsquo;s issued and
	outstanding share capital in any 12&nbsp;month period, with the exception of a consultant who may not receive grants of more than
	2% of ESSA&rsquo;s issued and outstanding share capital in any 12 month period; and, no more than an aggregate of 2% of ESSA&rsquo;s
	issued and outstanding Common Shares may be reserved for issue upon exercise of option grants made to persons engaged in investor
	relations activities at any one time.
</P>
<!-- FIELD: PAGE; SEQUENCE: 86 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Options granted under the Stock Option Plan must not have an
	exercise price that is less than the &ldquo;Market Price&rdquo; (as defined in the TSX Company Manual&rdquo;) of ESSA&rsquo;s Common
	Shares, and are prohibited from having an exercise period in excess of ten years following their award date. The Stock Option Plan
	contains a net settlement mechanism with respect to the exercise of Options whereby, in lieu of exercising an Option by delivery
	of an exercise notice along with payment of the exercise price, any optionee may elect to transfer and dispose of a specified number
	of Options to ESSA in exchange for a number of Common Shares having a fair market value equal to the intrinsic value of such Options
	disposed of and transferred to ESSA. The Options are non-assignable and non-transferable except in limited circumstances, including
	in the case of death or disability of an optionee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The maximum number of Common Shares that may be reserved and available
	for issuance upon exercise of Options is 5,000,000 Common Shares. Any Common Shares subject to an Option that expires or terminates
	without having been fully exercised may be made the subject of a further Option. The Stock Option Plan provides for adjustments
	to the Options in various circumstances, including adjustments to the number of Common Shares available under the Stock Option
	Plan, the number of Common Shares subject to any Option and the exercise price therefor in the event of a declaration of a stock
	dividend, or a consolidation, subdivision or reclassification of the Common Shares, and adjustments in the Common Shares receivable
	on the exercise of an Option in the event of an amalgamation, merger or entry into a plan of arrangement by ESSA. Further, upon
	a &ldquo;Change of Control&rdquo; (as defined in the Stock Option Plan), all Options become immediately exercisable, notwithstanding
	any contingent vesting provisions to which such Options may have otherwise been subject.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s administration of the Stock Option Plan is consistent
	with the policies and rules of the TSX and the Nasdaq and will comply with such other stock exchanges on which the Common Shares
	may be listed in the future. Certain amendments to the Options require disinterested shareholder approval, including reductions
	in the exercise price of, and extension of the expiry date of, an Option previously granted to an insider, and amendments to remove
	or to exceed the &ldquo;Insider Participation Limit&rdquo;. Certain other amendments, including amendments, modifications or terminations
	of the Stock Option Plan with respect to all Common Shares in respect of Options which have not been granted thereunder, changes
	in provisions relating to the manner of exercise of Options, changes to the terms, conditions and mechanics of grant, vesting,
	exercise and early expiry of Options, and changes to the provisions for termination or cancellation of Options may, subject to
	the requirements of the TSX Company Manual and the provisions of the Stock Option Plan, be made by the Board without consent or
	approval from any participant or shareholder of ESSA. In addition, the Stock Option Plan and any amendments thereto are subject
	to all necessary approvals of the applicable regulatory authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	NEO Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of September&nbsp;30, 2016, ESSA had six NEOs: Dr. David
	Parkinson, President and CEO, David Wood, CFO, Peter Virsik, EVP &amp; COO, Dr. Frank Perabo, EVP &amp; CMO, Paul Cossum, EVP
	of R&amp;D, and Dr. Marianne Sadar, CSO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Defined Benefits Plans
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA currently does not intend to have a defined benefits pension
	plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Defined Contribution Plans
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA currently does not intend to have a defined contribution plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Deferred Compensation Plans
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA currently does not intend to have a deferred compensation plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Termination and Change of Control Benefits
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Except as described below, there are no contracts, agreements, plans
	or arrangements that provide for payments to a NEO at, following, or in connection with any termination (whether voluntary, involuntary
	or constructive), resignation, retirement, a change in control of the Company or its subsidiary or a change in a NEO&rsquo;s responsibilities
	(excluding perquisites and other personal benefits if the aggregate of this compensation is less than $50,000).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company has entered into employment agreements with certain
	NEOs, which provide for certain rights upon termination of employment or a change of control of ESSA. ESSA believes that these
	provisions of the NEO employment agreements are reasonable in the context of similar-sized biopharmaceutical companies. The Company
	expects to offer similar provisions to executive-level employees in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Specific termination and change-of-control provisions of each NEO
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. David Parkinson:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	A payment of six months of base salary upon termination without cause and a payment of one year of base salary upon termination without cause after 12 months of employment.&nbsp;&nbsp;This amount increases to 18 months if the termination without cause occurs after a change of control event or within 60 days prior to a change of control event where such event was under consideration at the time of termination. Had Dr.&nbsp;Parkinson&rsquo;s employment been terminated without cause on September&nbsp;30, 2016, he would have received $215,000. Had Dr.&nbsp;Parkinson&rsquo;s employment been terminated without cause after a change of control event or within 60 days prior to a change of control event where such event was under consideration at the time of termination, he would have received $645,000.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immediate vesting of all stock options upon occurrence of a change of control event. Dr.&nbsp;Parkinson held 650,000 options as of the date of this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For David Wood:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	A payment to the employee of up to one year of base salary for termination without cause, whether or not the termination was caused by a change of control event. Had Mr.&nbsp;Wood been terminated without cause on September&nbsp;30, 2016, whether or not the termination was caused by a change of control event, he would have received up to C$265,200.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immediate vesting of all stock options upon occurrence of a change of control event. Mr.&nbsp;Wood held 275,000 options as of the date of this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. Frank Perabo:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	A payment to the employee of up to one year of base salary for termination without cause, whether or not the termination was caused by a change of control event. Had Dr. Perabo been terminated without cause on September 30, 2016, he would have received $430,000. If there is a change of control, and continuing employment is not offered, Dr. Perabo will receive one year of base salary.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immediate vesting of all stock options upon occurrence of a change of control event. Dr. Perabo held 500,000 options as of the date of this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. Paul Cossum:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	A payment to the employee of up to one year of base salary for termination without cause, whether or not the termination was caused by a change of control event. Had Dr. Cossum been terminated without cause on September&nbsp;30, 2016, he would have received up to $285,600. If there is a change of control, and continuing employment is not offered, Dr. Cossum will receive one year of base salary.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immediate vesting of all stock options upon occurrence of a change of control event. Dr. Cossum held 400,000 options as of the date of this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Mr. Peter Virsik:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	A payment of six months of base salary upon termination without cause and a payment of one year of base salary upon termination without cause after 12 months of employment.&nbsp;&nbsp;This amount increases to 18 months if the termination without cause occurs within 18 months after a change of control event. Had Mr. Virsik&rsquo;s employment been terminated without cause on September&nbsp;30, 2016, he would have received $182,500. Had Mr. Virsik&rsquo;s employment been terminated without cause within 18 months after a change of control event, he would have received $547,500.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Immediate vesting of all stock options upon occurrence of a change of control event. Mr. Virsik held 290,000 options as of the date of this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. Marianne Sadar:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	None
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Summary Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA's key management personnel include Dr. David Parkinson, CEO,
	David Wood, CFO, Peter Virsik, EVP &amp; COO, Dr.&nbsp;Frank Perabo, EVP &amp; CMO, Dr. Paul Cossum, EVP of R&amp;D, Dr.&nbsp;Marianne Sadar, CSO and Director, and Dr.&nbsp;Raymond Andersen, CTO and Director. Compensation
	paid to key management personnel are as follows: &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	YEAR ENDED
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	YEAR ENDED
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	YEAR ENDED
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SEPTEMBER&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SEPTEMBER&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SEPTEMBER&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	Salaries and consulting fees
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,454,401
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,710,995
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	439,239
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	975,927
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	825,768
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	419,229
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total compensation
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,430,328
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,536,763
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	858,468
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Director Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On January 1, 2015, ESSA adopted a compensation plan for independent
	members of the Board. Pursuant to this compensation plan, both cash payments and Options will be offered to independent directors.
	Each independent director will receive a retainer of $25,000 per annum. In addition, the Chair of the Board will receive a premium
	of $25,000 per annum and the Chair of each sub-committee will receive a premium of $10,000 per annum. Independent directors will
	also be paid a cash fee of $1,500 per in-person meeting, and $1,000 per teleconference meeting, $1,000 per sub-committee meeting,
	and receive an Option grant of 50,000 Options, with 20,000 Options vesting upon appointment to the Board, 15,000 vesting on the
	first anniversary of the grant and the remainder vesting on the second anniversary of the grant. Directors who are ESSA&rsquo;s
	officers, employees or consultants will receive no compensation under the terms of this compensation plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Incentive Plan Awards Outstanding
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As at September&nbsp;30, 2016, the end of the Company&rsquo;s last
	fiscal year, non-NEO directors held 545,000 Options in the Company, granted in prior years, resulting in $53,951 vested or earned
	in the year ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Options to Purchase Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As at the date of this Annual Report, 4,062,519 outstanding options
	to acquire Common Shares (the &ldquo;Options&rdquo;) are held by directors, consultants, employees and executive officers of the
	Company. Of these Options, 1,118,300 are exercisable at a price of C$0.80 per Common Share, 1,859,219 are exercisable at a price
	of C$2.00 per Common Share, 290,000 are exercisable at a price of C$3.49 per Common Share, 10,000 are exercisable at a price of
	C$5.15 per Common Share, 50,000 are exercisable at a price of C$5.35 per Common Share, 600,000 are exercisable at C$6.25 per Common
	Share, 20,000 are exercisable at a price of C$7.26 per Common Share, 60,000 are exercisable at a price of C$9.10 per Common Share,
	and 55,000 are exercisable at a price of C$14.90 per Common Share. The table below summarizes the 4,062,519 Options outstanding
	as at the date of this Annual Report.
</P>
<!-- FIELD: PAGE; SEQUENCE: 89 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Class of Optionee
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Number)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number of Common
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Share Options Held
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exercise Price (C$)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Expiry Date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 31%">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Marianne Sadar
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	300,000
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 23%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 23%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	January 31, 2018
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Scientific Officer
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Raymond Andersen
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	300,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	January 31, 2018
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Technical Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Jennifer Hamilton
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,300
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	October 21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Roger Ulrich
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	November 20, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Jim Bristol
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	November 20, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Kim Hewitt
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,250
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June 1, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6,750
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(4)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May 20, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Oreola Donini
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	former VP of R&amp;D
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	36,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(6)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June 1, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Bloom Burton&nbsp;&amp; Co. Inc.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	529,219
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(7)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	The later of October 24, 2019 or 48 months from the date the Company becomes a reporting issuer on a recognized stock exchange.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Paul Cossum
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	EVP of Research &amp; Development
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	400,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(8)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	April 14, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Stephen Plymate
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(9)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	July 1, 2018
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Gary Sollis
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	120,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(10)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May 20, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Kally Singh
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(4)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May 20, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	75,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(5)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May&nbsp;20,&nbsp;2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	200,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(11)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	July&nbsp;30, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Richard Glickman
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	75,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(12)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May 20, 2019
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 90 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Daisy Wong
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Consultant
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(4)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$0.80/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	May 20, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Frank Perabo
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	EVP &amp; Chief Medical Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	500,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(13)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	September 8, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Robert Rieder
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Former Chief Executive Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	150,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(14)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June 6, 2017
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 31%">
<FONT STYLE="FONT-SIZE: 10PT">
	Sequoia Partners Inc.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(15)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 23%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 23%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	December 18, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chandtip Chandhasin
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(16)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	November 23, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Nkengyal Barber
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(17)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	November 23, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Leah Dimascio
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(18)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$2.00/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	December 2, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Erin Rudsinski
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(19)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$5.15/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 3, 2020
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Franklin Berger
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(20)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$5.35/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 5, 2025
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Erica Osbourne
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(21)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$14.90/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June 23, 2020
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	David Parkinson
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(22)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$14.90/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	June 23, 2025
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	President &amp; Chief Executive Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	600,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(26)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$6.25/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	January 12, 2021
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Loleta Harris
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(23)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$9.10/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	September 9, 2025
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Steve Pondell
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	50,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(23)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$9.10/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	September 9, 2025
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Neil Thapar
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	20,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(25)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$7.26/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	November 6, 2019
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Peter Virsik
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	EVP &amp; Chief Operating Officer
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	290,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	(27)
</SUP>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	$3.49/Common Share
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	August 9, 2021
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest in equal monthly installments of 12,500 Options per month with the first installment of Options vesting on February&nbsp;28, 2013.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vested immediately.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vested according to the following schedule: (1)&nbsp;10,000 Options vest immediately on November&nbsp;20, 2012; (2)&nbsp;10,000 Options vest every three months after the anniversary date of the grant. All remaining Options will vest immediately upon any of the following events: (1)&nbsp;completion of a venture capital financing; (2)&nbsp;execution of a partnership agreement; (3)&nbsp;successful filing of IND application with the FDA.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on May 21, 2014; 20% in four equal monthly installments on the anniversary date of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on May 21, 2014; 20% in four equal monthly installments on the anniversary date of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vested in equal monthly installments of 5,000 Options per month with the first installment of Options vesting on June&nbsp;1, 2012.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	100% of these Options vest 12 months from the date the Company becomes a reporting issuer on a recognized stock exchange.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 10,000 options vest each month for the first 24 months of employment starting April 15, 2014. The remaining Options vest upon the following events: (1)&nbsp;100,000 Options upon filing a successful IND; (2)&nbsp;60,000 Options upon filing a successful IND application prior to February&nbsp;28, 2015; and (3)&nbsp;all unvested Options vest upon completion of a sale of the Company. Vested Options will automatically expire one year after the optionee elects to terminate employment with the Company for any reason.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: (1)&nbsp;20% on July&nbsp;1, 2013; (2)&nbsp;20% in four equal monthly installments on the anniversary date of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vested in equal quarterly installments of 10,000 Options per quarter with the first installment of Options vesting on April&nbsp;1, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(11)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: (1)&nbsp;20% on July&nbsp;30, 2014; (2)&nbsp;20% in four equal monthly installments on the anniversary date of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: (1)&nbsp;25% on May&nbsp;21, 2014; (2)&nbsp;25% in three equal monthly installments on the anniversary date of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options were granted pursuant to the terms of the Stock Option Plan and vest in equal monthly installments of 10,000 Options per month for 36 months with the first installment of Options vesting on September&nbsp;8, 2014. The remaining Options vest upon the following events: (1)&nbsp;40,000 Options upon dosing the first patient in a Phase 1/2 clinical trial; (2)&nbsp;50,000 Options upon dosing such patient prior to July&nbsp;31, 2015; (3)&nbsp;50,000 Options upon completing enrollment for such study prior to September&nbsp;30, 2017; and (4)&nbsp;all unvested Options vest upon completion of a sale of the Company. Vested Options will automatically expire one year after the optionee elects to terminate employment with the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(14)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options originally vested according to the following schedule: 25% on December 31, 2014; and 25% in three equal annual installments beginning on December 31, 2015. Upon resignation of Mr. Rieder on January 6, 2016, these Options were immediately vested and will expire June 6, 2017.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(15)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 10,000 Options on December 19, 2014; 10,000 Options three months after December 19, 2014; and 10,000 Options every three months thereafter.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(16)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on December 19, 2014; and 20% in four equal annual installments beginning on November 24, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(17)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on December 19, 2014; and 20% in four equal annual installments beginning on November 24, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(18)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on December 19, 2014; and 20% in four equal annual installments beginning on December 3, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(19)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Options vest according to the following schedule: 20% on March 2, 2015; and 20% in four equal annual installments beginning March 2, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(20)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Options vest according to the following schedule: 20,000 on March 5, 2015; 15,000 on March&nbsp;5, 2016; and 15,000 on March&nbsp;5, 2017.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(21)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on June 23, 2015; and 20% in four equal installments beginning June&nbsp;23, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(22)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Options vest according to the following schedule: 20,000 on June 23, 2015; 15,000 on June 23, 2016; and 15,000 on June&nbsp;23, 2017.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(23)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on September 9, 2015; and 20% in four equal installments beginning September 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(24)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on November 6, 2015; and 20% in four equal installments beginning November 6, 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(25)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 20% on November 6, 2015; and 20% in four equal installments beginning November 6, 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(26)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These Options vest according to the following schedule: 150,000 on January 12, 2017; and 12,500 every month thereafter.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(27)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	These Options vest according to the following schedule:
	72,500 on August 9, 2017; and 6,042 every month thereafter.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Board Practices
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Item&nbsp;6.A., &ldquo;
<I>
	Directors, Senior Management and Employees
	&ndash; Directors and Senior Management
</I>
	&rdquo; above sets out each directors&rsquo; and officers&rsquo; date of expiration
	of their current term of office, as applicable, and the period during which such person has served in that office.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For specific termination and change-of-control provisions for the
	Company&rsquo;s six NEO&rsquo;s, Dr. David Parkinson, David Wood, Peter Virsik, Dr. Frank Perabo, Dr. Paul Cossum, and Dr. Marianne
	Sadar, see Item&nbsp;6.B &ldquo;
<I>
	Compensation.
</I>
	&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of the date of this Annual Report, Richard Glickman, Gary Sollis,
	Dr. Marianne Sadar, Dr. Raymond Andersen, Franklin Berger, Dr. Frank Perabo and David Parkinson are not engaged in a contract providing
	for benefits upon termination of employment with the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Audit Committee
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The audit committee of the Board (the &ldquo;
<B>
	Audit Committee
</B>
	&rdquo;)
	is comprised of Franklin Berger (chair), Richard Glickman, and Gary Sollis, all of whom are &ldquo;financially literate&rdquo;
	as defined in National Instrument 52-110 &ndash; Audit Committees (&ldquo;
<B>
	NI 52-110
</B>
	&rdquo;) and the rules of the Nasdaq.
	Each member of the Audit Committee is considered independent pursuant to NI 52-110, Rule 10A-3 under the U.S. Exchange Act and
	the rules of the Nasdaq. Franklin Berger served as the Audit Committee&rsquo;s financial expert for the 2016 fiscal year. A description
	of the education and experience of each Audit Committee member that is relevant to the performance of his responsibilities as an
	Audit Committee member may be found above under the heading &ldquo;
<I>
	Directors, Senior Management and Employees &ndash; Directors
	and Senior Management
</I>
	&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Audit Committee is responsible for reviewing the Company&rsquo;s
	financial reporting procedures, internal controls and the performance of the financial management and the Auditor. The Audit Committee
	also reviews the annual audited financial statements and makes recommendations to the board. A copy of the Audit Committee&rsquo;s
	charter is set out below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Audit Committee Charter
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	I.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Purpose
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The main objective of the Audit Committee is to act as a liaison
	between the Board and the Company&rsquo;s independent auditor and to assist the Board in fulfilling its oversight responsibilities
	with respect to the financial statements and other financial information provided by the Company to its shareholders and others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	II.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Organization
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Committee shall consist of three or more directors and shall
	satisfy the laws governing the Company and the independence, financial literacy, expertise and experience requirements under applicable
	securities law, stock exchange requests and any other regulatory requirements applicable to the Audit Committee of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The members of the Committee and the Chair of the Committee shall
	be appointed by the Board. A majority of the members of the Committee shall constitute a quorum. A majority of the members of the
	Committee shall be empowered to act on behalf of the Committee. Matters decided by the Committee shall be decided by majority votes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Any member of the Committee may be removed or replaced at any time
	by the Board and shall cease to be a member of the Committee as soon as such member ceases to be a director.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Committee may form and delegate authority to subcommittees when
	appropriate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	III.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Meetings
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Committee shall meet as frequently as circumstances require.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Committee may invite, from time to time, such persons as it
	may see fit to attend its meetings and to take part in discussion and consideration of the affairs of the Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	IV.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Responsibilities
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee shall recommend to the Board:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the external auditor to be nominated for the purpose of preparing or issuing an auditor&rsquo;s report or performing other audit, review or attest services for the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the compensation of the external auditor.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee shall be directly responsible for overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor&rsquo;s report or performing other audit, review or attest services for the Company, including the resolution of disagreements between management and the external auditor regarding financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee must pre-approve all non-audit services to be provided to the Company or its subsidiary entities by the Company&rsquo;s external auditor.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee must review the Company&rsquo;s financial statements, MD&amp;A and annual and interim earnings press releases before the Company publicly discloses this information.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee must be satisfied that adequate procedures are in place for the review of the Company&rsquo;s public disclosure of financial information extracted or derived from the Company&rsquo;s financial statements, other than the public disclosure referred to in subsection (4), and must periodically assess the adequacy of those procedures.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Committee must establish procedures for:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls, or auditing matters; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	V.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Authority
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Committee shall have the following authority:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to engage independent counsel and other advisors as it determines necessary to carry out its duties,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to set and pay the compensation for any auditor or tax advisors employed by the Committee, and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	to communicate directly with the external auditor.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Audit Committee Oversight
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Since the commencement of the Company&rsquo;s most recently completed
	financial year, there has not been a recommendation of the Audit Committee to nominate or compensate an external auditor which
	was not adopted by the Company&rsquo;s Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Pre-Approval Policies and Procedures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Audit Committee has the authority and responsibility for pre-approval
	of all non-audit services to be provided to the Company or its subsidiary entities by the external auditor or the external auditor
	of the Company&rsquo;s subsidiary entities, unless such pre-approval is otherwise appropriately delegated or if appropriate specific
	policies and procedures for the engagement of non-audit services have been adopted by the Audit Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	External Auditor Service Fees by Category
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The aggregate fees billed by the Company&rsquo;s external auditor
	in each of the last three fiscal years for audit fees are set out in the table below. In the table, &ldquo;
<B>
	Audit Fees
</B>
	&rdquo;
	are fees billed by the Company&rsquo;s external auditor for services provided in auditing the Company&rsquo;s annual financial
	statements for the subject year. &ldquo;
<B>
	Audit-Related Fees
</B>
	&rdquo; are fees not included in audit fees that are billed by
	the auditor for assurance and related services that are reasonably related to the performance of the audit review of the Company&rsquo;s
	financial statements. &ldquo;
<B>
	Tax Fees
</B>
	&rdquo; are fees billed by the auditor for professional services rendered for tax compliance,
	tax advice and tax planning. &ldquo;
<B>
	All other fees
</B>
	&rdquo; are fees billed by the auditor for products and services not included
	in the foregoing categories. All amounts in the table are expressed in Canadian dollars.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
<B>
	Financial Year Ending
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Audit Fees
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Audit-
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Related&nbsp;Fees
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Tax&nbsp;Fees
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	All&nbsp;Other&nbsp;Fees
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 47%">
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30, 2016
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	56,610
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 0%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30, 2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	45,000
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30, 2014
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	32,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September&nbsp;30, 2013
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December&nbsp;31, 2012
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	nil
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Compensation Committee
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Prior to December 19, 2014, compensation matters were determined
	by the entire Board. At a meeting held on December 19, 2014, the Board formed a Compensation Committee. The Compensation Committee
	is currently comprised of Scott Requadt (chair), Richard Glickman and Gary Sollis. Under SEC and Nasdaq&nbsp;rules, there are heightened
	independence standards for members of the compensation committee. All of ESSA&rsquo;s compensation committee members meet these
	heightened standards. The Compensation Committee is responsible for reviewing the compensation plans and severance arrangements
	for management, to ensure they are commensurate with comparable companies. Factors that are taken into consideration when making
	compensation decisions include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the financial resources available or expected to be available to the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	comparative compensations levels for companies of ESSA&rsquo;s size in the biopharmaceutical industry;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the capabilities of individual contributors to the Company&rsquo;s success;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the reasonable compensation expectations of the individual contributor; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	relative equity with other ESSA contributors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Statement of Corporate Governance Practices
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On June&nbsp;30, 2005, National Instrument 58-101 &ndash;
<I>
	Disclosure
	of Corporate Governance Practices
</I>
	(&ldquo;
<B>
	NI 58
</B>
	-
<B>
	101
</B>
	&rdquo;) and National Policy 58-201 &ndash;
<I>
	Corporate Governance
	Guidelines
</I>
	(the &ldquo;
<B>
	Guidelines
</B>
	&rdquo;), came into force. The Guidelines address matters such as the constitution
	of and the functions to be performed by the Board. NI 58-101 requires that the Company disclose its approach to corporate governance
	with reference to the Guidelines. The Board is committed to ensuring that the Company has an effective corporate governance system,
	which adds value and assists the Company in achieving its objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s approach to corporate governance is set forth
	below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Mandate of the Board
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Board assumes responsibility for the stewardship of the Company
	and the creation of shareholder value. The Board is responsible for:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ensuring that management develops and implements a strategic plan that takes into account market realities and regulatory compliance;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	upholding a comprehensive policy for communications with shareholders and the public at large;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	developing and formalizing the responsibilities for each member of the board, including the responsibilities of the CEO vis-&agrave;-vis corporate objectives;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ensuring that the risk management of ESSA is prudently addressed; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(e)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	overseeing succession planning for management.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The frequency of meetings of the Board and the nature of agenda
	items may change from year to year depending upon the activities of ESSA. However, the Board meets at least quarterly and at each
	meeting there is a review of the business of ESSA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Board facilitates its exercise of independent supervision over
	the Company&rsquo;s management through frequent meetings of the Board being held to obtain an update on significant corporate activities
	and plans, both with and without members of the Company&rsquo;s management being in attendance. Further, the independent directors
	of the Board hold, at a minimum, two meetings annually without the presence of non-independent directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Composition of the Board
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Board is composed of seven directors, three of whom qualify
	as independent directors. For this purpose, a director is independent if he or she has no direct or indirect &ldquo;material relationship&rdquo;
	with ESSA. A &ldquo;material relationship&rdquo; is a relationship which could, in the view of the Board, be reasonably expected
	to interfere with the exercise of the director&rsquo;s independent judgment. An individual who has been an employee or executive
	officer of the Company within the last three years is considered to have a material relationship with the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Of the directors, Franklin Berger, Richard Glickman, and Gary Sollis
	are considered independent under Rule 5605(a)(2) of the Nasdaq listing standards. Three directors: (i)&nbsp;Dr. David Parkinson,
	President and Chief Executive Officer of the Company; (ii)&nbsp;Dr. Marianne Sadar, Chief Scientific Officer of the Company; (iii)&nbsp;Dr.
	Raymond Andersen, Secretary and Chief Technical Officer of the Company; and (iv) Scott Requadt, Managing Director of Clarus (a
	major shareholder) are considered not independent. The size of the Company is such that all the Company&rsquo;s operations are
	conducted by a small management team which is also represented on the Board. The Board believes that management is effectively
	supervised by the three independent directors, as the independent directors are actively and regularly involved in reviewing the
	operations of the Company and have regular and full access to management not represented on the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Directorships
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Currently, the following directors serve on the following boards
	of directors of other public companies:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 18%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DIRECTOR
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 81%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PUBLIC&nbsp;CORPORATION&nbsp;BOARD&nbsp;MEMBERSHIP
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Richard Glickman
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Cardiome Pharma Corp., Aurinia Pharmaceuticals Corp.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Franklin Berger
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Five Prime Therapeutics, Inc., Immune Design Corp., Bellus Health, Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Parkinson
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Threshold Pharmaceuticals, Inc., Cerulean Pharma Inc., 3SBio Inc.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Scott Requadt
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	VBI Vaccines Inc.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Orientation and Education
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA will provide new directors with copies of relevant financial,
	technical and other information regarding its R&amp;D programs. Board members are also encouraged to communicate with management
	and the Auditor and, to keep themselves current with industry trends and developments. Board members have full access to the Company&rsquo;s
	records.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Ethical Business Conduct
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has adopted a Code of Business Conduct applicable to all of
	its directors and employees, including its Chief Executive Officer and Chief Financial Officer, which is a &ldquo;code of ethics&rdquo;
	as defined in Item 16B of Form 20-F promulgated by the SEC and which is a &ldquo;code&rdquo; under National Instrument NI 58-101.&nbsp;The
	objective of the Code of Conduct is to (i) emphasize ESSA&rsquo;s commitment to ethics and compliance with the laws, (ii) set forth
	basic standards of ethical and legal behavior, (iii) provide reporting mechanisms for known or suspected ethical or legal violations
	and (iv) help prevent and detect wrongdoing. The full text of the Code of Business Conduct is posted on ESSA&rsquo;s website at
	www.essapharma.com. Information contained on, or that can be accessed through, the Company&rsquo;s website does not constitute
	a part of this and is not incorporated by reference herein.&nbsp;If ESSA makes any amendment to the Code of Business Conduct or
	grants any waivers, including any implicit waiver, from a provision of the code of conduct, ESSA will disclose the nature of such
	amendment or waiver on its website to the extent required by the rules and regulations of the SEC and the Canadian Securities Administrators.
	Under Item 16B of the SEC&rsquo;s Form 20-F, if a waiver or amendment of the Code of Business Conduct applies to the Company&rsquo;s
	principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting
	any of the values described in Item 16B(b) of such Form 20-F, ESSA will disclose such waiver or amendment on its website in accordance
	with the requirements of Instruction 4 to such Item&nbsp;16B.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Nomination of Directors
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has adopted a director nomination policy to ensure that it
	identifies nominees for the Board in compliance with applicable securities laws and regulations and exchange requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Director nominees will be recommended for the Board&rsquo;s selection
	by a minimum of three Independent Directors constituting a majority of the Board&rsquo;s independent directors in a vote in which
	only independent directors participate.&nbsp;The term &ldquo;independent director&rdquo; has the meaning given to such term in
	the listing standards of the Nasdaq.&nbsp;In making nominee recommendations, such independent directors will consider:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the competencies and skills considered necessary for the Board as a whole to possess;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the competencies and skills that each existing director possesses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	the competencies and skills each new nominee will bring to the Board; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	whether the nominee will be an independent director.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition, such independent directors will consider whether each
	new nominee can devote sufficient time and resources to his or her duties as a member of the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Assessments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Board and each individual director will be regularly assessed
	regarding his or its effectiveness and contribution. The assessment will consider and take into account:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	in the case of the Board, its mandate and charter; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	in the case of an individual director, the competencies and skills each individual director is expected to possess.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	D. Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of the date of this Annual Report, ESSA has a total of 25 employees
	and consultants on a full-time or part-time basis. ESSA has in the past, and may in the future, retain additional expert consultants
	on an ad-hoc basis if required in connection with the Company&rsquo;s development program. None of ESSA&rsquo;s employees are represented
	by a union. The following table sets forth the total number of ESSA&rsquo;s employees at September 30, 2016, 2015 and 2014, respectively,
	and a breakdown of persons employed by category of activity and geographic location for the corresponding periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September&nbsp;30,
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employees and consultants by category of activity:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 58%">
<FONT STYLE="FONT-SIZE: 10PT">
	Management
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Administration
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Research
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total Number of Employees and Consultants
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	23
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employees and consultants by geographic location:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	14
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Total Number of Employees and Consultants
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	23
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Share Ownership
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As at the date of this Annual Report, as a group, the Company&rsquo;s
	directors and executive officers beneficially owned, directly or indirectly, or exercised control over 8,755,478 Common Shares
	being 30.09% of the 29,096,889 Common Shares issued and outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table states the number of Common Shares beneficially
	owned by each person, directly or indirectly, or over which each person exercised control or direction as at December 14, 2016.
	The persons listed below are deemed to be the beneficial owners of Common Shares underlying stock options that are exercisable
	within 60 days from the above date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name of Beneficial Owner
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Common&nbsp;Shares
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Percent&nbsp;of&nbsp;Common&nbsp;Shares
<SUP>
	(2)
</SUP>
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 53%">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. David Parkinson
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	185,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.58
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Richard M. Glickman
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	831,250
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.60
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Marianne Sadar
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,189,296
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.98
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Raymond Andersen
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,186,296
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.97
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Gary Sollis
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	90,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.28
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	155,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	0.49
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Frank Perabo
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	380,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Paul Cossum
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	340,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.06
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Franklin Berger
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	398,636
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.25
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	These numbers include Common Shares underlying stock options that are exercisable within 60 days from December 14, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on an aggregate total of 31,951,158 Common Shares, being the 29,096,889 Common Shares issued and outstanding as at December 14, 2016 plus the 2,854,269&nbsp;Common Shares underlying stock options that are exercisable within 60 days from December 14, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Item&nbsp;6.B., &ldquo;
<I>
	Directors, Senior Management and Employees
	&ndash; Compensation
</I>
	&rdquo; above sets out information regarding options granted to members of the Board of Directors and describes
	arrangements for involving employees in the capital of the Company.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MAJOR SHAREHOLDERS
	AND RELATED PARTY TRANSACTIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Major Shareholders
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following table shows the name and information about ESSA&rsquo;s
	voting securities owned by each person or company which, as at December 14, 2016, owned of record, or which, to ESSA&rsquo;s knowledge,
	owned beneficially, directly or indirectly, more than 5% of any class or series of the Company&rsquo;s voting securities:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Name
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Number and Type of Securities
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Type&nbsp;of&nbsp;Ownership
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Percentage&nbsp;of
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	Class
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Percentage&nbsp;of&nbsp;Class&nbsp;
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	on&nbsp;a Diluted Basis
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 22%">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Marianne Sadar
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 26%">
<FONT STYLE="FONT-SIZE: 10PT">
	2,889,296 Common Shares
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%">
<FONT STYLE="FONT-SIZE: 10PT">
	Beneficial
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.93
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.18
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Raymond Andersen
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2,886,296 Common Shares
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Beneficial
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.92
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Eventide Asset Management
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2,719,410 Common Shares
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Beneficial
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.35
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.75
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Deerfield Funds
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2,121,601 Common Shares
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Beneficial
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.29
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.27
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Clarus Ventures
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2,121,212 Common Shares
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Beneficial
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.29
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.27
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on 29,096,889 outstanding Common Shares as of December 14, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on an aggregate total of 40,258,949 outstanding Common Shares on a fully diluted basis as of December 14, 2016, being the 29,096,889 Common Shares issued and outstanding as at December 14, 2016, and assuming the exercise of all outstanding 4,062,519 Options, 25,000 Bloom Burton Warrants, 256,363 Broker Warrants, 4,545,452 7-Year Warrants, and 2,272,726 2-Year Warrants, each on a one to one basis.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	No major shareholders have different voting rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The information in the table above was supplied by Computershare
	Trust Company of Canada, the Company&rsquo;s registrar and transfer agent, and by the individuals themselves.
</P>
<!-- FIELD: PAGE; SEQUENCE: 99 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of December 14, 2016, the number of registered shareholders of
	record (and the number and percentage of shares held by such shareholders) is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Location:
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number&nbsp;of&nbsp;registered
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	shareholders&nbsp;of&nbsp;record
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number&nbsp;of&nbsp;Common Shares
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Percentage&nbsp;of&nbsp;total Common
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	Canada
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	51
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17,308,077
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	85.00
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	United States
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	11,680,359
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	11.67
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Other
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	108,453
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.33
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;The Company is not aware that it is directly owned or controlled
	by another corporation, any foreign government or any other natural or legal person(s) severally or jointly. The Company is not
	aware of any arrangement, the operation of which may result in a change of control of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Related Party Transactions
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In addition to the compensation arrangements discussed under Item
	6.B &ldquo;
<I>
	Compensation
</I>
	,&rdquo; the following is a description of the material terms of those transactions with related
	parties to which ESSA is a party and which it is required to disclose pursuant to the disclosure rules of the SEC and the British
	Columbia Securities Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Agreements with Directors and Officers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Indemnity Agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has entered into indemnity agreements with its directors and
	certain officers which provide, among other things, that it will indemnify him or her to the fullest extent permitted by law from
	and against all liabilities, costs, charges and expenses incurred as a result of his or her actions in the exercise of his or her
	duties as a director or officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Employment Agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has entered into employment agreements with Dr. David
	Parkinson, President and Chief Executive Officer, David Wood, Chief Financial Officer, and Peter Virsik, Executive
	Vice President and Chief Operating Officer. Terms of employment for Dr. Frank Perabo, Executive Vice President of Clinical
	Development and Chief Medical Officer, and Dr. Paul Cossum, Executive Vice President of Research and Development, are as
	stated in letter agreements. For more information regarding certain of
	these agreements, see &ldquo;
<I>
	Compensation
</I>
	&rdquo; in Item 6.B of this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Consulting Agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has entered into consulting agreements with Dr. Marianne Sadar,
	Chief Scientific Officer, and Dr. Raymond Andersen, Chief Technical Officer. The specific provisions of each consulting agreement
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. Marianne Sadar:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The term of this consulting agreement expires on January&nbsp;31, 2018 and may be extended for additional periods of one year each by mutual written agreement between the parties.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	An annual fee to the consultant of C$180,000 per year shall be paid in equal monthly installments of C$15,000 throughout the term of the agreement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In connection with consulting services performed, on February&nbsp;1, 2013 Dr.&nbsp;Sadar received options to purchase 300,000 Common Shares at an exercise price of C$0.80 per share. Such options vest monthly in 24 equal installments of 12,500 Common Shares. Any unvested options will vest immediately upon the closing of this offering. In addition, on May&nbsp;1, 2011 ESSA granted Dr.&nbsp;Sadar options to purchase 120,000 Common Shares at an exercise price of C$0.50 per share. Such options vest monthly in 12 equal installments of 10,000 shares and vested options shall be exercisable any time and from time to time until April&nbsp;30, 2016; these options were exercised for 106,862 Common Shares on a cashless basis during the year ended September 30, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Sadar shall receive a one-time bonus within 10 days of us reaching certain significant milestones described within the consulting agreement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	At all times during the term of the consulting agreement, and for a period of 12 months thereafter, Dr.&nbsp;Sadar will be restricted from competing against us.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For Dr. Raymond Andersen:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The term of this consulting agreement expires on January&nbsp;31, 2018 and may be extended for additional periods of one year each by mutual written agreement between the parties.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	An annual fee to the consultant of C$120,000 per year shall be paid in equal monthly installments of C$10,000 throughout the term of the agreement.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In connection with consulting services performed, on February&nbsp;1, 2013 Dr.&nbsp;Andersen received options to purchase 300,000 Common Shares at an exercise price of C$0.80 per share. Such options vest monthly in 24 equal installments of 12,500 Common Shares. Any unvested options will vest immediately upon the closing of this offering. In addition, on May&nbsp;1, 2011 ESSA granted Dr.&nbsp;Andersen options to purchase 120,000 Common Shares at an exercise price of C$0.50 per share. Such options vest monthly in 12 equal installments of 10,000 shares and vested options shall be exercisable any time and from time to time until April&nbsp;30, 2016; these options were exercised for 106,862 Common Shares on a cashless basis during the year ended September 30, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Dr.&nbsp;Andersen shall receive a one-time bonus within 10 days of us reaching certain significant milestones described within the consulting agreement.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	At all times during the term of the consulting agreement, and for a period of 12 months thereafter, Dr.&nbsp;Andersen will be restricted from competing against ESSA.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Equity Awards
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Since ESSA's inception, it has granted equity awards to certain
	of its directors and officers. ESSA describes its equity plans under &ldquo;
<I>
	Executive Compensation
</I>
	&rdquo; in Item 6 of this
	Annual Report
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Included in accounts payable and accrued liabilities at September
	30, 2016 is $276,399 (compared to $82,414 on September&nbsp;30, 2015) due to related parties with respect to the transactions described
	under &ldquo;
<I>
	Executive Compensation
</I>
	&rdquo; in Item 6 of this Annual Report and expense reimbursements. Amounts due to related
	parties are non-interest bearing, with no fixed terms of repayment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Included in accounts payable and accrued liabilities at September&nbsp;30,
	2015 is $82,414 (compared to $21,709 on September&nbsp;30, 2014) due to related parties with respect to the transactions described
	under &ldquo;
<I>
	Executive Compensation
</I>
	&rdquo; in Item 6 of this Annual Report and expense reimbursements. Amounts due to related
	parties are non-interest bearing, with no fixed terms of repayment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Indebtedness of Directors, Executive Officers and Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	None of ESSA's directors, executive officers, employees, former
	directors, former executive officers or former employees, and none of their associates, is indebted to ESSA or another entity whose
	indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar agreement or understanding provided
	by ESSA, except for routine indebtedness as defined under applicable securities legislation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Significant Influence
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company previously completed the January 2016 Financing, a private
	placement for gross proceeds of approximately $15,000,000. For greater detail see Item 4.A &ldquo;
<I>
	History and development of
	the Company &ndash; 2016
</I>
	.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As a result of the January 2016 Financing, Scott Requadt, Managing
	Director of Clarus Ventures, LLC, was appointed to the Board of the Company. Pursuant to the terms of a subscription agreement
	between the Company and Clarus in connection with the January 2016 Financing, Clarus is entitled to nominate two directors to the
	board of directors of the Company, one of which must be an independent director and pre-approved by the Company. The nomination
	rights will continue for so long as Clarus holds greater than or equal to 1,060,606 common shares, subject to adjustment in certain
	circumstances. As of the date of this Annual Report, Clarus has significant influence on the Company beneficially owning 2,121,212
	Common Shares, representing 7.29% of the issued and outstanding Common Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	98
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Interests of Experts and Counsel
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Consolidated Statements and Other Financial Information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s audited consolidated financial statements as
	at and for the years ended September 30, 2016, 2015, and 2014, as required under this Item&nbsp;8, are attached hereto and found
	immediately following the text of this Annual Report. The audit report of Davidson&nbsp;&amp; Company LLP is included herein immediately
	preceding the consolidated financial statements and schedules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Legal Proceedings
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	From time to time, ESSA may become involved in legal or regulatory
	proceedings arising in the ordinary course of business. ESSA is not currently a party to any material litigation or regulatory
	proceeding and it is not aware of any pending or threatened litigation or regulatory proceeding against it that could have a material
	adverse effect on its business, operating results, financial condition or cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Dividend Policy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has never declared or paid any dividends on its securities.
	ESSA does not have any present intention to pay cash dividends on its Common Shares and it does not anticipate paying any cash
	dividends on its Common Shares in the foreseeable future. ESSA currently intends to invest its future earnings, if any, to fund
	its growth. However, any future determination as to the declaration and payment of dividends will be at the discretion of ESSA's
	board of directors and will depend on its financial condition, operating results, contractual restrictions, capital requirements,
	business prospects and other factors its board of directors may deem relevant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Significant Changes
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Other than the 2016 Loan and Security Agreement, there have been
	no significant changes in the Company&rsquo;s financial condition since the most recent consolidated financial statements for the
	fiscal year ended September&nbsp;30, 2016. See &ldquo;
<I>
	Summary Corporate History and Intercorporate Relationships
</I>
	&rdquo;
	in Item&nbsp;4 of this Annual Report.
</P>
</EFX_LEGAL_PROCEEDINGS>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_LISTING>
<A NAME="FIS_LISTING"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 9.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	THE OFFER AND LISTING
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Offer and Listing Details
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As at the date of this Annual Report, the Company had 29,096,889
	Common Shares outstanding. On January&nbsp;27, 2015, the Common Shares began trading on the TSX-V under the symbol &ldquo;EPI&rdquo;.
	On July 28, 2015, ESSA delisted from the TSX-V and began trading its Common Shares on the TSX under the same symbol, &ldquo;EPI&rdquo;.
	On July&nbsp;9, 2015, the Common Shares began trading on the Nasdaq under the symbol &ldquo;EPIX&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Using information from published sources, the following information
	shows the high and low trading values of ESSA&rsquo;s Common Shares for the periods indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 102 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	99
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<U>
	NASDAQ (&ldquo;EPIX&rdquo;)
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the month ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 58%">
<FONT STYLE="FONT-SIZE: 10PT">
	November 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.48
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.80
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	87,745
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25,313
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.26
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	71,003
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.60
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	74,808
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	July 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.95
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.61
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	102,903
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	June 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.12
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.86
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,740
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the quarter ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.95
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.26
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	248,714
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	June 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.39
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.86
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	662,183
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.34
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	600,354
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 31, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	81,313
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	For the period from July 9, 2015 to September 30, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.45
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.90
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	105,092
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the year ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7.00
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.26
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,592,564
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	For the period from July 9, 2015 to September 30, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.45
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.90
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	105,092
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<U>
	TSX (&ldquo;EPI&rdquo;)
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the month ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(C$)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(C$)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 57%">
<FONT STYLE="FONT-SIZE: 10PT">
	November 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.35
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.39
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	273,630
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2.90
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	190,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.05
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	83,800
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.57
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.40
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	196,600
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	July 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.80
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.40
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	205,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	June 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.65
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	310,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the quarter ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.80
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.05
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	485,900
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	June 30, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.41
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.65
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	589,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	March 31, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.90
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.21
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	777,400
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 31, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.03
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.57
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	300,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	For the period from July 28, 2015 to September 30, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.60
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	447,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	For the year ended
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	High
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Low
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Volume
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 61%">
<FONT STYLE="FONT-SIZE: 10PT">
	September 30, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.03
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.05
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,153,700
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	For the period from July 28, 2015 to September 30, 2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6.60
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	447,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Plan of Distribution
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	100
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Markets
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s Common Shares are listed on the Nasdaq under
	the symbol &ldquo;EPIX&rdquo;. The Company&rsquo;s Common Shares commenced trading on the TSX under the symbol &ldquo;EPI&rdquo;
	on July 28, 2015, while the Company&rsquo;s Common Shares were concurrently delisted from the TSX-V. The Company&rsquo;s Common
	Shares trade in U.S. dollars on the Nasdaq and in Canadian dollars on the TSX. On December 13, 2016, the closing price of the Company&rsquo;s
	Common Shares on the TSX and the Nasdaq was C$2.99 and $2.08, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Selling Shareholders
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Dilution
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Expenses of the Issue
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_LISTING>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_ADDITIONAL_INFORMATION>
<A NAME="FIS_ADDITIONAL_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	ITEM 10. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Share Capital
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Memorandum and Articles of Association
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company incorporates by reference into this Annual Report the
	information contained in the Company&rsquo;s registration statement on Form 20-F (File No. 377-00939) originally filed with the
	SEC on February 24, 2015, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Material Contracts
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Except for contracts entered into in the ordinary course of business,
	the only contracts entered into by ESSA within two years immediately preceding this Annual Report that are still in effect, which
	may be regarded as material, are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Cancer Research Grant Contract between CPRIT and the Company dated July&nbsp;9, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement between the BC Cancer Agency, UBC and the Company dated December&nbsp;22, 2010, as amended on February&nbsp;10, 2011 and May&nbsp;27, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2014 Agency Agreement between the Company and Haywood Securities Inc. dated October&nbsp;22, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2015 Agency Agreement between the Company and Bloom Burton&nbsp;&amp; Co. Limited dated January&nbsp;16, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2014 Special Warrant Indenture between the Company and the Special Warrant Agent dated October&nbsp;22, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	6.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2015 Special Warrant Indenture between the Company and the Special Warrant Agent dated January&nbsp;16, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	7.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease for 2130 West Holcombe Boulevard, Houston, Texas, United States dated April 7, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	8.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement for David Wood.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	101
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	9.
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Employment Agreement for David Parkinson.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	10.
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Employment Agreement for Peter Virsik.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	11.
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Loan and Security Agreement between the Company and Silicon Valley
	Bank dated November 18, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exchange Controls
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company is not aware of any Canadian federal or provincial laws,
	decrees, or regulations that restrict the export or import of capital, including foreign exchange controls, or that affect the
	remittance of dividends, interest or other payments to non-Canadian holders of the Common Shares.&nbsp;There are no limitations
	under the laws of Canada or by the charter or other constituent documents of the Company, except the
<I>
	Investment Canada Act
</I>
	which may require review and approval by the Minister of Industry (Canada) of certain acquisition of control of the Company by
	non-Canadians.&nbsp;The threshold for acquisitions of control is generally defined as being one-third or more of ESSA&rsquo;s voting
	shares. If the investment is potentially injurious to national security it may be subject to review under the Investment Canada
	Act notwithstanding the percentage interest acquired or amount of the investment. &ldquo;Non-Canadian&rdquo; generally means an
	individual who is not a Canadian citizen, or a corporation, partnership, trust or joint venture that is ultimately controlled by
	non-Canadians.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	E.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Taxation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	U.S. Federal Income Tax Considerations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following is a summary of the anticipated U.S. federal income
	tax consequences generally applicable to U.S. Holders (as defined below) of the acquisition, ownership and disposition of Common
	Shares. This summary addresses only holders who acquire and hold Common Shares as &ldquo;capital assets&rdquo; (generally, assets
	held for investment purposes).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following summary does not purport to address all U.S. federal
	income tax consequences that may be relevant to a U.S. Holder (as defined below) as a result of the acquisition, ownership and
	disposition of Common Shares, nor does it take into account the specific circumstances of any particular holder, some of which
	may be subject to special tax rules (including, but not limited to, brokers, dealers in securities or currencies, traders in securities
	that elect to use a mark-to-market method of accounting for securities holdings, tax-exempt organizations, insurance companies,
	banks, thrifts and other financial institutions, persons liable for alternative minimum tax, persons that hold an interest in an
	entity that holds the Common Shares, persons that will own, or will have owned, directly, indirectly or constructively 10% or more
	(by vote or value) of ESSA&rsquo;s stock, persons that hold the common shares as part of a hedging, integration, conversion or
	constructive sale transaction or a straddle, or persons whose functional currency is not the U.S. dollar).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This summary is based on the U.S. Internal Revenue Code of 1986,
	as amended (the &ldquo;
<B>
	Code
</B>
	&rdquo;), U.S. Treasury regulations, administrative pronouncements and rulings of the United
	States Internal Revenue Service (the &ldquo;
<B>
	IRS
</B>
	&rdquo;) and judicial decisions, all as in effect on the date hereof, and
	all of which are subject to change (possibly with retroactive effect) and to differing interpretations. Except as specifically
	set forth below, this summary does not discuss applicable income tax reporting requirements. This summary does not describe any
	state, local or foreign tax law considerations, or any aspect of U.S. federal tax law other than income taxation (e.g., estate
	or gift tax or the Medicare contribution tax). U.S. Holders (as defined below) should consult their own tax advisers regarding
	such matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	No legal opinion from U.S. legal counsel or ruling from the IRS
	has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership or disposition
	of Common Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different
	from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based
	are subject to various interpretations, the IRS and U.S. courts could disagree with one or more of the positions taken in this
	summary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 105 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	102
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As used in this summary, a &ldquo;
<B>
	U.S. Holder
</B>
	&rdquo; is a
	beneficial owner of Common Shares who, for U.S. federal income tax purposes, is (i)&nbsp;a citizen or individual resident of the
	United States, (ii)&nbsp;a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes)
	that is created or organized in or under the laws of the United States, any State thereof or the District of Columbia, (iii)&nbsp;an
	estate whose income is subject to U.S. federal income tax regardless of its source, or (iv)&nbsp;a trust if (A)&nbsp;a U.S. court
	can exercise primary supervision over the trust&rsquo;s administration and one or more U.S. persons are authorized to control all
	substantial decisions of the trust, or (B)&nbsp;the trust has a valid election in effect to be treated as a U.S. person for U.S.
	federal income tax purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The tax treatment of a partner in a partnership (or other entity
	or arrangement classified as a partnership for U.S. federal income tax purposes) may depend on both the partnership&rsquo;s and
	the partner&rsquo;s status and the activities of the partnership. Partnerships (or other entities or arrangements classified as
	a partnership for U.S. federal income tax purposes) that are beneficial owners of Common Shares, and their partners and other owners,
	should consult their own tax advisers regarding the tax consequences of the acquisition, ownership and disposition of Common Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Taxation of Common Shares
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
<U>
	Distributions on Common Shares
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In general, subject to the passive foreign investment company rules
	discussed below, the gross amount of any distribution received by a U.S. Holder with respect to the Common Shares (including amounts
	withheld to pay Canadian withholding taxes) will be included in the gross income of the U.S. Holder as a dividend to the extent
	attributable to the Company&rsquo;s current and accumulated earnings and profits, as determined under U.S. federal income tax principles.
	The Company does not intend to calculate its earnings and profits under U.S. federal income tax rules. Accordingly, U.S. Holders
	should expect that a distribution generally will be treated as a dividend for U.S. federal income tax purposes. Subject to the
	passive foreign investment company rules discussed below, distributions on Common Shares to certain non-corporate U.S. Holders
	that are treated as dividends may be taxed at preferential rates. Such dividends will not be eligible for the &ldquo;dividends
	received&rdquo; deduction ordinarily allowed to corporate shareholders with respect to dividends received from U.S. corporations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The amount of any dividend paid in Canadian dollars (including amounts
	withheld to pay Canadian withholding taxes) will equal the U.S. dollar value of the Canadian dollars calculated by reference to
	the exchange rate in effect on the date the dividend is received by the U.S. Holder, regardless of whether the Canadian dollars
	are converted into U.S. dollars. A U.S. Holder will have a tax basis in the Canadian dollars equal to their U.S. dollar value on
	the date of receipt. If the Canadian dollars received are converted into U.S. dollars on the date of receipt, the U.S. Holder should
	generally not be required to recognize foreign currency gain or loss in respect of the distribution. If the Canadian dollars received
	are not converted into U.S. dollars on the date of receipt, a U.S. Holder may recognize foreign currency gain or loss on a subsequent
	conversion or other disposition of the Canadian dollars. Such gain or loss will be treated as U.S. source ordinary income or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Distributions on Common Shares that are treated as dividends generally
	will constitute income from sources outside the United States and generally will be categorized for U.S. foreign tax credit purposes
	as &ldquo;passive category income.&rdquo; A U.S. Holder may be eligible to elect to claim a U.S. foreign tax credit against its
	U.S. federal income tax liability, subject to applicable limitations and holding period requirements, for Canadian tax withheld,
	if any, from distributions received in respect of the Common Shares. A U.S. Holder that does not elect to claim a U.S. foreign
	tax credit may instead claim a deduction for Canadian tax withheld, but only for a taxable year in which the U.S. Holder elects
	to do so with respect to all foreign income taxes paid or accrued in such taxable year. The rules relating to U.S. foreign tax
	credits are complex, and each U.S. Holder should consult its own tax adviser regarding the application of such rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
<U>
	Sale, Exchange or Other Taxable Disposition of Common Shares
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	A U.S. Holder generally will recognize gain or loss on the sale,
	exchange or other taxable disposition of Common Shares in an amount equal to the difference, if any, between the amount realized
	on the sale, exchange or other taxable disposition and the U.S. Holder&rsquo;s adjusted tax basis in the Common Shares exchanged
	therefor. Subject to the passive foreign investment company rules discussed below, such gain or loss will be capital gain or loss
	and will be long-term capital gain (currently taxable at a reduced rate for non-corporate U.S. Holders) or loss if, on the date
	of the sale, exchange or other taxable disposition, the Common Shares have been held by such U.S. Holder for more than one year.
	The deductibility of capital losses is subject to limitations. Such gain or loss generally will be sourced within the United States
	for U.S. foreign tax credit purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 106 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	103
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Passive Foreign Investment Company Rules
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	A foreign corporation will be considered a passive foreign investment
	company (&ldquo;
<B>
	PFIC
</B>
	&rdquo;) for any taxable year in which (1)&nbsp;75% or more of its gross income is &ldquo;passive income&rdquo;
	under the PFIC rules or (2)&nbsp;50% or more of the average quarterly value of its assets produce (or are held for the production
	of) &ldquo;passive income.&rdquo; For this purpose, &ldquo;passive income&rdquo; generally includes interest, dividends, rents,
	royalties, and certain gains. Interest, dividends, rents and royalties received from a related person (within the meaning of the
	PFIC rules) are excluded from passive income to the extent such payments are properly allocable to the active income of such related
	person. Moreover, for purposes of determining if the foreign corporation is a PFIC, if the foreign corporation owns, directly or
	indirectly, at least 25%, by value, of the shares of another corporation, it will be treated as if it holds directly its proportionate
	share of the assets and receives directly its proportionate share of the income of such other corporation. If a corporation is
	treated as a PFIC with respect to a U.S. Holder for any taxable year, the corporation will continue to be treated as a PFIC with
	respect to that U.S. Holder in all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC requirements
	in such years, unless certain elections are made.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The determination as to whether a foreign corporation is a PFIC
	is based on the application of complex U.S. federal income tax rules, which are subject to differing interpretations, and the determination
	will depend on the composition of the income, expenses and assets of the foreign corporation from time to time and the nature of
	the activities performed by its officers and employees. The Company believes that it was not classified as a PFIC for the taxable
	year ending September 30, 2016, and the Company believes it will not be classified as a PFIC for the current taxable year and in
	future taxable years. However, the Company&rsquo;s actual PFIC status for the current or any future taxable year is uncertain and
	cannot be determined until after the end of such taxable year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the Company is classified as a PFIC, a U.S. Holder that does
	not make any of the elections described below would be required to report any gain on the disposition of Common Shares as ordinary
	income, rather than as capital gain, and to compute the tax liability on the gain and any &ldquo;
<B>
	Excess Distribution
</B>
	&rdquo;
	(as defined below) received in respect of Common Shares as if such items had been earned ratably over each day in the U.S. Holder&rsquo;s
	holding period (or a portion thereof) for the Common Shares. The amounts allocated to the taxable year during which the gain is
	realized or distribution is made, and to any taxable years in such U.S. Holder&rsquo;s holding period that are before the first
	taxable year in which the Company is treated as a PFIC with respect to the U.S. Holder, would be included in the U.S. Holder&rsquo;s
	gross income as ordinary income for the taxable year of the gain or distribution. The amount allocated to each other taxable year
	would be taxed as ordinary income in the taxable year during which the gain is realized or distribution is made at the highest
	tax rate in effect for the U.S. Holder in that other taxable year and would be subject to an interest charge as if the income tax
	liabilities had been due with respect to each such prior year. For purposes of these rules, gifts, exchanges pursuant to corporate
	reorganizations and use of Common Shares as security for a loan may be treated as a taxable disposition of the Common Shares. An
	&ldquo;Excess Distribution&rdquo; is the amount by which distributions during a taxable year in respect of a Common Share exceed
	125% of the average amount of distributions in respect thereof during the three preceding taxable years (or, if shorter, the U.S.
	Holder&rsquo;s holding period for the Common Shares).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Certain additional adverse tax rules will apply to a U.S. Holder
	for any taxable year in which the Company is treated as a PFIC with respect to such U.S. Holder and any of its subsidiaries is
	also treated as a PFIC (a &ldquo;
<B>
	Subsidiary PFIC
</B>
	&rdquo;). In such a case, the U.S. Holder will generally be deemed to own
	its proportionate interest (by value) in any Subsidiary PFIC and be subject to the PFIC rules described above with respect to the
	Subsidiary PFIC regardless of such U.S. Holder&rsquo;s percentage ownership in the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The adverse tax consequences described above may be mitigated if
	a U.S. Holder makes a timely &ldquo;qualified electing fund&rdquo; election (a &ldquo;
<B>
	QEF election
</B>
	&rdquo;) with respect
	to its interest in the PFIC. Consequently, if the Company is classified as a PFIC, it would likely be advantageous for a U.S. Holder
	to elect to treat the Company as a &ldquo;qualified electing fund&rdquo; (a &ldquo;
<B>
	QEF
</B>
	&rdquo;) with respect to such U.S.
	Holder in the first year in which it holds Common Shares. If a U.S. Holder makes a timely QEF election with respect to the Company,
	the electing U.S. Holder would be required in each taxable year that the Company is considered a PFIC to include in gross income
	(i)&nbsp;as ordinary income, the U.S. Holder&rsquo;s pro rata share of the ordinary earnings of the Company and (ii)&nbsp;as capital
	gain, the U.S. Holder&rsquo;s pro rata share of the net capital gain (if any) of the Company, whether or not the ordinary earnings
	or net capital gain are distributed. An electing U.S. Holder&rsquo;s basis in Common Shares will be increased to reflect the amount
	of any taxed but undistributed income. Distributions of income that had previously been taxed will result in a corresponding reduction
	of basis in the Common Shares and will not be taxed again as distributions to the U.S. Holder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 107 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	104
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	A QEF election made with respect to the Company will not apply to
	any Subsidiary PFIC; a QEF election must be made separately for each Subsidiary PFIC (in which case the treatment described above
	would apply to such Subsidiary PFIC). If a U.S. Holder makes a timely QEF election with respect to a Subsidiary PFIC, it would
	be required in each taxable year to include in gross income its pro rata share of the ordinary earnings and net capital gain of
	such Subsidiary PFIC, but may not receive a distribution of such income. Such a U.S. Holder may, subject to certain limitations,
	elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge (which would not be deductible
	for U.S. federal income tax purposes if the U.S. Holder were an individual).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	If the Company determines that it, and any subsidiary in which the
	Company owns, directly or indirectly, more than 50% of such subsidiary&rsquo;s total aggregate voting power, is likely a PFIC in
	any taxable year, the Company intends to make available to U.S. Holders, upon request and in accordance with applicable procedures,
	a &ldquo;PFIC Annual Information Statement&rdquo; with respect to the Company and any such subsidiary for such taxable year. The
	&ldquo;PFIC Annual Information Statement&rdquo; may be used by U.S. Holders for purposes of complying with the reporting requirements
	applicable to a QEF election with respect to the Company and any Subsidiary PFIC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The U.S. federal income tax on any gain from the disposition of
	Common Shares or from the receipt of Excess Distributions may be greater than the tax if a timely QEF election is made. It is recommended
	that, if the Company were to be classified as a PFIC, a U.S. Holder make a QEF election with respect to the Company and any Subsidiary
	PFIC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Alternatively, if the Company were to be classified as a PFIC, a
	U.S. Holder could also avoid certain of the rules described above by making a mark-to-market election (instead of a QEF election),
	provided the Common Shares are treated as regularly traded on a qualified exchange or other market within the meaning of the applicable
	Treasury regulations. However, a U.S. Holder will not be permitted to make a mark-to-market election with respect to a Subsidiary
	PFIC. U.S. Holders should consult their own tax advisers regarding the potential availability and consequences of a mark-to-market
	election, as well as the advisability of making a protective QEF election in case the Company is classified as a PFIC in any taxable
	year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During any taxable year in which the Company or any Subsidiary PFIC
	is treated as a PFIC with respect to a U.S. Holder, that U.S. Holder must file IRS Form 8621. U.S. Holders should consult their
	own tax advisers concerning annual filing requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Required Disclosure with Respect to Foreign Financial Assets
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Certain U.S. Holders are required to report information relating
	to an interest in Common Shares, subject to certain exceptions (including an exception for Common Shares held in accounts maintained
	by certain financial institutions), by attaching a completed IRS Form 8938, Statement of Specified Foreign Financial Assets, with
	their tax return for each year in which they hold an interest in Common Shares. U.S. Holders should consult their own tax advisers
	regarding information reporting requirements relating to their ownership of Common Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Certain Material Canadian Federal Income Tax Considerations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following is a summary, as of today&rsquo;s date, of the principal
	Canadian federal income tax considerations under the
<I>
	Income Tax Act
</I>
	(Canada) (
<B>
	&ldquo;Tax Act&rdquo;
</B>
	) that generally
	apply to an investor who acquires Common Shares, who, for the purposes of the Tax Act and at all relevant times, deals at arm&rsquo;s
	length, and is not affiliated with ESSA and who acquires and holds ESSA&rsquo;s Common Shares, as capital property (a
<B>
	&ldquo;Holder&rdquo;
</B>
	).
	Generally, Common Shares will be considered to be capital property to a Holder provided that the Holder does not use Common Shares
	in the course of carrying on a business of trading or dealing in securities and such Holder has not acquired them or been deemed
	to have acquired them in one or more transactions considered to be an adventure or concern in the nature of trade.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 108 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	105
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This summary is based upon the current provisions of the
<I>
	Canada-United
	States Income Tax Convention (1980)
</I>
	(
<B>
	&ldquo;Treaty&rdquo;
</B>
	), the Tax Act and its regulations and the current published
	administrative policies and assessing practices of the Canada Revenue Agency (&ldquo;
<B>
	CRA
</B>
	&rdquo;). This summary takes into
	account all specific proposals to amend the Tax Act and its regulations publicly announced by or on behalf of the Minister of Finance
	(Canada) prior to the date hereof (the
<B>
	&ldquo;Tax Proposals&rdquo;
</B>
	) and assumes that the Tax Proposals will be enacted in
	the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. This
	summary does not otherwise take into account any changes in law or in the administrative policies or assessing practices of the
	CRA, whether by legislative, governmental or judicial decision or action, nor does it take into account or consider any provincial,
	territorial or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income
	tax considerations discussed in this summary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This summary only applies to Holders who (i)&nbsp;for the purposes
	of the Tax Act, have not and will not be resident in Canada at any time, (ii)&nbsp;do not use or hold the common shares in carrying
	on a business in Canada, and (iii)&nbsp;are resident in the United States for income tax purposes and entitled to benefits under
	the Treaty. Special rules, which are not discussed in this summary, may apply to a United States Holder that is an insurer that
	carries on business in Canada and elsewhere.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This summary is of a general nature only, is not exhaustive of all
	possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice
	to any particular Holder. Holders should consult their own tax advisors with respect to their particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Currency
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	For purposes of the Tax Act, all amounts relating to the acquisition,
	holding or disposition of Common Shares must be expressed in Canadian dollars. Amounts denominated in any other currency must be
	converted into Canadian dollars using the rate of exchange quoted by the Bank of Canada at noon on the day the amount first arose,
	or such other rate of exchange as is acceptable to the CRA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dividends
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Dividends paid or credited or deemed to be paid or credited to a
	Holder by ESSA are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend unless such rate
	is reduced by the terms of the Treaty. The rate of withholding tax on dividends paid or credited to a Holder who is resident in
	the U.S. for purposes of the Treaty, entitled to benefits under the Treaty, and is the beneficial owner of the dividend is generally
	limited to 15% of the gross amount of the dividend (or 5% in the case of such a Holder that is a company beneficially owning at
	least 10% of ESSA&rsquo;s voting shares). Holders should consult their own tax advisors regarding the application of the Treaty
	to dividends based on their particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Dispositions of Common Shares
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	A Holder generally will not be subject to tax under the Tax Act
	in respect of a capital gain realized on the disposition or deemed disposition of Common Shares, nor will capital losses arising
	therefrom be recognized under the Tax Act, unless Common Shares constitute &ldquo;
<B>
	taxable Canadian property
</B>
	&rdquo; to the
	Holder for purposes of the Tax Act, and the gain is not exempt from tax pursuant to the terms of the Treaty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Provided Common Shares are listed on a &ldquo;designated stock exchange&rdquo;,
	as defined in the Tax Act (which currently includes the TSX and the Nasdaq), at the time of disposition, the Common Shares generally
	will not constitute taxable Canadian property of a Holder at that time, unless at any time during the 60 month period immediately
	preceding the disposition the following two conditions are met concurrently:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	(i) the Holder, persons with whom the Holder did not deal
	at arm&rsquo;s length, and partnerships in which the Holder or such non-arm&rsquo;s length person holds a membership interest (either
	directly or indirectly through one or more partnerships), or the Holder together with all such persons, owned 25% or more of the
	issued shares of any class or series of ESSA&rsquo;s shares; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 109 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	106
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	(ii) more than 50% of the fair market value of the Common
	Shares was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, &ldquo;Canadian
	resource properties&rdquo; (as defined in the Tax Act), &ldquo;timber resource properties&rdquo; (as defined in the Tax Act) or
	an option, an interest or right in such property, whether or not such property exists.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Notwithstanding the foregoing, a Common Share may otherwise be deemed
	to be taxable Canadian property to a Holder for purposes of the Tax Act in particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Holders whose Common Shares are taxable Canadian property should
	consult their own tax advisors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	F.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Dividends and Paying Agents
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	G.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Statement by Experts
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The consolidated financial statements as of September 30, 2016,
	2015 and 2014, and the related consolidated statements of loss and comprehensive loss, changes in shareholders&rsquo; equity, and
	cash flows for the years ended September 30, 2016, 2015, and 2014, and a summary of significant accounting policies and other explanatory
	information included in this Annual Report have been audited by Davidson &amp; Company LLP, 1200-609 Granville Street, Vancouver,
	B.C., Canada V7Y 1G6, an independent registered public accounting firm, as stated in their report appearing herein. Such financial
	statements are included in reliance upon the report of such firm given upon their consent and authority as experts in accounting
	and auditing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	H.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Documents on Display
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This Annual Report and the related exhibits are available for viewing
	at the offices of ESSA, 999 West Broadway, Suite 720, Vancouver, BC V5Z 1K5, telephone: (778)&nbsp;331-0962. Copies of ESSA&rsquo;s
	financial statements and other continuous disclosure documents required under the Securities Act (Ontario) are available for viewing
	on SEDAR at www.sedar.com. All of the documents referred to are in English.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	You may also read and copy all or any portion of the Annual Report
	of other information in the Company&rsquo;s files in the SEC&rsquo;s public reference room at 100 F. Street, NE, Room 1580, Washington,
	D.C. 20549. You may request copies of these documents, upon payment of a duplicating fee, by writing to the Commission. Please
	call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	I.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Subsidiary Information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_ADDITIONAL_INFORMATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 11.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company is exposed to various market risks associated with its
	underlying assets, liabilities and anticipated transactions. Refer to Item&nbsp;18, &lsquo;&lsquo;Financial Statements - Note 16
	Financial Instruments and Risk&rsquo;&rsquo; of the Company&rsquo;s audited consolidated financial statements for the year ended
	September&nbsp;30, 2016, for a qualitative and quantitative discussion of the Company&rsquo;s exposure to these market risks.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_OTHER_SECURITIES>
<A NAME="FIS_OTHER_SECURITIES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 12.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 110 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	107
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_SECURITIES>
</EFX_PART_I>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	PART
	II
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_DEFAULTS>
<A NAME="FIS_DEFAULTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 13.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DEFAULTS, DIVIDEND ARREARAGES
	AND DELINQUENCIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Indebtedness
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Dividends
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_DEFAULTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_MATERIAL_MODIFICATIONS>
<A NAME="FIS_MATERIAL_MODIFICATIONS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 14.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Not applicable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Not applicable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Not applicable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Not applicable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
	E.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Not applicable.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_MATERIAL_MODIFICATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 15.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	CONTROLS AND PROCEDURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Disclosure Controls and Procedures
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company conducted an evaluation of the effectiveness of the
	design and operation of its disclosure controls and procedures. The evaluation was conducted under the supervision and with the
	participation of management, including the chief executive officer and chief financial officer, as of September 30, 2016. Based
	on the evaluation, the Company&rsquo;s chief executive officer and chief financial officer concluded that such disclosure controls
	and procedures &ndash; as defined in Canada under National Instrument 52-109, Certification of Disclosure in Issuers&rsquo; Annual
	and Interim Filings, and in Rules 13a-15(f) and 15d-15(f) promulgated under the United States Securities Exchange Act of 1934,
	as amended (the U.S. Exchange Act) &ndash; are effective as at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	It should be noted that while the Company&rsquo;s disclosure controls
	and procedures are designed to provide a reasonable level of assurance of achieving its objectives, its chief executive officer
	and chief financial officer do not expect such disclosure controls and procedures or internal control over financial reporting
	to prevent all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute,
	assurance that the objectives of the control system are met.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	B.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Management&rsquo;s Annual Report on Internal Control Over Financial Reporting
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Section 404 of the United States
<I>
	Sarbanes-Oxley Act, Management
	Assessment of Internal Controls
</I>
	(&ldquo;
<B>
	Section 404
</B>
	&rdquo;), requires that management (a) have the responsibility for
	establishing and maintaining an adequate internal control structure and procedure for financial reporting, and (b) assess and report
	on the effectiveness of internal control over financial reporting annually. As of September 30, 2015, under the supervision and
	with the participation of the Company's Chief Executive Officer and Chief Financial Officer, management has assessed the effectiveness
	of the Company&rsquo;s internal control over financial reporting based on the framework set forth in Internal Control &ndash; Integrated
	Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&quot;
<B>
	COSO
</B>
	&quot;). Based
	on this assessment, management has determined the Company&rsquo;s internal control over financial reporting was effective as of
	September 30, 2016. Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements
	on a timely basis. Also, projections of any evaluation of internal controls over financial reporting to future periods are subject
	to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
	may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 111 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	108
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	C.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Report of the Independent Public Accounting Firm
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable. Under the JOBS Act, emerging growth companies are
	exempt from Section 404(b) of Sarbanes-Oxley, which generally requires public companies to provide an independent auditor attestation
	of management's assessment of the effectiveness of internal control over financial reporting. The Company qualifies as an emerging
	growth company under the JOBS act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	D.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Changes in Internal Control over Financial Reporting
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	There were no significant changes to the Company&rsquo;s internal
	control over financial reporting in the year ended September 30, 2016.&nbsp;
</P>
</EFX_AUDITORS_OPINION>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_AUDIT_COMMITTEE_EXPERT>
<A NAME="FIS_AUDIT_COMMITTEE_EXPERT"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16A
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	AUDIT COMMITTEE FINANCIAL EXPERT
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Board has determined that Franklin Berger, an individual serving
	on the audit committee of the Company&rsquo;s Board, is an audit committee financial expert and is independent as defined in Item
	16.A of Form 20-F under the Securities Exchange Act of 1934, as amended. See &ldquo;
<I>
	Directors, Senior Management and Employees
	&ndash; Directors and Senior Management
</I>
	&rdquo; in Item 6.A of this Annual Report for a description of Franklin Berger&rsquo;s
	relevant financial experience.
</P>
</EFX_AUDIT_COMMITTEE_EXPERT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CODE_OF_ETHICS>
<A NAME="FIS_CODE_OF_ETHICS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16B
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	CODE OF ETHICS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has adopted a Code of Business Conduct applicable to all of
	its directors and employees, including its Chief Executive Officer and Chief Financial Officer, which is a &ldquo;code of ethics&rdquo;
	as defined in Item 16B of Form 20-F promulgated by the SEC and which is a &ldquo;code&rdquo; under National Instrument NI 58-101.&nbsp;The
	objective of the Code of Conduct is to (i) emphasize ESSA&rsquo;s commitment to ethics and compliance with the laws, (ii) set forth
	basic standards of ethical and legal behavior, (iii) provide reporting mechanisms for known or suspected ethical or legal violations
	and (iv) help prevent and detect wrongdoing. The full text of the Code of Business Conduct is posted on ESSA&rsquo;s website at
	www.essapharma.com. Information contained on, or that can be accessed through, the Company&rsquo;s website does not constitute
	a part of this Annual Report and is not incorporated by reference herein.&nbsp;If ESSA makes any amendment to the Code of Business
	Conduct or grants any waivers, including any implicit waiver, from a provision of the code of conduct, ESSA will disclose the nature
	of such amendment or waiver on its website to the extent required by the rules and regulations of the SEC and the Canadian Securities
	Administrators. Under Item 16B of the SEC&rsquo;s Form 20-F, if a waiver or amendment of the Code of Business Conduct applies to
	the Company&rsquo;s principal executive officer, principal financial officer, principal accounting officer or controller and relates
	to standards promoting any of the values described in Item 16B(b) of such Form 20-F, ESSA will disclose such waiver or amendment
	on its website in accordance with the requirements of Instruction 4 to such Item&nbsp;16B.
</P>
</EFX_CODE_OF_ETHICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16C
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PRINCIPAL ACCOUNTANT FEES AND SERVICES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	See Item 6.B &ldquo;
<I>
	Board Practices
</I>
	&rdquo; elsewhere in this
	Annual Report.
</P>
</EFX_ACCOUNTANT_FEES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="FIS_EXEMPTIONS_FROM_LISTING"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16D
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	EXEMPTIONS FROM LISTING STANDARDS FOR AUDIT COMMITTEES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_EXEMPTIONS_FROM_LISTING>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_PURCHASES_OF_EQUITY>
<A NAME="FIS_PURCHASES_OF_EQUITY"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16E
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_PURCHASES_OF_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="FIS_CHANGE_IN_ACCOUNTANT"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16F
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 112 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	109
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CORPORATE_GOVERNANCE>
<A NAME="FIS_CORPORATE_GOVERNANCE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16G
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	CORPORATE GOVERNANCE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA&rsquo;s Common Shares are quoted for trading on the Nasdaq
	under the symbol EPIX. As a Canadian corporation listed on the Nasdaq, ESSA is not required to comply with most of the Nasdaq corporate
	governance standards, so long as it complies with Canadian corporate governance practices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following is a summary of the significant ways in which ESSA&rsquo;s
	corporate governance practices differ from those required to be followed by U.S. domestic issuers under the Nasdaq corporate governance
	standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Quorum
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	ESSA has informed the Nasdaq that, as permitted by Rule 5615 of
	the Nasdaq Marketplace Rules, it intends to follow British Columbia practice with respect to quorum requirements in lieu of those
	required by Rule 5620(c) of the Nasdaq Marketplace Rules (which provides that a quorum for a shareholder meeting of a Nasdaq-listed
	company must be at least 33-1/3% of ESSA&rsquo;s outstanding common shares). Under the Articles, the quorum for the transaction
	of business at a meeting of shareholders is one or more persons who are, or who represent by proxy, one or more shareholders who
	in the aggregate hold at least 10% of ESSA&rsquo;s issued shares entitled to be voted at the meeting. If there is only one shareholder
	entitled to vote at a meeting of shareholders, the quorum is that shareholder, present in person or by proxy. ESSA&rsquo;s quorum
	requirements are not prohibited by the requirements of the Act, applicable Canadian securities laws or the rules of the TSX, the
	primary market for the Common Shares in Canada.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 0">
<I>
	Director Independence
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 6PT 0 0">
	Rule 5605(b)(1) of the Nasdaq Marketplace Rules requires that
	a majority of the members of the board of directors of a listed company must be &ldquo;independent directors&rdquo; as defined
	in Rule 5605(a)(2). ESSA has informed the Nasdaq that it follows applicable Canadian laws with respect to independence requirements,
	which do not require that a majority of the members of the board of directors be independent. Upon the designation of Dr. David
	Parkinson as ESSA's Chief Executive Officer in January 2016, the number of independent members of the Board was reduced to a minority
	(three of seven). Further, Rule 5605(d)(2) of the Nasdaq Marketplace Rules requires that the compensation committee must be comprised
	of &quot;independent directors&quot; as defined in Rule 5605(a)(2) of the Nasdaq Marketplace Rules.&nbsp;&nbsp; ESSA has informed
	the Nasdaq that it follows applicable Canadian laws with respect to compensation committee composition, which do not mandate a
	compensation committee comprised entirely of independent directors. Scott Requadt, who is not an independent director, was appointed
	to ESSA's compensation committee on March 10, 2016.
</P>
</EFX_CORPORATE_GOVERNANCE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM&nbsp;16H
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	MINE SAFETY DISCLOSURE
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_II>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	PART
	III
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 17.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	FINANCIAL STATEMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	See Item&nbsp;18 &ldquo;
<I>
	Financial Statements
</I>
	&rdquo; located
	elsewhere in this Annual Report.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 18.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	FINANCIAL STATEMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The following attached financial statements are attached hereto,
	incorporated herein and found immediately following the text of this Annual Report:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&rsquo;s audited consolidated financial statements as at and for the years ended September 30, 2016, 2015, and 2014, together with the notes thereto and the auditor&rsquo;s report thereon.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ITEM 19.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	EXHIBITS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	Articles of Incorporation*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 113 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	110
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Material Contracts
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Cancer Research Contract between CPRIT and the Company, dated July 9, 2014*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement between the BC Cancer Agency, UBC and the Company, dated December 22, 2010, as amended on February 10, 2011 and May 27, 2014&dagger;*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2014 Agency Agreement between the Company and Haywood Securities Inc. dated October 22, 2014*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2015 Agency Agreement between the Company and Bloom Burton &amp; Co. Limited dated January 16, 2015*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2014 Special Warrant Indenture between the Company and the Special Warrant Agent, dated October 22, 2014*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2015 Special Warrant Indenture between the Company and the Special Warrant Agent, dated January 16, 2015*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 70.9PT; TEXT-INDENT: -34.9PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 47PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease for 2130 West Holcombe Boulevard, Houston, Texas, United States dated April 7, 2015**
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement for David Wood***
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement for David Parkinson
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.10
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement for Peter Virsik
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.11
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Loan and Security Agreement between the Company and Silicon Valley Bank dated November 18, 2016****
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	8.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	List of Subsidiaries*
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	12.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	12.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48PX">
<FONT STYLE="FONT-SIZE: 10PT">
	13.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as added by Section 906 of the Sarbanes &ndash; Oxley Act of 2002.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21PX">
<FONT STYLE="FONT-SIZE: 10PT">
	&dagger;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Confidential treatment has been requested for portions of this document. The omitted portions of this document have been filed with the Securities and Exchange Commission.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 15.75PT; TEXT-INDENT: -15.75PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21PX">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Previously filed (No. 377-00939) with the SEC on Form 20-F of the Company on February 24, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21PX">
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;Previously filed (No.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37410)
	with the SEC on Form 20-F of the Company on December 15, 2015.
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21PX">
<FONT STYLE="FONT-SIZE: 10PT">
	***
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Previously filed (No. 377-00939) with the SEC on Form 20-F of the Company on April 7, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	****
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Previously filed (No. 001-37410) with the SEC on Form 6-K of the Company on November 21, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 114 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	111
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_III>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Registrant hereby certifies that it meets all of the requirements
	for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA PHARMA INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 45%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	DATED: December 14, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ David Wood
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 3.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 90%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	Page
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&rsquo;s audited consolidated financial statements as at and for the years ended September 30, 2016, 2015, and 2014, together with the notes thereto and the auditor&rsquo;s report thereon.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	F-2
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 115 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	112
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001279569-16-004844_ESSALOGO.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Expressed in United States dollars)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015
	AND 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 116; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001279569-16-004844_IMAGE_004.JPG" ALT="">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: BOLD 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	To the Shareholders and Directors of
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	ESSA Pharma Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated
	financial statements of ESSA Pharma Inc., which comprise the consolidated statements of financial position as of September 30,
	2016, 2015, and 2014, and the related consolidated statements of loss and comprehensive loss, changes in shareholders&rsquo; equity
	(deficiency), and cash flows for the years ended September&nbsp;30,&nbsp;2016, 2015, and 2014, and a summary of significant accounting
	policies and other explanatory information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Management&rsquo;s Responsibility for
	the Consolidated Financial Statements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Management is responsible for the preparation
	and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards
	as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary
	to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or
	error.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Auditors&rsquo; Responsibility
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our responsibility is to express an opinion
	on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted
	auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require
	that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated
	financial statements are free from material misstatement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	An audit involves performing procedures to
	obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend
	on the auditors&rsquo; judgment, including the assessment of the risks of material misstatement of the consolidated financial statements,
	whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity&rsquo;s
	preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate
	in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity&rsquo;s internal control.
	An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates
	made by management, as well as evaluating the overall presentation of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We believe that the audit evidence we have
	obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Opinion
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, these consolidated financial
	statements present fairly, in all material respects, the financial position of ESSA Pharma Inc. as at September 30, 2016, 2015,
	and 2014 and its financial performance and its cash flows for the years ended September 30, 2016, 2015, and 2014 in accordance
	with International Financial Reporting Standards as issued by the International Accounting Standards Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Emphasis of Matter
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Without qualifying our opinion, we draw attention
	to Note 1 in the consolidated financial statements which indicate that ESSA Pharma Inc. has suffered recurring losses from operations
	and has a net capital deficiency. These matters, along with the other matters set forth in Note 1, indicate the existence of material
	uncertainties that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these
	matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from
	the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&ldquo;DAVIDSON &amp; COMPANY LLP&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 47%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	Vancouver, Canada
</TD>
<TD STYLE="WIDTH: 53%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: RIGHT">
	Chartered Professional Accountants
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	December 8, 2016
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001279569-16-004844_IMAGE_005.JPG" ALT="">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001279569-16-004844_IMAGE_004.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	CONSENT
	OF Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We consent to the use in this Annual Report
	on Form 20-F of our report dated December 8, 2016, relating to the consolidated statements of financial position of ESSA Pharma
	Inc. as of September 30, 2016, 2015, and 2014, and the related consolidated statements of loss and comprehensive loss, changes
	in shareholders&rsquo; equity (deficiency), and cash flows for the years ended September 30, 2016, 2015, and 2014 of Essa Pharma
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We also consent to the reference to us under
	the caption &ldquo;Statement by Experts&rdquo; in this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&ldquo;DAVIDSON &amp; COMPANY LLP&rdquo;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	Vancouver, Canada
</TD>
<TD STYLE="WIDTH: 55%; PADDING-RIGHT: 4.5PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: RIGHT">
	Chartered Professional Accountants
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	December 14, 2016
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001279569-16-004844_IMAGE_005.JPG" ALT="">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 117; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	ESSA PHARMA INC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(Expressed in United States dollars)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	AS AT SEPTEMBER 30
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	ASSETS
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Current
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Cash
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	8,985,095
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,579,288
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	3,699,980
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,882
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,849,605
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	64,503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Prepaids (Note 4)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,018,232
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,661,335
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	62,408
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,019,209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,090,228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,826,891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Equipment (Note 5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	127,730
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	165,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,102
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Intangible assets (Note 6)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	255,623
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	284,081
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	360,840
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total assets
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,402,562
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,539,773
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,201,833
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Current
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Accounts payable and accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,538,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,091,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	587,353
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Income tax payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	91,191
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,629,952
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,091,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	587,353
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Product development and relocation grant (Note 17)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,640,352
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Derivative liability (Note 8)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,309,467
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	993,099
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Total liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,939,419
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,084,261
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,227,705
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Shareholders' equity (deficiency)
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Share capital (Note 9)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,974,742
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,419,004
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,193,735
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Preferred shares (Note 9)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,836,268
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Reserves (Note 10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,805,514
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,401,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	966,837
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Accumulated other comprehensive loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,076,479
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,738,716
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(73,503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(28,240,634
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,625,796
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,949,209
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(536,857
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,455,512
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,974,128
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total liabilities and shareholders&rsquo; equity (deficiency)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,402,562
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,539,773
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,201,833
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Nature and continuance of operations (Note
	1)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Commitments (Note 17)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent event (Note 19)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	On behalf of the Board on December 8, 2016
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	&ldquo;David Parkinson&rdquo;
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	&ldquo;Franklin Berger&rdquo;
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 118; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE
	LOSS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(Expressed in United States dollars)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	FOR THE YEARS ENDED SEPTEMBER 30&#9;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	OPERATING EXPENSES
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Research and development, net of recoveries (Note 18)
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	13,060,201
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	4,975,928
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	671,600
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	937,845
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	93,755
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	87,587
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;General and administration, net of recoveries (Note 18)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,644,118
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,259,166
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,065,350
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Total operating expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(19,642,164
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,328,849
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,824,537
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Foreign exchange
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79,543
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,559,213
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	391
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Interest income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	647
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	217
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Gain (loss) on derivative liability (Note 8)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,574,105
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(907,598
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Net loss for the year before taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,988,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Income tax expense (Note 13)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(151,272
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Net loss for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,139,788
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	OTHER COMPREHENSIVE LOSS
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Cumulative translation adjustment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(337,763
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,665,212
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(71,738
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Comprehensive loss for the year
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(13,477,551
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(11,341,799
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,895,667
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Basic and diluted loss per common share
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.49
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.53
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Weighted average number of common shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 12.6PT">
<B>
	outstanding
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	26,903,834
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	18,353,018
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	15,687,534
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 119; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(Expressed in United States dollars)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	FOR THE YEARS ENDED SEPTEMBER 30&#9;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(Note 2)
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	CASH FLOWS FROM OPERATING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Loss for the year
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(13,139,788
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Items not affecting cash:
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,181
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,385
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on derivative liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,574,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	907,598
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	910,101
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Product development and relocation grant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,427,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,153,181
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign exchange
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(140,139
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(789,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,879
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Share-based payments (Note 10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,246,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,510,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	494,221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Changes in non-cash working capital items:
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48,978
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,596
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54,605
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	644,089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,634,382
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(62,204
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,545,577
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,736,930
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	420,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Income tax payable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	91,191
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Net cash used in operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,300,969
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,339,982
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,081,193
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	CASH FLOWS FROM INVESTING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Acquisition of equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,983
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(174,054
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Net cash used in investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,983
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(174,054
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	CASH FLOWS FROM FINANCING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Advance on product development and relocation grant
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,786,667
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,793,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Proceeds on private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,999,992
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,208,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,183,270
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,080,189
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(869,641
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(207,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Convertible debenture issued
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	911,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,446
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,465
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	84,086
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Warrants exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,194
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	168,099
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,744,129
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,591,482
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,658,680
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Effect of foreign exchange on cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(27,370
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,198,138
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(102,776
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Change in cash for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,405,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,120,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,474,711
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Cash, beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,579,288
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,699,980
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	225,269
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Cash, end of year
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,985,095
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,579,288
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,699,980
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Supplemental Cash Flow Information (Note
	11)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 120; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 18PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&rsquo;
	EQUITY (DEFICIENCY)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	(Expressed in United States dollars)&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Reserves
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Preferred shares
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Special warrants
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Convertible debenture
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share-based payments
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cumulative translation adjustment
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Deficit
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 28%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, Sept 30, 2013 (Note 2)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	4,193,735
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	411,632
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	(1,765
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	(4,125,280
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: RIGHT">
	478,322
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance of convertible debenture
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	911,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	911,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(36,381
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,446
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,935
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Conversion of debenture
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	906,724
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(906,724
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,183,270
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,183,270
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(253,726
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,049
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(207,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	494,221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	494,221
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Foreign currency adjustment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(71,738
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(71,738
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, Sept 30, 2014 (Note 2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,193,735
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,836,268
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	905,853
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,984
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(73,503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,949,209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,974,128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,208,944
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,208,944
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(169,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44,434
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(125,366
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Conversion of special
<BR>
	warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,039,144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,039,144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Private placement &ndash; special warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,999,994
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,999,994
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,026,564
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,026,564
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Conversion of preferred shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,872,737
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,875,412
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,675
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Conversion of special
<BR>
	warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,976,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,976,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(61,199
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	84,086
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Warrants exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	231,142
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(59,594
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	255,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,510,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,510,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Foreign currency adjustment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,665,213
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,665,213
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, Sept 30, 2015 (Note 2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,419,004
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,355,196
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,824
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,738,716
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15,625,796
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,455,512
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,581,815
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,581,815
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(170,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(170,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	142,386
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(105,921
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,465
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Warrants exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,628
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(434
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,246,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,246,946
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Foreign currency adjustment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54,574
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54,574
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Effect of functional currency change
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	263,903
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(283,189
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	524,950
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	505,664
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;&nbsp;Loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,139,788
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,139,788
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	25,974,742
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,496,221
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	309,293
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,076,479
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(28,240,634
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(536,857
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 121; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NATURE
	AND CONTINUANCE OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Nature of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	ESSA Pharma Inc. (the &ldquo;Company&rdquo;)
	was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company&rsquo;s head office address
	is Suite 720 &ndash; 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26
<SUP>
	th
</SUP>
	Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the NASDAQ Capital Market (&ldquo;NASDAQ&rdquo;)
	under the symbol &ldquo;EPIX&rdquo;, and on the Toronto Stock Exchange (&ldquo;TSX&rdquo;) under the symbol &ldquo;EPI&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company is focused on the development
	of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the &ldquo;NTD
	Technology&rdquo;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia.
	As at September 30, 2016, no products are in commercial production or use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Change in Presentation Currency
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has retroactively changed
	its presentation currency to the United States dollar (&ldquo;US$&rdquo;) from the Canadian dollar (&ldquo;C$&rdquo;). The change
	is detailed in Note 2.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Going Concern
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	These financial statements have been
	prepared in accordance with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) assuming the Company will continue
	on a going-concern basis. The Company has incurred losses and negative operating cash flows since inception. The Company incurred
	a loss of $13,139,788 during the year ended September 30, 2016 and has an accumulated deficit of $28,240,634. The ability of the
	Company to continue as a going concern in the long-term depends upon its ability to develop profitable operations and to continue
	to raise adequate financing.&nbsp; As at September 30, 2016, the Company has not advanced its research into a commercially viable
	product. The Company&rsquo;s continuation as a going concern is dependent upon the successful development of its NTD Technology
	to a commercial standard. Management has forecasted that the Company&rsquo;s current working capital will not be sufficient to
	execute its planned expenditures for the coming year. These matters indicate the existence of material uncertainties that raises
	substantial doubt about its ability to continue as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Subsequent to September 30, 2016,
	the Company entered into a $10,000,000 term credit loan facility agreement (Note 19) pursuant to which the Company has initially
	drawn down $8,000,000. Management continues to seek sources of additional financing which would assure continuation of the Company&rsquo;s
	operations and research programs. However, there is no certainty that such financing will be provided or provided on favorable
	terms. Management believes that it will complete one or more of these arrangements in sufficient time to continue to execute its
	planned expenditures without interruption.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BASIS
	OF PRESENTATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Statement of Compliance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	These consolidated financial statements,
	including comparatives, have been prepared using accounting policies consistent with IFRS issued by the International Accounting
	Standards Board (&ldquo;IASB&rdquo;) and Interpretations of the International Financial Reporting Interpretations Committee (&ldquo;IFRIC&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Presentation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The consolidated financial statements
	have been prepared on a historical cost basis except for certain financial assets measured at fair value. In addition, these consolidated
	financial statements have been prepared using the accrual basis of accounting, except for cash flow information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 122; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BASIS
	OF PRESENTATION
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Presentation
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	All amounts expressed in these consolidated
	financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise
	indicated. References to &ldquo;$&rdquo; are to United States dollars and references to &ldquo;C$&rdquo; are to Canadian dollars.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Consolidation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The consolidated financial statements
	comprise the accounts of ESSA Pharma Inc., the parent company, and its wholly-owned subsidiary, ESSA Pharmaceuticals Corp., after
	the elimination of all material intercompany balances and transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Subsidiaries
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Subsidiaries are all entities over
	which the Company has exposure to variable returns from its involvement and has the ability to use power over the investee to affect
	its returns. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when
	assessing whether the Company controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred
	to the Company until the date on which control ceases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The accounts of subsidiaries are
	prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions,
	balances and unrealized gains or losses on transactions are eliminated upon consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Functional and Presentation Currency
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The functional
	currency of an entity is the currency of the primary economic environment in which the entity operates. From inception to January
	1, 2016, the functional currency of the Company has been the Canadian dollar and its subsidiary&rsquo;s the United States dollar.
	The functional currency determinations were conducted through an analysis of the consideration factors identified in IAS 21,
<I>
	The
	Effects of Changes in Foreign Exchange Rates
</I>
	. The financing completed in January 2016 and changes to the Company&rsquo;s operations
	have resulted in a change to the currency in which the Company&rsquo;s management conducts its operating, capital and financing
	decisions. Consequently, the functional currency of the Company became the US$ effective January 1, 2016.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	has adopted the US$ as the presentation currency for the consolidated entity retrospectively. For comparative reporting purposes,
	historical financial statements were translated into the US$ reporting currency whereby assets and liabilities were translated
	at the closing rate in effect at the end of the comparative periods; revenues, expenses and cash flows were translated at the average
	rate in effect for the comparative periods and equity transactions were translated at historic rates. The historic translation
	had an impact of $1,765 as an unrealized foreign exchange loss as at October 1, 2013. Upon the change of functional currency as
	at January 1, 2016, the Company recognized an impact of $283,189 to the accumulated comprehensive income (loss).
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	These financial
	statements are presented in United States dollars. All financial information is expressed in United States dollars unless otherwise
	stated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company makes estimates and assumptions
	about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated
	based on historical experience and other factors, including expectations of future events that are believed to be reasonable under
	the circumstances. In the future, actual results may differ from these estimates and assumptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 123; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BASIS
	OF PRESENTATION
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Estimates
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The effect of a change in an accounting
	estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects
	that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about
	the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that
	could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ
	from assumptions that have been made, relate to the following key estimates:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Intangible Assets &ndash; impairment
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The application of the Company&rsquo;s
	accounting policy for intangible assets expenditures requires judgment in determining whether it is likely that future economic
	benefits will flow to the Company, which may be based on assumptions about future events or circumstances. Estimates and assumptions
	may change if new information becomes available. If, after expenditures are capitalized, information becomes available suggesting
	that the recovery of expenditures is unlikely, the amount capitalized is written off in profit or loss in the period the new information
	becomes available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Intangible Assets &ndash; useful
	lives
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Following initial recognition, the
	Company carries the value of intangible assets at cost less accumulated amortization and any accumulated impairment losses. Amortization
	is recorded on a straight-line basis based upon management&rsquo;s estimate of the useful life and residual value. The estimates
	are reviewed at least annually and are updated if expectations change as a result of technical obsolescence or legal and other
	limits to use. A change in the useful life or residual value will impact the reported carrying value of the intangible assets resulting
	in a change in related amortization expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Product development and relocation
	grant
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Pursuant to the terms of the Company&rsquo;s
	grant from the Cancer Prevention Research Institute of Texas (&ldquo;CPRIT&rdquo;), the Company must meet certain terms and conditions
	to qualify for the grant funding. The Company has assessed its performance relative to these terms as detailed in Note 17 and has
	judged that there is reasonable assurance the Company will meet the terms of the grant and qualify for the funding. The Company
	has therefore recognized in profit or loss, as recoveries of research and development expenditures, a portion of the grant that
	represents expenses the Company has incurred to date under the grant parameters. The expenses are subject to assessment by CPRIT
	for compliance with the grant regulations which may result in certain expenses being denied and incurred in a future period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Share-based payments and compensation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has applied estimates
	with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments
	granted at the date the Company receives the goods or services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company measures the cost of
	equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are
	granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model,
	which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs
	to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility
	and dividend yield and making assumptions about them. Prior to listing on the TSX-V and the subsequent graduation to the TSX, the
	fair value of the underlying common shares was assessed as the most recent issuance price per common share for cash proceeds. Following
	graduation from the TSX-V to the TSX, the Company makes reference to prices quoted on the TSX. The assumptions and models used
	for estimating fair value for share-based payment transactions are discussed in Note 10.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 124; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BASIS
	OF PRESENTATION
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Estimates
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Derivative financial instruments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Certain warrants are treated as derivative
	financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains
	or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions
	such as volatility, dividend yield, expected term and liquidity discounts (Note 8).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	Foreign
	exchange
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The functional
	currency of an entity is the currency of the primary economic environment in which the entity operates. The functional currency
	of the Company is the United States dollar and its subsidiary&rsquo;s is the United States dollar. The functional currency determinations
	were conducted through an analysis of the consideration factors identified in IAS 21,
<I>
	The Effects of Changes in Foreign Exchange
	Rates
</I>
	.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Transactions
	in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At
	the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are
	translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues
	and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains
	and losses arising on translation are included in comprehensive loss.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On translation
	of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange
	rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange
	at the reporting date. Exchange gains and losses, including results of re-translation, are recorded in the foreign currency translation
	reserve.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	Equipment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has acquired office and
	computer equipment for use in its research and business activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Depreciation is recognized using
	the straight-line method at the rate of 30% per annum for computer equipment and 20% for office equipment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	Intangible assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company owns intangible assets
	consisting of patent licences. Intangible assets acquired separately are measured on initial recognition at cost. Following initial
	recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent
	expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they
	relate. All other expenditures are recognized in profit or loss as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company does not hold any intangible
	assets with indefinite lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Intangible assets with finite lives
	are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset
	may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least
	annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the
	asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting
	estimates. The amortization expense on intangible assets with finite lives is recognized in general and administrative expenses.
</P>
<!-- FIELD: PAGE; SEQUENCE: 125; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	Intangible assets
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Amortization is recognized in profit
	or loss on a straight-line basis over the estimated useful lives of intangible assets from the date they are available for use
	to September 15, 2030.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Impairment of long-lived assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s long-lived assets
	are reviewed for indications of impairment at the date of preparing each statement of financial position. If indication of impairment
	exists, the asset&rsquo;s recoverable amount is estimated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	An impairment loss is recognized
	when the carrying value of an asset, or its cash-generating unit, exceeds its recoverable amount. A cash-generating unit is the
	smallest identifiable group of assets that generates cash inflows that are largely independent of cash inflows from other assets
	or group of assets. For the purpose of impairment testing, the Company determined it has one cash-generating unit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The recoverable amount is the greater
	of the asset&rsquo;s fair value less cost to sell and value in use. In assessing fair value less cost to sell for the cash-generating
	unit, the Company&rsquo;s market capitalization is considered.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Provisions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Provisions are recorded when a present
	legal, statutory or constructive obligation exists as a result of past events where it is probable that an outflow of resources
	embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation
	can be made.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The amount recognized as a provision
	is the best estimate of the consideration required to settle the present obligation at the statement of financial position date,
	taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows
	estimated to settle the present obligation, if the effect is material, its carrying amount is the present value of those cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Government assistance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Government grants, including grants
	from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset
	acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the
	approved grant program and there is reasonable assurance that the grant will be received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Research grants that compensate the
	Company for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in
	which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized in profit or loss
	on a systematic basis over the useful life of the asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Research and development costs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Expenditures on research and development
	activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in
	profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income
	as the expenditures are incurred when there is reasonable assurance they will be realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 126; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Research and development costs
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Development activities involve a
	plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized
	only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic
	benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset.
	These criteria will be deemed by the Company to have been met when revenue is received by the Company and a determination that
	it has sufficient resources to market and sell its product offerings. Upon a determination that the criteria to capitalize development
	expenditures have been met, the expenditures capitalized will include the cost of materials, direct labour, and overhead costs
	that are directly attributable to preparing the asset for its intended use. Other development expenditures will be expensed as
	incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Capitalized development expenditures
	will be measured at cost less accumulated amortization and accumulated impairment losses. No development costs have been capitalized
	to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Financial instruments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Financial assets
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company classifies its financial
	assets into one of the following categories, depending on the purpose for which the asset was acquired. The Company's accounting
	policy for each category is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Fair value through profit or loss
	-
</I>
	This category comprises derivatives, or assets acquired or incurred principally for the purpose of selling or repurchasing
	it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized
	through profit or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Loans and receivables -
</I>
	These
	assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are
	carried at amortized cost less any provision for impairment. Individually significant receivables are considered for impairment
	when they are past due or when other objective evidence is received that a specific counterparty will default.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Held-to-maturity investments -
</I>
	These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company's
	management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective
	interest method. If there is objective evidence that the investment is impaired, determined by reference to external credit ratings
	and other relevant indicators, the financial asset is measured at the present value of estimated future cash flows. Any changes
	to the carrying amount of the investment, including impairment losses, are recognized through profit or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Available-for-sale -
</I>
	Non-derivative
	financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with
	changes in fair value recognized directly in equity. Where a decline in the fair value of an available-for-sale financial asset
	constitutes objective evidence of impairment, the amount of the loss is removed from equity and recognized through other comprehensive
	income (loss).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	All financial assets except for those
	at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are
	impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria
	to determine impairment are applied for each category of financial assets, which are described above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has classified its cash
	at fair value through profit or loss. The Company&rsquo;s receivables are classified as loans and receivables.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 127; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Financial instruments
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Financial liabilities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company classifies its financial
	liabilities into one of two categories, depending on the purpose for which the liability was acquired. The Company's accounting
	policy for each category is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Fair value through profit or loss
	-
</I>
	This category comprises derivatives, or liabilities acquired or incurred principally for the purpose of selling or repurchasing
	it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized
	through profit or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Other financial liabilities:
</I>
	This
	category consists of liabilities carried at amortized cost using the effective interest method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s accounts payable
	and accrued liabilities are classified as other financial liabilities. The derivative is classified as fair value through profit
	or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Financial instrument disclosures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company provides disclosures
	that enable users to evaluate (a) the significance of financial instruments for the entity&rsquo;s financial position and performance;
	and (b) the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and
	at the date of the statement of financial position, and how the entity manages these risks.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company provides information
	about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs
	used to estimate the fair value:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Level 1 &ndash; quoted prices (unadjusted)
	in active markets for identical assets or liabilities;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Level 2 &ndash; inputs other than
	quoted prices included in Level 1 that are observable for the asset or liability, either
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	directly (i.e.,
	as prices) or indirectly (i.e., derived from prices); and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Level 3 &ndash; inputs for the asset
	or liability that are not based on observable market data (unobservable inputs).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Embedded derivatives
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Derivatives may be embedded in other
	financial instruments (the &ldquo;host instrument&rdquo;). Embedded derivatives are treated as separate derivatives when their
	economic characteristics and risks are not clearly and closely related to those of the host instrument, the terms of the embedded
	derivative are the same as those of a stand-alone derivative, and the combined contract is not held for trading or designated at
	fair value. These embedded derivatives are measured at fair value with subsequent changes recognized in gains or losses on derivative
	instruments in the statement of loss and comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Convertible debt
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Convertible debt issued by the Company
	is comprised of convertible debentures that may be converted into shares of the Company. The terms of the debenture maintain control
	of the conversion option with the Company. The instrument is therefore equity and not a compound financial instrument. No value
	is attributed to debt in this circumstance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Preferred shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Preferred shares of the Company automatically
	converted to an equivalent number of common shares immediately prior to the listing of the common shares on an approved exchange.
	The preferred shares are a residual interest in the assets of the entity and are therefore classified within shareholders&rsquo;
	equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 128; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Share-based payments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18.4PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Share based payment arrangements
	in which the Company receives goods or services as consideration for its own equity instruments granted to non-employees are accounted
	for as equity settled share based payment transactions and measured at the fair value of goods and services received. If the fair
	value of the goods or services received cannot be estimated reliably, the share based payment transaction is measured at the fair
	value of the equity instruments granted at the date the Company receives the goods or services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Share-based compensation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/99% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company grants stock options
	to acquire common shares of the Company to directors, officers, employees and consultants. An individual is classified as an employee
	when the individual is an employee for legal or tax purposes, or provides services similar to those performed by an employee.
</P>
<P STYLE="FONT: 12PT/99% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/99% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The fair value of stock options
	is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the vesting period. Consideration
	paid for the shares on the exercise of stock options is credited to share capital.&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In situations where equity instruments
	are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically
	identified, they are measured at the fair value of the share-based payment. Otherwise, share-based payments are measured at the
	fair value of goods or services received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Basic and diluted loss per share
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Basic loss per share is computed
	by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the year.
	The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such
	conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities
	is reflected in diluted earnings per share by application of the &ldquo;if converted&rdquo; method. The dilutive effect of outstanding
	options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method.
	Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it
	would be anti-dilutive.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Income taxes
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Income tax is recognized
	in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in
	equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively
	enacted at period end, adjusted for amendments to tax payable with regards to previous years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Deferred tax is
	recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting
	purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible
	for tax purposes; the initial recognition of assets or liabilities that affect neither accounting nor taxable loss; and differences
	relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount
	of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities,
	using tax rates enacted or substantively enacted at the financial position reporting date.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	A deferred tax
	asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable
	that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting
	date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.
</P>
<!-- FIELD: PAGE; SEQUENCE: 129; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNIFICANT
	ACCOUNTING POLICIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Income taxes
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(cont&rsquo;d&hellip;)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Deferred tax assets
	and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities
	and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets
	and liabilities on a net basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	New standards not yet adopted
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	IFRS 9 Financial Instruments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	IFRS 9 was issued by the IASB in
	October 2010. It incorporates revised requirements for the classification and measurement of financial liabilities and carrying
	over the existing derecognition requirements from IAS 39 Financial Instruments: recognition and measurement. The revised financial
	liability provisions maintain the existing amortized cost measurement basis for most liabilities. New requirements apply where
	an entity chooses to measure a liability at fair value through profit or loss &ndash; in these cases, the portion of the change
	in fair value related to changes in the entity's own credit risk is presented in other comprehensive income rather than within
	profit or loss. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. The impact of IFRS 9 on the Company&rsquo;s
	consolidated financial statements has not yet been determined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	IFRS 15 Revenue from Contracts
	with Customers
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	IFRS 15 is a new standard to establish
	principles for reporting the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity&rsquo;s contracts
	with customers. It provides a single model in order to depict the transfer of promised goods or services to customers. IFRS 15
	supersedes IAS 11, Construction Contracts, IAS 18, Revenue, IFRIC 13, Customer Loyalty Programs, IFRIC 15, Agreements for the Construction
	of Real Estate, IFRIC 18, Transfers of Assets from Customers, and SIC-31, Revenue &ndash; Barter Transactions involving Advertising
	Service. IFRS 15 is effective for annual periods beginning on or after January 1, 2018. The impact of IFRS 15 on the Company&rsquo;s
	financial statements has not yet been determined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	IFRS 16, Leases
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	IFRS 16 is a new standard that sets
	out the principles for recognition, measurement, presentation, and disclosure of leases including guidance for both parties to
	a contract, the lessee and the lessor. The new standard eliminates the classification of leases as either operating or finance
	leases as is required by IAS 17 and instead introduces a single lessee accounting model. IFRS 16 is effective for annual periods
	beginning on or after January 1, 2019. The impact of IFRS 16 on the Company&rsquo;s leases has not yet been determined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PREPAID
	EXPENSES&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-TOP: BLACK 1PT DOUBLE; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT DOUBLE; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2016
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT DOUBLE; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2015
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT DOUBLE; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT DOUBLE">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Clinical program deposit
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	677,357
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,348,818
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Other deposits and prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	340,875
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	312,517
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	62,408
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Balance
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,018,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,661,335
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	62,408
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 130; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EQUIPMENT
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Furniture and fixtures
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Computer equipment
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Cost
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 46%; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	12,116
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,986
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	14,102
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 10PT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	136,921
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,133
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	174,054
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(363
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(99
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(462
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	148,674
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	187,694
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Additions
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,644
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,339
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,983
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	154,318
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	43,359
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	197,677
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Accumulated Amortization
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Amortization expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,806
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,047
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,853
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	273
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	104
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	377
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,079
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,151
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Amortization expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	33,515
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,202
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	47,717
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	49,594
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	20,353
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	69,947
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Net Book Value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,116
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,986
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,102
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	132,595
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,869
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	165,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	104,724
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,006
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	127,730
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Amortization expense has been recorded
	in &ldquo;general and administrative expenses&rdquo; in the statement of loss and comprehensive loss (Note 18).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INTANGIBLE
	ASSETS&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	NTD Technology
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-DECORATION: NONE; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Cost
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	446,125
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(71,440
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	374,685
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,401
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	361,284
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 131; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INTANGIBLE
	ASSETS
</B>
	(cont&rsquo;d&hellip;)&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	NTD Technology
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Accumulated Amortization
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	85,285
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Amortization expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,369
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,050
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90,604
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Amortization expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,407
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	105,661
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Net Book Value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	360,840
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	284,081
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	255,623
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Amortization expense has been recorded
	in &ldquo;general and administrative expenses&rdquo; in the statement of loss and comprehensive loss (Note 18).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The NTD Technology is held under
	a License Agreement signed in fiscal 2010. As consideration for the License Agreement, the Company issued common shares of the
	Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual
	sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates certain minimum advance royalty
	payments of C$40,000 for 2013 and escalating to C$85,000 by 2017. In addition, there are certain milestone payments for the first
	compound, to be paid in stages as to C$50,000 at the start of a Phase II clinical trial, C$900,000 at the start of a Phase III
	clinical trial, C$1,450,000 at application for marketing approval, and with further milestone payments on the second and additional
	compounds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEBENTURE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In April 2014, the Company issued
	a convertible debenture to the Bloom Burton Healthcare Structured Lending Fund LP (the &ldquo;Lender&rdquo;) for C$1,000,000. The
	convertible debenture terms include interest of 12% per annum payable at maturity (24 months from closing), as secured by various
	security agreements. The Company incurred transaction costs of C$23,541 and issued 25,000 warrants to the Lender valued at $14,935,
	each exercisable into one common share at a price of C$2.00 for a period of five years. The warrants were valued using the Black-Scholes
	model with a risk-free interest rate of 1.63%, term of 5 years, volatility of 80%, and dividend rate of 0%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The principal and accrued interest
	are convertible into common shares of the Company at maturity at a conversion price of C$1.20 unless the Company opts to settle
	the balance in cash. The terms of the debenture maintained control of the conversion option in the hands of the Company; therefore,
	the instrument has been recorded as equity in the statement of financial position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company and Lender agreed to
	proceed with early conversion of the debenture, including accrued interest, into 517,500 preferred shares of the Company upon the
	closing of the financing completed in July 2014 (Note 9(e)).
</P>
<!-- FIELD: PAGE; SEQUENCE: 132; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEBENTURE
</B>
	(cont&rsquo;d&hellip;)&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Proceeds on issuance of convertible debenture
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	911,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(36,381
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Interest accrued
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Conversion to preferred shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(906,724
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	Balance, September 30, 2014, 2015, and 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DERIVATIVE
	LIABILITIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Broker Warrants Denominated in
	Foreign Currency
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In accordance with IFRS, an obligation
	to issue shares for a price that is not fixed in the Company&rsquo;s functional currency, and that does not qualify as a rights
	offering, must be classified as a derivative liability and measured at fair value with changes recognized in the statement of loss
	and comprehensive loss as they arise. The derivative liability was designated as a financial liability carried at fair value through
	profit and loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Warrants exercisable in US dollars
	prior to January 1, 2016 and warrants exercisable in Canadian dollars after January 1, 2016, the date marking the Company&rsquo;s
	change in functional currency, are therefore classified as derivative liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In connection with the 2015 Special
	Warrant financing in January 2015 (Note 9), the Company issued 257,018 broker warrants. Each broker warrant is exercisable to purchase
	one common share until January 16, 2017 at a price of US$2.75 per broker warrant (Note 10).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	On issuance of the broker warrants,
	the Company recorded a derivative liability of $282,287 using the Black-Scholes model. As at December 31, 2015, the derivative
	liability had a fair value of $588,407 (September 30, 2015 - $993,099), using the Black-Scholes model with a risk-free interest
	rate of 0.52%, term of 1.04 years, volatility of 80.0%, and dividend rate of 0%. The Company has recorded the resulting change
	in fair value of $382,649 (2015 - $Nil) in the statement of loss and comprehensive loss. On January 1, 2016, the Company de-recognized
	the derivative liability of $588,407.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In April 2014, in connection with
	the issuance of a convertible debenture for $1,000,000, the Company issued 25,000 broker warrants valued at $14,935 (C$16,394),
	each exercisable into one common share at a price of C$2.00 for a period of five years (Note 10). The warrants were valued using
	the Black-Scholes model with a risk-free interest rate of 1.63%, term of 5 years, volatility of 80% and dividend rate of 0%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	On January 1, 2016, the Company recorded
	a derivative liability of $82,743 using the Black-Scholes model. As at September 30, 2016, the derivative liability had a fair
	value of $42,202 (September 30, 2015 - $Nil). The Company has recorded the resulting change in fair value of $40,541 (2015 - $Nil)
	in the statement of loss and comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 133; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DERIVATIVE
	LIABILITIES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	2016 Warrants
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In January 2016, the Company completed
	a private placement of 4,545,452 units of the Company at $3.30 per unit (&ldquo;Unit&rdquo;) for gross proceeds of $14,999,992.
	Each Unit consisted of one common share of the Company, one 7-year cash and cashless exercise warrant (the &ldquo;
<B>
	7-Year Warrants
</B>
	&rdquo;),
	and one half of one 2-year cash exercise warrant (the &ldquo;
<B>
	2-Year Warrants
</B>
	&rdquo;). The 7-Year Warrants and 2-Year Warrants
	have an exercise price of $3.30 per common share (collectively, the &ldquo;
<B>
	2016 Warrants
</B>
	&rdquo;). The holders of the 7-Year
	Warrants may elect, in lieu of exercising the 7-Year Warrants for cash, a cashless exercise option, in whole or in part, to receive
	common shares equal to the fair value of the 7-Year Warrants based on the number of 7-Year Warrants to be exercised multiplied
	by a ten-day weighted average market price less the exercise price with the difference divided by the weighted average market price.
	If a warrant holder exercises this option, there will be variability in the number of shares issued per 7-Year Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Additionally, the 2016 Warrants contain
	provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction,
	such as a change of control or sale of the Company&rsquo;s assets (&ldquo;Major Transaction&rdquo;). The redemption value would
	be subject to a Black Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable
	to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata
	to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants, in accordance with IFRS, requires
	the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	On issuance of the 7-Year and 2-Year
	Warrants in January 2016, the Company recorded derivative liabilities of $10,181,817 and $3,236,363, respectively using the Black-Scholes
	model. The 2016 Warrants are not traded in an active market. A liquidity discount of 20% has been applied to the per warrant fair
	value to account for the lack of marketability of the instruments. As at September 30, 2016, the 7-Year Warrants derivative liability
	had a fair value of $6,005,794 (2015 - $Nil). As at September 30, 2016, the 2-Year Warrants derivative liability had a fair value
	of $1,261,471 (2015 - $Nil). The Company has recorded the resulting change in fair value of $6,150,915 (2015 - $Nil) in the statement
	of loss and comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company uses the Black-Scholes
	option pricing model to estimate value. The following weighted average assumptions were used to estimate the fair value of the
	derivative warrant liabilities on initial recognition (January 1, 2016 with respect to the broker warrants and January 14, 2016
	with respect to the 2016 Warrants) and September 30, 2016:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	January 14, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	January 1, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Risk-free interest rate
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.21
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.55
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.62
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Expected life
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.62 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.33 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.29 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Expected annualized volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Dividend
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The derivative warrants are a recurring
	Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price and
	expected volatility. If the market price were to increase by a factor of 10% this would increase the obligation by approximately
	$1,105,837 as at September 30, 2016. If the market price were to decrease by a factor of 10% this would decrease the obligation
	by approximately $1,065,832. If the volatility were to increase by 10%, this would increase the obligation by approximately $636,750.
	If the volatility were to decrease by 10%, this would decrease the obligation by approximately $677,919 as at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 134; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DERIVATIVE
	LIABILITIES
</B>
	(cont&rsquo;d...)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	2016 Warrants (cont&rsquo;d&hellip;)
</I>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 42.55PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The following table is a continuity
	schedule of changes to the Company&rsquo;s derivative liabilities:&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Balance, September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT">
	Derivative liability on issuance of broker warrants
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	282,287
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Exercise of broker warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,449
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Change in fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	907,599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Net exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(193,338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	993,099
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT">
	Derivative liability on change in functional currency
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	82,743
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT">
	Derivative liability on issuance of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,418,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Change in fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,574,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Net exchange differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(22,043
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT">
	De-recognition of derivative liability on functional currency change
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(588,407
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,309,467
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHAREHOLDERS&rsquo;
	EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Authorized:
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Unlimited common shares, without
	par value.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Unlimited preferred shares,
	without par value.&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT DOUBLE; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Preferred shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Special warrants
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, September 30, 2013
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	15,687,534
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	4,193,735
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Conversion of debenture
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	517,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	906,724
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,185,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,183,270
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Financing costs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(253,726
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,687,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,193,735
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,702,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,836,268
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,043,274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,208,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,193,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Conversion of special
<BR>
	warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,363,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,976,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	679,640
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,039,144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,043,274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,015,249
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Conversion of preferred
<BR>
	Shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,382,540
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,872,737
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,382,540
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,875,412
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT; VERTICAL-ALIGN: MIDDLE">
	Warrants exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	104,363
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	231,142
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,629,271
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,419,004
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 135; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHAREHOLDERS&rsquo;
	EQUITY
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Authorized:
</I>
	(cont&rsquo;d&hellip;)
<I>
	&nbsp;
</I>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Preferred shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Special warrants
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2015
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	22,629,271
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	19,419,004
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Private placement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,212,118
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,581,815
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(170,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	254,724
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	142,386
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Warrants exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	776
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,628
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	29,096,889
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	25,974,742
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Listing on the TSX-V, TSX, and
	NASDAQ
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company completed its listing
	on the TSX-V on January 27, 2015 (&ldquo;Date of Listing&rdquo;) and began trading under the symbol &ldquo;EPI&rdquo;. Immediately
	prior to the listing, all of the Company&rsquo;s 2,382,540 issued and outstanding Preferred Shares were converted into common shares.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company completed its listing
	on the NASDAQ on July 9, 2015 and began trading under the symbol &ldquo;EPIX&rdquo;. As a result of the listing, each of the outstanding
	special warrants issued on January 16, 2015 was deemed to be exercised into one common share for no additional consideration on
	July 13, 2015.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company graduated from the
	TSX-V to the TSX on July 28, 2015 under its existing symbol &ldquo;EPI&rdquo;.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Restrictions on Transfer
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(a) Lock-Up Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 5,092,000
	common shares of the Company were exclusively subject to the voluntary lock-up agreement.&nbsp; 712,950 common shares were released
	on the Date of Listing, 763,872 common shares were released on March 5, 2015 and the remaining shares will be released in increments
	of 17.2% every 3 months beginning October 27, 2015 until the final 2.2% is released 21 months after the Date of Listing. As at
	September 30, 2016, 112,038 (2015 - 3,615,678) common shares remained subject to lock-up restrictions. Subsequent to September
	30, 2016, 112,038 common shares were released from lock-up restrictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(b) Escrow Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 1,125,034
	common shares of the Company were exclusively subject to the escrow agreement, whereby 10% of the common shares subject to escrow
	were released upon the Date of Listing with the remaining common shares to be released in 15% increments every 6 months thereafter.&nbsp;
	On July 28, 2015 (the &ldquo;TSX Listing Date&rdquo;), the Company became an &ldquo;established issuer&rdquo; (as defined in the
	escrow agreement) by obtaining a listing on the Toronto Stock Exchange and the escrow release schedule was altered whereby 15%
	of the common shares subject to escrow were released on the TSX Listing Date with the remaining common shares to be released in
	25% increments every 6 months following the Date of Listing. As at September 30, 2016, all common shares have been released from
	escrow (2015 - 562,528 common shares remained subject to escrow).&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 136; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHAREHOLDERS&rsquo;
	EQUITY
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Restrictions on Transfer
</I>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(c) Combined Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 9,470,000
	common shares held by Marianne Sadar, Raymond Anderson, Robert Rieder and Richard Glickman (collectively, the &ldquo;Founders&rdquo;)
	were subject to supplementary lock-up restrictions in addition to restrictions under the escrow agreement and the voluntary lock-up
	agreement (the &ldquo;Combined Restrictions&rdquo;), whereby increments of 14%, 32.2%, 17.2%, 11.6%, 22.8% and 2.2% will be released
	6, 9, 12, 15, 18 and 21 months after the Date of Listing, respectively.&nbsp; The release schedule reflects the most restrictive
	agreement at any point in time. As at September 30, 2016, 208,340 (2015 - 8,144,200) common shares remained subject to the Combined
	Restrictions. Subsequent to September 30, 2016, 208,340 common shares were released from the Combined Restrictions.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Private placements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	a) March 2016 Private
	Placement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In March 2016, the Company completed
	a private placement (the &ldquo;
<B>
	March 2016 Financing
</B>
	&rdquo;) of 1,666,666 common shares at a price of $3.00 per share for
	gross proceeds of approximately $5,000,000. The Company incurred financing costs of $62,797.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	b) January 2016 Private
	Placement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In January 2016, the Company completed
	a private placement (the &ldquo;
<B>
	January 2016 Financing
</B>
	&rdquo;) of 4,545,452 Units of the Company at a price of $3.30 per
	Unit for gross proceeds of approximately $15,000,000. Each Unit consisted of one common share, one 7-Year Warrant, and one-half
	of one 2-Year Warrant. The 7-Year Warrant and 2-Year were assigned fair values using the Black-Scholes model (Note 8). The residual
	value was assigned to the common share in the Unit in accordance with IAS 32
<I>
	Financial instruments: presentation
</I>
	. In connection
	with the January 2016 Financing, the Company paid a cash commission to a financial advisor of approximately $463,447 and incurred
	other financing costs of $553,942. The financing costs were recorded as $107,288 in equity for the issuance of the common shares
	and $910,101 to finance expense in the statement of loss and comprehensive loss for the issuance of the 2016 Warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In connection with the January 2016
	Financing, Clarus Lifesciences III, L.P. (&ldquo;
<B>
	Clarus
</B>
	&rdquo;) acquired 2,121,212 common shares, representing approximately
	9.4% of the issued and outstanding common shares as at December 29, 2015 on a non-diluted basis and excluding the warrants which
	were issued to Clarus on the closing date and the common shares issuable upon exercise thereof. Pursuant to the terms of the subscription
	agreement between the Company and Clarus, Clarus is entitled to nominate two directors to the board of directors of the Company,
	one of which must be an independent director and preapproved by the Company. These nomination rights will continue for so long
	as Clarus holds greater than or equal to 1,060,606 common shares, subject to adjustment in certain circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition, on the closing of the
	January 2016 Financing, certain shareholders, who in the aggregate controlled approximately 9,482,800 common shares constituting
	41.9% of the issued and outstanding common shares on a non-diluted basis as at December 29, 2015, entered into a voting agreement
	(the &ldquo;
<B>
	Voting Agreement
</B>
	&rdquo;) with Clarus providing that such shareholders will vote against certain change of control
	transactions, unless Clarus consents otherwise, and support Clarus&rsquo; nominees to the board of directors of the Company. The
	provisions of the Voting Agreement relating to change of control transactions will expire, at the latest, upon the six-month anniversary
	of the public release of the results of the completed Phase 2 portion of the Phase 1/2 clinical trial of EPI-506 by the Company
	or the public release of the results of the completed Phase 2 portion of an alternative program that is approved by the board of
	directors and the provisions relating to the Clarus nominees will continue for so long as Clarus is entitled to nominate directors
	to the Company&rsquo;s board of directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 137; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHAREHOLDERS&rsquo;
	EQUITY
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Private placements
</I>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	c) January 2015 Special
	Warrant Financing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In January 2015, the Company issued
	4,363,634 special warrants (the &ldquo;
<B>
	2015 Special Warrants
</B>
	&rdquo;) at a price of $2.75 per 2015 Special Warrant for gross
	proceeds of approximately $12,000,000. During the year ended September 30, 2015, the 2015 Special Warrants were converted into
	common shares of the Company at a rate of one common share per 2015 Special Warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In connection with the 2015 Special
	Warrant financing, Bloom Burton &amp; Co. and Roth Capital Partners, LLC, as Agents, and selling group members, received cash commissions
	equal to approximately $706,800 and 257,018 broker warrants. Each broker warrant is exercisable to purchase one common share until
	January 16, 2017 at a price of $2.75 per broker warrant. The warrants were valued at $282,287 using the Black-Scholes model with
	a risk-free interest rate of 0.87%, term of 2 years, volatility of 72.3%, and dividend rate of 0%, and had been recorded as a derivative
	liability until January 1, 2016 (Note 8).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	d) October 2014 Special
	Warrant Financing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In October 2014, the Company issued
	679,640 special warrants (the &ldquo;
<B>
	2014 Special Warrants
</B>
	&rdquo;) at a price of C$2.00 per 2014 Special Warrant for gross
	proceeds of C$1,359,280. Each 2014 Special Warrant was deemed exercised for, without payment of any additional consideration, one
	Class A Preferred share in the capital of the Company (each a &ldquo;
<B>
	Preferred Share
</B>
	&rdquo;) on December 15, 2014, being
	the fifth business day after the date on which a receipt for the final prospectus of the Company qualifying the distribution of
	the Preferred Shares issuable on exercise of the 2014 Special Warrants had been issued. During the year ended September 30, 2015,
	the Preferred Shares were converted into common shares of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In connection with the 2014 Special
	Warrant financing, the Company paid agent and finders&rsquo; fees at 7% of proceeds raised by those parties being $35,897, a cash
	fee to the Agent of $26,682 and other expenses of $62,786. In addition, the Agent, and associated selling group, were issued 22,675
	special broker warrants (the &ldquo;
<B>
	Special Broker Warrants
</B>
	&rdquo;), representing 7% of the number of 2014 Special Warrants
	sold by the Agent, and the finders were issued 2,680 Special Broker Warrants, representing 7% of the number of 2014 Special Warrants
	sold to purchasers introduced to the Company by such finders. Each Special Broker Warrant was deemed exercised for, without payment
	of any additional consideration, one broker warrant (the &ldquo;
<B>
	Broker Warrants
</B>
	&rdquo;).&nbsp; Each Broker Warrant is exercisable
	to acquire one common share, subject to adjustment in certain circumstances, at a price of C$2.00 until October 22, 2015. The Special
	Broker Warrants were valued at $44,434 using the Black-Scholes model with a risk-free interest rate of 1.00%, term of 1 year, volatility
	of 80% and dividend rate of 0%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	e) July 2014 Preferred
	Shares Financing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	On July 29, 2014, the Company completed
	a brokered private placement of 1,185,400 Preferred Shares at a price of C$2.00 per Preferred Share for aggregate gross proceeds
	of C$2,370,800. During the year ended September 30, 2015, the Preferred Shares were converted into common shares of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In conjunction with the private placement,
	the Company issued 79,479 warrants to Bloom Burton, the Company&rsquo;s advisor, and other finders exercisable at a price of C$2.00
	for a period of one year. The warrants were valued at $50,004 using the Black-Scholes model with a risk-free interest rate of 1.08%,
	term of 1 year, volatility of 80% and dividend rate of 0%. The Company paid finders&rsquo; fees of C$158,956 and other share issue
	costs of C$66,560.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 138; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Stock options
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has adopted a Stock Option
	Plan, pursuant to which up to a maximum of 5,000,000 shares may be reserved for issuance. The Stock Option Plan is consistent with
	the policies and rules of the TSX.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Stock option transactions are summarized
	as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
<BR>
	of Options
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2013
</TD>
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,119,250
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;0.73
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Options granted
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,950,469
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1.80
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,069,719
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Options granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	495,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.89
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Options exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(91,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1.15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,473,519
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Options granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	910,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Options exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(281,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Options expired/forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(40,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4.39
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Balance outstanding, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,062,519
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;2.76
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	&nbsp;Balance exercisable, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,634,269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&#9;1.84
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	At September 30, 2016, options were
	outstanding enabling holders to acquire common shares as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise price (C$)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of options
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted average remaining contractual life (years)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	C$
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	0.80
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	1,118,300
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	1.67
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,859,219
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	290,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.86
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	600,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.26
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.95
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	55,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8.28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,062,519
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	3.15
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Restrictions on Transfer
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s stock options
	exercisable at C$0.80 and 150,000 stock options exercisable at C$2.00 are subject to various exercise restrictions including the
	pooling agreement, the escrow agreement, the voluntary lock-up agreement and the supplementary lock-up agreement, which came into
	effect during the year ended September 30, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 139; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Restrictions on Transfer
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(a) Pooling Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 330,500
	stock options exercisable at C$0.50 and C$0.80 were exclusively subject to pooling restrictions.&nbsp; 66,100 options were released
	on the Date of Listing, and the remaining options will be released in increments of 20% every 3 months thereafter.&nbsp; As at
	September 30, 2016, all stock options have been released from pooling restrictions (2015 - 132,200 options remained subject to
	pooling restrictions).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(b) Escrow Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 195,000
	stock options exercisable at C$0.50 and C$0.80 were exclusively subject to the escrow agreement, whereby 10% of the options subject
	to escrow were released upon the Date of Listing with the remaining options to be released in 15% increments every 6 months thereafter.&nbsp;Upon
	the Company becoming an established issuer, the escrow release schedule was altered whereby 15% of the stock options subject to
	escrow were released on the TSX Listing Date with the remaining stock options to be released in 25% increments every 6 months following
	the Date of Listing. As at September 30, 2016, all stock options have been released from escrow (2015 - 97,500 options remained
	subject to escrow).
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(c) Lock-Up Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September
	30, 2015, the Company granted 150,000 stock options, exercisable at C$2.00, which are subject to both lock-up and supplementary
	lock-up restrictions, whereby increments of 14% 32.2%, 17,2%, 17.2%, 17.2% and 2.2% will be released 6, 9, 12, 15, 18 and 21 months
	after the Date of Listing, respectively.&nbsp; As at September 30, 2016, 3,300 (2015 - 129,000) options remained subject to lock-up
	and supplementary lock-up restrictions.&nbsp; Subsequent to September 30, 2016, all remaining stock options were released from
	lock-up and supplementary lock-up restrictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	(d) Combined Restrictions
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	As at September 30, 2014, 915,000
	stock options of the Founders, exercisable at C$0.50 and C$0.80 were subject to the Combined Restrictions, whereby increments of
	14%, 32.2%, 17.2%, 11.6%, 22.8% and 2.2% will be released 6, 9, 12, 15, 18 and 21 months after the Date of Listing, respectively.&nbsp;
	As at September 30, 2016, 20,130 (2015 - 786,900) stock options remained subject to the Combined Restrictions. Subsequent to September
	30, 2016, all remaining stock options were released from the Combined Restrictions.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Share-based compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During year ended September 30, 2016,
	the Company granted 910,000 (2015 &ndash; 495,000, 2014 &ndash; 1,950,469) stock options with a weighted average fair value of
	$1.98 per option (2015 &ndash; $2.56; 2014 &ndash; $0.83). The Company recognized share-based payments expense of $1,246,946 (2015
	- $1,510,542; 2014 - $494,221) for options granted and vesting during the year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Share-based payments
	expense is allocated to its functional expense as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Research and development expense (Note 18)
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	322,160
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	779,263
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	321,524
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,743
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	93,755
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55,482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	General and administrative (Note 18)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	897,043
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	637,524
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	117,215
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,246,946
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,510,542
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	494,221
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 140; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Share-based compensation
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The following weighted average assumptions
	were used for the Black-Scholes option-pricing model valuation of stock options granted:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Risk-free interest rate
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.63
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.39
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.57
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Expected life of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.58 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.13 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5.00 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Expected annualized volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Dividend
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Warrants
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Warrant transactions are summarized
	as follows:&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
<BR>
	of Warrants
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Warrants granted
</TD>
<TD STYLE="WIDTH: 8%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	104,479
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1.50
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	104,479
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Warrants granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	282,373
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Warrants exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(104,363
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1.51
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Balance, September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	282,489
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Warrants granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,818,178
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 10PT">
	Warrants exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(776
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Warrants expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(350
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1.48
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Balance outstanding and exercisable, September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,099,541
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	3.28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Warrants exercisable in Canadian
	dollars as at September 30, 2016 are translated at current rates to reflect the current weighted average exercise price in US dollars
	for all outstanding warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	At September 30, 2016, warrants
	were outstanding enabling holders to acquire common shares as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
<BR>
	of Warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise
<BR>
	Price
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiry Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	C$2.00
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 56%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	April 15, 2019
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	256,363
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$2.75
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	January 16, 2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,545,452
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$3.30
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	January 14, 2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,272,726
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	US$3.30
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	January 14, 2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,099,541
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 13.5PT">
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Detailed terms of the 2016 Warrants are included in Note 8.
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 141; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SUPPLEMENTAL
	DISCLOSURE WITH RESPECT TO CASH FLOWS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2016, the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Issued 213,724 common shares on the cashless exercise of 240,000 stock options.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On exercise of stock options and warrants, the Company transferred $105,921 and $434, respectively,
	from reserves to share capital.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Recognized a derivative liability of $13,418,180 on issuance of the 2-Year and 7-Year Warrants
	(Note 8).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2015, the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Issued agent warrants valued at $44,434 (Note 9).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Recognized a derivative liability of $228,287 on the issuance of broker warrants denominated in
	US dollars (Note 8).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2014, the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Accrued purchases of equipment of $15,806 through accounts payable and accrued liabilities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RELATED
	PARTY TRANSACTIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Key management personnel of the
	Company include the President and Chief Executive Officer, Chief Financial Officer, Chief Technical Officer, Chief Scientific
	Officer, Chief Medical Officer, Executive VP and Chief Operating Officer, Executive VP of Research and Development, and Directors
	of the Company. Compensation paid to key management personnel is as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Salaries, consulting fees, and director fees
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	2,651,651
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,662,575
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	439,239
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Share-based payments
<SUP>
	(a)
</SUP>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,029,878
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	764,565
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	419,229
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total compensation
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,681,529
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,427,140
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	858,468
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<SUP>
	(a)
</SUP>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share-based payments to related parties represents the fair value of options granted and vested
	in the period to key management personnel.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2016, the Company granted 890,000 (2015 &ndash; 250,000; 2014 &ndash; 970,000) options to key management personnel. The vesting
	of these options and options granted to key management personnel in prior periods were recorded as share-based payments expense
	in the statement of loss and comprehensive loss at a value of $1,029,878 (2015 - $1,154,548; 2014 - $419,229).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Included in accounts payable and
	accrued liabilities at September 30, 2016 is $276,399 (2015 &ndash; $82,414; 2014 - $21,709) due to related parties with respect
	to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with
	no fixed terms of repayment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Commitments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The CEO is entitled to a payment
	of six months of base salary upon termination without cause, increasing to one year following one year of employment. Additionally,
	the CEO is entitled to 18 months of salary if termination without cause occurs after a change of control event or within 60 days
	prior to a change of control event where such event was under consideration at the time of termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 142; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RELATED
	PARTY TRANSACTIONS
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Commitments
</I>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The CFO is entitled to a payment
	of one year of base salary upon termination without cause, whether or not the termination was caused by a change of control event.
	The CMO and Executive Vice-President of Research and Development are entitled to a payment of six months of base salary upon termination
	without cause, and one year of base salary if the termination was caused by a change of control event.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The COO is entitled to a payment
	of six months of base salary upon termination without cause, increasing to one year following one year of employment. Additionally,
	the COO is entitled to 18 months of salary if termination without cause occurs within 18 months after a change of control event.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Stock options held by the CEO, CFO,
	CMO, Executive Vice-President of Research and Development, and COO vest immediately upon a change of control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INCOME
	TAXES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 18.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 18.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 17.6PT">
	A reconciliation
	of income taxes at statutory rates is as follows:&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the years ended September 30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Loss for the year before income tax
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(12,988,516
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(9,676,587
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	(1,823,929
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Expected income tax recovery
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,377,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,516,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(474,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Non-deductible share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	352,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	376,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	123,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Other permanent differences including foreign exchange
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,709,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(294,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Adjustment for deferred income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(383,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Financing costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(142,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(119,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Changes in tax rates, foreign exchange rates
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(32,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Adjustment to prior year provision versus statutory return
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,308,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	257,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Change in unrecognized deductible temporary differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,704,272
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,677,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	383,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total income tax expense
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	151,272
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The significant components of the
	Company&rsquo;s unrecognized temporary tax differences are as follows:&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Operating losses carried forward
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	29,384,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	16,734,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	4,053,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Investment tax credits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	147,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	144,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Equipment and intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(346,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Financing costs
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,760,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	522,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Operating losses carried forward
	as at September 30, 2016 expire from 2031 &ndash; 2036. Financing costs expire from 2037 to 2040. Investment tax credits expire
	in 2034.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Tax attributes are subject
	to review, and potential adjustment, by tax authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2016, the Company received $nil (2015 - $59,666; 2014 - $215,984) in Scientific Research and Experimental Development tax credits
	from the Government of Canada which are included in research and development costs in the statement of loss and comprehensive loss.
</P>
<!-- FIELD: PAGE; SEQUENCE: 143; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INCOME
	TAXES
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 18.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has recorded an income
	tax expense of $151,272 for the year ended September 30, 2016 (2015 - $nil, 2014 - $nil) in relation to income earned by its US
	subsidiary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEGMENTED
	INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company works in one industry
	being the development of small molecule drugs for prostate cancer. The Company&rsquo;s equipment is located in the USA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAPITAL
	MANAGEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company considers its capital
	to be the components of shareholders&rsquo; equity. The Company&rsquo;s objective when managing capital is to maintain adequate
	levels of funding to support the development of its business and maintain the necessary corporate and administrative functions
	to facilitate these activities. This is done primarily through equity financing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In December 2015, the Company filed
	a short form base shelf prospectus in British Columbia, Alberta, and Ontario, and a corresponding shelf registration statement
	with the United States Securities and Exchange Commission on Form F-10, which enables issuances from time to time in order to increase
	the Company&rsquo;s available capital which was used in connection with the financings completed during the year (Note 9). Future
	financings are dependent on market conditions and the ability to identify sources of investment. There can be no assurance the
	Company will be able to raise funds in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	There were no changes to the Company&rsquo;s
	approach to capital management during the year. As at September 30, 2016, the Company is not subject to externally imposed capital
	requirements.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL INSTRUMENTS
	AND RISK
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s financial instruments
	consist of cash, receivables, accounts payable and accrued liabilities and derivative liabilities. Cash is measured based on level
	1 inputs of the fair value hierarchy. The fair value of receivables and accounts payable and accrued liabilities approximates their
	carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 8).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Fair value estimates of financial
	instruments are made at a specific point in time, based on relevant information about financial markets and specific financial
	instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined
	with precision. Changes in assumptions can significantly affect estimated fair values.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Financial risk factors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s risk exposures
	and the impact on the Company&rsquo;s financial instruments are summarized below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Credit risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Financial instruments that potentially
	subject the Company to a significant concentration of credit risk consist primarily of cash and receivables. The Company&rsquo;s
	receivables are primarily due from refundable GST and investment tax credits. The Company limits its exposure to credit loss by
	placing its cash with major financial institutions. Credit risk with respect to investment tax credits and GST is minimal as the
	amounts are due from government agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 144; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL INSTRUMENTS
	AND RISK
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	Financial risk factors
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Liquidity risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company&rsquo;s
	approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September
	30, 2016, the Company had working capital of $6,389,257. During the year ended September 30, 2016, the Company completed financings
	totaling approximately $20,000,000 (Note 9). All of the Company&rsquo;s current financial liabilities have contractual maturities
	of 30 days or due on demand and are subject to normal trade terms. The Company does not generate revenue and will be reliant on
	external financing and proceeds from the CPRIT grant to fund operations. Debt and equity financing is dependent on market conditions
	and may not be available on favorable terms. The CPRIT grant is dependent on the Company completing all the milestones (Note 17).
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Market risk
</I>
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Market risk
	is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
	rate risk
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	As at September
	30, 2016, the Company has cash balances and no interest-bearing debt and therefore is not exposed to risk in the event of interest
	rate fluctuations. Interest income is not significant to the Company&rsquo;s projected operational budget.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign
	currency risk
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	Historically,
	the Company has been exposed to foreign currency risk on fluctuations related to accounts payable and accrued liabilities that
	are denominated in US dollars as the Company was financed and functioning in Canadian dollars. Over time, the Company has become
	increasingly exposed to the US dollar due to the financings completed in US dollars, the US dollar-denominated CPRIT Grant (Note
	17) and movement of operations to Houston pursuant to the terms of the CPRIT Grant; accordingly, the Company adopted the US dollar
	as its functional currency from the Canadian dollar as of January 1, 2016, so that the Company&rsquo;s foreign currency risk exposure
	now relates to net monetary assets denominated in Canadian dollars. A 10% change in the foreign exchange rate between the Canadian
	and U.S. dollar would result in a fluctuation of $42,190 in the net loss realized for the year.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	The Company
	does not currently engage in hedging activities.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Price
	risk
</P>
<P STYLE="FONT: 10PT/99% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	The Company
	is exposed to price risk with respect to equity prices. The Company closely monitors individual equity movements, and the stock
	market to determine the appropriate course of action to be taken by the Company.
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 145; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/95% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMITMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company has the following obligations
	over the next five years:
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	Contractual obligations
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2017
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2018
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2019
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2020
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Minimum annual royalty per License Agreement (Note 6)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&#9;85,000
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	85,000
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	85,000
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	85,000
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	85,000
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Lease on Vancouver office space
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,953
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,953
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,953
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,953
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,953
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Total (in C$)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#9;125,953
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;125,953
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#9;125,953
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#9;125,953
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	C$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&#9;125,953
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	Lease on US office spaces
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	186,220
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	172,235
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	175,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44,474
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Product Development
	and Relocation Grant
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In February 2014 the Company received
	notice that it had been awarded a product development and relocation grant by the CPRIT whereby the Company is eligible to receive
	up to $12,000,000 on eligible expenditures over a three year period related to the development of the Company&rsquo;s androgen
	receptor n-terminus blocker program for prostate cancer. The funding under CPRIT is subject to a number of conditions including
	negotiation and execution of an award contract which details the milestones that must be met to release the tranched CPRIT funding,
	proof the Company has raised the 50% matching funds to release CPRIT monies, and relocation of the project to the State of Texas
	such that the substantial functions of the Company related to the project grant are in Texas and the Company uses Texas-based subcontractor
	and collaborators wherever possible.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30,
	2014, the Company received $2,793,533 as an advance on the CPRIT Grant, of which $1,153,181 in qualifying expenses was incurred
	in that same period. During the year ended September 30, 2015, the Company recognized the unclaimed portion of the grant from fiscal
	2014 as well as the full balance of the grant received subsequent to September 30, 2015, $3,786,667, as a reduction in the product
	development and relocation grant liability in the statement of loss and comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	If the Company is found to have used
	any grant proceeds for purposes other than intended, is in violation of the terms of the grant, or relocates its operations outside
	of the state of Texas, then the Company is required to repay any grant proceeds received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Under the terms of the grant, the
	Company is also required to pay a royalty to CPRIT, comprised of 4% of revenues until aggregate royalty payments equal $24,000,000,
	and 2% of revenues thereafter. The Company has the option to terminate the grant agreement by paying a one-time, non-refundable
	buyout fee, based on certain factors including the grant proceeds, and the number of months between the termination date and the
	buyout fee payment date.
<I>
	&nbsp;
</I>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	CPRIT Grant
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Product development and relocation grant, September 30, 2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Advance received
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	2,793,533
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Recoveries claimed
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,153,181
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Product development and relocation grant, September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,640,352
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Advance received
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,786,667
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Recoveries claimed
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,427,019
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	Product development and relocation grant, September 30, 2015 and September 30, 2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 146; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMITMENTS
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	Advisory Contract
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	In February 2014 the Company executed
	an Engagement Letter with Bloom Burton &amp; Co. (&ldquo;Bloom Burton&rdquo;), an investment bank, to retain their services to
	act as its exclusive agent and financial advisor in connection with a funding strategy for the Company to involve a private financing,
	that is compatible with the CPRIT grant, followed by an initial public offering on a major North American stock exchange. In exchange
	for their services, Bloom Burton would receive a percentage of any funds raised and warrants on successful completion of the financing.
	The Engagement Letter was for a term of nine months and has since expired; however, Bloom Burton retains a right of first refusal
	on all future financings occurring up to 24 months following the Company&rsquo;s initial public offering.
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	The October 2014 Special Warrant
	financing, and January 2015 Special Warrant financing were completed under the terms of the Advisory Contract (Note 9).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXPENSES
	BY NATURE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Research and development expenses
	include the following major expenses by nature:&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the year ended September 30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Clinical
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	2,920,104
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	304,142
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Consulting
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,333,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,072,039
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	309,610
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Legal patents and license fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	905,392
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	554,712
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	309,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Manufacturing
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,601,407
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,417,551
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	411,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	306,657
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	299,470
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,899
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Pharmacology
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	866,527
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,420,276
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	385,260
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Program administration
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	381,429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	428,096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Royalties
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,722
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Salaries and benefits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,194,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,671,567
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	92,799
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Share-based payments (Note 10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	322,160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	779,263
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	321,524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Travel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	182,927
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	437,226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	63,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	SR&amp;ED tax credits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(59,666
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(215,984
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT">
	CPRIT grant claimed on eligible expenses (Note 17)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,379,298
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,069,937
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,060,201
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,975,928
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	671,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 147; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 18PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<P STYLE="MARGIN: 0">
<B>
	ESSA PHARMA INC.
</B>
</P>
<P STYLE="MARGIN: 0">
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</P>
<P STYLE="MARGIN: 0">
	(Expressed in United States dollars)
</P>
<P STYLE="MARGIN: 0">
	FOR THE YEARS ENDED SEPTEMBER 30, 2016, 2015 AND 2014
</P>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_57"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXPENSES
	BY NATURE
</B>
	(cont&rsquo;d&hellip;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	General and administrative expenses
	include the following major expenses by nature:&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	For the year ended September 30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Amortization
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	66,181
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	42,223
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	23,385
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Consulting and subcontractor fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	87,014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	293,522
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	371,519
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Director fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	204,049
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128,362
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Insurance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	422,066
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	121,986
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,910
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Investor relations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	317,822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	219,312
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Office, IT and communications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	288,968
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	275,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,072
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Professional fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	776,339
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,807,112
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	442,133
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Regulatory fees and transfer agent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	131,302
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	535,088
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,456
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Rent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	620,023
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	278,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Salaries and benefits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,634,380
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	815,544
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	87,365
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Share-based payments (Note 10)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	897,043
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	637,524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	117,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	Travel and entertainment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	198,931
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	225,182
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,797
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.8PT; PADDING-LEFT: 8.8PT; PADDING-BOTTOM: 1PT">
	CPRIT grant claimed on eligible expenses (Note 17)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(120,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(83,696
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; TEXT-INDENT: -25.65PT; PADDING-LEFT: 25.65PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 2PT DOUBLE; PADDING-LEFT: 5.4PT">
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,644,118
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,259,166
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,065,350
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SUBSEQUENT
	EVENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Subsequent to September 30, 2016,
	the Company entered into a $10,000,000 capital term loan facility agreement with Silicon Valley Bank (&ldquo;SVB&rdquo;), pursuant
	to which the Company has initially drawn down $8,000,000, with a conditional option to receive an additional $2,000,000 by April
	28, 2017 upon positive data for its ongoing Phase 1 clinical trial of EPI-506 and receipt of the third and final tranche of the
	CPRIT grant of $5,422,000. The term loans bear an interest rate of Wall Street Journal Prime Rate plus 3% per annum and will mature
	on September 1, 2020. The loan agreement requires a final payment of 8.6% of the amount advanced under the term loans, due upon
	the earlier of the maturity or termination of the term loan facility. The term loans are secured by perfected first priority lien
	on all the Company&rsquo;s assets, with a negative pledge on intellectual property. The term loans are subject to standard events
	of default, including default in the event of a material adverse change. There are no financial covenants. Upon funding of the
	respective tranches, the Company granted to SVB warrants to purchase shares of the Company&rsquo;s common stock equal to 4% of
	the amount advanced, divided by the exercise price of the warrants, based on the five-day volume-weighted average trading price
	of the Company&rsquo;s common shares on the TSX, to be determined at the time of the issuance of the warrants. In connection with
	the initial $8,000,000 advance, the Company granted SVB and Life Sciences Loans II LLC an aggregate of 149,532 warrants, exercisable
	at a price of $2.14 per share for a period of seven years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	F-34
</P>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage150"></A>
<A NAME="EX49_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 9PT">
<B>
	Exhibit 4.9
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Parkinson
	ESSA (US) Employment Agreement
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Table of
	Contents
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Article
	1 Interpretation
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 7%">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 86%">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Definitions
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT; WIDTH: 7%">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Article
	2 Position, Duties and Service
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Position and Duties
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Changes to Duties
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Service to the Company
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Term
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Article3 Compensation Generally
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
<B>
	6
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	No Other Compensation
	or Benefits
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Salary
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Reimbursement for
	Expenses
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Other Expenses
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Vacation
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Benefits
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Incentive Compensation
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.8
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Stock Options
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Article
	4 Intellectual Property Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Obligation of Confidentiality
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Disclosure of Work
	Product
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assignment of Rights
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Moral Rights
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Goodwill
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	8
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assistance
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assistance with
	Proceedings
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Article
	5 Conflicts and Restrictive Covenant
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Disclosure of Conflicts
	of Interest
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	9
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Avoidance of Conflicts
	of Interest
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	10
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Restrictive Covenant
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	10
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Provisions Reasonable
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	10
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	5.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Right to Use Employee&rsquo;s
	Name and Likeness
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	11
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Article
	6 Termination
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	11
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination by Employee
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	11
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination by Company
	Without Cause
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	11
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Consequences of
	Termination Without Cause Unrelated to a Change of Control
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	11
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Consequences of
	Termination Without Cause After a Change of Control
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	12
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination in the
	Event of Death
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	12
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination by Company
	for Cause
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	12
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	No Damages for Termination
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	13
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.8
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination from
	ESSA Pharma
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	13
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="2" STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Article
	7 Genera
</B>
	l
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	13
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Agreement Confidential
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	13
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Binding Effect
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	13
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Counterparts
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Entire Agreement
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Further Assurances
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Governing Law
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Independent Legal
	Advice
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.8
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Injunctive Relief
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	14
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.9
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Non-Disparagement
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.10
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Notice
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.11
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Publicity
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.12
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Severability
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.13
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Surviving Obligations
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.14
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Waiver
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	7.15
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Acceptance
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	16
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Parkinson
	ESSA Employment Agreement
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	to be effective
	as of and from
<BR>
	the Effective Date (as defined below)
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PRIVATE AND CONFIDENTIAL
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. David Parkinson
<BR>
	David R. Parkinson
<BR>
	820 Anderson Ln
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Sebastopol, CA 95472
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Dear David:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42.55PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Re:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Terms of Employment of
	David Parkinson (&ldquo;you&rdquo; or the &ldquo;Employee&rdquo;)
</B>
<BR>
<B>
	with ESSA Pharmaceuticals Corp. (the &ldquo;Company&rdquo;)
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	This Agreement (as defined
	below) sets out the terms and conditions of your employment by the Company and will constitute your employment agreement.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	1
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Interpretation
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Definitions
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	For the purposes of this Agreement:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	$
</B>
	&rdquo;
	means US dollars.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Affiliate
</B>
	&rdquo;
	means with respect to a Person, any Person that, directly or indirectly, Controls, is
	Controlled by, or is under common Control with such Person, including, without limitation,
	any partner, officer, director, or member of such Person and any venture capital fund
	now or hereafter existing that is Controlled by or under common Control with one or more
	general partners or shares the same management company or investment manager with such
	Person, and including any parent or subsidiary company of such Person.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Agreement
</B>
	&rdquo;
	means this employment agreement and the exhibits hereto.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Board
</B>
	&rdquo;
	shall have the meaning set out in Section 2.1 (Position and Duties).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Business
</B>
	&rdquo;
	means the business of the Company described in Exhibit 1.1.5.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Business
	Information&rdquo;
</B>
	means all business information, including information regarding:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	commercial
	strategies, business plans, business methods, corporate plans, management systems, finances,
	new business opportunities, marketing or sales of any past, present or future product
	or service, including, without limitation, sales targets and statistics, market share
	and pricing statistics, marketing surveys and plans, market research reports, sales techniques,
	price lists, discount structures, advertising and promotional material;
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	financial
	information, compensation and investment arrangements, terms of agreements, financial
	structure, financial position, financial results or other financial affairs, actual or
	proposed transactions or investments or other confidential information; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	name, address, telephone number, contact name and identity of each of the Key Contacts,
	the nature of their business operation, and all confidential aspects of their business
	relationship or potential business relationship with the Company or any Affiliate of
	the Company.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Cause
</B>
	&rdquo;
	shall have the meaning set out in Section 6.6 (Termination by Company for Cause).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	CEO
</B>
	&rdquo;
	shall have the meaning set out in Section 2.1 (Position and Duties).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Change
	of Control
</B>
	&rdquo; shall be deemed to have occurred if any of the following occurs
	after the Effective Date:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	any
	&ldquo;person&rdquo; or &ldquo;group&rdquo; (as such terms are defined below) (a) is
	or becomes the beneficial owner (except that a &ldquo;person&rdquo; or &ldquo;group&rdquo;
	shall be deemed to have beneficial ownership of all shares of capital stock or other
	equity interests if such person or group has the right to acquire such shares or interests,
	whether such right is exercisable immediately or only after the passage of time), directly
	or indirectly, in a transaction or series of related transactions, of shares of capital
	stock or other interests (including partnership interests) of ESSA Pharma then outstanding
	and normally entitled (without regard to the occurrence of any contingency) to vote in
	the election of the directors, managers or similar supervisory positions (&ldquo;
<B>
	Voting
	Stock
</B>
	&rdquo;) of ESSA Pharma representing more than fifty percent (50%) of the total
	voting power of all outstanding classes of Voting Stock or (b) has the power, directly
	or indirectly, for reasons other than solely for investment purposes, to elect a majority
	of the members of the board of directors of ESSA Pharma;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	a
	sale of substantially all of the assets of ESSA Pharma; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	ESSA
	Pharma enters into a merger, reverse-merger, amalgamation, arrangement, consolidation
	or other form of business combination, share exchange, reorganization, recapitalization,
	transfer or other similar transaction with another Person (whether or not ESSA Pharma
	the surviving entity) and as a result of such transaction (a) the members of the board
	of directors of ESSA Pharma immediately prior to such transaction constitute less than
	a majority of the members of the board of directors of ESSA Pharma or such surviving
	entity immediately following such transaction or (b) the Persons that beneficially owned,
	directly or indirectly, the shares of Voting Stock of ESSA Pharma immediately prior to
	such transaction cease to beneficially own, directly or indirectly, shares of Voting
	Stock of ESSA Pharma representing at least a majority of the total voting power of all
	outstanding classes of Voting Stock of the surviving entity immediately following such
	transaction.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	2
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage153"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 70.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	A Change of Control
	that is incidental to a bona fide financing or recapitalization of the Company is deemed not to be a Change of Control for the
	purposes of this Agreement. Notwithstanding anything to the contrary, a transaction that does not constitute a change in control
	event under U.S. Treasury Regulation 1.409A-3(i)(5)(v) or (vii) will not be considered a Change of Control for purposes of this
	Agreement.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.10
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Code
</B>
	&rdquo;
	means the Internal Revenue Code of 1986, as amended.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.11
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Confidential
	Information
</B>
	&rdquo; means all non-public information, knowledge, or data pertaining
	to the business, affairs and technology of the Company or any Affiliate of the Company
	including without limitation ESSA Pharma, including:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Technical
	Information and Business Information;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	your
	Work Product; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	information
	secured by the Company from Persons subject to an obligation of confidentiality;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 70.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	and, in all cases, all
	copies and tangible embodiments thereof, in whatever form or medium, all whether furnished or prepared before or after the Effective
	Date.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.12
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Control
</B>
	&rdquo;
	or &ldquo;Controls&rdquo; means, in relation to a corporation or a partnership, as the
	case may be:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	right to cast a majority of the votes that may be cast at a general meeting of the shareholders
	of a corporation;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	right to elect or appoint, directly or indirectly, a majority of the directors of a corporation;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	to
	hold more than 50% of the interests of a partnership other than a limited partnership;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	to
	be the general partner of a limited partnership.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Effective
	Date
</B>
	&rdquo; shall have the meaning set out in Section 2.4 (Term).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	ESSA
	Pharma
</B>
	&rdquo; means ESSA Pharma Inc., the sole shareholder of the Company;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.15
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Inventions
</B>
	&rdquo;
	means any and all discoveries, developments, enhancements, improvements, concepts, formulas,
	processes, ideas, writings, whether or not reduced to practice, industrial and other
	designs, patents, patent applications, provisional patent applications, continuations,
	continuations-in-part, substitutions, divisionals, reissues, renewals, re-examinations,
	extensions, supplementary protection certificates or the like, trade secrets or utility
	models, copyrights and other forms of intellectual property including all applications,
	registrations and related foreign applications filed and registrations granted thereon.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	3
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage154"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Key
	Contacts
</B>
	&rdquo; means the actual and potential: licensors, licensees, sublicensees,
	collaborators, partners, investors, shareholders, acquirers, lenders or merger candidates,
	suppliers and customers of the Company or any Affiliate of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Notice
	Period
</B>
	&rdquo; shall have the meaning set out in Section 6.1 (Termination by Employee).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.18
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Person
</B>
	&rdquo;
	means any individual, partnership, joint venture, syndicate, sole proprietorship, company
	or corporation with or without share capital, trust, trustee, executor, administrator,
	or other legal personal representatives, regulatory body or agency, government or governmental
	agency, authority or entity howsoever designated or constituted.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Salary
</B>
	&rdquo;
	shall have the meaning set out in Section 3.2 (Salary).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.20
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Section
	409A
</B>
	&rdquo; shall have the meaning set out in Section 7.15 (Section 409A).
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.21
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Technical
	Information
</B>
	&rdquo; means all technical information of the Company or any Affiliate
	of the Company, including information regarding knowledge or data of an intellectual,
	technical, scientific or industrial nature, including compositions of matter, techniques,
	specifications, standards, technical data, uses of matter, practices, methods, computer
	data, scientific strategies and concepts, clinical and regulatory strategies and concepts,
	test data, research data, analytical and quality control data, formulation data, manufacturing
	data, development information, filings for the protection of intellectual property protection,
	drawings, specifications, designs, plans, proposals, reports, formulas, compilations,
	research data and manuals.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.22
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Term
	of Employment
</B>
	&rdquo; means the period from the Effective Date until this Agreement
	terminated in accordance with Article 6.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.1.23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&ldquo;
<B>
	Work
	Product
</B>
	&rdquo; means any and all works of authorship, including
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	all
	Inventions and possible Inventions relating to the Company&rsquo;s Business resulting
	from any work performed by you for the Company that you may invent or co-invent during
	your involvement in any capacity with the Company, except those Inventions invented by
	you entirely on your own time that do not relate to the Company&rsquo;s Business or do
	not derive from any equipment, supplies, facilities, Confidential Information or other
	information, gained, directly or indirectly, by you from or through your involvement
	in any capacity with the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	4
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage155"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1.5IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	all
	Technical Information and Business Information resulting from any work performed by you
	for the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 70.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	and includes all analyses,
	compilations, studies, reports or other documents prepared by you based upon or including any such information, data or knowledge
	of the Company or any Affiliate of the Company.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	2
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Position, Duties and Service
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Position
	and Duties
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You will be employed by and
	will serve the Company as President and Chief Executive Officer (the &ldquo;
<B>
	CEO
</B>
	&rdquo;), having the duties and functions
	customarily performed by, and having all responsibilities customary to, a CEO, including those described in Exhibit 2.1. . All
	payments and benefits provided to you pursuant to this Agreement are in full satisfaction of any and all services you provide
	to both the Company and ESSA Pharma.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You will report directly to
	the Board of Directors of ESSA Pharma (the &ldquo;
<B>
	Board
</B>
	&rdquo;). The rights of the Company as provided in this Agreement
	may be exercised on behalf of the Company only by the Board, or by a committee or person expressly designated for such purposes
	by the Board.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Changes
	to Duties
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Your duties and functions pertain
	to the Company or any Affiliate of the Company may be varied or added to from time to time by the Board in its discretion.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Service
	to the Company
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the Term of Employment,
	you will:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	well
	and faithfully serve the Company, at all times act in the best interests of the Company,
	and, to the extent necessary to discharge the responsibilities assigned to you hereunder,
	you will use your best efforts to perform faithfully and efficiently such responsibilities;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	apply
	your skill and experience to the performance of your duties in such employment;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	comply
	with all policies and procedures from time to time formulated by the Company;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	devote
	all of your working time, attention and energies to the business and affairs of the Company
	(other than any of your working time, attention and energies devoted to the business
	and affairs of ESSA Pharma), unless otherwise agreed; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.3.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	not,
	without the prior approval of the Company and the Board, carry on or engage in any other
	business or occupation or become a director, officer, employee or agent of or hold any
	position or office with any other company, firm, organization, or person other than the
	Company or ESSA Pharma, except as disclosed in Exhibit 2.3.5 or as a volunteer for a
	non-profit organization, engaging in civic, religious, educational or other community
	activities, or maintaining personal investments or a personal holding company, provided
	that such activities do not materially interfere with the performance of your duties
	under this Agreement.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	5
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage156"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Term
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The terms and conditions of
	this Agreement shall have effect as and from January 7, 2016 (the &ldquo;
<B>
	Effective Date
</B>
	&rdquo;) and throughout the Term
	of Employment.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	3
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Compensation Generally
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	No
	Other Compensation or Benefits
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You will be compensated as
	set out in this Article. You expressly acknowledge and agree that you will not be entitled by reason of your employment by the
	Company or by reason of any termination of such employment, to any remuneration, compensation, severance, damages or benefits
	other than as expressly set forth in this Agreement.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Salary
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the Term of Employment
	the Company will pay you an annual salary (the &ldquo;
<B>
	Salary
</B>
	&rdquo;) at the rate of $430,000 per annum, payable on a semi-monthly
	basis, subject to the withholding of all applicable statutory deductions, including any taxable benefits received in respect of
	your employment. As a managerial employee of the Company, you are not entitled to overtime pay.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Reimbursement
	for Expenses
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	As of the Effective Date, the
	Company agrees to reimburse you for reasonable travel, accommodation, and other expenses incurred in the course of employment,
	including travel between Sonoma County, California and Houston, Texas, and Vancouver, BC as may be required to fulfull your duties
	as CEO.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Other
	Expenses
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company will also reimburse
	you for up to six round-trip economy tickets each year for your spouse to travel between Sonoma County and Houston. For all such
	expenses, you will be required to keep proper accounts and to furnish such statements and vouchers to the Company. Certain of
	these expenses may be deemed to be a taxable benefit.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Vacation
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the Term of Employment,
	you will be entitled to 20 working days of vacation, pro-rated for any partial year of employment. The Company reserves the right
	to request that vacations be scheduled so as not to conflict with necessary business operations. Any unused vacation balance remaining
	at calendar year end may be carried over into the subsequent calendar year to a cumulative maximum of 30 working days of vacation.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	6
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage157"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Benefits
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company will reimburse
	you up to $12,000 per year for reasonable health insurance premiums paid by you, upon you providing satisfactory evidence of such
	premiums being paid or owed to your health insurance provider (the &ldquo;
<B>
	Health Care Premium Payment
</B>
	&rdquo;). Notwithstanding
	the foregoing, if the Company determines, in its sole discretion, that it cannot pay the Health Care Premium Payment without a
	substantial risk of violating applicable law, the Company instead will pay you, on the first day of each calendar month, a fully
	taxable cash payment equal to the amount of the Health Care Premium Payment, subject to applicable tax withholdings (such amount,
	the &ldquo;
<B>
	Special Cash Payment
</B>
	&rdquo;), until the month in which your employment with the Company is terminated.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Incentive
	Compensation
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You will be eligible for an
	annual bonus of up to 50% of base salary, which will be paid on the basis of your performance over each calendar year, and by
	no later than 60 days after the end of each calendar year. Bonus eligibility and performance criteria shall be set at the sole
	discretion of the Board. You will need to be employed with the Company through the end of each calendar year in order to be eligible
	to receive the annual bonus.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Stock
	Options
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Subject to the approval of the Board,
	you will be granted 600,000 options to purchase common shares in ESSA Pharma, subject to the terms and conditions of ESSA Pharma&rsquo;s
	stock option plan, and Board approval and any required shareholder approval.. These options shall vest over 4 years, with 25%
	of the options cliff-vesting on the one-year anniversary of the Effective Date of your employment and the remainder of the options
	vesting in equal monthly installments thereafter over the next three years, in all cases subject to continued employment with
	the Company and/or ESSA Pharma. Any additional option grants shall be at the sole discretion of the Board.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	4
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Intellectual Property Rights
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Obligation
	of Confidentiality
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You understand and agree that
	in the course of your employment with the Company, both before and after the Effective Date, you have obtained and will obtain
	knowledge of Confidential Information. You agree that unless the Company otherwise agrees in writing or except as required by
	law or disclosed pursuant to a confidential disclosure agreement executed by the Company and the recipient:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	you
	will keep all Confidential Information learned or acquired by you, disclosed to you or
	developed by you, as a result of or in connection with or during the course of your employment
	by the Company, whether before or after the Effective Date, strictly confidential;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	all
	Confidential Information shall, as between you and the Company, be and remain the property
	of the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	7
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage158"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	you
	will not at any time, during or after your employment with the Company, disclose any
	Confidential Information to any Person other than the Company, or use any Confidential
	Information for the benefit of any Person other than the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The above obligations with
	respect to Confidential Information shall not apply to Confidential Information which has become available to the general public
	through no fault of your own.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Disclosure
	of Work Product
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You agree to promptly and fully
	inform the Company of all of your Work Product, whether or not patentable, throughout the course of your involvement, in any capacity,
	with the Company or any Affiliate of the Company, whether or not developed before or after your execution of this Agreement. On
	your ceasing to be employed by the Company, you will immediately deliver up to the Company all of your Work Product. You further
	agree that all of your Work Product shall at all times be the Confidential Information of the Company.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assignment
	of Rights
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You will assign, and do hereby
	assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company&rsquo;s designee, your
	entire right, title and interest in and to all of your Work Product and all other rights and interests of a proprietary nature
	in and associated with your Work Product, including all patents, copyrights, trademarks, and applications filed therefore and
	other registrations granted thereon. To the extent that you retain or acquire legal title to any such rights and interests, you
	hereby declare and confirm that such legal title is and will be held by you only as trustee and agent for the Company. You agree
	that the Company&rsquo;s rights hereunder shall attach to all of your Work Product, notwithstanding that it may be perfected or
	reduced to specific form after you have terminated your relationship with the Company. You further agree that the Company&rsquo;s
	rights hereunder shall extend to every country of the world.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Moral
	Rights
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You agree to hereby waive in
	whole all moral rights and agree never to assert any moral rights which you may have in your Work Product, including, without
	limitation, the right to the integrity of such Work Product, the right to be associated with the Work Product, the right to restrain
	or claim damages for any distortion, mutilation or other modification or enhancement of the Work Product and the right to restrain,
	the use or reproduction of the Work Product in any context and in connection with any product, service, cause or institution and
	you further confirm that the Company may use or alter any such Work Product as the Company sees fit in its absolute discretion.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Goodwill
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You hereby agree that all goodwill
	you have established or may establish with Key Contacts relating to the business or affairs of the Company or any Affiliate of
	the Company, including without limitation ESSA Pharma, both before and after the Effective Date, shall, as between you and the
	Company, be and remain the property of the Company exclusively, for the Company to use, alter, vary, adapt and exploit as the
	Company shall determine in its discretion.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	8
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage159"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assistance
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You hereby agree to assist
	the Company and/or ESSA Pharma, at the Company&rsquo;s request and expense, both during your Term of Employment and at any time
	within 12 months of termination of your Term of Employment for any reason whatsoever, in:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	making
	patent applications for your Work Product, including instructions to lawyers and/or patent
	agents as to the characteristics of your Work Product in sufficient detail to enable
	the preparation of a suitable patent specification, to execute all formal documentation
	incidental to an application for letters patent and to execute assignment documents in
	favor of the Company for such applications;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	making
	applications for all other forms of intellectual property registration relating to your
	Work Product;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	prosecuting
	and maintaining the patent applications and other intellectual property relating to your
	Work Product; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.6.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	registering,
	maintaining and enforcing the patents and other intellectual property registrations relating
	to your Work Product.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Assistance
	with Proceedings
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You further agree to lend such
	assistance as you can, at the Company&rsquo;s request and expense, in connection with any enforcement of the Company&rsquo;s intellectual
	property rights or defense to an allegation of infringement of another Person&rsquo;s intellectual property rights, invalidity
	proceedings respecting, opposition to, or intervention regarding any applications for letters patent, copyright or trademark or
	other proceedings relating to intellectual property or applications for registration thereof.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	5
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Conflicts and Restrictive Covenant
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Disclosure
	of Conflicts of Interest
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During your employment with
	the Company, you will promptly, fully and frankly disclose to the Company in writing:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.1.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	nature and extent of any interest you have or may have, directly or indirectly, in any
	contract or transaction or proposed contract or transaction of or with the Company or
	any Affiliate of the Company or any Key Contact;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.1.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	every
	office you may hold or acquire, and every property you may possess or acquire, whereby
	directly or indirectly, a duty or interest might be created in conflict with the interests
	of the Company or any Affiliate of the Company, or your duties and obligations under
	this Agreement; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.1.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	nature and extent of any conflict referred to in Sections 5.1.1 and 5.1.2.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	9
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage160"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Avoidance
	of Conflicts of Interest
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You acknowledge that it is
	the policy of the Company that all interests and conflicts of the sort described in Section 5.1 (Disclosure of Conflicts of Interest)
	be avoided, and you agree to comply with all policies and directives of the Company from time to time regulating, restricting
	or prohibiting circumstances giving rise to interests or conflicts of the sort described in Section 5.1. During your employment
	with the Company, you shall not enter into any agreement, arrangement or understanding (other than the Canadian Agreement) with
	any other Person that would in any way conflict or interfere with this Agreement or your duties or obligations under this Agreement
	or that would otherwise prevent you from performing your obligations hereunder, and you represent and warrant that you have not
	prior to the Effective Date entered into any such agreement, arrangement or understanding.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Restrictive
	Covenant
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	In consideration of the Company&rsquo;s
	grant to you of options to purchase common shares in ESSA Pharma pursuant to Section 3.8, during the Term of Employment and for
	a period of 6 months thereafter for Sections 5.3.1 and 5.3.2, and a period of 24 months thereafter for Section 5.3.3, regardless
	of the reason for such termination or non-renewal, you will not, either alone or in partnership or in conjunction with any Person,
	whether as principal, agent, employee, director, officer, shareholder, consultant or in any capacity or manner whatsoever, whether
	directly or indirectly:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.3.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	carry
	on or be engaged in, or advise, or give financial assistance to, any business, enterprise
	or undertaking that is involved in the business or in the sale, distribution, development
	or supply of any product or service that is directly competitive with the Business or
	any product or service of the Business; provided, however, that the foregoing will not
	prohibit you from acquiring, solely as an investment and through market purchases, securities
	of any such enterprise or undertaking which are publicly traded, so long as you are not
	part of any control group of such entity and such securities, which if converted, do
	not constitute more than 5% of the outstanding voting power of that entity;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.3.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	solicit,
	agree to be employed by, or agree to provide services to any Person that was a Key Contact
	during the two years prior to the termination or expiry of the Term of Employment for
	any business purpose that is competitive with the Business or any product or service
	of the Company or any Affiliate of the Company; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.3.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	divert,
	entice or take away from the Company or any Affiliate of the Company or attempt to do
	so or solicit for the purpose of doing so, any business of the Company or any Affiliate
	of the Company, or any Person that was an employee or contractor of the Company or any
	Affiliate of the Company during the two years prior to the termination or expiry of the
	Term of Employment.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Need
	to limit corporate board of directors to three boards without the prior consent of the
	ESSA board of directors
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company acknowledges that
	Dr. Parkinson has transitioned to a venture advisor role with NEA; in that reduced role he will not take on any material responsibilities
	or receive material compensation as long as he is an employee of the Company.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	10
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage161"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Provisions
	Reasonable
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You hereby acknowledge and
	agree that:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	after
	the Effective Date the Company and any Affiliate of the Company will operate and compete
	globally, with respect to the Business;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	competitors
	of the Company and the Business and any Affiliate of the Company are located globally;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	in
	order to protect the Company adequately, any enjoinder of competition would have to apply
	globally;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	during
	the course of your employment by the Company, you will acquire knowledge of, and you
	will come into contact with, initiate and established relationships with Key Contacts,
	and that in some circumstances you may be the senior or sole representative of the Company
	or any Affiliate of the Company dealing with such Persons; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.5.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	in
	light of the foregoing, the provisions of Section 5.3 (Restrictive Covenant) are reasonable
	and necessary for the proper protection of the business, property and goodwill of the
	Company and the Business and any Affiliate of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Right
	to Use Employee&rsquo;s Name and Likeness
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the Term of Employment,
	you hereby grant to the Company the right to use your name, likeness and/or biography in connection with services performed by
	you under this Agreement and in connection with the advertising or exploitation of any project with respect to which you perform
	services for the Company.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	6
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Termination
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination
	by Employee
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You may resign from your position
	at any time, but only by giving the Company at least 60 days prior written notice of the effective date of your resignation (the
	&ldquo;
<B>
	Notice Period
</B>
	&rdquo;). On the giving of any such notice, the Company may accelerate your resignation, in lieu of
	the Notice Period or any part thereof, by notice in writing to you and payment to you of any compensation due to you on or before
	the end of the Notice Period pursuant to this Agreement, less applicable statutory deductions. A resignation from your position
	with the Company will be deemed to also be a resignation from any office you may hold with ESSA Pharma and you agree to execute
	any paperwork to that effect.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination
	by Company Without Cause
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company may terminate your
	employment at any time without Cause (as defined below) by giving you written notification of termination, which termination shall
	be effective immediately upon such notice. In the event that your employment is so terminated, you will have the common law duty
	to mitigate your damages.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	11
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage162"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Consequences
	of Termination Without Cause Unrelated to a Change of Control
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the first 12 months
	of your continuous employment with the Company and Subject to Section 6.4, on the giving of any notice referred to in Section
	6.2, the Company shall provide you with a lump sum cash payment equal to 6 months&rsquo; Salary. After 12 months of your continuous
	employment with the Company and Subject to Section 6.4, on the giving of any notice referred to in Section 6.2, the Company shall
	provide you with a lump sum cash payment equal to 12 months&rsquo; Salary. In either case, entitlement to such payment is subject
	to compliance with the release requirement in Section 6.7.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Consequences
	of Termination Without Cause After a Change of Control
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	On the giving of any notice
	referred to in Section 6.2: (i) at the same time as, or within the twelve (12) month period following, the consummation of a Change
	of Control or (ii) within the sixty (60) day period prior to the date of a Change of Control where the Change of Control was under
	consideration by the Board at the time of your termination, the Company shall provide you with a lump sum cash payment equal to
	18 months&rsquo; Salary. Entitlement to such payment is subject to compliance with the release requirement in Section 6.7, and
	such payment shall be in lieu of any payment under Section 6.3.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination
	in the Event of Death or Permanent Disability
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Your employment shall terminate
	immediately upon your death or permanent disability.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination
	by Company for Cause
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Notwithstanding any other provision
	in this Agreement, the Company may at any time summarily terminate your employment, without notice or payment, for &ldquo;Cause&rdquo;.
	In this Agreement, &ldquo;
<B>
	Cause
</B>
	&rdquo; means any of the following:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	commission
	of theft, embezzlement, fraud, obtaining funds or property under false pretences or similar
	acts of misconduct with respect to the property of the Company, any Affiliate of the
	Company, the Key Contacts, or their respective directors, officers, employees or contractors;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	oral
	or written representations made by you to the Company or any Affiliate of the Company
	with the intent to deceive or mislead;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	commission
	of an act of malfeasance, dishonesty or breach of trust against the Company, any Affiliate
	of the Company, the Key Contacts, or their respective directors, officers, employees
	or contractors, including a breach by you of any of your covenants or obligations under
	Article 4 (Intellectual Property Rights), Section 5.1 (Disclosure of Conflicts of Interest),
	Section 5.2 (Avoidance of Conflicts of Interest) or Section 5.3 (Restrictive Covenant);
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	the
	entering of a guilty plea by you or your conviction for a serious criminal offence which
	impacts adversely on the Company or any Affiliate of the Company; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.6.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	repeated
	and continued failure to fulfill your duties or obligations of employment or your breach
	of any material obligations and covenants under this Agreement. Termination for &ldquo;Cause&rdquo;
	pursuant to this Section 6.6.5 shall only occur if you have been given written notice
	of such failure to fulfill your duties or obligations and you have been given 30 days
	from receipt of such notice to correct such behavior, if such behavior is subject to
	correction.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage163"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 1IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	In the event the Company dismisses
	you for Cause pursuant to this Section 6.6 and, subsequently, a court or arbitrator rules that the Company did not have Cause,
	you hereby agree that you will only be entitled to damages in an amount equal to the compensation that would have been due to
	you had the Company terminated you pursuant to Section 6.3 (Consequences of Termination Without Cause), less any amounts earned
	by you in mitigation.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	No
	Damages for Termination
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	It is agreed that as a result
	of the termination of your employment, for any reason, you shall not be entitled to any notice, fee, salary, severance or other
	payments, benefits or damages in excess of what is specified or provided for in Section 6.1 (Termination by Employee), Section
	6.3 (Consequences of Termination Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination Without
	Cause After a Change of Control) and Section 6.6 (Termination by Company for Cause), whichever is applicable, except that you
	shall remain entitled to receive all salary and other entitlements, if any, which were due or which were accruing to you at the
	date of termination. Payment of any amounts pursuant to Section 6.1 (Termination by Employee), Section 6.3 (Consequences of Termination
	Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination Without Cause After a Change of Control),
	and Section 6.6 (Termination by Company for Cause) shall be subject to the withholding of all applicable statutory deductions
	by the Company. No payments shall be payable by Company under this Article 6 until you provide to the Company an executed release
	of all claims in form satisfactory to the Company. Notwithstanding anything to the contrary, you must execute and return the release
	on or before the date specified by the Company in the prescribed form (the &ldquo;
<B>
	Release Deadline
</B>
	&rdquo;). The Release
	Deadline will in no event be later than fifty-two (52) days after your termination of employment. If you fail to return the release
	on or before the Release Deadline, or if you revoke the release, then you will not be entitled to the payments described in Section
	6.3 or Section 6.4, as applicable. For purposes of this Agreement, no payment will be made to you upon termination of your employment
	unless such termination constitutes a &ldquo;separation from service&rdquo; within the meaning of Section 409A of the Code, and
	Section 1.409A-1(h) of the regulations promulgated thereunder.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Termination
	from ESSA Pharma
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any termination of your employment
	under this Article 6 shall also amount to a termination of your relationship with ESSA Pharma. You shall not be entitled to any
	further compensation in relation to the termination of any office you may hold with ESSA Pharma other than as is set out in this
	Agreement.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	7
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	General
</FONT>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Agreement
	Confidential
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Both parties shall keep the
	terms and conditions of this Agreement confidential except as may be required to enforce any provision of this Agreement or as
	may otherwise be required by any law, regulation or other regulatory or securities requirement.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	13
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage164"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Binding
	Effect
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	This Agreement shall be binding
	upon and inure to the benefit of the Company and its successors and assigns. Your rights and obligations contained in this Agreement
	are personal and such rights, benefits and obligations shall not be voluntarily or involuntarily assigned, alienated or transferred,
	whether by operation of law or otherwise, without the prior written consent of the Company. This Agreement shall otherwise be
	binding upon and inure to the benefit of your personal or legal representatives, executors, administrators, successors, heirs,
	distributees, devisees, legatees and permitted assigns.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Counterparts
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	This Agreement may be executed
	in several counterparts (including by fax or electronic transmission), each of which when so executed shall be deemed to be an
	original and shall have the same force and effect as an original but such counterparts together shall constitute but one and the
	same instrument.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Entire
	Agreement
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The terms and conditions of
	this Agreement are in addition to and not in substitution for the obligations, duties and responsibilities imposed by law on employees
	of corporations generally, and you agree to comply with such obligations, duties and responsibilities. Except as otherwise provided
	in this Agreement, this Agreement constitutes the entire agreement between you and the Company and supersedes all prior negotiations,
	proposals and agreements, whether oral or written, with respect to the subject matter hereof, and may only be varied by further
	written agreement signed by you and the Company. You further acknowledge and agree that you have not relied on any representation
	made by the Company, or any of its employees or agents, except as specifically set out in this Agreement.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Further
	Assurances
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Each of the parties hereto
	will, on demand by the other party hereto, execute and deliver all such further documents and instruments and do all such further
	acts and things as the party may either before or after the execution and delivery of this Agreement reasonably request to evidence,
	carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Governing
	Law
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	This Agreement shall be governed
	by and construed in accordance with the laws of the State of Texas, without giving effect to any principles of conflict of laws
	that would lead to the application of the laws of another jurisdiction, and the federal laws of the United States of America applicable
	therein, which shall be deemed to be the proper law hereof. The parties hereto hereby submit to the non-exclusive jurisdiction
	of the courts of Houston, Texas.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Independent
	Legal Advice
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You acknowledge and agree that
	the Company has given you the opportunity to seek, and have recommended that you obtain, independent legal advice with respect
	to the subject matter of this Agreement and, further, you hereby represent and warrant to the Company that you have sought independent
	legal advice or waive such advice.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	14
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage165"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Injunctive
	Relief
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You acknowledge and agree that
	any breach or threatened breach of any of the provisions of Article 4 (Intellectual Property Rights), Section 5.1 (Disclosure
	of Conflicts of Interest), Section 5.2 (Avoidance of Conflicts of Interest), or Section 5.3 (Restrictive Covenant) could cause
	irreparable damage to the Company, that such harm could not be adequately compensated by the Company&rsquo;s recovery of monetary
	damages, and that in the event of a breach or threatened breach thereof, the Company shall have, in addition to any and all remedies
	at law or in equity, the right to seek an injunction, specific performance or other equitable relief as well as any equitable
	accounting of all your profits or benefits arising out of any such breach. It is further acknowledged and agreed that the remedies
	of the Company specified in this Section 7.8 are in addition to and not in substitution for any rights or remedies of the Company
	at law or in equity and that all such rights and remedies are cumulative and not alternative and that the Company may have recourse
	to any one or more of its available rights or remedies as it shall see fit.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Non-Disparagement
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You shall not, directly or
	indirectly, make any disparaging comments or criticisms (whether of a professional or personal nature) to any Person regarding
	the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers, employees or contractors
	(or the terms of any agreement or arrangement of the Company) or regarding your relationship with the Company or any termination
	of such relationship which, in each case, are reasonably expected to result in material damage to the business or reputation of
	the Company, any Affiliate of the Company, a Key Contact, or any of their respective directors, officers, employees or contractors.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.10
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Notice
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any notice or other communication
	required or contemplated to be given hereunder must be in writing and shall be deemed effective when personally delivered or on
	the day following the sending when sent by facsimile transmission, addressed to the appropriate party as set forth below:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	If to the Employee:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	David R. Parkinson
<BR>
	820 Anderson Lane
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Sebastopol, CA 95472
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Home: 707 823 5099
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Cell: 858 345 0923
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	If to the Company:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ESSA Pharmaceuticals
	Corp.
</B>
<BR>
	c/o ESSA Pharma Inc.
<BR>
	Suite 720, 999 West Broadway
<BR>
	Vancouver, B.C. V5Z 1K5
<BR>
	F: (604) 677-6915
<BR>
	Attention: Chairman
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	With a copy to:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Blake, Cassels &amp;
	Graydon LLP
<BR>
	595 Burrard Street
<BR>
	P.O Box 49314
<BR>
	Vancouver, B.C. V7X 1L3
<BR>
	Attention: Joe Garcia
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	15
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage166"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.11
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Publicity
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	You shall not, without the
	prior written consent of the Company, make or give any public announcements, press releases or statements to the public or the
	press regarding your Work Product or any Confidential Information.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.12
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Severability
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	If any provision of this Agreement
	is determined to be void, illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement
	and will not impair the validity, legality or enforceability of any other provision of this Agreement and the remainder of this
	Agreement will continue to be binding on the parties hereto as if such provision had been deleted.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Surviving
	Obligations
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The obligations and covenants
	of the Employee under of Section 3.1 (3.1), Article 4 (Intellectual Property Rights), Section 5.3 (Restrictive Covenant) (in accordance
	with its terms), Section 5 (Provisions Reasonable), Article 6 (Termination) and Article 7 (General) shall survive the termination
	of this Agreement.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Waiver
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any waiver of any breach or
	default under this Agreement shall only be effective if made in writing, signed by the party against whom the waiver is sought
	to be enforced, and no waiver shall be implied by any other act or conduct or by any indulgence, delay or omission. Any waiver
	shall only apply to the specific matter waived and only in the specific instance in which it is waived.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.15
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Section
	409A
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 0PT; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	Notwithstanding
	anything else provided herein, to the extent any payments provided under this Agreement in connection with your termination of
	employment constitute deferred compensation subject to Section 409A of the Code and the regulations thereunder (&ldquo;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	Section
	409A
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&rdquo;), and you are deemed at the time of such termination of employment to be a &ldquo;specified
	employee&rdquo; under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of
	the six (6)-month period measured from your separation from service from the Company or (ii) the date of your death following
	such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse
	tax treatment to you including, without limitation, the additional tax for which you would otherwise be liable under Section 409A(a)(1)(B)
	in the absence of such a deferral. The first payment thereof will include a catch-up payment covering the amount that would have
	otherwise been paid during the period between your termination of employment and the first payment date as a result of the application
	of this provision, and the balance of the installments (if any) will be payable in accordance with their original schedule. To
	the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read
	in such a manner so that all payments hereunder comply with Section 409A. To the extent any payment under this Agreement may be
	classified as a &ldquo;short-term deferral&rdquo; within the meaning of Section 409A, such payment shall be deemed a short-term
	deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant
	to this Agreement are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.
</FONT>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	16
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage167"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Acceptance
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
	If the foregoing terms and
	conditions are acceptable to you, please indicate your acceptance of and agreement to the terms and conditions of this Agreement
	by signing below on this letter and on the enclosed copy of this letter in the space provided and by returning the enclosed copy
	so executed to us. Your execution and delivery to the Company of the enclosed copy of this letter will create a binding agreement
	between us.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 12PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Yours
	truly,
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 12PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ESSA
	Pharmaceuticals Corp.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 12PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Per:
<BR>
<BR>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0.25IN 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	______________________________________
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0.25IN 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Accepted
	and agreed to by David Parkinson effective January 7, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0.25IN 0 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0.25IN 0 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	______________________________________
<BR>
	David R. Parkinson
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	17
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage168"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0.25IN 0 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit
	1.1.5: Description of the Business
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 6PT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 6PT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	The
	Company is a development-stage pharmaceutical company focused on the development of oncology therapies or diagnostics based on
	targeting the N terminal domains of receptors including but not limited to the proprietary compounds named EPI-002 and EPI-506
	as a treatment for advanced prostate cancer. In addition, the Company is engaged in the business of developing novel therapeutics
	for cancer, and therefore compounds or classes of compounds that are actively being developed by the Company will be identified
	and included in the description of the Business, which may be amended by the Company from time to time.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	18
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage169"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 12PT 0 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit
	2.1: Description of Duties
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The CEO
	is responsible for all aspects of strategic development and implementation of the business of the Company and ESSA Pharma. The
	primary work location for the President and CEO will be Houston, Texas, and the work duties will be carried out in Houston, Texas
	and Vancouver, B.C. as needed and will include, but are not limited to, the following specific aspects of Company&rsquo;s activities:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	1.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Strategic
	Organizational Management:
</B>
</FONT>
</TD>
</TR>
</TABLE>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Provides the organization with
	the vision and leadership to carry out its mission.
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Works with board and staff
	to generate and update company strategy;
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Manages the implementation
	of the strategy
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Develops policies and strategies
	for financial management including all revenues, expenses, and investments.
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Ensures rigorous accountability
	and long term stability through the conservative fiscal management of&nbsp;resources and endowments.
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Guides and integrates the department
	heads&rsquo; efforts to design and implement business processes focused on achieving agreed upon objectives.
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 6PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Generation of annual updated
	corporate strategy and objectives that are consistent with that strategy.
</FONT>
</LI>
</UL>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	2.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Financial:
</B>
</FONT>
</TD>
</TR>
</TABLE>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Provides the leadership and
	long term vision necessary to ensure the organization is financed to carry out its business strategy;
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Interacts with investments
	banks and investors in order to ensure access to needed funding;
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 6PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Ensure that financial reporting,
	financial controls, and cash management practices, policies and activities are carried out to the standards mandated by the regulatory
	environments in which the Company operates.
</FONT>
</LI>
</UL>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	3.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Business
	Development:
</B>
</FONT>
</TD>
</TR>
</TABLE>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Ensures that the Company and
	ESSA Pharma has a business development strategy that is consistent with the overall strategy of the Company and ESSA Pharma;
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Participates as appropriate
	in business development activities;
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 3PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Manages the efforts of the
	head of Business Development
</FONT>
</LI>
<LI STYLE="MARGIN: 0 0 6PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Performs other duties related
	to the qualifications and requirements of the job.
</FONT>
</LI>
</UL>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	4.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Regulatory
</B>
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
</TD>
<TD STYLE="WIDTH: 0.2IN; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Ensures
	that the Company and ESSA Pharma meet all applicable standards in regard to all of the
	regulatory environments in which it operates.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	5.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Clinical
	Development
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.2IN">
</TD>
<TD STYLE="WIDTH: 0.2IN; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Ensures
	that appropriate clinical development strategies and policies are in place and are being
	appropriately implemented
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	6.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Other
	duties and Responsibilities
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 24PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The CEO
	will also have responsibility for any other duties and responsibilities as may be determined by the Board
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	19
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage170"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0 0 12PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exhibit 2.3.5: Permitted
	External Roles
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	You
	currently hold the following external corporate director positions:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Board
	Director, Cerulean Pharma, Inc
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Board
	Director, 3S Bio, Inc
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Board
	Director, Diatech, Inc
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 12PT 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	You
	further understand that the Board wants you to limit your external activities to no more than a total of three external corporate
	Board positions. The Board acknowledges that to this end you have agreed to transition as rapidly as possible (and in any event
	within three months of the Effective Date) out of your Board positions with Cellsee Diagnostics, Threshold Pharmaceuticals, and
	Tocagen, Inc. and will not take on any new external board positions without the prior consent of the Board.
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	You
	will transition from your current role as Venture Partner with NEA to the role of Venture
	Advisor and agree that you will not assume any material obligations to, nor receive any
	material compensation from, NEA in that new capacity.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	You
	agree that you will only continue any approved external roles to the extent they do not
	conflict with your duties as CEO and President of the Company and ESSA Pharma.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	20
</FONT>
</P>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage171"></A>
<A NAME="EX410_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 24PT; TEXT-ALIGN: CENTER">
<B>
	EMPLOYMENT AGREEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 24PT; TEXT-ALIGN: JUSTIFY">
	This Agreement made as of the 1
<SUP>
	st
</SUP>
	day of August, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT">
<B>
	BETWEEN:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 1IN 12PT">
<B>
	ESSA PHARMACEUTICALS CORP.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 1IN 12PT">
	(the &ldquo;
<B>
	Company
</B>
	&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT">
<B>
	AND:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 1IN 12PT">
<B>
	PETER VIRSIK
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 24PT 1IN">
	(the &ldquo;
<B>
	Employee
</B>
	&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT">
<B>
	WITNESSES THAT WHEREAS:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee will commence employment
	by the Company as the Company&rsquo;s Executive Vice President and Chief Operating Officer (the &ldquo;
<B>
	COO
</B>
	&rdquo;) on August
	1, 2016; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	B.
</FONT>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company and the Employee have agreed to continue the employment of the Employee on the new terms and conditions hereinafter set
	forth.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<B>
	THEREFORE
</B>
	in
	consideration of the recitals and the following representations and covenants, the sufficiency of which is acknowledged by each
	party, the parties agree on the following terms:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.1&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
	hereby agrees to employ the Employee in the position of COO of the Company and the Employee hereby agrees to accept such employment
	on the terms and conditions herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.2&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee
	shall report to the Chief Executive Officer (&ldquo;
<B>
	CEO
</B>
	&rdquo;) of ESSA Pharmaceuticals Corp. and shall perform the duties
	assigned to him from time to time by the CEO that are consistent with his position and are described in Schedule &ldquo;A&rdquo;
	attached hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.3&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Throughout
	the term of this Agreement, the Employee shall:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	diligently, honestly and faithfully serve the Company and shall use his best efforts to promote
	and advance the interests and goodwill of the Company;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	conduct himself at all times in a manner not prejudicial to the Company&rsquo;s interests; and
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	1 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage172"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	subject to section 1.4, devote his full working time and attention to the business and affairs
	of the Company to fulfill his obligations hereunder
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.4&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
	any other provision of this Agreement, nothing herein will prevent the Employee from rendering services with regard to Employee&rsquo;s
	family trusts and Employee&rsquo;s holding companies or to charitable or community service organizations, provided that such activities
	do not conflict or otherwise interfere with the Employee&rsquo;s duties and responsibilities hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.5&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee
	acknowledges and agrees that he is a fiduciary of the Company and the Company&rsquo;s affiliates and related companies that the
	Employee may provide duties to from time to time. Without in any way limiting the scope of the Employee&rsquo;s fiduciary obligations
	to the Company, the Employee agrees that, at all times during the term of this Agreement, the Employee shall not engage in competition
	with the Company, its affiliates or subsidiaries, aid others in any unfair competition with the Company, its affiliates or subsidiaries,
	in any way breach the confidence that the Company has placed in the Employee, misappropriate any proprietary or confidential information
	of the Company, or misappropriate any corporate opportunities of the Company. The Employee acknowledges and agrees that the Employee&rsquo;s
	execution of the Company&rsquo;s standard Employee Invention Assignment, Confidentiality and Non-Competition Agreement, attached
	hereto as
<U>
	Exhibit A
</U>
	, shall be a condition of the Employee&rsquo;s employment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	1.6&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee
	acknowledges and agrees that he will at times work remotely and that his official primary work location will be the Company&rsquo;s
	office in Houston, Texas. The Employee is required to travel as is reasonably necessary to fulfill the requirements of his position.
	The Employee agrees that at all times he will maintain the necessary lawful authority (permanent residency or applicable work permit
	or visa) to permit the Employee to discharge his duties under this Agreement primarily from the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	2.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term of Employment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	2.1&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee&rsquo;s
	employment hereunder shall continue until terminated in accordance with the terms of section 4 of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	3.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remuneration and Benefits
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.1&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Base
	Salary:
</U>
	During the currency of this Agreement, the Company shall pay to the Employee a salary of USD$365,000 per annum (&ldquo;
<B>
	Base
	Salary
</B>
	&rdquo;) in accordance with the regular payroll practices of the Company. The Base Salary shall be reviewed from time
	to time by the CEO and the Board of Directors (the &ldquo;
<B>
	Board
</B>
	&rdquo;) of ESSA Pharma Inc. (&ldquo;
<B>
	ESSA Pharma
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.2&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Incentive
	Compensation
</U>
	. You will be eligible for an annual bonus of up to 40% of base salary, which will be paid on the basis of your
	performance over each calendar year, and no later than sixty (60) days after the end of each calendar year. Bonus eligibility and
	performance criteria shall be set at the sole discretion of the Board. You will need to be employed with the Company through the
	end of the calendar year in order to be eligible to receive the annual bonus.
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	2 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage173"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Stock Options.
</U>
	The Employee will be eligible to participate in ESSA Pharmas stock option plan (the &ldquo;
<B>
	Plan
</B>
	&rdquo;). It will be recommended
	to the Board that the Employee be granted the opportunity to purchase up to 300,000 shares of Common Stock (&ldquo;
<B>
	Common Stock
</B>
	&rdquo;)
	of ESSA Pharma (approximately
<B>
	1%
</B>
	of current equity) at the fair market value of the Common Stock, as determined by the Board
	on the date the Board approves such grant, expiring 5 years after the date of issue (the &ldquo;
<B>
	Options
</B>
	&rdquo;). The Options
	shall vest over a period of three (3) years with 25% of the options cliff-vest on the one (1) year anniversary of the Effective
	date of the Employee&rsquo;s employment and the remainder of the options vesting in equal monthly instalments thereafter over the
	next two (2) years, in all cases subject to the Employee&rsquo;s continued employment with the Company. Any additional option grants
	shall be at the sole discretion of the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	All unvested options
	will automatically vest upon a Change in Control as defined in section 5.1 (subject to section 4.5).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The grant of the
	Options by ESSA Pharma is subject to the Board&rsquo;s approval and this promise to recommend such approval is not a promise of
	compensation and is not intended to create any obligation on the part of ESSA Pharma or the Company. Subject to this Agreement,
	all stock options granted to the Employee, including the Options, shall vest, terminate, be exercisable and be subject to such
	other terms as set out in the form of the stock option agreement in use by the Company at the time of such grant and in accordance
	with the terms of the Plan for employees as it exists from time to time and subject to necessary regulatory and Board approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.4&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>
	Benefits.
</U>
	The Employee will be eligible to participate in the Company&rsquo;s employee benefit plans, provided that such participation will
	be subject to all terms and conditions of such plans (including, without limitation, all waiting periods, eligibility requirements,
	contributions, exclusions or other similar conditions and limitations) at the Company&rsquo;s cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Reimbursement
	of Expenses.
</U>
	The Company shall reimburse the Employee for all reasonable expenses, actually and properly incurred by the Employee
	in the performance of his duties for the Company, including all expenses relating to travel by the Employee on behalf of the Company
	or any affiliates of the Company. The Employee shall furnish to the Company such statements, vouchers and other particulars of
	expenses as the Company may reasonably require. The Employee shall not be entitled to a general vehicle allowance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Vacation
</U>
	.
	The Employee shall be entitled to
<B>
</B>
	four (4) weeks paid vacation in each calendar year during the term of this Agreement.
	The timing of vacations shall be in accordance with the Company&rsquo;s policies and practices for senior management personnel
	and with the Company&rsquo;s needs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Other.
</U>
	The Company shall pay for the cost of the Employee to have a cellular phone for business purposes and will otherwise provide normal
	working equipment for the Employee&rsquo;s use in discharging his duties. If deemed necessary by the CEO, the Company will provide
	a stipend to be used by the Employee to lease an apartment in Houston, Texas, not to exceed $2,500 monthly.
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	3 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage174"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Statutory
	Deductions
</U>
	. The Company shall have the right to deduct and withhold from the Employee&rsquo;s compensation any amounts required
	to be deducted and remitted under applicable provincial, state or federal laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 12PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	4.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.1&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes
	of this Agreement, &ldquo;
<B>
	Cause
</B>
	&rdquo; means (i) a determination by the Board that the Employee&rsquo;s performance is unsatisfactory;
	(ii) conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude; (iii) engaging in an act of gross
	negligence or willful misconduct in the performance of the Employee&rsquo;s employment obligations and duties, (iv) committing
	an act of fraud against, material misconduct or willful misappropriation of property belonging to the Company; (v) engaging in
	any other misconduct that has had or will have an adverse effect on the Company&rsquo;s reputation or business; (vi) the Employee&rsquo;s
	breach of the Employee Invention Assignment, Confidentiality and Non-Competition Agreement or other unauthorized misuse of the
	Company&rsquo;s trade secrets or proprietary information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.2&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
	may terminate the Employee&rsquo;s employment under this Agreement at any time for Cause. If this Agreement and the Employee&rsquo;s
	employment are terminated for Cause, no notice, salary, compensation, benefits, allowances or pay in lieu of notice shall be paid
	or payable to the Employee after or as a result of such termination other than the Base Salary to the effective date of such termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.3&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
	may terminate the Employee&rsquo;s employment under this Agreement without Cause at any time by providing the Employee with, if
	not theretofore paid, the amount of the Employee's accrued and unpaid Base Salary and vacation pay for the period to and including
	the effective date of termination; and notice of termination or pay in lieu of such notice of termination equal to:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	180 days of notice if notice is given in the first year of employment; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	One year of notice if notice is given after the first year of employment
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT 1IN; TEXT-ALIGN: JUSTIFY">
	(the &ldquo;
<B>
	Notice Period
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	At the time that
	the Company provides notice of termination to the Employee pursuant to this section or at any time during the applicable Notice
	Period, the Company shall have the right to elect to pay the Employee a lump sum payment equal to the Base Salary payable during
	the Notice Period or such proportion of the Notice Period that remains outstanding at the time of the Company&rsquo;s election,
	and all other benefits and entitlements shall terminate as of the date of such election.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In addition, if
	the Employee is participating in the Company&rsquo;s group health insurance plans on the date of the termination, and timely elects
	to continue such coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, or, if applicable, comparable state
	or local insurance laws (&ldquo;COBRA&rdquo;), then the company will pay, directly to the COBRA carrier, as and when due, the COBRA
	premiums necessary to continue such health insurance converage for the Employee and his eligible dependents until the earliest
	of: (i) the first 6 or 12 months, as may be applicable, following the Employee&rsquo;s separation from service, (ii) the expiration
	of eligibility for COBRA coverage, or (iii) the date when the Employee or his dependents become eligible for substantially equivalent
	health insurance coverage in connection with new employment or self-employment.
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	4 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage175"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Employee&rsquo;s
	right to notice, or pay in lieu of notice, and the other payments and benefits in this Section 4.3 are expressly contingent on
	the Employee&rsquo;s execution of a general release of claims in favor of the Company and its affiliated entities, in a form approved
	by the Company, and the Employee&rsquo;s satisfaction of all conditions to make the release effective pursuant to its terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.4&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Employee
	desires to terminate the employment relationship without Cause, the Employee agrees that the Employee shall make reasonable efforts
	to provide at least 14 calendar days&rsquo; prior written notice to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.5&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Employee
	resigns from employment for any reason or the Employee&rsquo;s employment is terminated with Cause or without Cause, options will
	cease to vest as of the date that notice of termination is given or received by the Employee. All vested options will expire three
	months after the Company provides notice of termination for any reason and one year after the Employee provides notice of termination
	for any reason.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	4.6&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee
	acknowledges and agrees that unless otherwise expressly agreed in writing between the Employee and the Company, the Employee shall
	not be entitled, by reason of his employment with the Company or by reason of any termination of such employment, however so arising,
	to any remuneration, compensation or other benefits other than as expressly provided for in this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	5.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Definitions
</U>
	.
	For the purposes of this Agreement, &quot;
<B>
	Change in Control
</B>
	&quot; means situations where after giving effect to the contemplated
	transaction and as a result of such transaction: (i) any one Person holds a sufficient number of voting shares of the Company or
	resulting company to affect materially the control of the Company or resulting company; or (ii) any combination of Persons, acting
	in concert by virtue of an agreement, arrangement, commitment or understanding, holds in total a sufficient number of voting shares
	of the Company or its successor to affect materially the control of the Company or its successor; in either case where such Person
	or combination of Persons did not previously hold a sufficient number of voting shares to materially affect control of the Company
	or its successor and, in the absence of evidence to the contrary, any Person or combination of Persons acting in concert by virtue
	of an agreement, arrangement, commitment or understanding, holding more than 20% of the voting shares of the Company or resulting
	company is deemed to materially affect control of the Company or resulting company; or (iii) there is a sale of substantially all
	of the assets of the Company; or (iv) the Company enters into a merger, reverse-merger, amalgamation, arrangement, consolidation
	or other form of business combination, share exchange, reorganization, recapitalization, transfer or other similar transaction
	with another Person (whether or not the Company is the surviving entity) and as a result of such transaction (a) the members of
	the board of directors immediately prior to such transaction constitute less than a majority of the members of the board of directors
	of the Company or such surviving entity immediately following such transaction or (b) the Persons that beneficially owned, directly
	or indirectly, the voting shares of the Company immediately prior to such transaction cease to beneficially own, directly or indirectly,
	voting shares of the Company representing at least a majority of the total voting power of all outstanding classes of voting shares
	of the surviving entity immediately following such transaction.
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	5 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage176"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&ldquo;
<B>
	Person
</B>
	&rdquo;
	means any individual, partnership, limited partnership, joint venture, syndicate, sole proprietorship, company or corporation with
	or without share capital, unincorporated association, trust, trustee, executor, administrator or other legal personal representative,
	regulatory body or agency, government or governmental agency, authority or entity however designated or constituted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Continuation
	of Employment Following a Change in Control
</U>
	. Upon a Change in Control, the Company agrees to continue the Employee in its employ,
	in accordance with the terms and provisions of this Agreement, on the same terms and conditions which were in effect immediately
	prior to the Change in Control or on such other terms as may be subsequently agreed upon in writing between the Company and the
	Employee. Upon a Change in Control, the provisions of this section and section 5.3 shall become operative.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Obligations
	of the Company upon Termination
</U>
	. If the Employee&rsquo;s employment is terminated by the Company at any time within a eighteen
	(18) month period following a Change of Control, other than for Cause, then:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the Company shall continue to pay the Employee the then-current base salary for the eighteen (18)
	months following the Employee&rsquo;s termination on the Company&rsquo;s normal payroll schedule . In addition, the Company shall
	pay a lump sum payment to the Employee within 10 days of the termination equal to:
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1.8IN">
</TD>
<TD STYLE="WIDTH: 0.3IN">
	(i)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	if not theretofore paid, the amount of the Employee's accrued and unpaid Base Salary and vacation
	pay for the period to and including the effective date of termination; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	all unvested Options shall vest upon the effective date of that termination and any unexercised
	portion of such Options will thereafter be exercisable by the Employee for the remaining term to expiry for such Options (being
	the original term of the Options at the time of grant).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	if the Employee is participating in the Company&rsquo;s group health insurance plans on the date
	of the termination, and timely elects to continue such coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985,
	or, if applicable, comparable state or local insurance laws (&ldquo;COBRA&rdquo;), then the company will pay, directly to the COBRA
	carrier, as and when due, the COBRA premiums necessary to continue such health insurance converage for the Employee and his eligible
	dependents until the earliest of: (i) the first 18 months following the Employee&rsquo;s separation from service, (ii) the expiration
	of eligibility for COBRA coverage, or (iii) the date when the Employee or his dependents become eligible for substantially equivalent
	health insurance coverage in connection with new employment or self-employment.
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	6 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage177"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Restrictions on Competition
	and Solicitation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;The Employee
	covenants and agrees with the Company that the Employee will not, without the prior written consent of the Board, at any time within
	a period of six (6) months following the termination of the Employee&rsquo;s employment with the Company for any reason, either
	individually or in partnership or in conjunction with any person, whether as principal, agent, shareholder, director, officer,
	employee, investor, or in any other manner whatsoever, directly or indirectly, advise, manage, carry on, be engaged in, own or
	lend money to, permit the Employee&rsquo;s name or any part thereof to be used or employed by any person managing, carrying on
	or engaged in the business of developing and marketing for sale drugs to provide recurrent prostate cancer patients the potential
	for significant increases in progression-free survival. Nothing in this section 6.1 shall prevent the Employee from acquiring or
	holding not more than 1% of the shares of a company whose shares are listed on a public stock exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	6.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;The
	Employee shall not, for a period of six (6) months following the termination of the Employee&rsquo;s employment for any
	reason, without the prior written consent of the Board, for his account or jointly with another, either directly or
	indirectly, for or on behalf of himself or any individual, partnership, corporation or other legal entity, as principal,
	agent, employee or otherwise, solicit, influence, entice or induce, or attempt to solicit, influence, entice or induce:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any person who is employed by the Company or any affiliated company to leave such employment; or
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 12PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any person, firm or corporation whatsoever, who or which has at any time in the last two (2) years
	of the Employee's employment with the Company or any predecessor of the Company, been a customer of the Company, any affiliated
	company, or of any of their respective predecessors, provided that this subsection shall not prohibit the Employee from soliciting
	business from any such customer if the business is in no way similar to the business carried on by the Company, an affiliated company,
	any of their respective predecessors, subsidiaries or associates, to cease its relationship with the Company or any affiliated
	company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	6.3&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Employee
	acknowledges that, in connection with the Employee&rsquo;s employment by the Company, the Employee will receive or will become
	eligible to receive substantial benefits and compensation. The Employee acknowledges that the Employee&rsquo;s employment by the
	Company and all compensation and benefits and potential compensation and benefits to the Employee from such employment will be
	conferred by the Company upon the Employee only because and on condition of the Employee&rsquo;s willingness to commit the Employee&rsquo;s
	best efforts and loyalty to the Company, including protecting the Company&rsquo;s right to have its Confidential Information protected
	from disclosure by the Employee and abiding by the confidentiality and other provisions herein and the Employee Invention Assignment,
	Confidentiality and Non-Competition Agreement. The Employee understands the Employee&rsquo;s duties and obligations as set forth
	in sections 6.1 and 6.2 and agrees that such duties and obligations would not unduly restrict or curtail the Employee&rsquo;s legitimate
	efforts to earn a livelihood following any termination of the Employee&rsquo;s employment with the Company. The Employee agrees
	that the restrictions contained in sections 6.1 and 6.2 are reasonable and valid. The Employee further acknowledges and agrees
	that the Company shall be entitled to any appropriate legal, equitable, or other remedy, including injunctive relief, in respect
	of any failure or continuing failure of the Employee to comply with the provisions of sections 6.1 or 6.2.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	7 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage178"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	7.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	7.1&#9;The Employee
	represents and warrants to the Company that the execution and performance of this Agreement will not result in or constitute a
	default, breach, or violation, or an event that, with notice or lapse of time or both, would be a default, breach, or violation,
	of any understanding, agreement or commitment, written or oral, express or implied, to which the Employee is a party or by which
	the Employee or the Employee&rsquo;s property is bound.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
<B>
	8.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Waiver
</U>
	.
	No consent or waiver, express or implied, by any party to this Agreement or any breach or default by any other party in the performance
	of its obligations under this Agreement or of any of the terms, covenants or conditions of this Agreement shall be deemed or construed
	to be a consent or waiver of any subsequent or continuing breach or default in such party&rsquo;s performance or in the terms,
	covenants or conditions of this Agreement. The failure of any party to this Agreement to assert any claim in a timely fashion for
	any of its rights or remedies under this Agreement shall not be construed as a waiver of any such claim and shall not serve to
	modify, alter or restrict any such party&rsquo;s right to assert such claim at any time thereafter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Survival
</U>
	.
	The provisions of section 5 and 6 shall survive the termination of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Notices
</U>
	.
	Any notice relating to this Agreement or required or permitted to be given in accordance with this Agreement shall be in writing
	and shall be personally delivered or mailed by registered mail, postage prepaid if to the Company to, ESSA Pharma Inc.,
<B>
</B>
	Suite
	720 - 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5, and and if to the Employee to the home address of the Employee on the
	Company&rsquo;s records. Any notice shall be deemed to have been received if delivered, when delivered, and if mailed, on the fifth
	day (excluding Saturdays, Sundays and holidays) after the mailing thereof. If normal mail service is interrupted the sender shall
	deliver such notice in order to ensure prompt receipt thereof. A party may change its address for service by notice in writing
	to the other party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Applicable
	Law
</U>
	. This Agreement shall be governed by and construed in accordance with the laws of the state of Texas, without giving effect
	to any principles of conflict of laws that would lead to the application of the laws of another jurisdiction, and the federal laws
	of the United States of America applicable therein, which shall be deemed to be the proper law hereof. The parties hereto hereby
	submit to the non-exclusive jurisdiction of the courts of Houston, Texas.
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	8 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage179"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Severability
</U>
	.
	If any provision of this Agreement for any reason is declared invalid, such declaration shall not affect the validity of any remaining
	portion of the Agreement, which remaining portion shall remain in full force and effect as if this Agreement had been executed
	with the invalid portion thereof eliminated and it is hereby declared the intention of the parties that they would have executed
	the remaining portions of this Agreement without including therein any such part, parts or portion which may, for any reason, be
	hereafter declared invalid.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Entire Agreement
</U>
<I>
	.
</I>
	This Agreement constitutes the entire Agreement between the parties hereto and there are no representations or warranties,
	express or implied, statutory or otherwise other than as set forth in this Agreement and there are no Agreements collateral hereto
	other than as are expressly set forth or referred to herein. This Agreement supersedes any prior agreements, written or oral in
	respect of the Employee&rsquo;s employment with the Company. This Agreement cannot be amended or supplemented except by a written
	Agreement executed by all parties hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Counterpart
</U>
	.
	This Agreement may be executed in counterparts and such counterparts together shall constitute one and the same instrument and
	notwithstanding the date of execution shall be deemed to bear the date as set out on the first page of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;
<U>
	Independent
	Legal Advice
</U>
	. The Employee acknowledges that this Agreement has been prepared by counsel for the Company, and acknowledges
	that the Employee has had sufficient time to review this Agreement thoroughly, that he has read and understood the terms of this
	Agreement and that the Employee has been given the opportunity to obtain independent legal advice concerning the interpretation
	and effect of this Agreement prior to its execution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="LETTER-SPACING: 0.15PT">
<I>
	[T
</I>
</FONT>
<I>
	he
<FONT STYLE="LETTER-SPACING: -0.2PT">
</FONT>
<FONT STYLE="LETTER-SPACING: 0.05PT">
	r
</FONT>
<FONT STYLE="LETTER-SPACING: -0.15PT">
	e
</FONT>
<FONT STYLE="LETTER-SPACING: 0.2PT">
	m
</FONT>
	a
<FONT STYLE="LETTER-SPACING: -0.05PT">
	i
</FONT>
	nder
<FONT STYLE="LETTER-SPACING: -0.4PT">
</FONT>
	of t
<FONT STYLE="LETTER-SPACING: 0.1PT">
	h
</FONT>
<FONT STYLE="LETTER-SPACING: -0.05PT">
	i
</FONT>
	s
<FONT STYLE="LETTER-SPACING: -0.1PT">
</FONT>
	p
<FONT STYLE="LETTER-SPACING: 0.1PT">
	a
</FONT>
	ge
<FONT STYLE="LETTER-SPACING: -0.1PT">
</FONT>
<FONT STYLE="LETTER-SPACING: -0.05PT">
	i
</FONT>
	nt
<FONT STYLE="LETTER-SPACING: 0.1PT">
	e
</FONT>
	nt
<FONT STYLE="LETTER-SPACING: 0.05PT">
	i
</FONT>
	on
<FONT STYLE="LETTER-SPACING: 0.1PT">
	a
</FONT>
<FONT STYLE="LETTER-SPACING: -0.05PT">
	l
</FONT>
<FONT STYLE="LETTER-SPACING: 0.2PT">
	l
</FONT>
	y
<FONT STYLE="LETTER-SPACING: -0.6PT">
</FONT>
<FONT STYLE="LETTER-SPACING: -0.05PT">
	l
</FONT>
	e
<FONT STYLE="LETTER-SPACING: 0.1PT">
	f
</FONT>
	t
<FONT STYLE="LETTER-SPACING: -0.15PT">
</FONT>
	b
<FONT STYLE="LETTER-SPACING: 0.05PT">
	l
</FONT>
	an
<FONT STYLE="LETTER-SPACING: 0.2PT">
	k.
</FONT>
<FONT STYLE="LETTER-SPACING: -0.05PT">
	Si
</FONT>
<FONT STYLE="LETTER-SPACING: 0.1PT">
	g
</FONT>
	na
<FONT STYLE="LETTER-SPACING: 0.1PT">
	t
</FONT>
	u
<FONT STYLE="LETTER-SPACING: 0.05PT">
	r
</FONT>
	e
	page follows.]
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	9 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage180"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1IN">
<B>
	IN WITNESS WHEREOF
</B>
	the parties have duly executed this Agreement as of the date first written above.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_58"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD ROWSPAN="3">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ESSA PHARMACEUTICALS CORP.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD ROWSPAN="2" STYLE="PADDING-TOP: 3PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD ROWSPAN="2" STYLE="PADDING-TOP: 3PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Per:
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Authorized Signatory
</FONT>
</TD>
</TR>
</TABLE>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 47%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	SIGNED, SEALED AND DELIVERED in the presence of:
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
</TD>
<TD ROWSPAN="9" STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD ROWSPAN="9" STYLE="VERTICAL-ALIGN: TOP; WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	)&nbsp;
</FONT>
</P>
</TD>
<TD ROWSPAN="2" STYLE="VERTICAL-ALIGN: TOP; WIDTH: 39%; PADDING-TOP: 1IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR>
<TD ROWSPAN="2" STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Witness
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD ROWSPAN="7" STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE">
<B>
	PETER VIRSIK
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD ROWSPAN="3" STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Name
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Address
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</TD>
<TD>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-TOP: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Occupation
</FONT>
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 9PT">
</FONT>
</P>
	Page 10 of 12
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage181"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Schedule &ldquo;A&rdquo;
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General Description:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In this position you will report to the President and Chief Executive
	Officer. In collaboration with the senior management team you will be responsible for:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	Contributing to setting the strategic direction of the companies assets;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	Develop strategies to strengthen current relationships and establish opportunities with industry partners;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD>
	Task with meeting with additional investors and potential partnering opportunities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Responsibilities:
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Provides leadership to execute a deal strategy that will allow the company to fulfill its scientific mission and build shareholder
	value;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Assumes full management responsibility for the company&rsquo;s deal making;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Contributes to the company's strategic business development plan and build on initiatives currently underway;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Develops and secure new business opportunities through identification, outreach and follow-ups with high potential partners;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Actively participates in future fund-raising activities for the company;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Contributes to the development and implementation of corporate strategy;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Partners closely with the executive team to implement the strategic business development plan;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Provides managerial guidance to the company&rsquo;s product development staff as needed;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	Forges strong and ongoing relationships with key opinion leaders and industry;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD>
	In collaboration with the CEO, CFO and CMO provides managerial guidance to the company&rsquo;s general and administrative functions.
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 9PT">
	Page
	11 of 12
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage182"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: CENTER">
<B>
<U>
	Exhibit A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Employee Invention Assignment, Confidentiality
	and Non-Competition Agreement
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 9PT">
	Page 12 of 12
</FONT>
</P>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage183"></A>
<A NAME="EX121_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 12.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Certification of the Chief Executive Officer
	of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ESSA Pharma Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Pursuant to Section 302 of the Sarbanes-Oxley
	Act of 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	I, David Parkinson, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 20-F of ESSA Pharma Inc. (the &quot;Company&quot;);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.1IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.1IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Date: December 14, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ David Parkinson
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Parkinson
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA Pharma Inc.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage184"></A>
<A NAME="EX122_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12_2"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 12.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Certification of the Principal Financial
	Officer of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ESSA Pharma Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Pursuant to Section 302 of the Sarbanes-Oxley
	Act of 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	I, David Wood, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 20-F of ESSA Pharma Inc. (the &quot;Company&quot;);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.1IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.7IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 67PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX">
<FONT STYLE="FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1.1IN; TEXT-INDENT: -0.4IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Date: December 14, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ David Wood
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	ESSA Pharma Inc.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage185"></A>
<A NAME="EX131_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 13.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF CEO AND CFO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
	ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In connection with the annual report of ESSA Pharma Inc.
	(the &quot;Registrant&quot;) filed under cover of Form 20-F for the period ended September 30, 2016, as filed with the
	Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), David Parkinson as Chief
	Executive Officer of the Registrant and David Wood as Chief Financial Officer of the Registrant, each hereby certifies,
	pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, to the best of his
	knowledge that:&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.3IN; TEXT-INDENT: -0.3IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 10PT">
	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ David Parkinson
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="WIDTH: 43%">
<FONT STYLE="FONT-SIZE: 10PT">
	David Parkinson
</FONT>
</TD>
<TD STYLE="WIDTH: 51%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Date:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ David Wood
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name: &nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 43%">
<FONT STYLE="FONT-SIZE: 10PT">
	David Wood
</FONT>
</TD>
<TD STYLE="WIDTH: 51%">
	&nbsp;
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Title: &nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Date:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This certification accompanies the Report pursuant to &sect; 906
	of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed
	by the Registrant for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_13>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
